<SEC-DOCUMENT>0001280776-23-000010.txt : 20230511
<SEC-HEADER>0001280776-23-000010.hdr.sgml : 20230511
<ACCEPTANCE-DATETIME>20230511065247
ACCESSION NUMBER:		0001280776-23-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230511
DATE AS OF CHANGE:		20230511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		23908722

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtl-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:40f41647-d1d2-404b-8a31-83c86744a64e,g:f57fa659-71e4-427e-b4f1-2f0099ec97ac,d:0106de04e136427182589f4ebdcdf181--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:vtl="http://vitaltherapies.com/20230331" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtl-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGFibGU6NDhjYWI4MTY4NmNiNGNlY2I1MTQzODA5MmJiYzMxYzgvdGFibGVyYW5nZTo0OGNhYjgxNjg2Y2I0Y2VjYjUxNDM4MDkyYmJjMzFjOF8yLTEtMS0xLTQwODc0_9bf216d8-9c79-4cb6-8c30-c128fb4c7026">2023</ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGFibGU6NDhjYWI4MTY4NmNiNGNlY2I1MTQzODA5MmJiYzMxYzgvdGFibGVyYW5nZTo0OGNhYjgxNjg2Y2I0Y2VjYjUxNDM4MDkyYmJjMzFjOF8zLTEtMS0xLTQwODc0_0a9a29a1-71df-4c2c-ab8d-b66655e3308f">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGFibGU6NDhjYWI4MTY4NmNiNGNlY2I1MTQzODA5MmJiYzMxYzgvdGFibGVyYW5nZTo0OGNhYjgxNjg2Y2I0Y2VjYjUxNDM4MDkyYmJjMzFjOF80LTEtMS0xLTQwODc0_58651050-a69d-4c42-acd0-d83ad5afda6c">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGV4dHJlZ2lvbjplN2M0YmM2ZGUzMmU0NDEzOGUzNmZhZWVhNjI2MDNhZl8zOA_68e41c74-e59c-4a76-8bc8-f8ad6a30f3b1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGV4dHJlZ2lvbjplN2M0YmM2ZGUzMmU0NDEzOGUzNmZhZWVhNjI2MDNhZl82Nw_ae5af24a-1dfa-4139-a46c-2c150ead2c95">0001280776</ix:nonNumeric><ix:nonNumeric contextRef="iec0275452bd148d5ac1ac3d3ab914a50_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNDU2Mg_39b56566-c533-42eb-a49d-8d8409f1a003">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_78b0eeb2-f243-4b7a-92e7-d8188a462216">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_a04b00e1-dad3-420e-abd4-51c63bcf0717">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_e9a3cedd-15f8-4c7a-8ef7-0f175db48d87">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_ebd123b0-afec-4aee-8416-c7a76f3dc937">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7e8e321395104641a2c172c323a23d47_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MzAz_cd4f286e-f982-4745-9e25-2b9dea81d824">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtl-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i09350f81250c464d865db34f18f61a93_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i388fe32242894fcda0ee04da0a4a7628_I20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9320051a944145d6816da95e5465e3c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifac372e93e304225887151b04d10d097_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4155178cdc7140cea775b3cb724f22e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88a78d905402443da1f001d06d684730_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7525d297b7a4cc7892a3e0337f40706_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca9c2ca745541f18b5bfa39907baf2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b147340b42946ed8ca10d452b403ebd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51a8f285fcfb4ccdb68607df5a39ef94_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37e69ee3daf843cfb2cc88838d672346_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070ed8b98474469aaa446823ba89a721_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf37e7e42a624bb69e55ab937f3c9269_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ba80912a12245ab9ea6a2e70d9fcaab_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6dad41e267c41f9a02c026710ea4d78_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1de0f235b8444c6af6405b255d75604_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4656bcc3b5664116bbc2110cb69413a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cee35bd9f1448618979791eff9cb402_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80d5e7c542364e6b91f404a68cce14b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c1dfb8586a4e62b290f57d6b21e26a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25dc5ed916e5432d902a28c2209cb1cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9bda424319e448ea9036287dc26278f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d6bb7eeb17b42b6b560d2d0c4e347ca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe801d7b5694d349caf6bc6c0349f78_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief4990a110a04802be1e5c3f245e10cf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b791530e898489c8c22614be6c3f978_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e51941010cc4d6998cdc6318cacc80e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b6c17ec488454d8d2239bc02df935c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67dc7d2117dd4e95a74b60a330d24d53_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691582ba1b7640458a1c80bf290a4a95_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971971525ba148019837a545259b6684_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>vtl:employee</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>vtl:lease</xbrli:measure></xbrli:unit><xbrli:context id="i1c1ce43c473547e99f3821322556a079_D20140417-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-17</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8c1a45128834deeb7c989373a0d3a57_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170f226050a64272899ebe618949d15c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e9633735014256ae003a713d8ab86d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="financialinstitution"><xbrli:measure>vtl:financialInstitution</xbrli:measure></xbrli:unit><xbrli:context id="i00dbb5ea0444479bb49ade8df06bec2a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i883c7dc6250c4a088e84c151079c3725_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea3055f090434c34a36eb882151b2a4b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a332d0cac3410a9bf57d9923328244_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c7e38a236f14a20b7ca1838765c36ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7d9669b6d842baa047cfedec92e62b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0275452bd148d5ac1ac3d3ab914a50_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98492f22019748cd8f198e6e858d4908_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieede7680228b4ced8b38713bf5d0aae3_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1bab50058db432a95481b3b7f2efba9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ab2a7b7c1b48578feac81bbc5e3e28_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b55fff4633243a0adf3497ef994823d_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbacc1604fd34d488c15218cae45490d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec03675d217d4626a6ad2990f79e3eb7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ddf70d08824b6aa7e7f010c23a3377_I20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20527b0f049e4fc49cf34f6e19f78f53_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805e70466a81410da29a22178dd65ce1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a80cba888e746d6bd629ae229623ef3_D20230201-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9be709dcc341ec81501791438f59e7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia456402de7a84422945fba2d356a2128_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed67899138440fca6e702a05a6fe016_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c299796fa64dfcb61bc9a98dffb9ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6756bb299bd64a4c8756ee0392611ce8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7caa4e1db0ad42d798b24b3737f23fc6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i040bb11041164505a47e1dcaaf723bb1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cde7bfdcbc64b08a49fea0cfd6c4e66_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dce7e6602844c5d9fae5f312b27e08c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc410b5e83414c3aa3d99f8cfd2413d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fed83fa3cd84a30b2fbc0c3d3a7d5f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfd52b7f358e4ee28cc0c52c348d53e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40bc641f88774d5fa4e4a507ac82f713_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87d89dc42f6849f8bf05f2e1420914fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81bb32c6f29a45bbbd7f764bbf7b6bd0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13e792ced17e4aac8f2baa208d221702_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a93cf1f6efd47c68682b156780ea43f_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebae0eb40a444df390db58fc0a4f5613_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a10625444a64e53bdfa92e91315ad3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30b5afb1f0ff4c47b8c3bc25cc38daed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="i82a88f6ec9b74cc5a1e1440f7bbdd771_I20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd443fc4f014d7bbdc8e6eea80617c5_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2a13be659d44aba86b85693c76e9613_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a98a2bf0d84695bd517c220ad9693a_I20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7adc4e97d78648e5a2e35c0c4f324c4f_D20221010-20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a7ff65586d1477a96c00b182f10e2cc_I20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95409047e69d4309b31a843a98de93fb_D20221010-20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>vtl:vote</xbrli:measure></xbrli:unit><xbrli:context id="ibb7897fe5a4546198de6a00c37cae9e1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i239a3919cf64453b8bbede15f2c98d15_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d5a0313e25e42cba4239ba45c3be9ba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21c8c85594c4ad8acb51bd91760547e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f016a323654ddd9934856d79e1aff3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ec42d4c505493aa4e52b6dc975c57c_D20210425-20210425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-25</xbrli:startDate><xbrli:endDate>2021-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf59c539b0384772b43fdb06eff0b23d_I20210425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd619ffa1b7c439ab600c4800cda19f8_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief8ab69f94cf44e4842f469e423648c7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87843dae4e154ef4b4771cc451754b9d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f47deb3c97419e8cb5ad85105d41f3_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18240f287ce143488e8e2fbd786ce30c_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0e3c9196e14a1f9b8819f2efee359f_D20200101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id29dd56a8d2343fa923b6c1b453533a6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa554797e5fd4c1abf0e6346028845b6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e8e321395104641a2c172c323a23d47_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id849626157e04b04b98545bea26e1a7f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01801c5e4d9a456585f4460c4186beac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b7b2db1cbc453baca9109f8891d37e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i852628a8fa954ea88ef5db4e6f88f6c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e4d9d710764b0db319b9d428403670_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bac232d450542c29d7d8a2d9b455e83_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e6755fc97ea425cb1262657c7ed624c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae0ab47bf4b483788aa093a0ceca4cf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16d1c96118c4a888e6a5395e0e4dc9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781801a508af47b1a07f6605aa4e43d7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ef55c12c6414e5eb8e4e206bc43438d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1cbf03fbb447069ee8da6cfe57e37e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d852c9c8633413dac4a33c96a487447_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76cd333d69ab4f47b9c2c6dc6ce0348f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1948e072c9f494ba65be7555fdc7188_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c71bdc1a2f64a69a40ac91eb07d2ad7_D20221228-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:LongTermEquityIncentiveAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-26</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0106de04e136427182589f4ebdcdf181_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF84Mw_18578dea-1d06-4bbb-ad4e-1cb078575e4a">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MWE4ZjM3NGQwNjhkNGRjNGJmZmQyNTkyYjM0MjgyNDQvdGFibGVyYW5nZToxYThmMzc0ZDA2OGQ0ZGM0YmZmZDI1OTJiMzQyODI0NF8wLTAtMS0xLTQwODc0_8d7c889d-9c11-4df3-b64a-78a30dc0bb08">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xMDk5NTExNjI5ODky_b0bb7e1d-6659-4427-9e13-8d495b2d155f">March 31, 2023</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6NTlmNzAxNmIyYjM4NGQwNjhkNGNjZDMxMDQ3NjJlZGMvdGFibGVyYW5nZTo1OWY3MDE2YjJiMzg0ZDA2OGQ0Y2NkMzEwNDc2MmVkY18wLTAtMS0xLTQwODc0_5d229bf7-fd88-4b4d-9fe9-454c1f8965c0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8yNDA_c284f1ae-d97f-4ca1-abb4-b79c730a37c1">001-36201</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8yNDU_dc52c30b-6005-428a-8988-f99411e29a6c">Immunic, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.654%"><tr><td style="width:1.0%"></td><td style="width:46.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF8wLTAtMS0xLTQwODc0_da602159-55d8-4a2b-b2c8-2dbb4b85e9dc">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF8wLTItMS0xLTQwODc0_9b299a27-36ba-4881-af34-35367ea70f61">56-2358443</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF8zLTAtMS0xLTQwODc0_e7d3f82b-1fb9-4f7b-ae1e-95475c21b17d">1200 Avenue of the Americas</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF80LTAtMS0xLTQwODc0_49b9f81c-1bdb-49bd-9bae-c8a9a8225262">Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF81LTAtMS0xLTQwODc0_55ce6ab9-a06e-4456-be33-ec32b0c7353d">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF81LTEtMS0xLTQwODc0_e71f8d3b-8fea-4cb9-b50c-271a57cd80c6">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF81LTItMS0xLTQwODc0_d1810375-8024-4935-b04c-88bff10e6f93">10036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xOTYw_46573e52-538e-4e65-a061-4760419986ae">332</ix:nonNumeric>) <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xOTYx_18c68d2c-65c5-4f87-a714-3754a38dfa0b">255-9818</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.976%"><tr><td style="width:1.0%"></td><td style="width:35.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGE5ZmYxNjBkZDJlNDVlOTgwMDIzMGY5OTk3NWJlYjIvdGFibGVyYW5nZTowYTlmZjE2MGRkMmU0NWU5ODAwMjMwZjk5OTc1YmViMl8xLTAtMS0xLTQwODc0_fb4e9e79-d0d0-4aae-8f38-457509d02f67">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGE5ZmYxNjBkZDJlNDVlOTgwMDIzMGY5OTk3NWJlYjIvdGFibGVyYW5nZTowYTlmZjE2MGRkMmU0NWU5ODAwMjMwZjk5OTc1YmViMl8xLTEtMS0xLTQwODc0_87dfe6ab-e5e4-48a7-a007-a991854522ab">IMUX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGE5ZmYxNjBkZDJlNDVlOTgwMDIzMGY5OTk3NWJlYjIvdGFibGVyYW5nZTowYTlmZjE2MGRkMmU0NWU5ODAwMjMwZjk5OTc1YmViMl8xLTItMS0xLTQwODc0_c0253517-f3ca-4d43-aa51-d6b6d22137c8">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF83ODk_0719b273-7b46-435f-a560-902d6eb89acf">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xMTI2_987237a7-e591-4aa3-be33-c5d3f3a26c40">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGRkNjYwNmUzMzc1NDExYzk2ODU4ZTZjYmM1ZGMzNjYvdGFibGVyYW5nZTowZGQ2NjA2ZTMzNzU0MTFjOTY4NThlNmNiYzVkYzM2Nl8yLTAtMS0xLTQwODc0_fa1a4777-ffb2-4feb-895a-f451e54c1db5">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGRkNjYwNmUzMzc1NDExYzk2ODU4ZTZjYmM1ZGMzNjYvdGFibGVyYW5nZTowZGQ2NjA2ZTMzNzU0MTFjOTY4NThlNmNiYzVkYzM2Nl8yLTMtMS0xLTQwODc0_244d8342-7600-452d-a85b-7bfb548d70ee">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGRkNjYwNmUzMzc1NDExYzk2ODU4ZTZjYmM1ZGMzNjYvdGFibGVyYW5nZTowZGQ2NjA2ZTMzNzU0MTFjOTY4NThlNmNiYzVkYzM2Nl80LTMtMS0xLTQwODc0_ed56c5c2-0a07-437c-ae78-7e8f815028b0">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xODcw_fd7c006c-6bd4-46c1-8fbb-41503d22a88f">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 2, 2023, <ix:nonFraction unitRef="shares" contextRef="i388fe32242894fcda0ee04da0a4a7628_I20230502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xODk4_2345edd0-2116-4791-82d8-6cf8c342ec8d">44,403,838</ix:nonFraction> shares of common stock, $0.0001 par value, were outstanding.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_13">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_13">Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_13">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_16">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_19">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_22">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_28">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_61">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_73">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_76">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_79">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_82">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_85">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_88">Unregistered Sales of Equity Securities</a> and Use of Proceeds</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_88">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_88">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_94">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_97">Other Information </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_97">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0106de04e136427182589f4ebdcdf181_100">33</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:73.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNC0xLTEtMS00MDg3NA_c3819a31-1c91-4b76-b7e6-29156581fb3c">92,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNC0zLTEtMS00MDg3NA_8f782362-1562-4726-9604-f0ff74d875e9">106,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments - other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNS0xLTEtMS00MTcyOA_099f2814-86bc-42e4-be6b-ee441a5826b5">4,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNS0zLTEtMS00MTcyOA_4ec60bff-b584-4046-9af5-70cbbc25ccad">9,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNS0xLTEtMS00MDg3NA_af26ff9a-456a-48eb-b241-192d1f2b9ed5">9,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNS0zLTEtMS00MDg3NA_2502fc23-a0d4-472f-ab2a-62ff5cda6c95">9,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNi0xLTEtMS00MDg3NA_5fa5d027-233a-400a-a2d4-c6c741ecabd7">106,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNi0zLTEtMS00MDg3NA_eccd8128-24ec-48ef-afb9-e48bdb77ff67">125,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNy0xLTEtMS00MDg3NA_3558571d-a42f-4896-92d1-a797638b72ad">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNy0zLTEtMS00MDg3NA_faacef58-b005-47f7-bffb-c6d4ac0c84a8">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfOS0xLTEtMS00MDg3NA_b59ffb80-6f51-44fa-a1f8-7cf2f190eb92">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfOS0zLTEtMS00MDg3NA_6d06c48c-df1b-4b4a-9a15-98e5148235dc">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTAtMS0xLTEtNDA4NzQ_e2e9ffff-7e70-4e64-8752-22f8e5ce9c3e">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTAtMy0xLTEtNDA4NzQ_8652e48f-a5ca-48b0-9a4b-f8850cc3a40e">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTEtMS0xLTEtNDA4NzQ_ef3e7987-ee92-4daa-ba62-cf46eee9b415">108,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTEtMy0xLTEtNDA4NzQ_d4d0c1eb-79bd-45e5-bdba-516bdbe9bac6">127,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTQtMS0xLTEtNDA4NzQ_ae02cf9e-2957-4c36-80e4-a0cd076115f5">5,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTQtMy0xLTEtNDA4NzQ_58099939-c3d1-4a8c-935b-509efbae0a42">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTUtMS0xLTEtNDA4NzQ_4e385b0b-a6ee-4c2f-addc-144eee1869ce">10,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTUtMy0xLTEtNDA4NzQ_f4dff87f-db9c-459d-9a60-b78bc0d5b159">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTYtMS0xLTEtNDA4NzQ_679d9d6e-16a0-46c6-8340-f6732e50e7cc">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTYtMy0xLTEtNDA4NzQ_79d910c3-cccc-461b-96dd-5874e4800dde">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTctMS0xLTEtNDA4NzQ_117c648d-a440-4234-8b1b-72163e7385dd">16,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTctMy0xLTEtNDA4NzQ_fddb3641-86b3-40b5-9338-391cdea5ff02">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTktMS0xLTEtNDA4NzQ_a4a21c87-91ad-42d0-af29-9e24d5c887d1">1,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTktMy0xLTEtNDA4NzQ_50fda20b-37a4-4a5e-9ef9-4bf0aa4b8e03">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjAtMS0xLTEtNDA4NzQ_e1bbddc4-c427-4171-a980-802de356a291">1,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjAtMy0xLTEtNDA4NzQ_8bbe3392-542c-436d-b42c-b726abec9c54">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjEtMS0xLTEtNDA4NzQ_e4821378-2bce-4a71-9239-39253433ed2a">17,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjEtMy0xLTEtNDA4NzQ_cc458772-a295-49d1-a3f2-a84a4e040614">14,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjItMS0xLTEtNDA4NzQ_dd415815-9f82-4e00-97b2-9d1ef320afdf"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjItMy0xLTEtNDA4NzQ_8f0a7361-243a-4bf1-95c2-a58af28eb612"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV8yMQ_4689f2ac-9aaf-405f-aa1e-a065da3317d8"><ix:nonFraction unitRef="usdPerShare" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV8yMQ_600d209e-66f9-4d80-96b9-4c7a3acca4dd">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV8zNQ_4c681fff-b28e-4d29-ad2f-9629800cd4c4"><ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV8zNQ_e93a258a-d4d6-4198-9c76-6c6645c64aa7">20,000,000</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV81Mw_33ae33b6-244b-47c0-a82a-1a8bd2f53868"><ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV81Mw_bab0ed99-a0b1-4856-88dc-f53c9e30f89a"><ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV81Mw_ca6e6e7c-3de0-44bb-a623-d09b101624db"><ix:nonFraction unitRef="shares" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV81Mw_cb4864c7-c93e-4426-a474-d1cd8c2510ce">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of March 31, 2023 and December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMS0xLTEtNDA4NzQ_93df23dc-1cdf-4cbc-a5ae-e17e0144073c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMy0xLTEtNDA4NzQ_37844a12-2ae5-44c9-8688-29e213024742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF8xOA_54a0f569-9a48-4b22-a278-b0eb01825c75"><ix:nonFraction unitRef="usdPerShare" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF8xOA_68c68434-4f4a-4a66-8853-7b6cc0915651">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF8zMg_082f5670-c550-4760-8912-68e0a7856016"><ix:nonFraction unitRef="shares" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF8zMg_137e2b6e-9708-41c4-b5ca-348f107ee2eb">130,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF81Nw_375f3394-1b07-415b-b7cd-8bae8469fc62"><ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF81Nw_84adfa37-3261-4370-bd3c-5f6a48155ac7">44,403,838</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF82NA_9a80e0ff-05e0-4f2a-9011-20789d8e8edd"><ix:nonFraction unitRef="shares" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF82NA_ad653254-2ac5-4b6f-a6eb-423d268119b5">39,307,286</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMS0xLTEtNDA4NzQ_9c9cdc83-7580-4c7d-b29c-6bdce1fee60b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMy0xLTEtNDA4NzQ_e88e24d2-d42b-471a-b918-744bb2b890cb">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjYtMS0xLTEtNDA4NzQ_0be0feeb-5609-4c6b-8a5b-e0b486361f9b">429,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjYtMy0xLTEtNDA4NzQ_fea22acb-5eba-4596-86e3-f43821c05fb4">427,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjctMS0xLTEtNDA4NzQ_0bd4d0f5-5d9c-49d8-8550-8e3733f59b25">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjctMy0xLTEtNDA4NzQ_6b8f2201-cc22-43a2-b5de-2d9a6c77425d">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjgtMS0xLTEtNDA4NzQ_fe718bc9-0772-4370-ae4b-90ced30a5af4">342,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjgtMy0xLTEtNDA4NzQ_743a4d4f-a74c-42d8-acce-fb0a0ff0c15d">317,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjktMS0xLTEtNDA4NzQ_d9beaf7e-9d8c-4686-a370-22a73c3b99f1">91,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjktMy0xLTEtNDA4NzQ_e3cd0138-2965-4249-a123-f7bf8c69ddf5">113,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMzAtMS0xLTEtNDA4NzQ_32e45bc8-56c0-49c7-9516-54059da8fee0">108,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMzAtMy0xLTEtNDA4NzQ_7529600a-ce93-400d-8bc5-5518d8bf7d69">127,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMy01LTEtMS00MDg3NA_0fa193e8-03a0-4faf-984a-5102bef21deb">22,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMy03LTEtMS00MDg3NA_4e94d165-1976-4ac6-8df1-caabb3ea9941">17,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNC01LTEtMS00MDg3NA_2a9c80fe-33f4-46d5-8d80-b05818ae400e">4,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNC03LTEtMS00MDg3NA_5bd635fd-9e2c-473e-ae7b-8be1afadfcad">3,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNi01LTEtMS00MDg3NA_4e1473e9-8872-4278-af20-20cd6cc39c8e">27,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNi03LTEtMS00MDg3NA_70ec626d-6dd1-4c32-9b7a-5f4b89cd723d">21,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNy01LTEtMS00MDg3NA_8ef55275-ae0c-4b95-be53-d8bb1832e806">27,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNy03LTEtMS00MDg3NA_3e5d2d67-b53e-4045-a561-78ae04684fce">21,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfOS01LTEtMS00MDg3NA_47f854ee-9e48-4442-987f-b2229b287d0d">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfOS03LTEtMS00MDg3NA_bde8d0f9-f5f8-4f54-b595-184439ec2141">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other  income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTAtNS0xLTEtNDA4NzQ_a1b97087-a62f-48ed-9159-61fc8b5a28cd">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTAtNy0xLTEtNDA4NzQ_9218f540-7a16-4a5e-9bf0-f4fb735f24f5">620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTEtNS0xLTEtNDA4NzQ_fb9a6fc7-e491-42b7-bf08-5e5f1f6d21e2">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTEtNy0xLTEtNDA4NzQ_b7e622e3-4b60-47a2-9bdb-e5cfc89e1211">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTItNS0xLTEtNDA4NzQ_a496a62c-8d27-4527-968c-a2a980e0b52b">25,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTItNy0xLTEtNDA4NzQ_fdea558f-73c8-410a-a04b-3dfc2f07bb1f">20,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTQtNS0xLTEtNDA4NzQ_a62a9f8f-fb58-475f-92b1-5a85e8cf8989"><ix:nonFraction unitRef="usdPerShare" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTQtNS0xLTEtNDA4NzQ_af8c8ad6-aa41-45be-9e97-1edefe2c9c12">0.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTQtNy0xLTEtNDA4NzQ_4e512b1a-83f2-4de9-85e9-d6a10a6cb078"><ix:nonFraction unitRef="usdPerShare" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTQtNy0xLTEtNDA4NzQ_dbfe888a-37be-40d0-8a17-10a8c44e8a72">0.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTYtNS0xLTEtNDA4NzQ_3d13bfd9-bbce-464d-a4c0-e4ad39ad07d2"><ix:nonFraction unitRef="shares" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTYtNS0xLTEtNDA4NzQ_cd678802-affe-4bd0-bf21-afc5b8bb8aa0">43,664,783</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTYtNy0xLTEtNDA4NzQ_90b64933-dff4-4cda-992a-afd9d6a92c25"><ix:nonFraction unitRef="shares" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTYtNy0xLTEtNDA4NzQ_a4351bb5-1106-4f44-adca-996aaf6ef607">28,127,288</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:78.333%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfMi01LTEtMS00MDg3NA_a496a62c-8d27-4527-968c-a2a980e0b52b">25,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfMi03LTEtMS00MDg3NA_fdea558f-73c8-410a-a04b-3dfc2f07bb1f">20,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfNC01LTEtMS00MDg3NA_6f08a813-6b9c-429a-8293-7eab1d360ebf">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfNC03LTEtMS00MDg3NA_8e9e136c-1434-43ba-ad76-c5280072add7">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfNS01LTEtMS00MDg3NA_f388ca93-58dc-4ee4-8abc-7d2d2bf99dac">24,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfNS03LTEtMS00MDg3NA_8ac49506-9167-4c28-9a1a-2a546046ba00">20,866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_22"></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:43.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4155178cdc7140cea775b3cb724f22e5_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy0xLTEtMS00MDg3NA_f94dd559-5071-4088-ab80-6472e08ad378">39,307,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4155178cdc7140cea775b3cb724f22e5_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy0zLTEtMS00MDg3NA_9c0a0159-5c39-4df6-999e-b4a7a2d2a223">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a78d905402443da1f001d06d684730_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy01LTEtMS00MDg3NA_4f35a880-9d35-4c38-9171-caa0f05a7bdc">427,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7525d297b7a4cc7892a3e0337f40706_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy03LTEtMS00MDg3NA_a471f9ac-f1bf-4345-ac94-9aab388109e0">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca9c2ca745541f18b5bfa39907baf2d_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy05LTEtMS00MDg3NA_b2ce9c59-c2ce-41b7-b383-b0436446326e">317,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy0xMS0xLTEtNDA4NzQ_93b88882-ce10-45ea-938f-287fdacbafa3">113,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b147340b42946ed8ca10d452b403ebd_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNC05LTEtMS00MDg3NA_bd8bdf48-0676-4fc6-9d1d-a6852654a753">25,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNC0xMS0xLTEtNDA4NzQ_aece4413-54d4-406f-a0f6-90f64fae0936">25,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a8f285fcfb4ccdb68607df5a39ef94_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNS01LTEtMS00MDg3NA_c3cee257-9edd-4b9c-acb6-daf945cc0466">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNS0xMS0xLTEtNDA4NzQ_deb251d0-0d69-4180-b14f-375469477514">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37e69ee3daf843cfb2cc88838d672346_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNi03LTEtMS00MDg3NA_dedc8d17-a7c1-4f0d-8100-aa927070e252">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNi0xMS0xLTEtNDA4NzQ_ee4252d2-0983-40b4-a6de-fd463807e629">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued from exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i070ed8b98474469aaa446823ba89a721_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNy0xLTEtMS00MDg3NA_6b2a22af-8498-4c89-a5b2-9dae90991118">5,096,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51a8f285fcfb4ccdb68607df5a39ef94_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNy01LTEtMS00MDg3NA_a347426e-c461-41a8-b850-2f045719f756">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNy0xMS0xLTEtNDA4NzQ_60172a6c-561d-44fb-832a-71f9f3d9004c">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf37e7e42a624bb69e55ab937f3c9269_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS0xLTEtMS00MDg3NA_e2e29fc4-0932-40da-9008-842436a5e3ad">44,403,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf37e7e42a624bb69e55ab937f3c9269_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS0zLTEtMS00MDg3NA_f237eb99-2e63-4147-8930-4e917546a47f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ba80912a12245ab9ea6a2e70d9fcaab_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS01LTEtMS00MDg3NA_5fb015f1-cfd5-40fe-967c-93750155e8b4">429,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6dad41e267c41f9a02c026710ea4d78_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS03LTEtMS00MDg3NA_c6c0de54-4d46-415c-a64e-952f4e859dd8">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1de0f235b8444c6af6405b255d75604_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS05LTEtMS00MDg3NA_3e7fe657-66db-4bdc-acf6-75290e59a873">342,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS0xMS0xLTEtNDA4NzQ_c36de0fd-cf55-4413-b907-900e60e47d7d">91,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:42.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4656bcc3b5664116bbc2110cb69413a6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy0xLTEtMS00MDg3NA_b26b108a-c47d-4a2b-99c6-de1510c749c6">26,335,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4656bcc3b5664116bbc2110cb69413a6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy0zLTEtMS00MDg3NA_ec19ba92-d178-433c-9621-e050340fed8f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cee35bd9f1448618979791eff9cb402_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy01LTEtMS00MDg3NA_f523296c-1ef6-4304-a159-39c60647e15b">324,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80d5e7c542364e6b91f404a68cce14b0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy03LTEtMS00MDg3NA_2c8ad3b9-a558-4047-b972-5ff2b8b8d837">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5c1dfb8586a4e62b290f57d6b21e26a_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy05LTEtMS00MDg3NA_af13c68f-b635-43f1-8545-38df83f33d44">196,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25dc5ed916e5432d902a28c2209cb1cb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy0xMS0xLTEtNDA4NzQ_230e2361-6293-41b9-b6de-ed60835261dd">127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9bda424319e448ea9036287dc26278f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNC05LTEtMS00MDg3NA_0a09f92a-84ce-4467-a59c-00b7729ede43">20,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNC0xMS0xLTEtNDA4NzQ_6c2858fa-4e37-4caa-b70d-5d8f278222b4">20,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6bb7eeb17b42b6b560d2d0c4e347ca_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNS01LTEtMS00MDg3NA_44895851-8a0a-45eb-ba9d-d9fa34f04349">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNS0xMS0xLTEtNDA4NzQ_786de5bf-b315-4abf-b82f-b0050cabaf23">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fe801d7b5694d349caf6bc6c0349f78_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNi03LTEtMS00MDg3NA_3e20f13d-4d15-4f7f-9f7b-d44202650d4a">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNi0xMS0xLTEtNDA4NzQ_7a4c3e1f-2a68-497a-b6b2-8328b637c047">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief4990a110a04802be1e5c3f245e10cf_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNy0xLTEtMS00MDg3NA_36b7936e-e7c1-44df-b2ae-aa28250cb88d">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6bb7eeb17b42b6b560d2d0c4e347ca_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNy01LTEtMS00MDg3NA_d0868181-638e-4e7f-84d6-6815492086f1">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNy0xMS0xLTEtNDA4NzQ_98f4f66f-0724-4b9c-aa90-d21fbc1d3323">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - At The Market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i8b791530e898489c8c22614be6c3f978_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0wLTEtMS00MTg1My90ZXh0cmVnaW9uOjZkM2E2MzdhOWM3ZTRhNjE4ZjdkZWU3ZWY5ZDNjOTQ1XzU0OTc1NTgxMzk4Mg_e9482a98-56cc-4df2-ad6d-977a1c2fb238">918</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief4990a110a04802be1e5c3f245e10cf_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0xLTEtMS00MTg1Mw_726565c9-9547-4d97-8f57-61f60d2d92c9">2,904,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6bb7eeb17b42b6b560d2d0c4e347ca_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC01LTEtMS00MTg1Mw_f5335747-754a-4849-97f0-3a533878bda2">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0xMS0xLTEtNDE4NTM_2bd1bb7c-b31f-4118-9de9-58499c9dcf9a">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e51941010cc4d6998cdc6318cacc80e_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0xLTEtMS00MDg3NA_2ccee734-f1a7-4a9c-ae14-06c7b02d0310">29,240,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e51941010cc4d6998cdc6318cacc80e_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0zLTEtMS00MDg3NA_4c34140d-5441-4f01-8f8f-380f0fef6bf1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0b6c17ec488454d8d2239bc02df935c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC01LTEtMS00MDg3NA_dbe15817-e954-40b7-8124-182db75edc1c">355,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67dc7d2117dd4e95a74b60a330d24d53_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC03LTEtMS00MDg3NA_6b93f686-2998-4dee-beb2-e90ebfbc6d5b">310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i691582ba1b7640458a1c80bf290a4a95_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC05LTEtMS00MDg3NA_755f8441-8c31-4a6b-a1d4-95441567f383">217,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971971525ba148019837a545259b6684_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0xMS0xLTEtNDA4NzQ_4816bbf2-8ad7-4bbf-9751-c9aa23e2ed4f">137,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_28"></div><hr style="page-break-after:always"/><div style="min-height:27.36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.622%"><tr><td style="width:1.0%"></td><td style="width:79.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMy0xLTEtMS00MDg3NA_bc3d1e90-3f9c-4aca-a010-07a014f4fc03">25,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMy0zLTEtMS00MDg3NA_62d7e6a1-2a22-49af-8451-736f5725eb94">20,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfNS0xLTEtMS00MDg3NA_d6a13b9f-1a4e-4e52-9ec6-6650ab9d6d86">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfNS0zLTEtMS00MDg3NA_3bceba05-f1b0-440f-8a4d-ed06f6aff678">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign currency  loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfNi0xLTEtMS00MDg3NA_f3a8a6d1-38d2-4772-836d-ff4f3aed11e4">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfNi0zLTEtMS00MDg3NA_0e34699b-c960-49e4-9a54-44d4f5d8b4fb">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfOC0xLTEtMS00MDg3NA_a875b342-5671-436b-91c9-dc2b0076e508">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfOC0zLTEtMS00MDg3NA_2f7a3ef1-943d-424e-9a78-f4349771f21e">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTEtMS0xLTEtNDA4NzQ_f7bf1a86-fbb3-4097-987b-fdc544279933">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTEtMy0xLTEtNDA4NzQ_b391019c-542a-489a-8822-919d166f3733">2,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTItMS0xLTEtNDA4NzQ_9c542d81-4fbf-4e09-bc43-475c4ef15d61">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTItMy0xLTEtNDA4NzQ_7d969e99-e007-4c3d-a393-ef53dc30ad4c">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTMtMS0xLTEtNDA4NzQ_dd073c42-0765-434b-b595-9a2fd434f89d">2,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTMtMy0xLTEtNDA4NzQ_15edeea6-e8a5-40ff-91d6-366e8d952000">558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTQtMS0xLTEtNDA4NzQ_1e5be543-3acd-4d71-975c-fc47746480b9">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTQtMy0xLTEtNDA4NzQ_c01563fb-cda5-49b7-ab4b-fd33f27ebb57">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTUtMS0xLTEtNDA4NzQ_ea9cfa26-867a-4be4-b249-a04fa4689784">19,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTUtMy0xLTEtNDA4NzQ_906e7b59-96ce-44ab-a4a6-77acae6d26fa">20,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of investments - other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjAtMS0xLTEtNDUxMDc_61db040f-e8e9-4623-a54c-4812fca48cb4">5,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjAtMy0xLTEtNDUxMTI_4c080a72-fc86-4f04-9929-13468ee3bf56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjAtMS0xLTEtNDA4NzQ_a0b20a55-1451-4524-aaba-e24a3ea9e2a8">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjAtMy0xLTEtNDA4NzQ_7f307204-ae46-4928-94f1-6fcd01d0ac4d">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjItMS0xLTEtNDA4NzQ_bb60b431-d849-4d53-965d-fc7fa20a0532">5,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjItMy0xLTEtNDA4NzQ_cf7dc61c-b439-4aa5-8899-f76daa890a74">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock through  At The Market Sales Agreement, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjUtMS0xLTEtNDA4NzQ_ecf73b28-0865-4394-8e4a-fb39ddba00f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjUtMy0xLTEtNDA4NzQ_21f0739e-2f9c-435e-9df2-1d93fdc2ca37">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjctMS0xLTEtNDUxNDM_c3d1ef31-1793-48e5-a670-ca579ab215b8">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjctMy0xLTEtNDUxNDc_256a6e34-2e13-4e0a-bfa5-8a81d6888e64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjYtMS0xLTEtNDA4NzQ_d24796ce-5253-4d73-97af-6f3a6420a7ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjYtMy0xLTEtNDA4NzQ_59eaf773-4e52-42ab-a290-e72574fe2ef5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjgtMS0xLTEtNDA4NzQ_11ebe760-6b18-4585-9a2d-201887fe7683">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjgtMy0xLTEtNDA4NzQ_a46b3805-df27-4d3b-b6f1-8fd9743f93a5">29,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjktMS0xLTEtNDA4NzQ_b21ea866-8cb2-4ddc-9e86-064857cdb2e6">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjktMy0xLTEtNDA4NzQ_ba45ab18-4696-4bb0-89d6-2f0323b1e552">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzAtMS0xLTEtNDA4NzQ_aa64d8f2-0bd8-4842-ae1a-f545e3e0e3a6">13,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzAtMy0xLTEtNDA4NzQ_a4159d37-dfb3-468f-9a7d-3b7602b0092d">8,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzEtMS0xLTEtNDA4NzQ_2e6453fd-d2c0-4d50-9b14-4e098f0ae7cd">106,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25dc5ed916e5432d902a28c2209cb1cb_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzEtMy0xLTEtNDA4NzQ_2d37598c-e0ce-4238-bafe-af6b38bbb465">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzItMS0xLTEtNDA4NzQ_e014acb0-c78c-4afd-b9ca-5995cbb32d4f">92,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971971525ba148019837a545259b6684_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzItMy0xLTEtNDA4NzQ_3995e74a-e4bf-4c0b-a9ba-d080a4ab20fc">95,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of use asset obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzgtMS0xLTEtNDA4NzQ_f2f6c77f-122c-4869-8c9f-3d571ca2da5f">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzgtMy0xLTEtNDA4NzQ_dabc6f54-edf7-4c64-9668-c5ffbbfec9fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:27.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i0106de04e136427182589f4ebdcdf181_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTY2MQ_461a6074-2f61-4c23-b770-9fb6cea75bba" continuedAt="i05b4aaffddd7495197706c6aecbbe3c1" escape="true">Description of Business and Basis of Financial Statements</ix:nonNumeric></span></div><ix:continuation id="i05b4aaffddd7495197706c6aecbbe3c1" continuedAt="ic8451d8adf1b4b25aa8d2798e3ed8398"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company currently has approximately <ix:nonFraction unitRef="employee" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfMTY0OTI2NzQ2MDA0OQ_ca5f8040-1441-42e1-9500-6cec6827011d">73</ix:nonFraction> employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); and the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's <ix:nonFraction unitRef="lease" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="vtl:NumberOfDevelopmentPrograms" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTQ5NzU1ODIyOTEz_c2cb3399-77f5-4a51-be61-ab8d2285788e">three</ix:nonFraction> development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfMjIwOQ_2f60970d-1391-4efe-892a-303485ec6db8">342.6</ix:nonFraction> million as of March 31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfMjIzNw_21e31704-16f0-455e-a0de-90e0d7b670e3">317.3</ix:nonFraction> million as of December 31, 2022.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2023, Immunic has raised net cash of approximately $<ix:nonFraction unitRef="usd" contextRef="i1c1ce43c473547e99f3821322556a079_D20140417-20230331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTQ5NzU1ODMyMjc4_4641a744-9ada-4293-940e-31b6f4e263a4">355.6</ix:nonFraction> million from private and public offerings of preferred and common stock. As of March 31, 2023, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfMzE1OA_940b8e57-4568-4ed7-b1ca-0389aadde451">92.8</ix:nonFraction> million and investments - other of $<ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-5" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTQ5NzU1ODI0MTg2_67c3e77b-32a9-450c-86ab-c9c9241cdd9a">4.4</ix:nonFraction> million.  With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTY2NQ_bc582966-16a7-49f4-a240-388c14d6b3c6" continuedAt="i37de99804ab44fdab85ee365286a65c6" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8451d8adf1b4b25aa8d2798e3ed8398"><ix:continuation id="i37de99804ab44fdab85ee365286a65c6">statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</ix:continuation></ix:continuation> </span></div><div id="i0106de04e136427182589f4ebdcdf181_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODM_99beb41c-8a78-4a25-a80b-43aab7a0896d" continuedAt="i1f32ea6b36d14304a749219b90d36c00" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i1f32ea6b36d14304a749219b90d36c00" continuedAt="i94672dc42c02405f9df6a940c7d08d9b"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODA_927cfbeb-db68-4baf-8125-2163e9823869" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5NzM_615e8eb1-fcfb-4986-91c3-eede5976f505" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA1Mw_d201b127-545c-40b1-9853-ad4a9a4e478a" continuedAt="id86aa8829a9f4b99bb2f49d1139ca306" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S of approximately $<ix:nonFraction unitRef="usd" contextRef="ib8c1a45128834deeb7c989373a0d3a57_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA1NQ_7cdfbc18-1fe2-48da-847b-aaf3dad96267">69.2</ix:nonFraction>&#160;million, Germany of approximately $<ix:nonFraction unitRef="usd" contextRef="i170f226050a64272899ebe618949d15c_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA3MA_d8f3961d-bad6-4b9b-b377-4c19592fd34d">27.5</ix:nonFraction>&#160;million and Australia of approximately $<ix:nonFraction unitRef="usd" contextRef="i97e9633735014256ae003a713d8ab86d_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA4NQ_10834f4a-f73d-4a71-a1af-f947e4977c9c">0.4</ix:nonFraction>&#160;million as of March 31, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with <ix:nonFraction unitRef="financialinstitution" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="vtl:NumberOfFinancialInstitutionsUsedForCashDeposits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODM3NTA2_98dd0bac-5291-4d17-99c6-c55391ead651">two</ix:nonFraction> large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="i00dbb5ea0444479bb49ade8df06bec2a_I20230331" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA0OQ_1f1c1e7e-2e19-4dd6-9dc5-70bc2a6d1b52">4.7</ix:nonFraction>%. Cash and cash equivalents in Germany are earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="i883c7dc6250c4a088e84c151079c3725_I20230331" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA1NQ_65521475-efeb-4918-8eda-93550b4b4120">1.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="iea3055f090434c34a36eb882151b2a4b_I20230331" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA2MQ_24b03c08-174c-4d3a-b313-6dd2605987d1">2.75</ix:nonFraction>%.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i94672dc42c02405f9df6a940c7d08d9b" continuedAt="i5b5fa0c9b2c7424a91de3d3444f40382"><ix:continuation id="id86aa8829a9f4b99bb2f49d1139ca306" continuedAt="i055486c34f0a4951b58738b371ffbbc8"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:InvestmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA5OA_54b61336-3b39-4367-80b8-3d3a804d83e1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i68a332d0cac3410a9bf57d9923328244_I20230331" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmM5YWUyMDUzOTcyMjRjYzk5NjcwZjE1MGMwYmYzMWE4L3RhYmxlcmFuZ2U6YzlhZTIwNTM5NzIyNGNjOTk2NzBmMTUwYzBiZjMxYThfMS0yLTEtMS00MTk5Ng_87271994-4346-4389-ba5e-27e254911a77">4,351</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i3c7e38a236f14a20b7ca1838765c36ed_I20221231" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmM5YWUyMDUzOTcyMjRjYzk5NjcwZjE1MGMwYmYzMWE4L3RhYmxlcmFuZ2U6YzlhZTIwNTM5NzIyNGNjOTk2NzBmMTUwYzBiZjMxYThfMS00LTEtMS00MTk5Ng_97d8dc39-db42-46db-a4ad-1db87a335a24">9,629</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmM5YWUyMDUzOTcyMjRjYzk5NjcwZjE1MGMwYmYzMWE4L3RhYmxlcmFuZ2U6YzlhZTIwNTM5NzIyNGNjOTk2NzBmMTUwYzBiZjMxYThfMi0yLTEtMS00MTk5Ng_12ef7e11-429d-4cd4-bec6-fd6e6e59a8b7">4,351</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmM5YWUyMDUzOTcyMjRjYzk5NjcwZjE1MGMwYmYzMWE4L3RhYmxlcmFuZ2U6YzlhZTIwNTM5NzIyNGNjOTk2NzBmMTUwYzBiZjMxYThfMi00LTEtMS00MTk5Ng_3fa2ff6f-17b6-4453-b1cd-a7c7bf35f027">9,629</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i055486c34f0a4951b58738b371ffbbc8">The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="i1a7d9669b6d842baa047cfedec92e62b_I20230331" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODM3OTg2_164b7d32-45be-42b7-bd07-a5ce0f5a4e09">0.87</ix:nonFraction>% and matured in January and April, 2023, respectively.</ix:continuation>  </span></div><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODQ_fc6c1e72-9a75-4f09-b56d-49a6f3f108b7" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5NzU_dd955382-940c-457f-9123-7b5006b097dd" continuedAt="i838dcec39f9a4f20a5c52d31fa56f636" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i838dcec39f9a4f20a5c52d31fa56f636">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNDU2Mg_39b56566-c533-42eb-a49d-8d8409f1a003">three</span> to <ix:nonNumeric contextRef="i98492f22019748cd8f198e6e858d4908_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNDU2OA_c02ef43e-8865-48dc-be50-6c62ff4ec071">thirteen years</ix:nonNumeric>.</ix:continuation> Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODY1NzM0_904fd63e-c777-4c33-ae1a-6f76a47657a0">32,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODY1NzM4_f614c30d-13ac-4449-96a2-ee2124d0b3a6">21,000</ix:nonFraction> for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODE_a1b8b08a-409b-4aab-a086-7528486ea9b1" continuedAt="ie41b28e1f3da4d3590484e65e9d6cfe4" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie41b28e1f3da4d3590484e65e9d6cfe4">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTAxOA_64f24589-b419-4466-8533-9a1a6c122c59"><ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTAxOA_b0d1bd02-f33e-4e24-a687-e1fbae86227c">no</ix:nonFraction></ix:nonFraction> impairment losses during the three months ended March 31, 2023 and 2022.</span></div><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTA5OTUxMTY4NTE0MA_7d3567dd-df57-4343-9665-2c3e78fe1492" continuedAt="i5f14f1ac3e614ebcaa0d02ad9bd2417f" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f14f1ac3e614ebcaa0d02ad9bd2417f">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5b5fa0c9b2c7424a91de3d3444f40382" continuedAt="i399e02fa255049b5af0c74b5a687b84c"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $<ix:nonFraction unitRef="usd" contextRef="ieede7680228b4ced8b38713bf5d0aae3_D20221001-20221231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODcwOTA4_541e5668-9428-4e02-9d02-fd75faa8a608">33.0</ix:nonFraction>&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance.  </span></div><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5OTA_52fdd616-6a15-454b-8e7f-0ef53850f643" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC, PMS and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODU_475726bb-262e-4e1d-af9b-7d07c38e9cbb" continuedAt="i341db940f3a44ed1aa08895caa9064e6" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i341db940f3a44ed1aa08895caa9064e6">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</ix:continuation> </span></div><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzEwMg_aaaf1543-4cec-488c-b242-37a9bf2cf70b" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of <ix:nonFraction unitRef="number" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="3" name="vtl:GovernmentAssistanceRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyODA5_0fb0717a-5adb-40ff-bfd0-14f4ea559fd4">43.5</ix:nonFraction>% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to one million Euros per year.  We recognized $<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA2OA_02a33004-ad18-47ae-810a-9e720331b009">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA4Mg_eaab70bd-509d-4449-b8fd-4e7371953c3c">0.7</ix:nonFraction>&#160;million of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_78b0eeb2-f243-4b7a-92e7-d8188a462216"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_a04b00e1-dad3-420e-abd4-51c63bcf0717">other income</span></span> related to research activities performed during the three months ended March 31, 2023 and 2022, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i399e02fa255049b5af0c74b5a687b84c" continuedAt="ia02c4b6cd0b24c2f9631b5971a30f246"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODY_7195f43e-d854-4507-9d7d-e8f446cd79aa" escape="true"><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5NzY_7311d728-e3c9-43a5-b48a-a32de846b27c" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODI_2dfea6e1-e25a-4e62-934e-c9e09b1c9771" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than <ix:nonNumeric contextRef="id1bab50058db432a95481b3b7f2efba9_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODU4ODQ0_951e854a-c3e5-4b0b-b380-3417754ee19b">12</ix:nonNumeric> months and up to <ix:nonNumeric contextRef="ic8ab2a7b7c1b48578feac81bbc5e3e28_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODU4ODU4_1979db7a-d73c-4199-bc2f-e70e86093b75">60</ix:nonNumeric> months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzEwMw_3361e7fd-49e2-42ad-b9b1-b5ea4bc3b45e">three</ix:nonFraction> existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODc_85ec4fab-1007-437d-a7be-60164c032dc6" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5OTI_4c5684c5-4f11-4378-99df-d3339e845702" continuedAt="ie7074f9892b44ae8989b7f20334b03c1" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia02c4b6cd0b24c2f9631b5971a30f246"><ix:continuation id="ie7074f9892b44ae8989b7f20334b03c1"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div></ix:continuation><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzEwNQ_a2c835ff-e1ba-488b-b734-15b8476adeb9" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's <ix:nonFraction unitRef="shares" contextRef="i1b55fff4633243a0adf3497ef994823d_I20230131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzEwNw_4c961808-9ba6-4e0f-a6eb-0642fa6014ca">5,096,552</ix:nonFraction> pre-funded warrants were exercised in January 2023.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5Nzc_84a9175d-5ccd-4cea-a353-18fc140a5f77" continuedAt="i437e260117e8466bb827cd09b2676930" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i437e260117e8466bb827cd09b2676930">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</ix:continuation> </span></div><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5Nzg_f7f811a9-e597-4036-ab20-55893195ad0f" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbacc1604fd34d488c15218cae45490d_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmRmZGJhZmI2NzJjNTRiMTM4MDJlYzhmYzI3NTFlMGUyL3RhYmxlcmFuZ2U6ZGZkYmFmYjY3MmM1NGIxMzgwMmVjOGZjMjc1MWUwZTJfMi0xLTEtMS00MDg3NA_ca5e3a8d-954d-451e-a979-27a73f8fb673">5,595,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec03675d217d4626a6ad2990f79e3eb7_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmRmZGJhZmI2NzJjNTRiMTM4MDJlYzhmYzI3NTFlMGUyL3RhYmxlcmFuZ2U6ZGZkYmFmYjY3MmM1NGIxMzgwMmVjOGZjMjc1MWUwZTJfMi0zLTEtMS00MDg3NA_f6929ee2-c334-4ca9-b810-cd6660e6ef03">3,423,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODg_773c22be-44a1-474f-ac9f-464eb37624cf" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i0106de04e136427182589f4ebdcdf181_40"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RleHRyZWdpb246OTY0YjBmZWRjOWM1NGJkZjhmZTc0ZmMyYTc4OTM1YWZfMzU1_21c596ff-0958-4afe-9c2c-d638429e2fff" continuedAt="i5564cd6e9b464e5da11893d182f124aa" escape="true">Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="i5564cd6e9b464e5da11893d182f124aa"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RleHRyZWdpb246OTY0YjBmZWRjOWM1NGJkZjhmZTc0ZmMyYTc4OTM1YWZfMzUz_9d4d6ea4-4987-4ecc-9e75-9e1c2f64c24a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expense consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfMi0xLTEtMS00MDg3NA_5b73cfb1-4286-493c-8c87-08f40add691a">3,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfMi0zLTEtMS00MDg3NA_f20bb3f9-bbc6-4efd-8faf-9bc94d69c5f1">5,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfMy0xLTEtMS00MDg3NA_2f5e6026-1849-4c28-a8ff-90cb11d7b6a8">843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfMy0zLTEtMS00MDg3NA_c73282ff-be90-495a-b01b-6cd1ffbd931e">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNC0xLTEtMS00MDg3NA_653b2918-aab8-4c59-a462-4d382773d9ff">2,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNC0zLTEtMS00MDg3NA_8f11643a-4a97-41e8-9ba4-33d63eeb53cd">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNS0xLTEtMS00MDg3NA_6d16ae1e-dd14-4ec6-80c1-496fa30af509">1,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNS0zLTEtMS00MDg3NA_10ff75a2-7f96-4833-aadd-895c00d082e1">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNi0xLTEtMS00MDg3NA_9c978448-8135-4f42-ace6-a564f8d94410">9,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNi0zLTEtMS00MDg3NA_ee690171-012a-4249-98a1-0c5b3c8afb0e">9,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RleHRyZWdpb246OTY0YjBmZWRjOWM1NGJkZjhmZTc0ZmMyYTc4OTM1YWZfMzU5_9efec160-d3c4-49c3-a3e3-c75e7eb64d7b" continuedAt="i372cd67d13914d9494fcc5920b837265" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfMi0xLTEtMS00MDg3NA_ea67449f-de04-4469-8f83-a1d545e9155f">4,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfMi0zLTEtMS00MDg3NA_d4aad6c0-58c7-4191-9f48-0dd6ca3c3262">3,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfMy0xLTEtMS00MDg3NA_04a8c908-f84d-4130-894c-a2f60ded64ca">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfMy0zLTEtMS00MDg3NA_e4c2505d-a746-40d3-b663-b7c436244e51">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfNS0xLTEtMS00MDg3NA_537c8b35-0f2e-4fac-8a42-a65570167973">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfNS0zLTEtMS00MDg3NA_4ab6546c-cbe8-442a-ae13-b8c6a44d28ae">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfNi0xLTEtMS00MDg3NA_29301c11-31a8-42ee-9af1-889c483abe7c">5,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfNi0zLTEtMS00MDg3NA_12401a96-9e33-45e5-9c23-c6483f3351d6">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:continuation id="i372cd67d13914d9494fcc5920b837265"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfMi0xLTEtMS00MDg3NA_33d2de0f-e825-4100-a946-35707a03eade">9,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfMi0zLTEtMS00MDg3NA_75c88c03-dbe3-42cc-b004-621de32c9d6c">6,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfMy0xLTEtMS00MDg3NA_67bc33bc-90c5-4704-8080-1c254ca8c1bd">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfMy0zLTEtMS00MDg3NA_4893d1da-6939-4481-aa15-564d26a67623">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNC0xLTEtMS00MDg3NA_36b9384d-778d-4440-9751-438a4047895a">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNC0zLTEtMS00MDg3NA_3ab36cde-f16b-48ab-b602-51f2beb97a5a">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNS0xLTEtMS00MDg3NA_6353a546-950d-4021-8f33-d082f62d1e36">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNS0zLTEtMS00MDg3NA_724c66e1-c47d-420b-91d4-7f854c8d3b0a">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNi0xLTEtMS00MDg3NA_54de8acd-ef77-400b-ba80-efdf3ab86183">10,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNi0zLTEtMS00MDg3NA_ac991eef-dd8d-4e16-b657-846dc9755718">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RleHRyZWdpb246OTY0YjBmZWRjOWM1NGJkZjhmZTc0ZmMyYTc4OTM1YWZfMzU3_9334ac4b-075e-4740-bf41-fc93ae467abd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:72.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.389%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_e9a3cedd-15f8-4c7a-8ef7-0f175db48d87"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_ebd123b0-afec-4aee-8416-c7a76f3dc937">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0xLTEtMS00MDg3NA_45f1e059-31f1-4fff-929c-5e97e859c132">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0zLTEtMS00MDg3NA_a9437c7f-2ff7-4678-b070-e07ff5d09972">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMy0xLTEtMS00MDg3NA_47bcd048-ce22-4fe8-a4c1-10189357cad7">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMy0zLTEtMS00MDg3NA_a8ca203f-29bf-470d-b142-a84bb8c5dbc3">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfNC0xLTEtMS00MDg3NA_6736ab46-6d2f-45ed-973a-2aec7acff7d9">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9320051a944145d6816da95e5465e3c1_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfNC0zLTEtMS00MDg3NA_0772b66a-4c44-48e4-80f8-cb9a39e2bb15">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i0106de04e136427182589f4ebdcdf181_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfNTMxNw_3996461c-d7b7-4440-bdbd-a135452d88f9" continuedAt="id115e7475c6d4fe4ad8002f0471dad6f" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="id115e7475c6d4fe4ad8002f0471dad6f" continuedAt="i9437be39b314409181f4826420c01e8d">Operating Lease</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9437be39b314409181f4826420c01e8d" continuedAt="i23e29ba3fc234ac7bd3d92bd50d3b14d"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#228;felfing, Germany office and November 30,  2028 related to the new lease of a research laboratory in Planegg, Germany.  The Company formerly leased office space in Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025.  The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a <ix:nonNumeric contextRef="i89ddf70d08824b6aa7e7f010c23a3377_I20200407" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1MzUyOA_f7f5caa3-b9b8-448f-b307-bd187b6d4923">five year</ix:nonNumeric> lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a <ix:nonNumeric contextRef="i20527b0f049e4fc49cf34f6e19f78f53_D20230101-20230331" name="vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1MzUyOQ_d08de07a-6248-4608-95db-15cba37c8b63">six month</ix:nonNumeric> rent holiday at the beginning of the lease as well as a <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTA5OTUxMTY0MDk3Ng_b3bac2be-9d4e-4f7a-aa86-4c78a362650e">three month</ix:nonNumeric> rent holiday upon the <ix:nonNumeric contextRef="i805e70466a81410da29a22178dd65ce1_I20230331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTA5OTUxMTY0MDYyNA_008a7662-3c70-4d4d-bb1e-55d5d7f64b83">27</ix:nonNumeric> month extension starting May 2023. There were net additions of $<ix:nonFraction unitRef="usd" contextRef="i9a80cba888e746d6bd629ae229623ef3_D20230201-20230228" decimals="-3" name="vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1NDQzMg_92cca5e7-c726-4166-b315-d2fddca3e47a">544,000</ix:nonFraction> related to the addition of new laboratory space in Planegg, Germany in February 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be <ix:nonFraction unitRef="number" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="2" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfNTQ5NzU1ODIzMjc4_b9feda2f-05b7-430c-a0ad-9f425f10c85f">6</ix:nonFraction>% for the original leases and <ix:nonFraction unitRef="number" contextRef="i805e70466a81410da29a22178dd65ce1_I20230331" decimals="2" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfNTQ5NzU1ODIzMzEw_edc4bd6b-9161-4543-90dd-d84df0aa7708">8</ix:nonFraction>% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $<ix:nonFraction unitRef="usd" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1NDQ0Mg_69e106df-dfb8-4deb-a70e-2e6653fcba1b">195,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1NDQ1Mg_9de7b730-f787-4202-82b4-a95c4b103ffe">130,000</ix:nonFraction> for the three months ended March 31, 2023 and 2022, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfNTMyMA_b2d3fee4-dc50-4b1f-a209-b44823bdcc20" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of March 31, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:83.833%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfMC0yLTEtMS00MDg3NA_2284e582-bd39-4caa-afdf-c7f0b361e2bb">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfMS0yLTEtMS00MDg3NA_0ef7b832-8766-4e27-8701-e2aac33f3e78">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfMi0yLTEtMS00MDg3NA_be00dff1-8e65-45f7-a7e5-3d7d9bbee7c5">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfMy0yLTEtMS00MDg3NA_5a143bb6-b019-4aba-a2f1-e2bda5bcbc17">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfNC0yLTEtMS00MDg3NA_6ebe1655-26be-4581-bb25-40c8b0675085">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="vtl:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfNS0yLTEtMS00MDg3NA_10c970d1-c946-4e7d-86cd-c88e72919eb4">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfNi0yLTEtMS00MDg3NA_a5fe08ab-3116-40a8-bfe7-05b437127af4">2,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfNy0yLTEtMS00MDg3NA_2169fefc-8ec5-4069-91b3-4f69cadf492e">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfOC0yLTEtMS00MDg3NA_b5f524ca-f704-423e-ba59-9f25e9833340">2,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company has non-cancelable contractual obligations under certain agreements related to its development programs vidofludimus calcium, IMU-935 and IMU-856 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1NDQ2Mg_3edb0fe7-23f4-4796-9996-02a512c63ff9">4.4</ix:nonFraction>&#160;million, all of which is expected to be paid in 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i23e29ba3fc234ac7bd3d92bd50d3b14d"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div></ix:continuation><div id="i0106de04e136427182589f4ebdcdf181_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RleHRyZWdpb246NWZlYWMyYzc3ZjllNDdjMmJmZjFjNGU1ZjJiNTNjYzBfODcz_0364440f-4338-4d46-aeef-19f7e05045e2" continuedAt="i6211a621c1ed481fad71f67d16e3a17a" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="i6211a621c1ed481fad71f67d16e3a17a" continuedAt="if5b4a72be2724d75aef38a45ff267df3"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RleHRyZWdpb246NWZlYWMyYzc3ZjllNDdjMmJmZjFjNGU1ZjJiNTNjYzBfODc0_9c126703-aeb8-4a39-acec-3e6d73733e46" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf9be709dcc341ec81501791438f59e7_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfMy0xLTEtMS00MDg3NA_f1caaaaa-02cf-4d5d-9054-6adee812961f">69,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia456402de7a84422945fba2d356a2128_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfMy0zLTEtMS00MDg3NA_2634c361-4fb2-4b64-9c59-5890c465005f">69,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed67899138440fca6e702a05a6fe016_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfMy01LTEtMS00MDg3NA_3e27752b-09b0-491e-bbcb-bc411d34dd55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c299796fa64dfcb61bc9a98dffb9ea_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfMy03LTEtMS00MDg3NA_9e58ad80-1d85-4e00-9813-88855e8d22b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6756bb299bd64a4c8756ee0392611ce8_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfNC0xLTEtMS00MDg3NA_5d6d9f16-c609-4be0-b860-efe16e102692">69,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7caa4e1db0ad42d798b24b3737f23fc6_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfNC0zLTEtMS00MDg3NA_91c9df34-19ce-46ea-a96f-ee2897a09a93">69,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040bb11041164505a47e1dcaaf723bb1_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfNC01LTEtMS00MDg3NA_db898f51-adf9-467d-a53e-bcd5e0852339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cde7bfdcbc64b08a49fea0cfd6c4e66_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfNC03LTEtMS00MDg3NA_bf3ce315-f2f7-4fe5-83b7-0627d23e12ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dce7e6602844c5d9fae5f312b27e08c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfMy0xLTEtMS00MDg3NA_7348a4d4-9e0c-4f32-a1fb-1b2554249fdc">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc410b5e83414c3aa3d99f8cfd2413d3_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfMy0zLTEtMS00MDg3NA_1301b097-18dc-4dee-aaa2-60e9442ee6fd">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fed83fa3cd84a30b2fbc0c3d3a7d5f8_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfMy01LTEtMS00MDg3NA_2766a990-10e7-450b-babd-9effbbcd3661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd52b7f358e4ee28cc0c52c348d53e5_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfMy03LTEtMS00MDg3NA_1623710b-61d1-48bd-934f-0bd7d09b9963">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bc641f88774d5fa4e4a507ac82f713_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfNC0xLTEtMS00MDg3NA_ac5b13d7-65ca-40c8-8a25-51a4c14751d4">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d89dc42f6849f8bf05f2e1420914fe_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfNC0zLTEtMS00MDg3NA_27de326e-6f3c-41f6-b1a6-036fbadc49f4">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bb32c6f29a45bbbd7f764bbf7b6bd0_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfNC01LTEtMS00MDg3NA_8d032d6e-9b53-41d9-9134-4825bc3365f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13e792ced17e4aac8f2baa208d221702_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfNC03LTEtMS00MDg3NA_6b94ed1e-6a78-4266-8ffe-9f58445053ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="i00dbb5ea0444479bb49ade8df06bec2a_I20230331" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RleHRyZWdpb246NWZlYWMyYzc3ZjllNDdjMmJmZjFjNGU1ZjJiNTNjYzBfMTY0OTI2NzQ0NDMwMQ_9b74860e-9b2d-4c35-a4d6-3356c014fa1d">4.7</ix:nonFraction>% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of March 31, 2023. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if5b4a72be2724d75aef38a45ff267df3">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</ix:continuation>  </span></div><div id="i0106de04e136427182589f4ebdcdf181_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDYyNA_9d96bd36-bcc4-46d6-91a3-08ffdb079562" continuedAt="ice61839a334d468bbc1ec09ee22b11e2" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="ice61839a334d468bbc1ec09ee22b11e2" continuedAt="i61223e275170473bbcd90bc43cac1c31"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="i3a93cf1f6efd47c68682b156780ea43f_I20201130" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIwMTk3_f1ba99f7-04eb-4132-9693-12fbfcd35cfc">250.0</ix:nonFraction>&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of February 17, 2023, there is $<ix:nonFraction unitRef="usd" contextRef="iebae0eb40a444df390db58fc0a4f5613_I20230217" decimals="-5" name="vtl:ShelfRegistrationStatementAmountRemaining" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIwMzc2_7780d88c-6fd5-4513-bb57-63828d20c7b7">75.0</ix:nonFraction>&#160;million remaining on this shelf registration statement </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i5a10625444a64e53bdfa92e91315ad3a_I20201231" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIwNTcy_33903cf2-f9df-4825-a894-ba1da8ca238b">50.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under an at-the-market sales agreement </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i61223e275170473bbcd90bc43cac1c31" continuedAt="i1e40a22e628e4c3da7878a60acc3591a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="i30b5afb1f0ff4c47b8c3bc25cc38daed_I20230331" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIxMzU2_eb5d891e-a8df-40bc-ba72-2d7d37bd0c3d">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 2, 2023, $<ix:nonFraction unitRef="usd" contextRef="i82a88f6ec9b74cc5a1e1440f7bbdd771_I20230502" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIxNTMy_70def97d-fe60-4f83-bcf9-7514e1aa094f">8.4</ix:nonFraction>&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="icbd443fc4f014d7bbdc8e6eea80617c5_I20220531" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIyOTA1_f3cfdef4-b7f3-4216-8fdd-8707cf480995">80.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="if2a13be659d44aba86b85693c76e9613_I20230331" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIzNjQz_7e8556d5-2f19-4fdd-abc8-ae1f732088ab">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.  As of May 2, 2023, $<ix:nonFraction unitRef="usd" contextRef="i46a98a2bf0d84695bd517c220ad9693a_I20230502" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIzODE5_2114f52b-6db4-4f35-a9b6-fa64211c9f83">80.0</ix:nonFraction>&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to <ix:nonFraction unitRef="number" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="3" name="vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMjcyNQ_b19bf41a-9f97-43f0-9c01-3d4407773b55">3.0</ix:nonFraction>% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three months ended March 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2022, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMjk3OA_8189f0ba-bb4b-49da-aa30-b5ba89c99a4f">30.6</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzAzNQ_8c41fbb9-7d85-4093-b321-0d6d22e9d200">2,904,113</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzA5Mg_a00f061c-394c-44e4-af36-ca0e9baf0099">10.54</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were $<ix:nonFraction unitRef="usd" contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzE1NQ_87d22944-0b04-4ca6-9f9f-392331207c4c">29.7</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzIwMQ_8e33224c-a0b9-40a6-b055-04e67af987d4">0.9</ix:nonFraction>&#160;million.  During the second quarter of 2022, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzI3OA_8fb6416b-8994-4468-9a6f-06a422746a56">10.3</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzMzNQ_f8b394da-86c9-4d79-926d-196f5319cd71">1,300,000</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzM5Mg_8674882b-7604-4330-ab05-f7f901ccfacf">7.90</ix:nonFraction> per share. The net proceeds were $<ix:nonFraction unitRef="usd" contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzQyOA_fff0d3db-31b6-4c3b-8d7f-063a82455fed">10.0</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzQ3NA_b9961477-18b6-4a39-8dc9-de84d4964c7e">0.3</ix:nonFraction>&#160;million.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) <ix:nonFraction unitRef="shares" contextRef="i7adc4e97d78648e5a2e35c0c4f324c4f_D20221010-20221010" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI1NzA0_716a75f9-d9f2-4ebb-b7f1-49846f9383d3">8,696,552</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i9a7ff65586d1477a96c00b182f10e2cc_I20221010" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI1NzU2_06ecef17-76c4-4e8f-9a97-fdcd78129837">0.0001</ix:nonFraction> per share (the &#8220;Shares&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9a7ff65586d1477a96c00b182f10e2cc_I20221010" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI1ODA5_0e57bd2f-97c3-4d44-a61a-f968461a9365">4.35</ix:nonFraction> per Share, and (ii) <ix:nonFraction unitRef="shares" contextRef="i95409047e69d4309b31a843a98de93fb_D20221010-20221010" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI1ODMz_19f3ad3c-b2d8-41fa-9845-e5f6a3f5648a">5,096,552</ix:nonFraction> pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2MDMy_dfddbb58-c392-427c-abd0-ac099be64d55">4.34</ix:nonFraction> per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2MTEw_cb50d3a0-1383-4a1e-aada-b51fdba5bdf6">0.01</ix:nonFraction> per share of Common Stock, are immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than <ix:nonFraction unitRef="number" contextRef="i9a7ff65586d1477a96c00b182f10e2cc_I20221010" decimals="4" name="vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2MzY3_835e2523-9440-4cb7-a6e2-5451d6efbdd7">9.99</ix:nonFraction>% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of <ix:nonFraction unitRef="number" contextRef="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010" decimals="4" name="vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2NTY3_6e333bda-6469-4863-a72d-48852d49d6df">19.99</ix:nonFraction>% by providing at least <ix:nonNumeric contextRef="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010" name="vtl:EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2NTkz_cf76aa9a-0744-4661-bfd9-39cd099534c2">61</ix:nonNumeric> days&#8217; prior notice to the Company.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzcwNA_3fa4dee7-d1e2-4fe3-b94b-ceb12d42853d">130,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzc0NA_507ac777-e963-4ad3-af90-e8d603a4922c">0.0001</ix:nonFraction> per share. The voting, dividend and liquidation rights of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1e40a22e628e4c3da7878a60acc3591a"><div style="margin-top:12pt;padding-right:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="vtl:NumberOfVotesPerEachShareOfCommonStock" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzk5OQ_b5108e99-9865-4590-ae26-fb9fa40c268a">one</ix:nonFraction> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. Through March 31, 2023, <ix:nonFraction unitRef="usdPerShare" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDIwNg_19011198-35c7-41fa-8387-e4bce16ee926"><ix:nonFraction unitRef="usdPerShare" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDIwNg_8578b056-2d3d-44dd-90b1-164f715f2b92">no</ix:nonFraction></ix:nonFraction> cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-funded Warrants</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's <ix:nonFraction unitRef="shares" contextRef="i1b55fff4633243a0adf3497ef994823d_I20230131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI3NDk2_4c961808-9ba6-4e0f-a6eb-0642fa6014ca">5,096,552</ix:nonFraction> pre-funded warrants were exercised in January 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDM2OA_b43f2a7b-d147-4caf-be47-e3f19edf261e">20</ix:nonFraction> million shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDM4MQ_b57dbe0e-bdf8-43a9-a843-4158af7d96ff">0.0001</ix:nonFraction> par value preferred stock, rights and preferences to be set by the Board of Directors. <ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDQ3MQ_3ced29a2-2b5e-4e14-97e5-5cc01803da0e">No</ix:nonFraction> preferred shares were outstanding as of March 31, 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDYyNg_bc081e0f-a879-42d5-b444-294cee5bc2db" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at March 31, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb7897fe5a4546198de6a00c37cae9e1_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfMi0xLTEtMS00MDg3NA_8d15216c-5ceb-423b-8ffb-2c045a511c31">116,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i239a3919cf64453b8bbede15f2c98d15_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfMy0xLTEtMS00MDg3NA_ad5273ae-267d-4028-b218-f7f4a7dd44db">5,595,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d5a0313e25e42cba4239ba45c3be9ba_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfNS0xLTEtMS00MDg3NA_89b6f9a0-462d-4755-af70-8aa7083eff1e">43,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie21c8c85594c4ad8acb51bd91760547e_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfNi0xLTEtMS00MDg3NA_c20cff41-7aff-4f43-8d23-cfb4f6a34c56">46,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6f016a323654ddd9934856d79e1aff3_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfNy0xLTEtMS00MDg3NA_3295cbeb-fc73-4ce6-ac49-3c20c7cd8402">313,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfOC0xLTEtMS00MDg3NA_17d6652f-89a1-48ca-8fcd-48a2443408d2">6,116,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i0106de04e136427182589f4ebdcdf181_52"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjIzMQ_40a42b91-38a0-4dfa-a23e-8ef75a9af2a8" continuedAt="icf5f4d8c5b2544b197b3b1f72f8080a1" escape="true">Stock-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="icf5f4d8c5b2544b197b3b1f72f8080a1" continuedAt="i27f75b34bcb946eb8f963edb0ce04c09"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of <ix:nonFraction unitRef="number" contextRef="ic8ec42d4c505493aa4e52b6dc975c57c_D20210425-20210425" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODIxNjQ1_a990311b-fb32-4748-a61c-eae5ae0261ac">15</ix:nonFraction>% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) <ix:nonFraction unitRef="number" contextRef="ic8ec42d4c505493aa4e52b6dc975c57c_D20210425-20210425" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODIxODU4_7316e13f-cc4c-4a80-a758-4c00eb04161e">85</ix:nonFraction>% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is <ix:nonFraction unitRef="shares" contextRef="iaf59c539b0384772b43fdb06eff0b23d_I20210425" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODIyMDY4_393f5004-9e78-438b-9df1-4cd7d20ecc83">200,000</ix:nonFraction> shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued <ix:nonFraction unitRef="shares" contextRef="idd619ffa1b7c439ab600c4800cda19f8_D20210801-20210801" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfMTY0OTI2NzQ1NDc0NQ_3af3e9b0-1377-4438-91c3-df359a3668db">83,109</ix:nonFraction>  shares life-to-date under the ESPP.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ief8ab69f94cf44e4842f469e423648c7_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfMTY0OTI2NzQ1NDczNg_989dc8a2-99cd-44cd-9410-8acabf62e53d">46,000</ix:nonFraction> and  $<ix:nonFraction unitRef="usd" contextRef="i87843dae4e154ef4b4771cc451754b9d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfMTM1NQ_0a8eabf9-7c72-437f-af76-1948c7c089a0">28,000</ix:nonFraction> of expense related to the plan during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board of Directors (the"Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of <ix:nonFraction unitRef="shares" contextRef="ie3f47deb3c97419e8cb5ad85105d41f3_I20190731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI0MjI3_e6c7da5f-a419-46c4-991c-1779829d7d05">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to <ix:nonFraction unitRef="number" contextRef="i18240f287ce143488e8e2fbd786ce30c_D20190701-20190731" decimals="INF" name="vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI0NDA1_3cd1cd97-6a65-461f-b3c9-66fc643e673c">4</ix:nonFraction>% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i27f75b34bcb946eb8f963edb0ce04c09" continuedAt="i8c9d75fb716145488f556dc3feb0a124"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase of <ix:nonFraction unitRef="shares" contextRef="i18240f287ce143488e8e2fbd786ce30c_D20190701-20190731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI0NDk2_aa5e7631-9f42-43a5-9362-543cc2ff6bfd">4,900,000</ix:nonFraction> shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of <ix:nonFraction unitRef="shares" contextRef="idb0e3c9196e14a1f9b8819f2efee359f_D20200101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI0NjU1_f86c5d43-f72a-4006-9f1e-370ffb60bd19">4,408,871</ix:nonFraction> shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than <ix:nonNumeric contextRef="id29dd56a8d2343fa923b6c1b453533a6_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MDkx_17e0b1e5-b85c-4f4e-a6e5-1a6cd53e060d">ten years</ix:nonNumeric>. Incentive stock options granted to employees typically vest over <ix:nonNumeric contextRef="ifa554797e5fd4c1abf0e6346028845b6_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MTYx_20c46d12-80a4-4a9a-bd14-7603bc56065a">four years</ix:nonNumeric>. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MzAz_cd4f286e-f982-4745-9e25-2b9dea81d824">three</span> or <ix:nonNumeric contextRef="id849626157e04b04b98545bea26e1a7f_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MzEw_867bd2c2-38e5-434e-b8a3-05ff8606f07c">four years</ix:nonNumeric>. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjIyNA_122e5720-8a65-4a2a-b5bb-58bd5d18df34" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the quarters ended March 31, 2023 and 2022, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01801c5e4d9a456585f4460c4186beac_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMS0xLTEtMS00MDg3NA_79d84a5a-3839-4d9b-a78e-1d0684002a68">3,791,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01801c5e4d9a456585f4460c4186beac_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMS0zLTEtMS00MDg3NA_bb5865bc-75b8-4ccd-9151-9f148d198725">11.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMi0xLTEtMS00MDg3NA_c42f421e-58d5-4d9a-9f45-543e12818010">1,815,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMi0zLTEtMS00MDg3NA_8f8183e2-9dfc-4065-810a-0b6241f177ae">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMy0xLTEtMS00MDg3NA_82aa3fd2-a4f7-4288-8645-eba42f3c2cb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMy0zLTEtMS00MDg3NA_9d54e652-93db-49a9-b3d3-ccf740285438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNC0xLTEtMS00MDg3NA_9a0e818e-8ba0-4d9b-8b71-dfe67c25330d">11,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNC0zLTEtMS00MDg3NA_03579926-acbc-4584-83d6-d5f873860809">13.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNS0xLTEtMS00MDg3NA_a2e19251-d13b-4caa-826b-44df0e854312">5,595,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNS0zLTEtMS00MDg3NA_81974e78-bfab-4a9a-83ca-63fb6f4ab3d8">8.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNS01LTEtMS00MDg3NA_75cfb84e-2839-441d-a292-c944f7065195">8.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNS03LTEtMS00MDg3NA_4b70c091-b7ed-471f-a6a2-99811bdc519d">161,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNi0xLTEtMS00MDg3NA_93c946a6-4ee8-44f0-8782-2e9c761c5224">5,595,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNi0zLTEtMS00MDg3NA_2c524395-3875-4183-b7e0-e9110b40ec40">8.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNi01LTEtMS00MDg3NA_3415fd8f-e594-4b30-a053-a31c5768517d">8.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNi03LTEtMS00MDg3NA_fa2706d0-6ca7-4706-af3e-b7096b3b7654">161,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNy0xLTEtMS00MDg3NA_775893aa-346c-41b2-b123-ce26075f9173">1,888,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNy0zLTEtMS00MDg3NA_4699a077-52cf-42da-873c-96e38d27c297">12.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNy01LTEtMS00MDg3NA_dc62f6e1-bfcc-4014-b3a2-bc9a74cff05f">7.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNy03LTEtMS00MDg3NA_6e72ed41-9c06-47b4-be58-e545504575d0">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i852628a8fa954ea88ef5db4e6f88f6c3_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMS0xLTEtMS00MDg3NA_05a84555-e0c8-4d8a-8b39-4955d737749d">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i852628a8fa954ea88ef5db4e6f88f6c3_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMS0zLTEtMS00MDg3NA_dfc34f36-ffc5-4339-889a-027f5579ef35">13.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMi0xLTEtMS00MDg3NA_5b65922d-2ce6-4337-b3c7-2678ce56229d">1,301,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMi0zLTEtMS00MDg3NA_eea583dc-e8be-4d4f-9638-a44c60b901fe">10.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMy0xLTEtMS00MDg3NA_2958564a-005d-468d-a5ae-8280b06bf080">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMy0zLTEtMS00MDg3NA_b70608c4-aed9-4f9a-bd31-48e98eb8ba4e">5.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNC0xLTEtMS00MDg3NA_77e646a1-106f-4f63-9cfc-8bc01b83b2c7">34,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNC0zLTEtMS00MDg3NA_51a8af7e-e67d-40c2-8222-00a29870f470">12.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNS0xLTEtMS00MDg3NA_88fdbe37-9a79-4637-9e61-63ec2b51cbbf">3,423,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNS0zLTEtMS00MDg3NA_f47a2f60-24e1-4305-8f36-480a9f9a708b">12.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNS01LTEtMS00MDg3NA_41ae656b-74bd-47f0-a261-f524e56d8f67">9.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNS03LTEtMS00MDg3NA_11bf08bd-4eab-4851-af64-46d7e4a067d7">1,464,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNi0xLTEtMS00MDg3NA_52ec82f5-5e8d-4530-b90d-b03ee60d4cc3">3,423,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNi0zLTEtMS00MDg3NA_82bdac1e-e517-4351-88d7-0864a0fb0bc1">12.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNi01LTEtMS00MDg3NA_ecc464c2-9cb5-4c1d-b386-7c5d6bf13ec7">9.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNi03LTEtMS00MDg3NA_287caa0c-24db-4ab1-9f7d-3512943944df">1,464,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNy0xLTEtMS00MDg3NA_216cc72d-6da3-4198-b5d6-9cc5aada376f">952,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNy0zLTEtMS00MDg3NA_912aede6-fa0d-474d-b08b-fc314496a647">13.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNy01LTEtMS00MDg3NA_3fbcdd58-2f00-49aa-aa5e-043755c457af">8.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNy03LTEtMS00MDg3NA_54803f5f-2cbb-4c2b-b292-ba366cd0cd98">215,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="number" contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfMzcyNw_a579b711-0b93-44dc-97e2-a7059c71a277">zero</ix:nonFraction>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8c9d75fb716145488f556dc3feb0a124" continuedAt="i48ffa9d263f04cddb90fb28a82fbf38d"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the three months ended March 31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI2ODE1_26c48520-edf6-4e78-8e2c-2a657f4da572">1.15</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNDYwMg_8caaa766-7373-4c19-92e6-66adf95f4c7d">8.48</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjIyOQ_4e848378-dfb4-4fd3-a719-876acdb76a42" continuedAt="i30f10a1785354c4abcd0d75d32d3da2b" escape="true">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</ix:nonNumeric></span><ix:continuation id="i30f10a1785354c4abcd0d75d32d3da2b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfMi0xLTEtMS00MDg3NA_84d0cb2d-9670-4d42-b525-2cdb30a844e9">3.97</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfMi0yLTEtMS00MDg3NA_e8db1f40-0444-4b1d-a9d2-4abba82a0919">1.53</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfMy0xLTEtMS00MDg3NA_c3cd8793-248d-40be-9ea6-1838651a8129">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfMy0yLTEtMS00MDg3NA_1bfa87c0-0fcd-4d13-b373-ead1c056fff1">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfNC0xLTEtMS00MDg3NA_363d860a-49b4-4f32-993e-b113c3ff765f">102.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfNC0yLTEtMS00MDg3NA_f941012d-7ca5-4252-b716-238f3dd0a30b">97.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfNS0xLTEtMS00MDg3NA_fc0e480f-d184-46d6-bb8d-fa73d7d45979">6.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfNS0yLTEtMS00MDg3NA_3d42c12b-5bd6-42c8-aade-63c4ad617b14">6.02</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjIzMA_a4e8dfb9-5e4c-4adf-b499-5319c03c9a65" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:72.529%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bac232d450542c29d7d8a2d9b455e83_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfMi01LTEtMS00MDg3NA_2c28285a-2bfa-4f74-accf-3c9c235f46ee">903,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e6755fc97ea425cb1262657c7ed624c_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfMi03LTEtMS00MDg3NA_a05439b1-2efd-437f-8a97-c36989f5af06">796,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae0ab47bf4b483788aa093a0ceca4cf_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfMy01LTEtMS00MDg3NA_fd1caff3-d858-431f-b411-315ccab90893">1,076,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic16d1c96118c4a888e6a5395e0e4dc9a_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfMy03LTEtMS00MDg3NA_5f5cb429-ce6d-49b9-b016-e5d56d1fc5a7">1,273,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781801a508af47b1a07f6605aa4e43d7_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfNC01LTEtMS00MDg3NA_cd2a952e-3c12-4341-8562-a2febc319bef">1,979,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ef55c12c6414e5eb8e4e206bc43438d_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfNC03LTEtMS00MDg3NA_e75a41fe-0349-46f9-a31b-7564e5fa7778">2,069,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTA0NA_a43aa7e8-3817-4e63-90c3-0375becb59af">15.8</ix:nonFraction> million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI3NTAz_c31bdea9-12d4-49fd-bf56-5e06ab2b4b77">3.06</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital Therapies, Inc.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 12, 2019, we assumed the equity incentive plans of Vital Therapies, Inc. (&#8220;Vital&#8221;) following an exchange transaction (the &#8220;Transaction&#8221;) with Immunic AG.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the Transaction, holders of ordinary shares of Immunic AG exchanged all of their shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary. Following the Transaction, we changed our name to Immunic, Inc.  Upon completion of the Transaction with Vital on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain <ix:nonFraction unitRef="shares" contextRef="ibb1cbf03fbb447069ee8da6cfe57e37e_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTU4Nw_6873da97-c076-4955-89a9-69851d2b2c48">43,311</ix:nonFraction> shares available for grant under the 2014 Plan as of March 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan <ix:nonFraction unitRef="shares" contextRef="i8d852c9c8633413dac4a33c96a487447_I20170930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTgxMA_10367027-e601-42ed-b8a3-9fc6ec3d29e3">46,250</ix:nonFraction> shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76cd333d69ab4f47b9c2c6dc6ce0348f_D20220101-20220331" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjA5OQ_2186aee7-b6b4-4a11-922b-98b614f112dd"><ix:nonFraction unitRef="usd" contextRef="ie1948e072c9f494ba65be7555fdc7188_D20230101-20230331" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjA5OQ_51554057-97c8-4fc7-928b-557e6d8d1b8f">No</ix:nonFraction></ix:nonFraction> expense was recorded for the plans assumed from Vital during the three months ended March 31, 2023 and 2022, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i48ffa9d263f04cddb90fb28a82fbf38d">respectively.</ix:continuation></span></div><div style="margin-top:17.6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i0106de04e136427182589f4ebdcdf181_55"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81NS9mcmFnOjA0ZTdhNjMyZTUzNTRiNjhhMGRlMzQxOWRlNzk4OWMyL3RleHRyZWdpb246MDRlN2E2MzJlNTM1NGI2OGEwZGUzNDE5ZGU3OTg5YzJfMTY0OTI2NzQ0NDAzNw_06180d45-a7b5-4b00-aca3-5c0a765133db" continuedAt="i8e3c4ab4d1c54ae0b619f44fbc93c12d" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8e3c4ab4d1c54ae0b619f44fbc93c12d"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $<ix:nonFraction unitRef="usd" contextRef="i0c71bdc1a2f64a69a40ac91eb07d2ad7_D20221228-20231231" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81NS9mcmFnOjA0ZTdhNjMyZTUzNTRiNjhhMGRlMzQxOWRlNzk4OWMyL3RleHRyZWdpb246MDRlN2E2MzJlNTM1NGI2OGEwZGUzNDE5ZGU3OTg5YzJfNTQ5NzU1ODE2MDU4_09e06d09-1b9e-492a-a2c6-31dbe519bffa">30,250</ix:nonFraction> per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i0106de04e136427182589f4ebdcdf181_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81OC9mcmFnOmUxNzUzMzJkYTI5YTQ0MzNiZmMxOWU3Y2IyN2IwOWEyL3RleHRyZWdpb246ZTE3NTMzMmRhMjlhNDQzM2JmYzE5ZTdjYjI3YjA5YTJfMTY1Mw_1639a521-2eb2-49c2-883d-b2c16027ba25" continuedAt="i9c50284cd7024e4890877057ae6ad6e1" escape="true">Subsequent Events </ix:nonNumeric></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i9c50284cd7024e4890877057ae6ad6e1"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appointment of Richard Rudick, M.D. to Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, the Company announced the appointment of Dr. Richard Rudick as a member of the Board of Directors of the Company, effective as of April 26, 2023. As a Class III director, Dr. Rudick&#8217;s term lasts until the Company&#8217;s 2023 Annual Meeting of Stockholders . Dr. Rudick is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr. Rudick and any other persons pursuant to which he was selected as a director.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with his appointment as director, Dr. Rudick was granted a long-term equity incentive grant in the form of an option (the &#8220;Option&#8221;) to purchase a total of <ix:nonFraction unitRef="shares" contextRef="i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81OC9mcmFnOmUxNzUzMzJkYTI5YTQ0MzNiZmMxOWU3Y2IyN2IwOWEyL3RleHRyZWdpb246ZTE3NTMzMmRhMjlhNDQzM2JmYzE5ZTdjYjI3YjA5YTJfMTY0OTI2NzQ2MDc5Ng_980fcbe7-17c2-44b0-941f-b99bd5ea60f2">32,000</ix:nonFraction> shares of the Company&#8217;s common stock on April 26, 2023. The option to purchase <ix:nonFraction unitRef="shares" contextRef="i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81OC9mcmFnOmUxNzUzMzJkYTI5YTQ0MzNiZmMxOWU3Y2IyN2IwOWEyL3RleHRyZWdpb246ZTE3NTMzMmRhMjlhNDQzM2JmYzE5ZTdjYjI3YjA5YTJfMTY0OTI2NzQ2MDgwNA_3a8eb9dc-2004-467c-909b-cd562ecfa137">32,000</ix:nonFraction> shares vests in monthly increments over a period of <ix:nonNumeric contextRef="i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81OC9mcmFnOmUxNzUzMzJkYTI5YTQ0MzNiZmMxOWU3Y2IyN2IwOWEyL3RleHRyZWdpb246ZTE3NTMzMmRhMjlhNDQzM2JmYzE5ZTdjYjI3YjA5YTJfMTY0OTI2NzQ2MDgxMQ_a763ebb9-102b-4469-9f03-acb07d55de95">three years</ix:nonNumeric> from the grant date. The Option has an exercise price per share equal to the closing price of the Company&#8217;s common stock on The Nasdaq Stock Market on the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Additionally, Dr. Rudick and the Company entered into the Company&#8217;s standard form of indemnification agreement for directors and executive officers.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i0106de04e136427182589f4ebdcdf181_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and notes thereto included in Item&#160;1 &#8220;Financial Statements&#8221; in this Quarterly Report and audited Consolidated Financial Statements for the years ended December 31, 2022 and 2021 of Immunic, Inc. filed with the Securities and Exchange Commission ("SEC"), on our Annual Report on Form 10-K on February 23, 2023. As used in this report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; or &#8220;Immunic&#8221; refer to Immunic, Inc. and its subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical information, this Quarterly Report includes forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to certain risks and uncertainties, many of which are beyond our control. Such statements include, but are not limited to, statements preceded by, followed by or that otherwise include the words, &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; or similar expressions and the negatives of those terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements discuss matters that are not historical facts. Our forward-looking statements involve assumptions that, if they ever materialize or prove correct, could cause our results to differ materially from those expressed or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implied by such forward-looking statements. In this Quarterly Report, for example, we make forward-looking statements, among others, regarding potential strategic options; financial estimates and projections; and the sufficiency of our capital resources to fund our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The inclusion of any forward-looking statements in this Quarterly Report should not be regarded as a representation that any of our plans will be achieved. Our actual results may differ from those anticipated in our forward-looking statements as a result of various factors, including those noted below under the caption &#8220;Part II, Item 1A-Risk Factors,&#8221; and the differences may be material. These risk factors include, but are not limited to statements relating to our two development programs and the targeted diseases; the potential for vidofludimus calcium and IMU-856 to safely and effectively target diseases; the nature, strategy and focus of the Company; expectations regarding our capitalization and financial resources; the development and commercial potential of any product candidates of the Company; and our ability to retain certain personnel important to our ongoing operations and to maintain effective internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update such statements to reflect events or circumstances after the date hereof, except as required by law.</span></div><div id="i0106de04e136427182589f4ebdcdf181_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic, Inc. ("Immunic," &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gr&#228;felfing near Munich, Germany. We currently have approximately 73 employees.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); and the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the potential indications, clinical targets and clinical development status of our three product candidates:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><img src="vtl-20230331_g1.jpg" alt="pipeline_05_2023_2000px.jpg" style="height:261px;margin-bottom:5pt;vertical-align:text-bottom;width:654px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our most advanced drug candidate, vidofludimus calcium (IMU-838), is being tested in several ongoing MS trials as part of its overall clinical program in order to support a potential approval for patients with MS in major markets. The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (&#8220;RMS&#8221;), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and the supportive Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (&#8220;PMS&#8221;) are ongoing and actively enrolling patients. Our current </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expectation is to report data from the interim analysis of the CALLIPER trial in the second half of 2023 and to read-out top-line data at the end of 2024. Moreover, we currently expect to report data from the interim analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials at the end of 2025. Although we currently believe that each of these goals is achievable, they are each dependent on numerous factors, most of which are not under our direct control and can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If approved, we believe that vidofludimus calcium, with combined anti-inflammatory, anti-viral, and neuroprotective effects, has the potential to be a unique treatment option targeted to the complex pathophysiology of MS. Multiple publications from 2022 have highlighted the enhanced understanding of the triggers and ongoing neuronal destruction of MS, namely, that MS is triggered by infection from Epstein-Barr virus (&#8220;EBV&#8221;) followed by cross-reactive antibody production and associated auto-inflammation and neuronal damage. Vidofludimus calcium is a known inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;), which is a key enzyme in the metabolism of overactive immune cells and virus-infected cells. This mechanism is associated with the anti-inflammatory and anti-viral effects of vidofludimus calcium. Additionally, recent evidence indicates that vidofludimus calcium activates a yet-to-be-disclosed target with direct neuroprotective properties, which may enhance its potential benefit for patients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that the combined mechanisms of vidofludimus calcium are unique in the MS space and support the therapeutic performance shown in our Phase 2 EMPhASIS trial in relapsing-remitting multiple sclerosis patients, in particular, via data illustrating the potential to reduce magnetic resonance imaging lesions, prevent relapses, reduce the rate of disability progression, and reduce levels of serum neurofilament light chain (&#8220;NfL&#8221;), an important biomarker of neuronal death. Vidofludimus calcium has shown a consistent pharmacokinetic, safety and tolerability profile and has already been exposed to more than 1,400 human subjects and patients in either of the drug&#8217;s formulations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IMU-856 is an orally available and systemically acting small molecule modulator that targets Sirtuin 6 ("SIRT6"), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. Based on preclinical data, we believe this compound may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other intestinal barrier function associated diseases. We believe that, because IMU-856 has been shown in preclinical investigations to avoid suppression of immune cells, it may therefore have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Data from the final portion of a Phase 1 clinical trial in celiac disease patients during periods of gluten-free diet and gluten challenge demonstrated positive effects for IMU-856 over placebo in four key dimensions of celiac disease pathophysiology: protection of the gut architecture, improvement of patients&#8217; symptoms, biomarker response, and enhancement of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial. We are preparing clinical Phase 2b testing of IMU-856 in ongoing active celiac disease, while also considering further potential clinical applications in other gastrointestinal disorders.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic has selected IMU-381 as a development candidate to specifically address the needs of gastrointestinal diseases. IMU-381 is a next generation molecule with improved overall properties, supported by a series of chemical derivatives. IMU-381 is currently in preclinical testing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional antiviral-directed development activities remain ongoing through preclinical research examining the potential to treat a broad set of viral indications with new antiviral molecules. We are exploring several options to possibly support further development of our antiviral portfolio, including a potential spin-off into a new or existing company and potential licensing transactions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to lead most of our research and development activities from our Gr&#228;felfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams conduct their activities. Due to these teams' key relationships with local and international service providers, we anticipate that this will result in more timely and cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne, Australia to expedite the early clinical trials for  IMU-856. We also conduct preclinical work in Halle/Saale, Germany through a collaboration with the Fraunhofer Institute.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of our clinical trials to meet their endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms, if at all, to complete the development and commercialization of our three development programs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Strategy </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on the development of new molecules that maximize the therapeutic benefits for patients by uniquely addressing biologically relevant immunological targets. We take advantage of our established research and development infrastructure and operations in Germany and Australia to more efficiently develop our product candidates in indications of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">high unmet need and where the product candidates have the potential to elevate the standard of care for the benefit of patients. Given the mechanisms of action and the data generated for our product candidates, to date, we continue to execute on the clinical development of our programs for established indications as well as explore additional indications where patients could potentially benefit from the unique profiles of each product candidate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently focused on maximizing the potential of our development programs through the following strategic initiatives:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Executing the ongoing Phase 3 ENSURE and Phase 2 CALLIPER clinical trial programs of vidofludimus calcium in MS.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Exploring potential next steps for vidofludimus calcium in UC and other inflammatory bowel disease indications.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Executing the IMU-856 development program, including preparation of a Phase 2b clinical trial in patients with ongoing active celiac disease.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued preclinical research to complement the existing clinical activities, explore additional indications for future development, and where appropriate, generate additional molecules for future development.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Facilitating readiness for potential commercial launch of our product candidates through targeted and stage-appropriate pre-commercial activities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluating potential strategic collaborations for each product candidate in order to complement our existing research and development capabilities and to facilitate potential commercialization of these product candidates by taking advantage of the resources and capabilities of strategic collaborators in order to enhance the potential and value of each product candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. We have an accumulated deficit of approximately $342.6 million as of March 31, 2023. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the development of our product candidates and add personnel necessary to advance our pipeline of product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2023, we have raised net cash of approximately $355.6 million from private and public offerings of preferred and common stock. As of March 31, 2023, we had cash and cash equivalents of approximately $92.8 million and investments - other of $4.4 million.  With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Presentation of Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2023, we announced the presentation of clinical and preclinical data for IMU-856 as a virtual e-poster at Digestive Disease Week 2023. Included in this presentation were new data on IMU-856&#8217;s mode of action as a potent modulator of SIRT6, a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, we announced positive results from the part C portion of our Phase 1 clinical trial of IMU-856 in patients with celiac disease. The data demonstrated positive effects for IMU-856 over placebo in four key dimensions of celiac disease pathophysiology: protection of the gut architecture, improvement of patients&#8217; symptoms, biomarker response, and enhancement of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that this data set provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture. The data provides first clinical evidence that IMU-856&#8217;s ability, observed in preclinical studies, to re-establish proper gut cell renewal translates into clinical benefits for patients with celiac disease. Most importantly, the observed protection of intestinal villi from gluten-induced destruction, independent of targeting immune mechanisms involved specifically in celiac disease, appears to be unique among proposed therapeutic approaches and may be applicable to other gastrointestinal diseases such as UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appointment of Richard Rudick, M.D. to Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, we announced the appointment of Dr. Richard Rudick as a member of our Board of Directors, effective as of April 26, 2023. As a Class III director, Dr. Rudick&#8217;s term lasts until our 2023 Annual Meeting of Stockholders to be held on June 28, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Richard Rudick, age 72, has over 35 years of experience in the biopharmaceutical industry and academic medicine. Since January 2023, Dr. Rudick has been the President and CEO of Astoria Biologic, a private biotechnology company developing novel therapies for multiple sclerosis. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014 until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January 1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine. The Nominating and Corporate Governance Committee and the Board believe that Dr. Rudick&#8216;s extensive leadership in clinical research and development of multiple sclerosis treatments provides valuable clinical, strategy and management skills to the Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Not Standing for Re-Election at the 2023 Annual Meeting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on April 26, 2023, Dr. Vincent Ossipow notified the Board that he plans to retire from the Board at the end of his current term and will not stand for re-election at the 2023 Annual Meeting. Dr. Ossipow will continue to serve as a member of the Board until the date of the Annual Meeting, and as a member of the Nominating and Corporate Governance Committee until the date of the Annual Meeting, June 28, 2023. Dr. Ossipow&#8217;s decision not to stand for re-election was not the result of any disagreement with the Company or its management on any matter relating to the Company&#8217;s operations, policies or practices.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe UC</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, we reported positive data from the maintenance phase of our Phase 2b CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe UC. The data showed a dose-linear increase in clinical remission as compared to placebo at week 50. Moreover, an exploratory statistical analysis confirmed the 30 mg dose of vidofludimus calcium to be statistically superior (p=0.0358) in achieving clinical remission at week 50, with a 33.7% absolute improvement over placebo. A similar effect on clinical remission rates at week 50 was also found among those patients who received corticosteroids during the induction phase. Finally, a dose-linear increase in endoscopic healing was observed, with the 30 mg dose of vidofludimus calcium being associated with a 37.8% absolute improvement over placebo and also achieving statistical significance in an exploratory statistical analysis (p=0.0259).</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that the maintenance phase data of CALDOSE-1 confirms vidofludimus calcium's activity in the absence of chronic corticosteroid co-administration. Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in the maintenance phase of this trial was observed to be safe and well-tolerated.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deprioritization of Izumerogant (IMU-935) Development Program</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to focus on the rapidly advancing vidofludimus calcium and IMU-856 programs, and considering the totality of available data for izumerogant, including changes in expected time to market and increased complexity of potential further development in this competitive field, we announced on April 5, 2023 to focus our resources and, therefore, deprioritized the clinical portion of our izumerogant development program in psoriasis and castration-resistant prostate cancer.</span></div><div id="i0106de04e136427182589f4ebdcdf181_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates or achieving market acceptance and commercial success for any product that does receive regulatory approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research activities, including our product discovery efforts and the development of our product candidates. Our research and development expenses include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses and milestone payments incurred under arrangements with third parties, such as CROs, contract manufacturing organizations, collaborations with partners, consultants, and our scientific advisors; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal personnel expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are capitalized as prepaid expenses and expensed when the service has been performed or when the goods have been received.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in March 2016, we have spent a total of approximately $237.8 million in research and development expenses through March 31, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. We have spent the majority of our research and development resources on vidofludimus calcium, our lead development program, for clinical trials in MS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Immunic AG received a grant of up to approximately $730,000 from the German Federal Ministry of Education and Research, in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project.  The grant funds have been used to fund a three-year research project relating to autoimmune diseases by us and our three project partners.  Since the inception of the grant, we have recorded $611,000 of income in total of which $0 and $59,000 were recorded in the quarters ending March 31,  2023 and 2022, respectively, and were classified in Other Income in the accompanying consolidated statement of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development expenses are expected to increase in the foreseeable future as we continue to conduct ongoing research and development activities, initiate new preclinical and clinical trials and build our pipeline of product candidates.   Our research and development expenses may also increase in the foreseeable future due to the current inflationary environment as well as supply chain shortages, which result in increased costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the development and regulatory success of each product candidate, and ongoing assessments as to each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, professional fees for legal, accounting, tax and business consulting services, insurance premiums and stock-based compensation. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our money market funds and bank accounts which are a portion of our cash and cash equivalents balance. Our interest income has been increasing throughout 2022 and 2023 as global interest rates have been increasing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of a research and development tax incentive related to clinical trials performed in Australia, a German Government research and development grant and foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future.  The intercompany loan between Immunic Inc. and Immunic AG was settled on September 28, 2022 through an equity infusion from Immunic Inc. to Immunic AG.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2023 and 2022 </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the three months ended March 31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,435&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,816)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,272)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,808)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,464)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $5.5 million during the three months ended March 31, 2023, as compared to the three months ended March 31, 2022. The increase reflects (i) a $4.0 million increase in external development costs related to the Phase 3 program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $0.9 million increase in external development costs related to the Phase 2 trial of vidofludimus calcium in progressive multiple sclerosis, (iii) a $0.9 million increase in external development costs related to the Phase 1 clinical trial of IMU-856, (iv) a $0.4 million increase in personnel expense in research and development related to an increase in headcount, $0.1 million of which was due to non-cash stock based compensation and (v) a $0.2 million increase related to costs across numerous categories. The increases were partially offset by (i)  a decrease of $0.6 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis and (ii) a decrease of $0.3 milllion related to the IMU-935 program.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses increased by $0.3 million during the three months ended March 31, 2023, as compared to the three months ended March 31, 2022. The increase was primarily due to (i) a $0.2 million increase in travel expense and (ii) a $0.3 million increase across numerous categories. The increases were partially offset by a decrease of $0.2 million in non-cash stock based compensation expense. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income increased by $1.4 million during the three months ended March 31, 2023, as compared to the three months ended March 31, 2022. The increase was primarily attributable to (i) a $1.1 million research allowance attributable to tax year 2021 from the German Federal Ministry of Finance and (ii) a $0.8 million increase in interest income as a result of higher interest rates. The increase was partially offset by (i) a $0.3 million decrease in foreign exchange gains and (ii) a $0.2 million decrease in research and development tax incentives for clinical trials in Australia as a result of decreased spending on clinical trials in Australia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016.  We have an accumulated deficit of approximately $342.6 million at March 31, 2023 and $317.3 million as of December 31, 2022.  Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the development of our product candidates and add personnel necessary to operate as a company with an advanced pipeline of product candidates. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2023, we have raised net cash of approximately $355.6 million from private and public offerings of preferred and common stock. As of March 31, 2023, we had cash and cash equivalents of approximately $92.8 million and investments - other of $4.4 million. With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement").   The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of May 2, 2023, there is $75.0&#160;million remaining on this shelf registration statement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink as agent ("December 2020 ATM"). We have used and intend to continue to use the net proceeds from the December 2020 ATM to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 2, 2023, $8.4 million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Securities LLC as agent. We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Securities LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Securities LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 2, 2023, $80.0 million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any ATM activity during the three months ended March 31, 2023.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2022, we raised gross proceeds of $30.6 million pursuant to the December 2020 ATM through the sale of 2,904,113 shares of common stock at a weighted average price of $10.54 per share. The net proceeds from the December 2020 ATM were $29.7 million after deducting underwriter commissions of $0.9 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we have not generated any revenue from product sales and we do not know when, or if, we will generate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. At the same time, we expect our expenses to increase as we continue the ongoing research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. We also incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future expenses and capital requirements are difficult to forecast and will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options and transactions, if any;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of any future litigation;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation expenses related to retention and termination of personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, duration, results and costs of research and development and ongoing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of future regulatory submissions;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of developing and validating the manufacturing processes for any potential product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of any commercialization activities, including reimbursement, marketing, sales and distribution costs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we pursue;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with being a public company;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount from the sales of, or royalties on, any future products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of stock offerings, debt financings, strategic alliances, collaborations and licensing arrangements. Recent developments, however, will make it more difficult and costly for us to obtain funding for our cash needs. We do not expect to achieve revenue from product sales prior to the use of all the net proceeds from our public and private offerings to date. We do not have any committed external source of funds. Additional funds may not be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of our stockholders will be diluted and it may be on terms that are not favorable to us or our stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales of equity securities will also be more difficult for at least the foreseeable future because of general volatility in the equity markets for companies like us, as well as the significant decline in the trading price of our stock following our announcement on October 21, 2022 of the Phase 1b interim analysis of izumerogant in moderate-to-severe psoriasis.  Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt or other terms that are not favorable to us or our stockholders. Also, the cost of debt financing has increased due to the rise in interest rates beginning in March 2022.  If we raise additional funds through collaborations and licensing arrangements with third parties, we would expect to relinquish substantial rights to our technologies or our future products, or grant licenses on terms that may not be favorable to us. If we were to complete a merger, we may relinquish all control over the organization and could experience detrimental tax effects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to raise adequate funds, we may have tocurtail our product development programs and liquidate some or all of our assets. Any of these factors could harm our operating results and could result in substantial declines in the trading price of our common stock.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we had approximately $92.8&#160;million in cash and cash equivalents and $4.4 million of investments - other. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the three months ended March 31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2023, operating activities used $19.5 million of cash. The use of cash primarily resulted from (i) our net loss of $25.3 million adjusted for non-cash charges of $2.0 million related to stock-based compensation, $0.5 million related to unrealized foreign currency loss and depreciation and amortization and (ii) a $3.3 million net decrease in our operating assets and liabilities. Changes in our operating assets and liabilities during the three months ended March 31, 2023 consisted primarily of  a decrease of $3.2 million in accounts payable and other accrued expenses as well as a $0.1 million decrease in our other current assets and prepaid expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2022, operating activities used $20.7 million of cash. The use of cash primarily resulted from (i) our net loss of $20.8 million adjusted for non-cash charges of $2.2 million related to stock-based compensation, unrealized foreign currency loss and depreciation and amortization and (ii) a $2.1 million net increase in our operating assets and liabilities. Changes in our operating assets and liabilities during the three months ended March 31, 2022 consisted primarily of  an increase of $2.3 million increase in our other current assets and prepaid expenses as a result of the continued startup of our Phase 3 trials in relapsing multiple sclerosis and a Phase 2 trial in progressive multiple sclerosis, partially offset by an increase of $0.2 million in accounts payable and other accrued expenses.  </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, net investing activities provided $5.3 million of cash, primarily due to the sale of $5.4 million of time deposits partially offset by the purchase of $104,000 of property and equipment.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was  $12,000 during the three months ended March 31, 2022, which was related to the purchase of property and equipment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $51,000 during the three months ended March 31, 2023 consisting of net cash proceeds from the issuance of common stock related to the exercise of pre-funded warrants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $29.6 million during the three months ended March 31, 2022 consisting of net cash proceeds from the sale of common stock under the ATM. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 31, 2023, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 - Collaboration Arrangements of the Notes to the Financial Statements regarding the Company&#8217;s obligations under the option agreement with Daiichi Sankyo, which includes the potential payment of future development, regulatory and sales milestone payments, as well as royalties related to IMU-856</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of March 31, 2023:</span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:84.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we have non-cancelable contractual obligations under certain agreements related to our development programs vidofludimus calcium, IMU-935 and IMU-856 totaling approximately $4.4&#160;million, all of which is expected to be paid in 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements are prepared in conformity with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. We have reviewed these critical accounting policies and related disclosures with the Audit Committee of our Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three months of 2023, there were no significant changes in our critical accounting policies or in the methodology used for estimates. Our significant accounting policies are described in more detail in (i) Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report and (ii) Note 2 to our audited consolidated financial statements for the years ended December 31, 2022 and 2021 filed in our Annual Report on Form 10-K on February 23, 2023.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i0106de04e136427182589f4ebdcdf181_73"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash and cash equivalents and investments of $97.1 million as of March 31, 2023, which were held for working capital purposes. We do not enter into investments for trading or speculative purposes. We do not believe that we have any material exposure to changes in the fair value of these investments as a result of changes in interest rates due to their short-term nature. However, $23.2 million of these funds are held in German bank accounts that were earning between 1.5%-2.75% interest as of March 31, 2023.  Decreases or increases in interest rates, however, will reduce or increase future investment income, respectively, to the extent we have funds available for investment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development operations are conducted in our facilities in Germany. We have entered into and may continue to enter into international agreements, primarily related to our clinical studies. Accordingly, we have exposure to foreign currency exchange rates and fluctuations between the U.S. dollar and foreign currencies, primarily the euro and the Australian dollar, which could adversely affect our financial results, including income and losses as well as assets and liabilities. To date, we have not entered into, and do not have any current plans to enter into, any foreign currency hedging transactions or derivative financial transactions. Our exposure to foreign currency risk will fluctuate in future periods as our research and clinical development activities in Europe and Australia change. We currently maintain a significant amount of our assets outside of the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of our foreign subsidiaries are the applicable local currencies. Accordingly, the effects of exchange rate fluctuations on the net assets of these operations are accounted for as translation gains or losses in accumulated other comprehensive income (loss) within stockholders&#8217; equity.  Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). Our German subsidiary is currently a significant portion of our business and, accordingly, a change of 10% in the currency exchange rates, primarily the euro, could have a material impact on their financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although operating in local currencies may limit the impact of currency rate fluctuations on the results of operations of our German and Australian subsidiaries, rate fluctuations may impact the consolidated financial position as the assets and liabilities of our foreign operations are translated into U.S. dollars in preparing our consolidated balance sheets. As of March 31, 2023, our German and Australian subsidiaries had net current assets (defined as current assets less current liabilities), subject to foreign currency translation risk, of $21.6 million. A decrease of approximately $2.2 million in net current assets would result as of March 31 2023, from a hypothetical 10% adverse change in quoted foreign currency exchange rates, primarily due to the euro.  In addition, a 10% change in the foreign currency exchange rates for the three months ended March 31, 2023, would have impacted our net loss by approximately $2.2 million, primarily due to the euro.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced a general increase in costs as a result of global inflation, however, we do not believe that inflation and changing prices had a material impact on our results of operations for any periods presented herein.</span></div><div id="i0106de04e136427182589f4ebdcdf181_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-bottom:8.85pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Principal Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934, as amended ("the Exchange Act"), as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and our Principal Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:0.2pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i0106de04e136427182589f4ebdcdf181_79"></div><div><span><br/></span></div><div id="i0106de04e136427182589f4ebdcdf181_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II - OTHER INFORMATION</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us, that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, we may be involved in various legal proceedings from time to time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition, or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Events involving limited liquidity, defaults, non-performance, or other adverse developments that affect financial institutions, transactional counterparties, or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have recently led to market-wide liquidity problems. In March 2023, Silicon Valley Bank, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although financial regulators have taken measures to prevent further bank closures, these concerns risks remain. If we were to borrow money in the future and if any of our lenders or counterparties to any such instruments were to be placed into receivership, or if we had cash deposits at any such banks, we may be unable to access our funds. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we assess our banking and financing relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations, clinical programs and product development could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit, or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and stricter financial and operating covenants, or limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws if, for example, we were unable to obtain access to deposits used for payroll. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i0106de04e136427182589f4ebdcdf181_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0106de04e136427182589f4ebdcdf181_91"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0106de04e136427182589f4ebdcdf181_94"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i0106de04e136427182589f4ebdcdf181_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0106de04e136427182589f4ebdcdf181_100"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm">Amended and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm">Certificate</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm"> of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm">Third Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_ex4-2.htm">2019 Omnibus Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 20, 2019</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522001344/e621975_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-1.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-2.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-3.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit2312023.htm">Consent of Baker Tilly U.S. LLP, Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Power of Attorney (included on the signature page)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-33123xexhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-33123xexhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-3x31x23xexhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-33123xexhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Database.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i0106de04e136427182589f4ebdcdf181_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;11, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Daniel Vitt                                 </span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Daniel Vitt</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Chief Executive Officer and President</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exhibit2312023.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2d831fcd7ef94a64b7c93879293dcdbc_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the Registration Statements on Form S&#8209;3 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">225230, 333-250083, 333-255303, and 333-268737), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Form S&#8209;4 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">229510</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">), and Form S-8 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">233864 and 333-258235</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">) of Immunic, Inc. of our report dated February 23, 2023, relating to the consolidated financial statements of Immunic, Inc., which appears in this annual report on Form 10-K for the year ended December 31, 2022. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">s&#47; Baker Tilly US, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Minneapolis, Minnesota </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">February 23, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>imux-33123xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if018f87880b0481f8460be3aac97eff4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Vitt, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>imux-33123xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7120a2af7ec04f729e8b771fa2ce7cc3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Glenn Whaley, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>imux-3x31x23xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia695d2c4fbaf47f8b6e98bfb34b229dd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel Vitt, as Chief Executive Officer and President of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>imux-33123xexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id98a16d78cae4f0dbf721e2f5f419d99_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-K of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Glenn Whaley as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 11, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>vtl-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:40f41647-d1d2-404b-8a31-83c86744a64e,g:f57fa659-71e4-427e-b4f1-2f0099ec97ac-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtl="http://vitaltherapies.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vitaltherapies.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://vitaltherapies.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofCashFlows" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatements" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements">
        <link:definition>0000009 - Disclosure - Description of Business and Basis of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetails" roleURI="http://vitaltherapies.com/role/BalanceSheetDetails">
        <link:definition>0000011 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies">
        <link:definition>0000012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://vitaltherapies.com/role/FairValue">
        <link:definition>0000013 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://vitaltherapies.com/role/CommonStock">
        <link:definition>0000014 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions">
        <link:definition>0000016 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://vitaltherapies.com/role/SubsequentEvents">
        <link:definition>0000017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000018 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000019 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsTables" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables">
        <link:definition>0000020 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000021 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://vitaltherapies.com/role/FairValueTables">
        <link:definition>0000022 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://vitaltherapies.com/role/CommonStockTables">
        <link:definition>0000023 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables">
        <link:definition>0000024 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatementsDetails" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails">
        <link:definition>0000025 - Disclosure - Description of Business and Basis of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInvestmentsDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails">
        <link:definition>0000027 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
        <link:definition>0000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail">
        <link:definition>0000029 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccountsPayableDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail">
        <link:definition>0000030 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccruedExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail">
        <link:definition>0000031 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail">
        <link:definition>0000032 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000033 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails">
        <link:definition>0000034 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1">
        <link:definition>0000034 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000035 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueAdditionalInformationDetail" roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail">
        <link:definition>0000036 - Disclosure - Fair Value - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockShelfRegistrationStatementDetails" roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails">
        <link:definition>0000037 - Disclosure - Common Stock - Shelf Registration Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityOfferingDetails" roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails">
        <link:definition>0000038 - Disclosure - Common Stock - Equity Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockCommonStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails">
        <link:definition>0000039 - Disclosure - Common Stock - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPrefundedWarrantsDetails" roleURI="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails">
        <link:definition>0000040 - Disclosure - Common Stock - Pre-funded Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPreferredStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails">
        <link:definition>0000041 - Disclosure - Common Stock - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockSharesReservedforFutureIssuanceDetails" roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails">
        <link:definition>0000042 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails">
        <link:definition>0000043 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansSummaryofStockOptionActivityDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails">
        <link:definition>0000044 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
        <link:definition>0000045 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
        <link:definition>0000046 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>0000047 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://vitaltherapies.com/role/SubsequentEventsDetails">
        <link:definition>0000048 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" abstract="false" name="NumberOfFinancialInstitutionsUsedForCashDeposits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_AustraliaAndGermanyMember" abstract="true" name="AustraliaAndGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_DuaneNashMDJDMBAMember" abstract="true" name="DuaneNashMDJDMBAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ShelfRegistrationTerminationPriorWrittenNotice" abstract="false" name="ShelfRegistrationTerminationPriorWrittenNotice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_SharesIssuedWeightedAverageSharePricePerShare" abstract="false" name="SharesIssuedWeightedAverageSharePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtl_OperatingAndVariableLeasesCost" abstract="false" name="OperatingAndVariableLeasesCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_A2017InducementEquityIncentivePlanMember" abstract="true" name="A2017InducementEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ResearchAndDevelopmentTaxIncentiveCurrent" abstract="false" name="ResearchAndDevelopmentTaxIncentiveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_May2022ATMMember" abstract="true" name="May2022ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_NumberOfVotesPerEachShareOfCommonStock" abstract="false" name="NumberOfVotesPerEachShareOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_AccruedCompensationCurrent" abstract="false" name="AccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_TwoThousandFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_GrafelfingGermanyMember" abstract="true" name="GrafelfingGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ShelfRegistrationStatementAmountRemaining" abstract="false" name="ShelfRegistrationStatementAmountRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" abstract="false" name="EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_GovernmentAssistanceRate" abstract="false" name="GovernmentAssistanceRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" abstract="false" name="EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_IncentiveEmployeeStockOptionMember" abstract="true" name="IncentiveEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_NonStatutoryEmployeeStockOptionMember" abstract="true" name="NonStatutoryEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_OperatingLeaseIncrementalBorrowingRate" abstract="false" name="OperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_LongTermEquityIncentiveAwardMember" abstract="true" name="LongTermEquityIncentiveAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" abstract="false" name="EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_NewYorkCityMember" abstract="true" name="NewYorkCityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" abstract="false" name="MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_SalaryCostsMonthlyBaseSalary" abstract="false" name="SalaryCostsMonthlyBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_LesseeOperatingLeasesNumberOfExistingLeases" abstract="false" name="LesseeOperatingLeasesNumberOfExistingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_AccruedLegalAndAuditCostsCurrent" abstract="false" name="AccruedLegalAndAuditCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_LegalAndAuditCostsPayableCurrent" abstract="false" name="LegalAndAuditCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ExecutiveChairmanAgreementMember" abstract="true" name="ExecutiveChairmanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" abstract="false" name="CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vtl_PrepaidClinicalAndRelatedCostsCurrent" abstract="false" name="PrepaidClinicalAndRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_December2020ATMMember" abstract="true" name="December2020ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_A2019OmnibusEquityIncentivePlanMember" abstract="true" name="A2019OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_AtTheMarketSalesAgreementMember" abstract="true" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ClinicalCostsPayableCurrent" abstract="false" name="ClinicalCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_PlaneggGermanyMember" abstract="true" name="PlaneggGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_SaleOfStockRemainingCapacity" abstract="false" name="SaleOfStockRemainingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_AccruedClinicalCostsCurrent" abstract="false" name="AccruedClinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vtl_NumberOfDevelopmentPrograms" abstract="false" name="NumberOfDevelopmentPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_EmployeeStockOptionsforFutureGrantMember" abstract="true" name="EmployeeStockOptionsforFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>vtl-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:40f41647-d1d2-404b-8a31-83c86744a64e,g:f57fa659-71e4-427e-b4f1-2f0099ec97ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_176b02f9-7550-4d0e-ad2b-810d2d24c3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3e9a48d5-fc19-484f-a187-7a21dad5c6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_176b02f9-7550-4d0e-ad2b-810d2d24c3be" xlink:to="loc_us-gaap_LiabilitiesCurrent_3e9a48d5-fc19-484f-a187-7a21dad5c6e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9c4a02d1-e857-4e27-a3ef-904fae209ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_176b02f9-7550-4d0e-ad2b-810d2d24c3be" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9c4a02d1-e857-4e27-a3ef-904fae209ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_97236bd7-db59-4340-80a9-3d82b6de1724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c5c163f8-ac3a-4e07-a28f-734d5e09d092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_97236bd7-db59-4340-80a9-3d82b6de1724" xlink:to="loc_us-gaap_StockholdersEquity_c5c163f8-ac3a-4e07-a28f-734d5e09d092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dc33f059-6350-465a-8d74-1f1b9aca598a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_97236bd7-db59-4340-80a9-3d82b6de1724" xlink:to="loc_us-gaap_Liabilities_dc33f059-6350-465a-8d74-1f1b9aca598a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b114a5a5-b84a-4c58-bc62-c74ecb4d5125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_97236bd7-db59-4340-80a9-3d82b6de1724" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b114a5a5-b84a-4c58-bc62-c74ecb4d5125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_40aaa772-bea4-421b-acc6-2d817676edec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9ee91184-ec2a-4608-9238-dcef734783e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_40aaa772-bea4-421b-acc6-2d817676edec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9ee91184-ec2a-4608-9238-dcef734783e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0ef446d0-4500-4422-b61d-8e3c1f848d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1508d730-8da9-4cd5-8cc6-9f8ce752a9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0ef446d0-4500-4422-b61d-8e3c1f848d06" xlink:to="loc_us-gaap_PreferredStockValue_1508d730-8da9-4cd5-8cc6-9f8ce752a9f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2ee05935-2e6b-4e8a-9be1-9914cd3641ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0ef446d0-4500-4422-b61d-8e3c1f848d06" xlink:to="loc_us-gaap_CommonStockValue_2ee05935-2e6b-4e8a-9be1-9914cd3641ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_20253a75-6192-4543-9885-5de26680a52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0ef446d0-4500-4422-b61d-8e3c1f848d06" xlink:to="loc_us-gaap_AdditionalPaidInCapital_20253a75-6192-4543-9885-5de26680a52e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9a640f90-cc1c-4241-bbdb-9759b35afecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0ef446d0-4500-4422-b61d-8e3c1f848d06" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9a640f90-cc1c-4241-bbdb-9759b35afecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ebb60f42-d595-4049-be98-d43b8a405613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0ef446d0-4500-4422-b61d-8e3c1f848d06" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ebb60f42-d595-4049-be98-d43b8a405613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_89457b6d-756e-42f9-9bac-335210a4e674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_0156987d-9822-4dab-a1b0-5841d467a878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_89457b6d-756e-42f9-9bac-335210a4e674" xlink:to="loc_us-gaap_OtherShortTermInvestments_0156987d-9822-4dab-a1b0-5841d467a878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_90290917-7ec6-4287-b35a-6702df8e39c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_89457b6d-756e-42f9-9bac-335210a4e674" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_90290917-7ec6-4287-b35a-6702df8e39c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ed162e68-c795-4219-a17b-172a200e2aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_89457b6d-756e-42f9-9bac-335210a4e674" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ed162e68-c795-4219-a17b-172a200e2aa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f1850a7c-4164-4e96-ae52-c3dc8d2f5cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bb15394-7940-4226-9c48-f1325acd4290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f1850a7c-4164-4e96-ae52-c3dc8d2f5cef" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4bb15394-7940-4226-9c48-f1325acd4290" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9949e205-e85e-4af2-be6b-50f8775f7e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f1850a7c-4164-4e96-ae52-c3dc8d2f5cef" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9949e205-e85e-4af2-be6b-50f8775f7e3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c1bb2090-90d0-40e2-839f-32e99bce7174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f1850a7c-4164-4e96-ae52-c3dc8d2f5cef" xlink:to="loc_us-gaap_AccountsPayableCurrent_c1bb2090-90d0-40e2-839f-32e99bce7174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_07ded1f8-f629-4a82-8de2-13707addd626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3618e60e-e191-4958-ac0c-dbda83ba32d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ded1f8-f629-4a82-8de2-13707addd626" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3618e60e-e191-4958-ac0c-dbda83ba32d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_53b11243-6e30-4a56-ad42-915f85c7ddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ded1f8-f629-4a82-8de2-13707addd626" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_53b11243-6e30-4a56-ad42-915f85c7ddb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7dbc9c6c-95e6-44b4-93f6-ec6cd03e123a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ded1f8-f629-4a82-8de2-13707addd626" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7dbc9c6c-95e6-44b4-93f6-ec6cd03e123a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b5d897e8-f76a-4588-9852-c3dcad56bd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_07ded1f8-f629-4a82-8de2-13707addd626" xlink:to="loc_us-gaap_AssetsCurrent_b5d897e8-f76a-4588-9852-c3dcad56bd52" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_453eecd5-a484-4727-a7d9-e357935b3fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_149bd796-a685-4ddd-b8ba-0da01340cf69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_453eecd5-a484-4727-a7d9-e357935b3fa0" xlink:to="loc_us-gaap_OperatingIncomeLoss_149bd796-a685-4ddd-b8ba-0da01340cf69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ffeaa93f-7b1c-4b91-9a45-ba82e51e758e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_453eecd5-a484-4727-a7d9-e357935b3fa0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ffeaa93f-7b1c-4b91-9a45-ba82e51e758e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0e521a68-0cc1-42b9-8ddd-2edba96715c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2849a47-d855-4b35-a523-3679888fb50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0e521a68-0cc1-42b9-8ddd-2edba96715c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2849a47-d855-4b35-a523-3679888fb50f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ea2f6c4c-4f52-4508-9d20-579152455645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0e521a68-0cc1-42b9-8ddd-2edba96715c7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ea2f6c4c-4f52-4508-9d20-579152455645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_dff0dbad-1ff8-4dc6-b998-5b8c36125deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5b819cbc-225a-40ce-8b9e-4cf6604b31fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_dff0dbad-1ff8-4dc6-b998-5b8c36125deb" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5b819cbc-225a-40ce-8b9e-4cf6604b31fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d04f627a-b746-434c-88a9-53edae9bc8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_dff0dbad-1ff8-4dc6-b998-5b8c36125deb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d04f627a-b746-434c-88a9-53edae9bc8ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cd427c64-0fe5-4855-8c5a-8b3f2278323a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1d2d1ed0-b2bd-4299-bdf7-b3bf89dba0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cd427c64-0fe5-4855-8c5a-8b3f2278323a" xlink:to="loc_us-gaap_OperatingExpenses_1d2d1ed0-b2bd-4299-bdf7-b3bf89dba0d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_15450bec-17dd-4080-9ef7-fd6ea8ef39e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_64144f68-5a08-4aa8-bf1a-2fd73555b675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_15450bec-17dd-4080-9ef7-fd6ea8ef39e4" xlink:to="loc_us-gaap_NetIncomeLoss_64144f68-5a08-4aa8-bf1a-2fd73555b675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_61853632-badb-450e-be88-930ea22fa0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_15450bec-17dd-4080-9ef7-fd6ea8ef39e4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_61853632-badb-450e-be88-930ea22fa0b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d689766-f560-47c8-8ed8-fbd671ee3b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d6c1914-7302-494b-9905-788a49ea2cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d689766-f560-47c8-8ed8-fbd671ee3b35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d6c1914-7302-494b-9905-788a49ea2cc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39c1e995-1000-4cf4-8d40-36b8cd01413c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d689766-f560-47c8-8ed8-fbd671ee3b35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39c1e995-1000-4cf4-8d40-36b8cd01413c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_09240f19-61e9-43c0-878c-c29b7c8176e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d689766-f560-47c8-8ed8-fbd671ee3b35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_09240f19-61e9-43c0-878c-c29b7c8176e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a9bbce8-18c3-413e-aeb3-d9d3eda4c687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d689766-f560-47c8-8ed8-fbd671ee3b35" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a9bbce8-18c3-413e-aeb3-d9d3eda4c687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6a419cd-81a1-4fb9-9b61-275d66691f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_713d2982-b947-48f8-b87f-1499f59d0496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6a419cd-81a1-4fb9-9b61-275d66691f3d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_713d2982-b947-48f8-b87f-1499f59d0496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d370a685-edbe-434a-ae88-a84d8f80d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6a419cd-81a1-4fb9-9b61-275d66691f3d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d370a685-edbe-434a-ae88-a84d8f80d3ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_aec20362-2dfa-4994-92e2-402f08a26aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6a419cd-81a1-4fb9-9b61-275d66691f3d" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_aec20362-2dfa-4994-92e2-402f08a26aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9e4de0f-3522-4234-91a2-6ab9dc0a2187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d22cb34-4acf-467c-b0a0-67ac03f8d4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9e4de0f-3522-4234-91a2-6ab9dc0a2187" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d22cb34-4acf-467c-b0a0-67ac03f8d4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_c0f21c34-1c60-4a60-9c5c-62d0fcfd8032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f9e4de0f-3522-4234-91a2-6ab9dc0a2187" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_c0f21c34-1c60-4a60-9c5c-62d0fcfd8032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74c229f4-a9b6-4999-98fb-af51b5887dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5bad8279-805b-464e-acd8-629f1f7ca6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74c229f4-a9b6-4999-98fb-af51b5887dcd" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5bad8279-805b-464e-acd8-629f1f7ca6d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_94875840-7c15-4a2a-8a1b-cf8dec96d49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74c229f4-a9b6-4999-98fb-af51b5887dcd" xlink:to="loc_us-gaap_NetIncomeLoss_94875840-7c15-4a2a-8a1b-cf8dec96d49b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_418d274e-10ba-429b-bae2-d2442e589286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74c229f4-a9b6-4999-98fb-af51b5887dcd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_418d274e-10ba-429b-bae2-d2442e589286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_76a1207a-b723-472c-bed3-705961f59332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74c229f4-a9b6-4999-98fb-af51b5887dcd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_76a1207a-b723-472c-bed3-705961f59332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_587591f3-3c7a-4669-aab5-75dceb9b0e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74c229f4-a9b6-4999-98fb-af51b5887dcd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_587591f3-3c7a-4669-aab5-75dceb9b0e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_17099427-2c20-4cd9-a1b9-155a8a48509f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74c229f4-a9b6-4999-98fb-af51b5887dcd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_17099427-2c20-4cd9-a1b9-155a8a48509f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a7ed46a8-2cd3-4e58-abee-a619480e65f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74c229f4-a9b6-4999-98fb-af51b5887dcd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a7ed46a8-2cd3-4e58-abee-a619480e65f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ef3e9cc1-5d8a-4808-9f25-4e899ba5507f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74c229f4-a9b6-4999-98fb-af51b5887dcd" xlink:to="loc_us-gaap_ShareBasedCompensation_ef3e9cc1-5d8a-4808-9f25-4e899ba5507f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7059211e-ce09-4b64-9fcb-ed50846fd093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_bdb572f6-5f9f-4917-9b99-276bead17bbf" xlink:href="vtl-20230331.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7059211e-ce09-4b64-9fcb-ed50846fd093" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_bdb572f6-5f9f-4917-9b99-276bead17bbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_1dd85919-fc86-4f18-b09d-5cc60830f83c" xlink:href="vtl-20230331.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7059211e-ce09-4b64-9fcb-ed50846fd093" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_1dd85919-fc86-4f18-b09d-5cc60830f83c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_09e3f017-267b-4283-9cd4-799654f3a8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7059211e-ce09-4b64-9fcb-ed50846fd093" xlink:to="loc_us-gaap_OtherAssetsCurrent_09e3f017-267b-4283-9cd4-799654f3a8d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_77b4efd9-f0dc-4ae7-9eec-e8826773231d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7059211e-ce09-4b64-9fcb-ed50846fd093" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_77b4efd9-f0dc-4ae7-9eec-e8826773231d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_660aa7d6-7138-403e-9050-1b08522f992a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_fddd99e9-b850-48ae-b76e-caffa42cd3bd" xlink:href="vtl-20230331.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_660aa7d6-7138-403e-9050-1b08522f992a" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_fddd99e9-b850-48ae-b76e-caffa42cd3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_9222fc8b-a92c-4963-8853-d6e0a6e0cf72" xlink:href="vtl-20230331.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_660aa7d6-7138-403e-9050-1b08522f992a" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_9222fc8b-a92c-4963-8853-d6e0a6e0cf72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_8fedf767-9206-44b2-9261-42b8c237b1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_660aa7d6-7138-403e-9050-1b08522f992a" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_8fedf767-9206-44b2-9261-42b8c237b1fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_639a40c0-c697-491d-98de-be75ffa0f4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_71180894-25b8-40f4-b008-9dd74939fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639a40c0-c697-491d-98de-be75ffa0f4cb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_71180894-25b8-40f4-b008-9dd74939fd86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_7308c2dd-4081-4e85-9b2c-aaf8768b2859" xlink:href="vtl-20230331.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639a40c0-c697-491d-98de-be75ffa0f4cb" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_7308c2dd-4081-4e85-9b2c-aaf8768b2859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_69717c52-993f-4c97-b7e7-838da1b82e24" xlink:href="vtl-20230331.xsd#vtl_AccruedCompensationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639a40c0-c697-491d-98de-be75ffa0f4cb" xlink:to="loc_vtl_AccruedCompensationCurrent_69717c52-993f-4c97-b7e7-838da1b82e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_fbd54602-6025-4b37-9577-2639d4f132aa" xlink:href="vtl-20230331.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_639a40c0-c697-491d-98de-be75ffa0f4cb" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_fbd54602-6025-4b37-9577-2639d4f132aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1342d41d-4a7b-4fca-9685-78e539c38f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e295adea-24ef-45ce-9b68-863a7400401d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1342d41d-4a7b-4fca-9685-78e539c38f11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e295adea-24ef-45ce-9b68-863a7400401d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_39b2d6bc-2b04-4705-819c-647f1b4c0362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1342d41d-4a7b-4fca-9685-78e539c38f11" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_39b2d6bc-2b04-4705-819c-647f1b4c0362" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e81300a-c06c-4b50-96de-42c2abe8beb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f6836e4a-6ebe-4a14-8e01-23d1df579fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e81300a-c06c-4b50-96de-42c2abe8beb6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f6836e4a-6ebe-4a14-8e01-23d1df579fb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4a1ae7e7-35cf-4cc1-8fb9-e24b7d5653aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e81300a-c06c-4b50-96de-42c2abe8beb6" xlink:to="loc_us-gaap_OperatingLeaseLiability_4a1ae7e7-35cf-4cc1-8fb9-e24b7d5653aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_550fb353-d7bd-457d-8493-e86495b447a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e3f0f514-94e8-4860-a081-37a5e61a4fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_550fb353-d7bd-457d-8493-e86495b447a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e3f0f514-94e8-4860-a081-37a5e61a4fb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f8841af6-1330-471a-b19e-87863a794c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_550fb353-d7bd-457d-8493-e86495b447a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f8841af6-1330-471a-b19e-87863a794c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4ecdd1e0-f259-44a6-8008-d46bec913fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_550fb353-d7bd-457d-8493-e86495b447a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4ecdd1e0-f259-44a6-8008-d46bec913fe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1837808b-d3c9-478c-9bc0-8853a1473689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_550fb353-d7bd-457d-8493-e86495b447a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1837808b-d3c9-478c-9bc0-8853a1473689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7dab34e6-6d60-4e63-bd43-80ba86c8a5ca" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_550fb353-d7bd-457d-8493-e86495b447a8" xlink:to="loc_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7dab34e6-6d60-4e63-bd43-80ba86c8a5ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_abe7245b-1123-4a46-9514-51d87193bb22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_550fb353-d7bd-457d-8493-e86495b447a8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_abe7245b-1123-4a46-9514-51d87193bb22" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>vtl-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:40f41647-d1d2-404b-8a31-83c86744a64e,g:f57fa659-71e4-427e-b4f1-2f0099ec97ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="icc9cfaae2ce74a38a69ba42c98ad3285_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_102d5b61-53c9-4a5b-ac7d-1bd594acecdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_102d5b61-53c9-4a5b-ac7d-1bd594acecdd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_73c4162c-1fed-45c0-9c7f-0784bda33f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_73c4162c-1fed-45c0-9c7f-0784bda33f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e85f5f02-0153-4761-b688-33179c9e9a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockholdersEquity_e85f5f02-0153-4761-b688-33179c9e9a63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5b2d0b7d-64ac-476d-bfec-d7c0697eb868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_NetIncomeLoss_5b2d0b7d-64ac-476d-bfec-d7c0697eb868" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_db04b680-caf3-48d7-99ce-42e87cb750e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_db04b680-caf3-48d7-99ce-42e87cb750e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_83a8720b-e86e-4395-9dd9-ba2466cc3007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_83a8720b-e86e-4395-9dd9-ba2466cc3007" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7fd52d62-5066-4251-9712-7a60744e4f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7fd52d62-5066-4251-9712-7a60744e4f55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9ee43fab-32b2-4a75-a6e7-c7d5c49b4e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9ee43fab-32b2-4a75-a6e7-c7d5c49b4e40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40d2423c-959f-472f-8ef2-b748150fb101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40d2423c-959f-472f-8ef2-b748150fb101" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_894de273-b802-4377-be40-82b51e4d20a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_894de273-b802-4377-be40-82b51e4d20a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5daf167a-00c2-4ca2-9141-911b433d6239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c5c3693-a71e-47d9-87be-47388bb4d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5868e322-9a61-4333-a702-004a121f7456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_102d5b61-53c9-4a5b-ac7d-1bd594acecdd" xlink:to="loc_us-gaap_StatementTable_5868e322-9a61-4333-a702-004a121f7456" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b2a35a8a-9d01-4c8d-88c2-d466cf164b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5868e322-9a61-4333-a702-004a121f7456" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b2a35a8a-9d01-4c8d-88c2-d466cf164b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b2a35a8a-9d01-4c8d-88c2-d466cf164b30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2a35a8a-9d01-4c8d-88c2-d466cf164b30" xlink:to="loc_us-gaap_EquityComponentDomain_b2a35a8a-9d01-4c8d-88c2-d466cf164b30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2a35a8a-9d01-4c8d-88c2-d466cf164b30" xlink:to="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4021d909-5781-4da4-a874-7d429afc53d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:to="loc_us-gaap_CommonStockMember_4021d909-5781-4da4-a874-7d429afc53d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee2eb064-c5f9-407f-ad17-1f2d93859f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee2eb064-c5f9-407f-ad17-1f2d93859f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4db39620-743f-4a9e-a3f5-9e8bc02abd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4db39620-743f-4a9e-a3f5-9e8bc02abd20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5d1bd522-d460-467a-87e4-11edba02e850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:to="loc_us-gaap_RetainedEarningsMember_5d1bd522-d460-467a-87e4-11edba02e850" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i7041f855efd042c5ab43b72780f08359_CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_80a1cf8f-92b6-4231-8171-adfbb34a7778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_741c0922-23c6-4ac0-a542-0fd6167d231c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_80a1cf8f-92b6-4231-8171-adfbb34a7778" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_741c0922-23c6-4ac0-a542-0fd6167d231c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d428adf2-8a57-4500-a561-2eaacc6187f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_80a1cf8f-92b6-4231-8171-adfbb34a7778" xlink:to="loc_us-gaap_StatementTable_d428adf2-8a57-4500-a561-2eaacc6187f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ca71e381-13e3-4766-a86a-69547fb119ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d428adf2-8a57-4500-a561-2eaacc6187f5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ca71e381-13e3-4766-a86a-69547fb119ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca71e381-13e3-4766-a86a-69547fb119ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ca71e381-13e3-4766-a86a-69547fb119ff" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ca71e381-13e3-4766-a86a-69547fb119ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_581d2723-4dc4-4bab-bfaa-93360b794f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ca71e381-13e3-4766-a86a-69547fb119ff" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_581d2723-4dc4-4bab-bfaa-93360b794f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AtTheMarketSalesAgreementMember_0873ed12-00e7-4d15-ab93-176a333491c4" xlink:href="vtl-20230331.xsd#vtl_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_581d2723-4dc4-4bab-bfaa-93360b794f8e" xlink:to="loc_vtl_AtTheMarketSalesAgreementMember_0873ed12-00e7-4d15-ab93-176a333491c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended" id="i32ecb8f980994d80971774d3cb541fc9_DescriptionofBusinessandBasisofFinancialStatementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_1025ed5e-d446-4a5a-aacf-928554732da7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_dei_EntityNumberOfEmployees_1025ed5e-d446-4a5a-aacf-928554732da7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms_e60c35a3-879b-4382-be07-a72cb479c181" xlink:href="vtl-20230331.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_vtl_NumberOfDevelopmentPrograms_e60c35a3-879b-4382-be07-a72cb479c181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_491ffc1b-d528-4ca9-9dd6-a2c947b738b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_491ffc1b-d528-4ca9-9dd6-a2c947b738b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_68c4c35c-09ce-4ba4-995d-df505f41ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_68c4c35c-09ce-4ba4-995d-df505f41ab58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b0da5fb-175d-4d87-9433-aadb1c603219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b0da5fb-175d-4d87-9433-aadb1c603219" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_719aeaee-3755-4d6e-8ee4-cef9caa22c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_us-gaap_OtherShortTermInvestments_719aeaee-3755-4d6e-8ee4-cef9caa22c9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4d84c469-bb7d-4f75-a0ed-27789472cd38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_us-gaap_SubsequentEventTable_4d84c469-bb7d-4f75-a0ed-27789472cd38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_40560cf0-21d2-46ea-baba-496d69922259" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4d84c469-bb7d-4f75-a0ed-27789472cd38" xlink:to="loc_srt_StatementScenarioAxis_40560cf0-21d2-46ea-baba-496d69922259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_40560cf0-21d2-46ea-baba-496d69922259_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_40560cf0-21d2-46ea-baba-496d69922259" xlink:to="loc_srt_ScenarioUnspecifiedDomain_40560cf0-21d2-46ea-baba-496d69922259_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0cce8969-cf8e-4e1c-86b6-db71cda91ccc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_40560cf0-21d2-46ea-baba-496d69922259" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0cce8969-cf8e-4e1c-86b6-db71cda91ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d2791893-ea63-4e73-9fb3-fda8229cbd24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0cce8969-cf8e-4e1c-86b6-db71cda91ccc" xlink:to="loc_srt_ScenarioForecastMember_d2791893-ea63-4e73-9fb3-fda8229cbd24" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ie40848f0af234ba4bb05c37829b6778e_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_9d0be0e4-4ffa-4526-930c-62368aff154d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_InvestmentInterestRate_9d0be0e4-4ffa-4526-930c-62368aff154d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c3230dd-76dd-440e-bd40-759acdefe8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c3230dd-76dd-440e-bd40-759acdefe8c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_29e620b3-93d8-4f6e-aa34-a3cee45b39f5" xlink:href="vtl-20230331.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_29e620b3-93d8-4f6e-aa34-a3cee45b39f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_89a2fffb-a9d1-476b-8641-463585e4dbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_89a2fffb-a9d1-476b-8641-463585e4dbd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e1ccb0ed-3ed2-4f00-b324-f6a87c895388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_Depreciation_e1ccb0ed-3ed2-4f00-b324-f6a87c895388" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_529a02ff-0b34-46c2-9edd-a022f9c9ba23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_529a02ff-0b34-46c2-9edd-a022f9c9ba23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2f63f610-0962-4ad4-84aa-a322b9a54b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2f63f610-0962-4ad4-84aa-a322b9a54b95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceRate_0cc488e2-e183-4a89-9952-e4032b2bd8d1" xlink:href="vtl-20230331.xsd#vtl_GovernmentAssistanceRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_vtl_GovernmentAssistanceRate_0cc488e2-e183-4a89-9952-e4032b2bd8d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_12903f90-323b-4368-9d66-5cc0de48571f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_12903f90-323b-4368-9d66-5cc0de48571f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8d73bfbc-a460-47ac-a21e-afe06a599516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8d73bfbc-a460-47ac-a21e-afe06a599516" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_635658f7-2694-47a8-8a0f-09238c4c1e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_635658f7-2694-47a8-8a0f-09238c4c1e55" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_106dadb5-36b7-439d-9564-c324df8fe819" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_106dadb5-36b7-439d-9564-c324df8fe819" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_296a4e08-45ed-42f7-bdd3-a0e44429e18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_296a4e08-45ed-42f7-bdd3-a0e44429e18e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d956042c-dccb-4177-aff2-9bfbde067a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d956042c-dccb-4177-aff2-9bfbde067a89" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_177cc11c-e36d-45d8-a2b4-c34bb0563330" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:to="loc_srt_RangeAxis_177cc11c-e36d-45d8-a2b4-c34bb0563330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_177cc11c-e36d-45d8-a2b4-c34bb0563330_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_177cc11c-e36d-45d8-a2b4-c34bb0563330" xlink:to="loc_srt_RangeMember_177cc11c-e36d-45d8-a2b4-c34bb0563330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c353be7-5804-4450-bf44-7c789b018777" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_177cc11c-e36d-45d8-a2b4-c34bb0563330" xlink:to="loc_srt_RangeMember_7c353be7-5804-4450-bf44-7c789b018777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_975e5d92-4a34-4d4e-a8c7-32606df77f94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c353be7-5804-4450-bf44-7c789b018777" xlink:to="loc_srt_MaximumMember_975e5d92-4a34-4d4e-a8c7-32606df77f94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_26195474-4287-41a0-8af4-a8b493844813" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c353be7-5804-4450-bf44-7c789b018777" xlink:to="loc_srt_MinimumMember_26195474-4287-41a0-8af4-a8b493844813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7821d481-875a-456c-8f14-877fb69504d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:to="loc_srt_StatementGeographicalAxis_7821d481-875a-456c-8f14-877fb69504d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7821d481-875a-456c-8f14-877fb69504d3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7821d481-875a-456c-8f14-877fb69504d3" xlink:to="loc_srt_SegmentGeographicalDomain_7821d481-875a-456c-8f14-877fb69504d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7821d481-875a-456c-8f14-877fb69504d3" xlink:to="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AustraliaAndGermanyMember_63f395a3-a8d3-46fa-a95f-3d12a6bf59a3" xlink:href="vtl-20230331.xsd#vtl_AustraliaAndGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:to="loc_vtl_AustraliaAndGermanyMember_63f395a3-a8d3-46fa-a95f-3d12a6bf59a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0fd45ed4-a5f5-4081-96e0-c3aa779356b2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:to="loc_country_US_0fd45ed4-a5f5-4081-96e0-c3aa779356b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_da2e5838-adc2-4224-8435-8c41e503862c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:to="loc_country_DE_da2e5838-adc2-4224-8435-8c41e503862c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_12c76813-9a4f-429d-888b-a39d90dc8be5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:to="loc_country_AU_12c76813-9a4f-429d-888b-a39d90dc8be5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6e217d82-4783-4722-82e9-bb9551d0f802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:to="loc_us-gaap_InvestmentTypeAxis_6e217d82-4783-4722-82e9-bb9551d0f802" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6e217d82-4783-4722-82e9-bb9551d0f802_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_6e217d82-4783-4722-82e9-bb9551d0f802" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6e217d82-4783-4722-82e9-bb9551d0f802_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5d37e4f4-7a40-4d3b-8991-005b4e327f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_6e217d82-4783-4722-82e9-bb9551d0f802" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5d37e4f4-7a40-4d3b-8991-005b4e327f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_78d13da7-abaa-4afd-9f00-922bfa33d162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5d37e4f4-7a40-4d3b-8991-005b4e327f91" xlink:to="loc_us-gaap_MoneyMarketFundsMember_78d13da7-abaa-4afd-9f00-922bfa33d162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_46680a12-9d68-45b1-b2d6-08d0137f1ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5d37e4f4-7a40-4d3b-8991-005b4e327f91" xlink:to="loc_us-gaap_BankTimeDepositsMember_46680a12-9d68-45b1-b2d6-08d0137f1ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3514cf37-2179-4584-956d-fd0e6704a56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3514cf37-2179-4584-956d-fd0e6704a56a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3514cf37-2179-4584-956d-fd0e6704a56a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3514cf37-2179-4584-956d-fd0e6704a56a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3514cf37-2179-4584-956d-fd0e6704a56a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_22c8ece8-5a40-4d64-b851-157603753294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3514cf37-2179-4584-956d-fd0e6704a56a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_22c8ece8-5a40-4d64-b851-157603753294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_da5a15ec-b20e-44d1-9b18-469173be5365" xlink:href="vtl-20230331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_22c8ece8-5a40-4d64-b851-157603753294" xlink:to="loc_vtl_PreFundedWarrantsMember_da5a15ec-b20e-44d1-9b18-469173be5365" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#SummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended" id="icde5e599848d4d04b25ecd7a01bd50dc_SummaryofSignificantAccountingPoliciesInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_ee06de3b-a112-49d7-9c45-d8d4e0aaf996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_a0177e2f-56bc-42f4-9542-3e0d590a2690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ee06de3b-a112-49d7-9c45-d8d4e0aaf996" xlink:to="loc_us-gaap_OtherShortTermInvestments_a0177e2f-56bc-42f4-9542-3e0d590a2690" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_195e2bb7-1d1c-4ee6-abd4-30b4f10e1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ee06de3b-a112-49d7-9c45-d8d4e0aaf996" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_195e2bb7-1d1c-4ee6-abd4-30b4f10e1a8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_650986fa-00e5-4737-a7c9-89ba19c0ffec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_195e2bb7-1d1c-4ee6-abd4-30b4f10e1a8e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_650986fa-00e5-4737-a7c9-89ba19c0ffec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_650986fa-00e5-4737-a7c9-89ba19c0ffec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_650986fa-00e5-4737-a7c9-89ba19c0ffec" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_650986fa-00e5-4737-a7c9-89ba19c0ffec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9751989b-7c15-43ef-829e-3017f293dc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_650986fa-00e5-4737-a7c9-89ba19c0ffec" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9751989b-7c15-43ef-829e-3017f293dc24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_dac63fb2-b664-4fd3-974c-2958d36f3495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9751989b-7c15-43ef-829e-3017f293dc24" xlink:to="loc_us-gaap_BankTimeDepositsMember_dac63fb2-b664-4fd3-974c-2958d36f3495" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended" id="ie93aa0ce6d5d455384670acab5fc924e_SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c18c1329-1d2d-4ad4-a522-5620f5f9454b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f778c06-fa10-4820-9d3d-aab35f1528d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c18c1329-1d2d-4ad4-a522-5620f5f9454b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f778c06-fa10-4820-9d3d-aab35f1528d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4a35730-42a1-4dcb-a19e-2a8b68e8166f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c18c1329-1d2d-4ad4-a522-5620f5f9454b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4a35730-42a1-4dcb-a19e-2a8b68e8166f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bba0693-3ef6-43a3-8997-c31eab862ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4a35730-42a1-4dcb-a19e-2a8b68e8166f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bba0693-3ef6-43a3-8997-c31eab862ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0bba0693-3ef6-43a3-8997-c31eab862ad6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bba0693-3ef6-43a3-8997-c31eab862ad6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0bba0693-3ef6-43a3-8997-c31eab862ad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fe570c3-3420-4daf-b4d5-7ca3333871b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bba0693-3ef6-43a3-8997-c31eab862ad6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fe570c3-3420-4daf-b4d5-7ca3333871b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_7027e409-0279-40e2-8b19-06a61475033d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fe570c3-3420-4daf-b4d5-7ca3333871b0" xlink:to="loc_us-gaap_StockOptionMember_7027e409-0279-40e2-8b19-06a61475033d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i164b772228464e96ae5ce280de3135e1_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd116250-8cc2-40c3-b478-80a5b63da50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd116250-8cc2-40c3-b478-80a5b63da50b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_b718addd-d181-4720-a5d6-2fec571383b4" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_b718addd-d181-4720-a5d6-2fec571383b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_5b902b63-1e61-49ff-9942-9d339f505e23" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_5b902b63-1e61-49ff-9942-9d339f505e23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_508dc27e-1060-4ea5-a257-4d1bdf0296b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_508dc27e-1060-4ea5-a257-4d1bdf0296b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_570f6fba-136a-4823-88b3-36a4525e1bd4" xlink:href="vtl-20230331.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_570f6fba-136a-4823-88b3-36a4525e1bd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_4ecdf868-3a25-4ebb-9b28-3805a5ca6e4b" xlink:href="vtl-20230331.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_4ecdf868-3a25-4ebb-9b28-3805a5ca6e4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_da15107d-8258-4dac-96e6-8a5aac70ed46" xlink:href="vtl-20230331.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_da15107d-8258-4dac-96e6-8a5aac70ed46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_9940a9a1-eaee-438d-86d1-53ed4758e478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_us-gaap_ContractualObligation_9940a9a1-eaee-438d-86d1-53ed4758e478" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c6cd4f56-dd2b-4169-b68b-0a6e7aee3d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_us-gaap_LossContingenciesTable_c6cd4f56-dd2b-4169-b68b-0a6e7aee3d86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_32b2e0ec-e171-4cfe-b88e-920404318bbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c6cd4f56-dd2b-4169-b68b-0a6e7aee3d86" xlink:to="loc_srt_StatementGeographicalAxis_32b2e0ec-e171-4cfe-b88e-920404318bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32b2e0ec-e171-4cfe-b88e-920404318bbb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_32b2e0ec-e171-4cfe-b88e-920404318bbb" xlink:to="loc_srt_SegmentGeographicalDomain_32b2e0ec-e171-4cfe-b88e-920404318bbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_32b2e0ec-e171-4cfe-b88e-920404318bbb" xlink:to="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_2157cbf7-fa8f-4afa-9512-e4bc4781e0cf" xlink:href="vtl-20230331.xsd#vtl_GrafelfingGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:to="loc_vtl_GrafelfingGermanyMember_2157cbf7-fa8f-4afa-9512-e4bc4781e0cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_9ae931a3-caac-4e99-9fa2-edf4fe767a10" xlink:href="vtl-20230331.xsd#vtl_NewYorkCityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:to="loc_vtl_NewYorkCityMember_9ae931a3-caac-4e99-9fa2-edf4fe767a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember_0ccaa770-fc7a-4620-9302-64d36a8325de" xlink:href="vtl-20230331.xsd#vtl_PlaneggGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:to="loc_vtl_PlaneggGermanyMember_0ccaa770-fc7a-4620-9302-64d36a8325de" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i05eb74af3eaa47c895aa66dc9ef687a2_FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83cde11d-9453-4da4-b489-25cef2b9d940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bafb95b-8995-451d-a2af-640008ec012c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83cde11d-9453-4da4-b489-25cef2b9d940" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bafb95b-8995-451d-a2af-640008ec012c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9d4189ec-bd2b-4046-9585-fc98258a7795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bafb95b-8995-451d-a2af-640008ec012c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9d4189ec-bd2b-4046-9585-fc98258a7795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83cde11d-9453-4da4-b489-25cef2b9d940" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fbfc9716-0acc-4316-be48-df65be2f197f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fbfc9716-0acc-4316-be48-df65be2f197f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fbfc9716-0acc-4316-be48-df65be2f197f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fbfc9716-0acc-4316-be48-df65be2f197f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fbfc9716-0acc-4316-be48-df65be2f197f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_72b98190-6017-481d-be28-47c21be3afc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fbfc9716-0acc-4316-be48-df65be2f197f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_72b98190-6017-481d-be28-47c21be3afc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ed6ab06f-724f-440d-aea3-39c6c9e183a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_72b98190-6017-481d-be28-47c21be3afc7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ed6ab06f-724f-440d-aea3-39c6c9e183a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8c850297-da41-4ae6-abfb-63e074faace6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:to="loc_us-gaap_InvestmentTypeAxis_8c850297-da41-4ae6-abfb-63e074faace6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8c850297-da41-4ae6-abfb-63e074faace6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_8c850297-da41-4ae6-abfb-63e074faace6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8c850297-da41-4ae6-abfb-63e074faace6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b184a07e-0b2c-4214-8242-c0c112d52837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_8c850297-da41-4ae6-abfb-63e074faace6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b184a07e-0b2c-4214-8242-c0c112d52837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_45531ddd-ec1a-4b36-9e38-eff110aaee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b184a07e-0b2c-4214-8242-c0c112d52837" xlink:to="loc_us-gaap_MoneyMarketFundsMember_45531ddd-ec1a-4b36-9e38-eff110aaee0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fcc17cd-7adf-48ee-afca-15b685258065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fcc17cd-7adf-48ee-afca-15b685258065" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6fcc17cd-7adf-48ee-afca-15b685258065_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fcc17cd-7adf-48ee-afca-15b685258065" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6fcc17cd-7adf-48ee-afca-15b685258065_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fcc17cd-7adf-48ee-afca-15b685258065" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6c1918ab-01ce-46ea-9c62-713b5fd80d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6c1918ab-01ce-46ea-9c62-713b5fd80d02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9ccbb7da-71af-456a-b686-a20c97525926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9ccbb7da-71af-456a-b686-a20c97525926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9bc49659-6781-4876-83c3-0af6720e8745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9bc49659-6781-4876-83c3-0af6720e8745" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#FairValueAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="extended" id="i3c82f87d71a34115a3f1c07d9c42d740_FairValueAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266a7536-ac33-4b40-8dd4-448a2937cfda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_bec48a8c-c8d1-4d6c-9584-2e22bb890ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266a7536-ac33-4b40-8dd4-448a2937cfda" xlink:to="loc_us-gaap_InvestmentInterestRate_bec48a8c-c8d1-4d6c-9584-2e22bb890ff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9463ae74-1cb1-48df-bc3a-09e5a6741114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266a7536-ac33-4b40-8dd4-448a2937cfda" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9463ae74-1cb1-48df-bc3a-09e5a6741114" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6a6882b3-7468-43c9-bf94-56a4cfc200c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9463ae74-1cb1-48df-bc3a-09e5a6741114" xlink:to="loc_srt_StatementGeographicalAxis_6a6882b3-7468-43c9-bf94-56a4cfc200c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6a6882b3-7468-43c9-bf94-56a4cfc200c1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6a6882b3-7468-43c9-bf94-56a4cfc200c1" xlink:to="loc_srt_SegmentGeographicalDomain_6a6882b3-7468-43c9-bf94-56a4cfc200c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f55c810-771b-4a4d-bb6e-8ee56598545d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6a6882b3-7468-43c9-bf94-56a4cfc200c1" xlink:to="loc_srt_SegmentGeographicalDomain_1f55c810-771b-4a4d-bb6e-8ee56598545d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f29025ad-aa9a-4b6a-ac14-498dd5bd0184" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1f55c810-771b-4a4d-bb6e-8ee56598545d" xlink:to="loc_country_US_f29025ad-aa9a-4b6a-ac14-498dd5bd0184" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5a1427cb-f1f6-41c8-8d52-9b54e2e013d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9463ae74-1cb1-48df-bc3a-09e5a6741114" xlink:to="loc_us-gaap_InvestmentTypeAxis_5a1427cb-f1f6-41c8-8d52-9b54e2e013d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5a1427cb-f1f6-41c8-8d52-9b54e2e013d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_5a1427cb-f1f6-41c8-8d52-9b54e2e013d6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5a1427cb-f1f6-41c8-8d52-9b54e2e013d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b4df338d-0735-45a0-8c74-b1ac91edeb35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_5a1427cb-f1f6-41c8-8d52-9b54e2e013d6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b4df338d-0735-45a0-8c74-b1ac91edeb35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_abae56f3-3ea0-4b78-9891-2176b4d03c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4df338d-0735-45a0-8c74-b1ac91edeb35" xlink:to="loc_us-gaap_MoneyMarketFundsMember_abae56f3-3ea0-4b78-9891-2176b4d03c63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended" id="iec8488e5e61642e3b36ff8a4648b5eb7_CommonStockShelfRegistrationStatementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_d45a4ff4-5ebd-42c0-bb39-eb027fc890d9" xlink:href="vtl-20230331.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_d45a4ff4-5ebd-42c0-bb39-eb027fc890d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_2d3d57c8-73e5-4090-acfb-e8598c0df7fe" xlink:href="vtl-20230331.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_2d3d57c8-73e5-4090-acfb-e8598c0df7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_534f18fb-098b-440d-bac0-592ff6374b4f" xlink:href="vtl-20230331.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_534f18fb-098b-440d-bac0-592ff6374b4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_750f4533-d723-41f0-81f9-8a7bc71fa7fe" xlink:href="vtl-20230331.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_750f4533-d723-41f0-81f9-8a7bc71fa7fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_765b1d48-b0b7-460c-ab3b-bd31780b0c14" xlink:href="vtl-20230331.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_765b1d48-b0b7-460c-ab3b-bd31780b0c14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ecf87f6-d416-4003-9d69-5b454b7bdcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ecf87f6-d416-4003-9d69-5b454b7bdcaf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fdaeb2c6-19fe-416d-811f-9e0510c5077a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fdaeb2c6-19fe-416d-811f-9e0510c5077a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_5edea55f-60b9-4340-aa1d-5dd44708c873" xlink:href="vtl-20230331.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_5edea55f-60b9-4340-aa1d-5dd44708c873" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ffdb5ed4-107a-4da2-820d-08430322bdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ffdb5ed4-107a-4da2-820d-08430322bdee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_cd8c83ea-1bc6-4f60-89c5-0be8dd8e4949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_us-gaap_PaymentsForCommissions_cd8c83ea-1bc6-4f60-89c5-0be8dd8e4949" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_28a61d54-c569-491b-a04b-21c7c0cfdb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_28a61d54-c569-491b-a04b-21c7c0cfdb28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a4c796e5-d839-4453-8460-3c51aa2915c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_28a61d54-c569-491b-a04b-21c7c0cfdb28" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a4c796e5-d839-4453-8460-3c51aa2915c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a4c796e5-d839-4453-8460-3c51aa2915c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a4c796e5-d839-4453-8460-3c51aa2915c9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a4c796e5-d839-4453-8460-3c51aa2915c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4837df76-cb05-4b96-a890-e5490a5592fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a4c796e5-d839-4453-8460-3c51aa2915c9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4837df76-cb05-4b96-a890-e5490a5592fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_a6edbfc4-9387-44c5-9220-0cc9d9cebff0" xlink:href="vtl-20230331.xsd#vtl_December2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4837df76-cb05-4b96-a890-e5490a5592fe" xlink:to="loc_vtl_December2020ATMMember_a6edbfc4-9387-44c5-9220-0cc9d9cebff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_348b0c3f-7172-4d54-aafc-b5f0817cfe6f" xlink:href="vtl-20230331.xsd#vtl_May2022ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4837df76-cb05-4b96-a890-e5490a5592fe" xlink:to="loc_vtl_May2022ATMMember_348b0c3f-7172-4d54-aafc-b5f0817cfe6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_57e71e87-3f0f-46a6-a385-7ad29bc0ef8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_28a61d54-c569-491b-a04b-21c7c0cfdb28" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_57e71e87-3f0f-46a6-a385-7ad29bc0ef8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_57e71e87-3f0f-46a6-a385-7ad29bc0ef8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_57e71e87-3f0f-46a6-a385-7ad29bc0ef8a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_57e71e87-3f0f-46a6-a385-7ad29bc0ef8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a3b4fb84-39e2-45ec-b134-68776f7417cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_57e71e87-3f0f-46a6-a385-7ad29bc0ef8a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a3b4fb84-39e2-45ec-b134-68776f7417cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32ed9144-b760-4458-b5dc-b8fd00d96619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a3b4fb84-39e2-45ec-b134-68776f7417cc" xlink:to="loc_us-gaap_SubsequentEventMember_32ed9144-b760-4458-b5dc-b8fd00d96619" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockEquityOfferingDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="extended" id="i9a4088d2bce145eab35b3f4f6a80db82_CommonStockEquityOfferingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ccbae900-11f2-4eb8-a2d6-6d28c00d03c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ccbae900-11f2-4eb8-a2d6-6d28c00d03c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0a154ab5-0eb9-4c7e-a7c2-1358da652623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0a154ab5-0eb9-4c7e-a7c2-1358da652623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_c8ae802f-5898-4333-8542-e43f9ed9ac44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_us-gaap_SharePrice_c8ae802f-5898-4333-8542-e43f9ed9ac44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_e654b97b-a9b4-4a6a-9c2c-0350d180a405" xlink:href="vtl-20230331.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_e654b97b-a9b4-4a6a-9c2c-0350d180a405" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_2784ad84-eb38-4a01-a7ad-ead25dd8222c" xlink:href="vtl-20230331.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_2784ad84-eb38-4a01-a7ad-ead25dd8222c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_f40d4be1-a2b9-4cdb-9af6-1fdbfd40c113" xlink:href="vtl-20230331.xsd#vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_f40d4be1-a2b9-4cdb-9af6-1fdbfd40c113" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_cc600d06-c28c-4bd4-8b80-909a1e7ff144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_cc600d06-c28c-4bd4-8b80-909a1e7ff144" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f1f4649f-f3e0-4881-93f2-f397fa148fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_cc600d06-c28c-4bd4-8b80-909a1e7ff144" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f1f4649f-f3e0-4881-93f2-f397fa148fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f1f4649f-f3e0-4881-93f2-f397fa148fb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f1f4649f-f3e0-4881-93f2-f397fa148fb4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f1f4649f-f3e0-4881-93f2-f397fa148fb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200949c4-f005-4480-bf17-6428a8b3d5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f1f4649f-f3e0-4881-93f2-f397fa148fb4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200949c4-f005-4480-bf17-6428a8b3d5ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_10ea33f7-5427-416a-bab8-4d714d989b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200949c4-f005-4480-bf17-6428a8b3d5ae" xlink:to="loc_us-gaap_CommonStockMember_10ea33f7-5427-416a-bab8-4d714d989b6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_b517e62b-feaa-43b2-bbf5-0d53378d1c7c" xlink:href="vtl-20230331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200949c4-f005-4480-bf17-6428a8b3d5ae" xlink:to="loc_vtl_PreFundedWarrantsMember_b517e62b-feaa-43b2-bbf5-0d53378d1c7c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockPrefundedWarrantsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails" xlink:type="extended" id="ie730b3f3666b498cbcac50a577b5e965_CommonStockPrefundedWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_df68e6ac-99a4-4e66-94cc-edbc1668e322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3a0b9835-ffce-42d1-8a5a-deed9e258356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_df68e6ac-99a4-4e66-94cc-edbc1668e322" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3a0b9835-ffce-42d1-8a5a-deed9e258356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_180fbe59-8c2d-449c-84da-4db25b012b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_df68e6ac-99a4-4e66-94cc-edbc1668e322" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_180fbe59-8c2d-449c-84da-4db25b012b4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d6a58232-710c-4d39-9c6c-be9a0b856801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_180fbe59-8c2d-449c-84da-4db25b012b4e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d6a58232-710c-4d39-9c6c-be9a0b856801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6a58232-710c-4d39-9c6c-be9a0b856801_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d6a58232-710c-4d39-9c6c-be9a0b856801" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d6a58232-710c-4d39-9c6c-be9a0b856801_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26468448-f746-4e27-850c-df0cd6a9d527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d6a58232-710c-4d39-9c6c-be9a0b856801" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26468448-f746-4e27-850c-df0cd6a9d527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_81d2ad54-8129-483b-a55d-da0756b501fc" xlink:href="vtl-20230331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26468448-f746-4e27-850c-df0cd6a9d527" xlink:to="loc_vtl_PreFundedWarrantsMember_81d2ad54-8129-483b-a55d-da0756b501fc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended" id="iec11fe8eb4d146eeaae43265bbd17a6b_CommonStockSharesReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1a3effe8-a62d-447c-af9d-bad66f79494c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_55a0be59-3e1f-4290-a42b-0a1c6cc82522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a3effe8-a62d-447c-af9d-bad66f79494c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_55a0be59-3e1f-4290-a42b-0a1c6cc82522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4a785de3-e24c-4ab2-b8c9-611c5b664e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a3effe8-a62d-447c-af9d-bad66f79494c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4a785de3-e24c-4ab2-b8c9-611c5b664e0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06920f69-25f4-4087-aa68-3add36d3933b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4a785de3-e24c-4ab2-b8c9-611c5b664e0c" xlink:to="loc_us-gaap_AwardTypeAxis_06920f69-25f4-4087-aa68-3add36d3933b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06920f69-25f4-4087-aa68-3add36d3933b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_06920f69-25f4-4087-aa68-3add36d3933b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06920f69-25f4-4087-aa68-3add36d3933b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779c2be4-d29c-4891-9a51-9bb70af26e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_06920f69-25f4-4087-aa68-3add36d3933b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779c2be4-d29c-4891-9a51-9bb70af26e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c784a2ab-55ad-4b7b-abf9-fcf7eb3a1a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779c2be4-d29c-4891-9a51-9bb70af26e53" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c784a2ab-55ad-4b7b-abf9-fcf7eb3a1a32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_f763a0d6-5f3f-4af8-bc35-8ce5df2a5ce7" xlink:href="vtl-20230331.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779c2be4-d29c-4891-9a51-9bb70af26e53" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_f763a0d6-5f3f-4af8-bc35-8ce5df2a5ce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_89c90219-0ec6-4553-99ef-f55f361c5b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4a785de3-e24c-4ab2-b8c9-611c5b664e0c" xlink:to="loc_us-gaap_PlanNameAxis_89c90219-0ec6-4553-99ef-f55f361c5b5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_89c90219-0ec6-4553-99ef-f55f361c5b5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_89c90219-0ec6-4553-99ef-f55f361c5b5c" xlink:to="loc_us-gaap_PlanNameDomain_89c90219-0ec6-4553-99ef-f55f361c5b5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_89c90219-0ec6-4553-99ef-f55f361c5b5c" xlink:to="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_24c893e7-9ab7-4f8c-b3de-fc7f2c7b6670" xlink:href="vtl-20230331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_24c893e7-9ab7-4f8c-b3de-fc7f2c7b6670" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_5a9c5f88-fb9b-439c-a544-62757314a743" xlink:href="vtl-20230331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_5a9c5f88-fb9b-439c-a544-62757314a743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_c2aac1a9-e525-43b7-b71d-45bb3bda065e" xlink:href="vtl-20230331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_c2aac1a9-e525-43b7-b71d-45bb3bda065e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_73501882-3091-4e6b-99ac-205451fc0013" xlink:href="vtl-20230331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_73501882-3091-4e6b-99ac-205451fc0013" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended" id="i7ac38fd6e98d45a8844cb36dbdede9c4_StockBasedCompensationPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_e4e712ca-ed36-4e76-b41a-48a1b79926c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_e4e712ca-ed36-4e76-b41a-48a1b79926c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1bf735f8-0984-4e41-ad9b-45622b24dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1bf735f8-0984-4e41-ad9b-45622b24dc67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8cd5682c-7677-4531-b69b-26c22f871895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8cd5682c-7677-4531-b69b-26c22f871895" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c553dbf-b5c1-4abc-be00-38d3a293d985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c553dbf-b5c1-4abc-be00-38d3a293d985" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b31f2283-1826-462a-ade2-2619f0a11272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b31f2283-1826-462a-ade2-2619f0a11272" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_91434baf-251a-4bfc-aae6-de6f6d7314a0" xlink:href="vtl-20230331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_91434baf-251a-4bfc-aae6-de6f6d7314a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f61f9c4e-3c25-4036-8cbd-3a30e3e2f05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f61f9c4e-3c25-4036-8cbd-3a30e3e2f05a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4f5ae81f-50d5-4777-b1a3-337020b76ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4f5ae81f-50d5-4777-b1a3-337020b76ae3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3161ac1f-6422-4225-b974-aa5749fd2fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3161ac1f-6422-4225-b974-aa5749fd2fed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e4dcc1ec-0496-440d-a1e1-cf152203887c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e4dcc1ec-0496-440d-a1e1-cf152203887c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2b5b894a-945f-4205-9edd-f14c97808473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2b5b894a-945f-4205-9edd-f14c97808473" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ba09e160-9a79-4b77-83b2-17492e30693a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ba09e160-9a79-4b77-83b2-17492e30693a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f2c4f0c9-0673-49e5-9d67-7735f44a8de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f2c4f0c9-0673-49e5-9d67-7735f44a8de6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f01ee5eb-c4c4-44e7-a1eb-4fe023c9d454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:to="loc_us-gaap_PlanNameAxis_f01ee5eb-c4c4-44e7-a1eb-4fe023c9d454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f01ee5eb-c4c4-44e7-a1eb-4fe023c9d454_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f01ee5eb-c4c4-44e7-a1eb-4fe023c9d454" xlink:to="loc_us-gaap_PlanNameDomain_f01ee5eb-c4c4-44e7-a1eb-4fe023c9d454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f01ee5eb-c4c4-44e7-a1eb-4fe023c9d454" xlink:to="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_9bbdbdb0-9b75-4753-a801-1a2ff66b9db5" xlink:href="vtl-20230331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_9bbdbdb0-9b75-4753-a801-1a2ff66b9db5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_1f78615f-6257-439b-861a-4a836ea09322" xlink:href="vtl-20230331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_1f78615f-6257-439b-861a-4a836ea09322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_1f535b33-ef49-44ab-89d1-c91501b1f2ed" xlink:href="vtl-20230331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_1f535b33-ef49-44ab-89d1-c91501b1f2ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_48af5c74-98c5-4c8e-8b4c-229f5298eac1" xlink:href="vtl-20230331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_48af5c74-98c5-4c8e-8b4c-229f5298eac1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_19cb4c17-57a3-4666-a8a5-9a43399518fd" xlink:href="vtl-20230331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_19cb4c17-57a3-4666-a8a5-9a43399518fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8e0c48e6-1ad4-47ba-b3ce-e638426f935a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:to="loc_srt_RangeAxis_8e0c48e6-1ad4-47ba-b3ce-e638426f935a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8e0c48e6-1ad4-47ba-b3ce-e638426f935a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8e0c48e6-1ad4-47ba-b3ce-e638426f935a" xlink:to="loc_srt_RangeMember_8e0c48e6-1ad4-47ba-b3ce-e638426f935a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b726d419-9860-44df-93b6-48a15b823433" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8e0c48e6-1ad4-47ba-b3ce-e638426f935a" xlink:to="loc_srt_RangeMember_b726d419-9860-44df-93b6-48a15b823433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1974e2e4-63bc-480d-afce-8987619ce4f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b726d419-9860-44df-93b6-48a15b823433" xlink:to="loc_srt_MaximumMember_1974e2e4-63bc-480d-afce-8987619ce4f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_79d5cb94-e225-462f-be44-3383a9411de1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b726d419-9860-44df-93b6-48a15b823433" xlink:to="loc_srt_MinimumMember_79d5cb94-e225-462f-be44-3383a9411de1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d18c5f90-d721-4519-9226-def472b17daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:to="loc_us-gaap_AwardTypeAxis_d18c5f90-d721-4519-9226-def472b17daa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d18c5f90-d721-4519-9226-def472b17daa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d18c5f90-d721-4519-9226-def472b17daa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d18c5f90-d721-4519-9226-def472b17daa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bb4527e-4cbc-4d36-b3ca-5294aa39dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d18c5f90-d721-4519-9226-def472b17daa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bb4527e-4cbc-4d36-b3ca-5294aa39dbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_eb77d162-47e6-4283-84c0-e9ab6ac9aa7d" xlink:href="vtl-20230331.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bb4527e-4cbc-4d36-b3ca-5294aa39dbbd" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_eb77d162-47e6-4283-84c0-e9ab6ac9aa7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_ee46f5f5-978b-4071-9b1f-ef0a94ce621f" xlink:href="vtl-20230331.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bb4527e-4cbc-4d36-b3ca-5294aa39dbbd" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_ee46f5f5-978b-4071-9b1f-ef0a94ce621f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended" id="i665d80dd5fd24b80828aafe1e3535cfc_StockBasedCompensationPlansSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2f8b5161-f953-4519-a1e9-c4be55046151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2f8b5161-f953-4519-a1e9-c4be55046151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_199d960f-4463-48d0-a073-27d470c39d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_199d960f-4463-48d0-a073-27d470c39d0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3362314-5d88-41a7-89bb-e0b72318215d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3362314-5d88-41a7-89bb-e0b72318215d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0afe23bf-de2a-4bbf-b895-511c7801580f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0afe23bf-de2a-4bbf-b895-511c7801580f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2805da67-2b84-4e16-a2a7-f29d7c411935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_174592f6-368a-4fe6-af7e-70eb4572a9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_174592f6-368a-4fe6-af7e-70eb4572a9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e8528294-0d75-4a1d-917f-b2e7ec21e08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e8528294-0d75-4a1d-917f-b2e7ec21e08e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4f6d3716-9f3b-46fc-8201-fbf4c286760d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4f6d3716-9f3b-46fc-8201-fbf4c286760d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0bd49867-9e6f-4380-a171-d80087072901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0bd49867-9e6f-4380-a171-d80087072901" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16d5fe64-f3f4-4058-8838-896872bdb91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16d5fe64-f3f4-4058-8838-896872bdb91e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2cb15f2c-40cf-4791-b83e-f08a31b9bc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2cb15f2c-40cf-4791-b83e-f08a31b9bc9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14412a0d-3618-4bdf-905d-6586d8589297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_55cbfd72-701e-46a7-991b-cace43d7d406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_55cbfd72-701e-46a7-991b-cace43d7d406" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b87a8776-d1bb-4108-83f9-56a7e9385912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b87a8776-d1bb-4108-83f9-56a7e9385912" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bb691878-e5f6-46ca-8a7e-592f077111d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bb691878-e5f6-46ca-8a7e-592f077111d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a006c31c-a465-4f32-9134-e0dcb664170c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a006c31c-a465-4f32-9134-e0dcb664170c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_53661138-7f09-474a-97b8-1c0dea6a12f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_53661138-7f09-474a-97b8-1c0dea6a12f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30e88f78-36a3-4e1e-9028-3c216c6b205b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30e88f78-36a3-4e1e-9028-3c216c6b205b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3e2f89d2-3f4b-441b-a638-f8327bc3d9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3e2f89d2-3f4b-441b-a638-f8327bc3d9a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6f98f214-a3bf-4129-b747-d04d3bf26bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6f98f214-a3bf-4129-b747-d04d3bf26bfa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb11e5d1-9ca5-4d2c-8ade-a2634a89d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb11e5d1-9ca5-4d2c-8ade-a2634a89d4c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_621b9b7b-190c-4bcf-99a6-6ffb7808a392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb11e5d1-9ca5-4d2c-8ade-a2634a89d4c3" xlink:to="loc_us-gaap_AwardTypeAxis_621b9b7b-190c-4bcf-99a6-6ffb7808a392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_621b9b7b-190c-4bcf-99a6-6ffb7808a392_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_621b9b7b-190c-4bcf-99a6-6ffb7808a392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_621b9b7b-190c-4bcf-99a6-6ffb7808a392_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df95c4d1-cb1a-4c06-a50d-9ba880c13991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_621b9b7b-190c-4bcf-99a6-6ffb7808a392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df95c4d1-cb1a-4c06-a50d-9ba880c13991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d1506d92-d24b-4c4b-8978-e413c5cd2fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df95c4d1-cb1a-4c06-a50d-9ba880c13991" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d1506d92-d24b-4c4b-8978-e413c5cd2fcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_eebf6708-03af-4db5-9e61-8d220d4f0046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb11e5d1-9ca5-4d2c-8ade-a2634a89d4c3" xlink:to="loc_us-gaap_PlanNameAxis_eebf6708-03af-4db5-9e61-8d220d4f0046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_eebf6708-03af-4db5-9e61-8d220d4f0046_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_eebf6708-03af-4db5-9e61-8d220d4f0046" xlink:to="loc_us-gaap_PlanNameDomain_eebf6708-03af-4db5-9e61-8d220d4f0046_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0aa84691-1167-4756-869d-52a2f7c5c9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_eebf6708-03af-4db5-9e61-8d220d4f0046" xlink:to="loc_us-gaap_PlanNameDomain_0aa84691-1167-4756-869d-52a2f7c5c9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_4223e56d-0415-46ad-be8d-98f3fe9ac98e" xlink:href="vtl-20230331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0aa84691-1167-4756-869d-52a2f7c5c9fc" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_4223e56d-0415-46ad-be8d-98f3fe9ac98e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended" id="ia67f3a09e0e5416e8ca0ed5a345fedb1_StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6c06336f-6425-4061-a885-a96c9510258e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6c06336f-6425-4061-a885-a96c9510258e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b38761c8-4542-4505-a4aa-37ead1d4c6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b38761c8-4542-4505-a4aa-37ead1d4c6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c2fa734-adea-46cf-9fca-d65cfd4cda22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c2fa734-adea-46cf-9fca-d65cfd4cda22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e124a4b2-87a8-4200-bc84-182fe43b0050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e124a4b2-87a8-4200-bc84-182fe43b0050" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52fe5ea9-49d3-483b-a2a6-421982924152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52fe5ea9-49d3-483b-a2a6-421982924152" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_acdfb782-d221-44ed-bb56-64b714b21b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52fe5ea9-49d3-483b-a2a6-421982924152" xlink:to="loc_us-gaap_PlanNameAxis_acdfb782-d221-44ed-bb56-64b714b21b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_acdfb782-d221-44ed-bb56-64b714b21b6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_acdfb782-d221-44ed-bb56-64b714b21b6f" xlink:to="loc_us-gaap_PlanNameDomain_acdfb782-d221-44ed-bb56-64b714b21b6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_45397c8a-d0e8-46bb-95b3-c0050836f158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_acdfb782-d221-44ed-bb56-64b714b21b6f" xlink:to="loc_us-gaap_PlanNameDomain_45397c8a-d0e8-46bb-95b3-c0050836f158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_84fc9c63-281a-4b59-ba9c-fbdb1c41a15f" xlink:href="vtl-20230331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_45397c8a-d0e8-46bb-95b3-c0050836f158" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_84fc9c63-281a-4b59-ba9c-fbdb1c41a15f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended" id="i43b5884c65454a6f8da4dde6d31af358_StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6140ecec-33da-4375-9670-3c0856fc8f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fbf5dfd7-888b-4237-9f17-baf8af05a36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6140ecec-33da-4375-9670-3c0856fc8f68" xlink:to="loc_us-gaap_ShareBasedCompensation_fbf5dfd7-888b-4237-9f17-baf8af05a36f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_586180c7-d194-4682-a37b-c1fb8545f458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6140ecec-33da-4375-9670-3c0856fc8f68" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_586180c7-d194-4682-a37b-c1fb8545f458" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5a4a27d6-5c3a-4e3f-8770-e2658d48464a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_586180c7-d194-4682-a37b-c1fb8545f458" xlink:to="loc_srt_TitleOfIndividualAxis_5a4a27d6-5c3a-4e3f-8770-e2658d48464a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5a4a27d6-5c3a-4e3f-8770-e2658d48464a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5a4a27d6-5c3a-4e3f-8770-e2658d48464a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5a4a27d6-5c3a-4e3f-8770-e2658d48464a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3bab6fd3-c04b-4227-addd-fac331e0efb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5a4a27d6-5c3a-4e3f-8770-e2658d48464a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3bab6fd3-c04b-4227-addd-fac331e0efb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_06ef8e42-c3b4-4579-a5d5-49d474852958" xlink:href="vtl-20230331.xsd#vtl_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3bab6fd3-c04b-4227-addd-fac331e0efb0" xlink:to="loc_vtl_EmployeeMember_06ef8e42-c3b4-4579-a5d5-49d474852958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d72c2d1-da62-4873-abab-4c5986cc111c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_586180c7-d194-4682-a37b-c1fb8545f458" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d72c2d1-da62-4873-abab-4c5986cc111c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d72c2d1-da62-4873-abab-4c5986cc111c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d72c2d1-da62-4873-abab-4c5986cc111c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d72c2d1-da62-4873-abab-4c5986cc111c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_986d0e65-382b-4c09-ad71-04130bce02ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d72c2d1-da62-4873-abab-4c5986cc111c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_986d0e65-382b-4c09-ad71-04130bce02ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8d79f2bc-d0e6-4591-b620-8b52cc668712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_986d0e65-382b-4c09-ad71-04130bce02ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8d79f2bc-d0e6-4591-b620-8b52cc668712" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_62a15a7d-2b47-4cd3-b6dd-170759eca81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_986d0e65-382b-4c09-ad71-04130bce02ef" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_62a15a7d-2b47-4cd3-b6dd-170759eca81b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="i2aaa903d0f9d41e18f0762f8ee5cc881_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b32a3826-8214-48ef-8cb5-83d9ba7b9165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_64335a2a-eeac-4c9b-bb66-809de24e8ad0" xlink:href="vtl-20230331.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b32a3826-8214-48ef-8cb5-83d9ba7b9165" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_64335a2a-eeac-4c9b-bb66-809de24e8ad0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b32a3826-8214-48ef-8cb5-83d9ba7b9165" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_73af79c8-b9b0-40b5-a887-4b6b22ac7f16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_srt_CounterpartyNameAxis_73af79c8-b9b0-40b5-a887-4b6b22ac7f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73af79c8-b9b0-40b5-a887-4b6b22ac7f16_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_73af79c8-b9b0-40b5-a887-4b6b22ac7f16" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_73af79c8-b9b0-40b5-a887-4b6b22ac7f16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53e77b2-a1cd-4fb3-ba2a-c650bdde31e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_73af79c8-b9b0-40b5-a887-4b6b22ac7f16" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53e77b2-a1cd-4fb3-ba2a-c650bdde31e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_a2bf3a10-12b2-4742-8ddf-73e34be3c28b" xlink:href="vtl-20230331.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53e77b2-a1cd-4fb3-ba2a-c650bdde31e5" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_a2bf3a10-12b2-4742-8ddf-73e34be3c28b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_89fb5326-bfed-497e-bc7d-3a01c8816ae1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_srt_StatementScenarioAxis_89fb5326-bfed-497e-bc7d-3a01c8816ae1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_89fb5326-bfed-497e-bc7d-3a01c8816ae1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_89fb5326-bfed-497e-bc7d-3a01c8816ae1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_89fb5326-bfed-497e-bc7d-3a01c8816ae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_338749d6-fb6a-417c-abcb-60ad5c714dad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_89fb5326-bfed-497e-bc7d-3a01c8816ae1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_338749d6-fb6a-417c-abcb-60ad5c714dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b9c1ef3a-a932-4985-b006-0be2fab8cd57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_338749d6-fb6a-417c-abcb-60ad5c714dad" xlink:to="loc_srt_ScenarioForecastMember_b9c1ef3a-a932-4985-b006-0be2fab8cd57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_01ed394d-9135-479a-a79c-b549df1c5c76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_srt_TitleOfIndividualAxis_01ed394d-9135-479a-a79c-b549df1c5c76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_01ed394d-9135-479a-a79c-b549df1c5c76_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_01ed394d-9135-479a-a79c-b549df1c5c76" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_01ed394d-9135-479a-a79c-b549df1c5c76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_814b23b4-250d-462d-8d4e-85a540bd4100" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_01ed394d-9135-479a-a79c-b549df1c5c76" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_814b23b4-250d-462d-8d4e-85a540bd4100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_871e25e0-fa10-4e91-ba9e-3a4e982316a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_814b23b4-250d-462d-8d4e-85a540bd4100" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_871e25e0-fa10-4e91-ba9e-3a4e982316a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_17727a4e-80a0-47f5-8474-4afcff56d5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_17727a4e-80a0-47f5-8474-4afcff56d5a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_17727a4e-80a0-47f5-8474-4afcff56d5a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_17727a4e-80a0-47f5-8474-4afcff56d5a9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_17727a4e-80a0-47f5-8474-4afcff56d5a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3ef4edf7-2843-4262-b21c-3fb36b317eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_17727a4e-80a0-47f5-8474-4afcff56d5a9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3ef4edf7-2843-4262-b21c-3fb36b317eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_1f69c5ba-5883-4d63-a056-eea94af4196c" xlink:href="vtl-20230331.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3ef4edf7-2843-4262-b21c-3fb36b317eeb" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_1f69c5ba-5883-4d63-a056-eea94af4196c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a3babc38-ca66-4bf3-a19b-cc1a05d2f9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a3babc38-ca66-4bf3-a19b-cc1a05d2f9a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a3babc38-ca66-4bf3-a19b-cc1a05d2f9a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a3babc38-ca66-4bf3-a19b-cc1a05d2f9a0" xlink:to="loc_us-gaap_RelatedPartyDomain_a3babc38-ca66-4bf3-a19b-cc1a05d2f9a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_05a8fafb-ed36-482e-adb9-c58feb51849c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a3babc38-ca66-4bf3-a19b-cc1a05d2f9a0" xlink:to="loc_us-gaap_RelatedPartyDomain_05a8fafb-ed36-482e-adb9-c58feb51849c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_2acc2868-9865-4f2b-b930-f0aa939c9580" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_05a8fafb-ed36-482e-adb9-c58feb51849c" xlink:to="loc_srt_AffiliatedEntityMember_2acc2868-9865-4f2b-b930-f0aa939c9580" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="extended" id="ia33a7a8fe8f64335b4fd22f791e1329c_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e347fc5e-f762-4c76-bd81-32682615b9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e347fc5e-f762-4c76-bd81-32682615b9a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0ff576d5-e17e-4bb0-85fa-ca71ad45ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0ff576d5-e17e-4bb0-85fa-ca71ad45ab35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_53ebd4f5-adcc-40f0-a3c4-f49a5b185cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_53ebd4f5-adcc-40f0-a3c4-f49a5b185cb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_eeea5a02-de31-4e8e-be8e-eeee7d8b43c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:to="loc_us-gaap_SubsequentEventTable_eeea5a02-de31-4e8e-be8e-eeee7d8b43c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4d31650-4c76-4c83-9f32-8f694cdfddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_eeea5a02-de31-4e8e-be8e-eeee7d8b43c2" xlink:to="loc_us-gaap_AwardTypeAxis_d4d31650-4c76-4c83-9f32-8f694cdfddd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4d31650-4c76-4c83-9f32-8f694cdfddd6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d4d31650-4c76-4c83-9f32-8f694cdfddd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4d31650-4c76-4c83-9f32-8f694cdfddd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72c81c75-debb-4773-b42d-3b5d2b8e7106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d4d31650-4c76-4c83-9f32-8f694cdfddd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72c81c75-debb-4773-b42d-3b5d2b8e7106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LongTermEquityIncentiveAwardMember_66d2fddd-3311-4b36-a250-aa5fd7e14967" xlink:href="vtl-20230331.xsd#vtl_LongTermEquityIncentiveAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72c81c75-debb-4773-b42d-3b5d2b8e7106" xlink:to="loc_vtl_LongTermEquityIncentiveAwardMember_66d2fddd-3311-4b36-a250-aa5fd7e14967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9380e3e9-c8d8-4482-94c0-6a633b8e608b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_eeea5a02-de31-4e8e-be8e-eeee7d8b43c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9380e3e9-c8d8-4482-94c0-6a633b8e608b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9380e3e9-c8d8-4482-94c0-6a633b8e608b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9380e3e9-c8d8-4482-94c0-6a633b8e608b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9380e3e9-c8d8-4482-94c0-6a633b8e608b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d9e6f304-3054-49ac-9c4b-ecd7bd5d9cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9380e3e9-c8d8-4482-94c0-6a633b8e608b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d9e6f304-3054-49ac-9c4b-ecd7bd5d9cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_69af1b62-3eb9-4ec0-aff4-007d445663b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d9e6f304-3054-49ac-9c4b-ecd7bd5d9cad" xlink:to="loc_us-gaap_SubsequentEventMember_69af1b62-3eb9-4ec0-aff4-007d445663b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vtl-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:40f41647-d1d2-404b-8a31-83c86744a64e,g:f57fa659-71e4-427e-b4f1-2f0099ec97ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0fd9417d-fabb-428f-91b3-0460baa1ee3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3611f966-9570-4757-94b1-7ef943f5da04_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_779c1f7a-c08a-4d9a-9548-a42caedf990c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Presentation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_3428fb4f-a23a-49d3-8b3b-53ce74fc3cd8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_711d8d12-412a-4aa6-98a5-3cedf2503dac_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6b3a2aa8-e587-40c6-8a16-2d483710846e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_07b9a16b-b9eb-435a-b772-31bf1e47df1e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e53cdfd9-317f-4d55-a05b-3913f1c6d275_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_22502bc1-8b02-4364-b26a-29f4c630bfb5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_684adc08-e898-4490-afd8-431d25dffa86_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d541e039-344e-4ffc-83d5-a214d1f73387_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1c36941d-33f1-4639-8f28-b1f9edc03bf4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d3842ac3-47bb-4229-bf69-f01e552baa67_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5ec5db91-792a-47ff-b744-56b167f4dad5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a2058ddd-2eef-4fb5-8307-a7d0a8b18511_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ee1bebeb-c9f0-481a-85f7-252c7acbc0c1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d8910511-240b-4c80-9f78-889b9ea04d5c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_c57a5ed0-8063-4de9-a416-70eef6710643_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_e6047600-0730-4732-a855-a1dd13bbd45f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends paid (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_eb68eea2-d699-40db-b492-3fa0aaeab180_terseLabel_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical costs</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent" xlink:href="vtl-20230331.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ClinicalCostsPayableCurrent" xlink:to="lab_vtl_ClinicalCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9216145b-32bc-4f51-b0e1-c9a169172176_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_58aff9b4-2790-4bcd-8885-3028c09b9525_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,403,838 and 39,307,286 shares issued and outstanding as of March 31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_c108ceec-81cc-4161-8029-bdabb50477f1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6dd5b485-3df3-491a-98ee-88c0b7f3d5c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LongTermEquityIncentiveAwardMember_c639d3b3-a6fd-4ac6-a25c-fd944437b83c_terseLabel_en-US" xlink:label="lab_vtl_LongTermEquityIncentiveAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Equity Incentive Award</link:label>
    <link:label id="lab_vtl_LongTermEquityIncentiveAwardMember_label_en-US" xlink:label="lab_vtl_LongTermEquityIncentiveAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Equity Incentive Award [Member]</link:label>
    <link:label id="lab_vtl_LongTermEquityIncentiveAwardMember_documentation_en-US" xlink:label="lab_vtl_LongTermEquityIncentiveAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Equity Incentive Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LongTermEquityIncentiveAwardMember" xlink:href="vtl-20230331.xsd#vtl_LongTermEquityIncentiveAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LongTermEquityIncentiveAwardMember" xlink:to="lab_vtl_LongTermEquityIncentiveAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_5abe844a-44d3-4fa7-a79a-985d21263d2d_terseLabel_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase or decrease not in excess of percentage</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_label_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_documentation_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:href="vtl-20230331.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:to="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2f23a440-8185-4112-ad20-e33d899c5ea5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_19711a08-31e1-41e4-b928-4d5bfb22e788_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentInterestRate_87c20db7-b58f-41e0-a8ca-ecc210e04220_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment interest rate</link:label>
    <link:label id="lab_us-gaap_InvestmentInterestRate_label_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentInterestRate" xlink:to="lab_us-gaap_InvestmentInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0867a15a-f957-437d-bec8-f7b2466fe48b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_db2df8fe-cf57-4adb-bc26-30dc694234f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_49fdc152-f0d2-4c06-a041-365b4fbf487e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1a84c78e-b1a9-40b5-8d5c-f55d8a31720a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0bfff51d-899f-468a-a85f-84726edfba7f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3c0f201b-bec4-4351-8ad0-54fc8d150bf4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_10e622c2-ada0-494a-b5c6-759767bbacb7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued from exercise of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_f35ff5a2-3a64-4d6f-9f78-89301ea74d9b_terseLabel_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:href="vtl-20230331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e186172-430e-4452-a74d-04fef292983e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f47ca50-5cbe-4b87-87c1-36d5059eab15_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb3b96c0-2602-4a70-966a-8eb2cbdc7eba_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_76a07006-3bdf-4b83-8466-9af477cc0510_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1e0c3ccc-b8d7-4e4b-b995-0709d83d1854_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_May2022ATMMember_71258e3b-1a0c-46a2-a8bc-207f6c9bd0c6_terseLabel_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:label id="lab_vtl_May2022ATMMember_label_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM [Member]</link:label>
    <link:label id="lab_vtl_May2022ATMMember_documentation_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember" xlink:href="vtl-20230331.xsd#vtl_May2022ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_May2022ATMMember" xlink:to="lab_vtl_May2022ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_e51c8ab1-9a74-4fbf-a1d7-6f89f193df14_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_691eb7c0-c37e-47fa-b43e-4f9b560b7bbb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_8613f664-45f5-4f2c-9550-84a82c647e97_terseLabel_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in operating lease, right-of-use asset</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="vtl-20230331.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_bd6459b1-acfc-436b-b17a-b6d478096635_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_afabd8ef-40de-4d56-9792-20093f8d0998_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7498504c-8e49-4514-891e-98c06c82b708_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_791cb0aa-60b5-4edb-b250-4c4d52f5bdf8_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cdcf4762-6482-4657-a802-8c83dcc8d863_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c184d8a2-bc95-430d-9e79-c4677d213b3d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_99b2538c-7bbc-43b6-af75-2c2412bec4a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b6097dc-1f1d-4e4d-b9a4-8d58cff0510d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e87825aa-14e0-4749-9c0f-5d488285d880_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_47cc869e-8858-4bc5-a289-2f1d7b107491_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_05f6a394-23e6-4abc-be71-d71d8502040f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_88e057a1-95b0-4673-8aeb-5c2068418b87_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_75e48d59-26d7-4182-9c3e-a3df43c0feae_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_0e044c32-7f94-4f4b-aab2-ffbacc08d826_terseLabel_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_label_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement [Member]</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_documentation_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember" xlink:href="vtl-20230331.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ExecutiveChairmanAgreementMember" xlink:to="lab_vtl_ExecutiveChairmanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_3c1b938c-95de-4371-a12e-db91fa232c9d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9e98021d-6edf-4cff-9a32-d7b7146faf88_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_87bad00e-bbd4-4f26-9a89-47c954b0bc1a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeMember_dcbe7ace-ddd6-4655-8b45-bd56b14e43cb_terseLabel_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_vtl_EmployeeMember_label_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_vtl_EmployeeMember_documentation_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember" xlink:href="vtl-20230331.xsd#vtl_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeMember" xlink:to="lab_vtl_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a5594ebc-248c-49fa-928c-11763c4bbf5c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_8df2719c-e99e-4f30-8355-71fec876a5db_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ff6f08f4-c7ce-42d2-abc0-3e8ab927e36b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_33915de4-4a72-49e8-9bc5-b822405ad831_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ba2f4b95-941f-4611-b07f-adf570363569_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_d68ad5a4-f272-43e8-b682-9a98c1af5c03_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_400aa138-d481-4efc-a1b4-93c41da43ca9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_94537262-f6d2-4e78-bd90-c07a9e1e29ed_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of existing operating leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:to="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68ed4b39-a7f0-4d77-a9ff-a45d22f1ef71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_45ec0a94-72e0-4460-b14d-d069f4f08fd4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e8597516-b628-4661-bae9-704c4144beef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_6bccfe76-8f08-4364-a944-8619b8d5275c_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2ad9eb83-02c0-44c3-9096-abd62df2d490_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ae78ae88-8967-4e0b-be02-2ea29e2b30ee_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_24d5477d-f544-4f3a-b96d-3b96f648f836_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_836036c0-3d99-49b4-8232-f7f67a7f1a3e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f514e4f9-46fa-4c9d-b958-0d6ee4d5e69c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7a280311-f229-4b6e-95e0-8038c318519d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a4bb006a-030f-4978-95ff-f575e166c0ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1e889c63-f603-4adf-88f3-203aeb2fdf03_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_726f141f-3f27-47fb-80ae-2cf1678e8e44_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_21d188a0-f366-4aa4-ba12-cab0bce33b1c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_671b6438-8d68-494d-99d3-c252ce58db06_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_524880a1-189d-47aa-9134-13e9204410f6_terseLabel_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:href="vtl-20230331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:to="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5e571bbe-316b-42ae-ac37-41f19857de99_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52b84b1f-1707-4157-8dde-825950164135_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef00438f-c036-447d-b37c-033230371beb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AtTheMarketSalesAgreementMember_50e3f95c-bc85-4ea4-83c9-662c56d4ff68_terseLabel_en-US" xlink:label="lab_vtl_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Sales Agreement</link:label>
    <link:label id="lab_vtl_AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_vtl_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Sales Agreement [Member]</link:label>
    <link:label id="lab_vtl_AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_vtl_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AtTheMarketSalesAgreementMember" xlink:href="vtl-20230331.xsd#vtl_AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AtTheMarketSalesAgreementMember" xlink:to="lab_vtl_AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_1087deec-339f-46ce-a7ec-8133535b1df4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_01123a22-bb32-405b-b84d-3dea4e57e640_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4679e248-28be-443a-b35f-8ef737f97698_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PlaneggGermanyMember_39e4f6eb-914d-4191-9e2b-7eaf09f7e5ef_terseLabel_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planegg, Germany</link:label>
    <link:label id="lab_vtl_PlaneggGermanyMember_label_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planegg, Germany [Member]</link:label>
    <link:label id="lab_vtl_PlaneggGermanyMember_documentation_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planegg, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember" xlink:href="vtl-20230331.xsd#vtl_PlaneggGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PlaneggGermanyMember" xlink:to="lab_vtl_PlaneggGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_b7541126-4309-41e9-863d-ba3fe1f48eaa_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ca593981-0c12-4692-9c14-1657c1506f69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GrafelfingGermanyMember_5b8b363a-2614-4c62-9074-95afd0d2a47d_terseLabel_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_label_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany [Member]</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_documentation_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember" xlink:href="vtl-20230331.xsd#vtl_GrafelfingGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GrafelfingGermanyMember" xlink:to="lab_vtl_GrafelfingGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_45846bb1-acc2-4b28-8504-64fbd3613b5a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2b9287ad-50c4-45a2-914a-88d6530d4870_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_32132dab-9a2c-4d96-ad4f-99dddc74a78e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_de55eaa2-2e0e-4725-a67f-efecf6f39ef9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4a81e59-9e44-42f9-ad2c-303b29fbb855_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_040b3a36-11d0-4c89-83a9-8cbb9ecb1882_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6cd38c2a-0a44-424d-9da6-d6bee4760724_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_7ef2e05d-d9a5-4881-8114-89c7645dcf7a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d313f6b4-cf69-4945-ae72-f94890d13872_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_73b6d3bb-ffbd-4ddb-a6e9-2d12dd2803a4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_998a9eb1-f406-4409-a670-37fa714529ea_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c66828ef-3341-4e6e-8410-10a0159b1e95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_28f66181-b4c5-4ef5-a325-fe8a4e82f899_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_565534b7-178a-4a56-9074-2f28cdc54840_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_176d69ab-c5c8-4c38-b1be-5702dd0df793_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_5ef09423-bd85-4b0c-b439-3d99a36019c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments - other</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3e71c849-4713-4d11-b301-06edb4ab48ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_98e6d1d7-498f-400e-8fc8-4b5a38c9c1fd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GovernmentAssistanceRate_b4ac3e6f-e8b8-431e-83dd-f4e547bbdb08_terseLabel_en-US" xlink:label="lab_vtl_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance rate</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceRate_label_en-US" xlink:label="lab_vtl_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance Rate</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceRate_documentation_en-US" xlink:label="lab_vtl_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceRate" xlink:href="vtl-20230331.xsd#vtl_GovernmentAssistanceRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GovernmentAssistanceRate" xlink:to="lab_vtl_GovernmentAssistanceRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d19c45ff-7576-4585-8900-c95b5aa4334c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8de1fe20-cb76-40db-9055-4a8a99f87f7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e06b03d5-8515-4475-bf96-54384b30f524_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9752875e-74d2-4e5d-8d8e-1624ec16e843_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_6371cd2d-86a4-4847-b864-e1f7224b542e_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_744807d5-2bcd-4eb2-b4d6-5edbe5424020_verboseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0a71392a-5040-4a30-af2e-68ddce436bd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9780feec-e1a1-415a-8e84-3dfbb8996c67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_1f896f79-174f-4f0c-a24e-6041f51378e2_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_9ac2c29d-7e95-49b8-a1e9-930101dd4908_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e1dea071-8b98-46ae-b819-7b7788c92b04_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_093ecd70-47a3-45b0-babd-79fcfb58199f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8cbee0e2-bf31-4228-b470-930ff9cc76c0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_533c996c-b212-4652-8714-7ca9a1f99d46_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b2ee16d3-fe8f-4fe4-8bea-f8d8bb354db2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31dc42a8-7e46-4a8d-9ea0-e9618def54cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7210c6d8-21ee-40ab-92dd-7163c308a63a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c4f2a98f-376d-43ad-8cbb-3bbb131245b5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_00bb5058-ba67-4b32-a3ff-92eca4f96492_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fbd7feec-e303-4035-a341-5acced352cdb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_42d583f1-5291-4c43-a64d-89b289c62c74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_321d9b65-12da-49ff-96e4-a4c8e7ffd5e3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c85b7e0c-612f-4b13-9111-e861e1ffc011_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e05310d6-6e60-4f26-b1ba-89f127f841b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0156698c-39d2-4de6-8c66-9c3a86100a1e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_7acdceeb-a598-446a-bebe-0408c4369f16_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_f3af8503-f722-482e-ad10-e07326327302_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_50f98128-a850-490c-b521-67197c668b4d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_4a5d44d5-557e-4b26-83e8-9597829ba29d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_bdc735c8-763a-43d7-8879-085d5704d711_terseLabel_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments- other</link:label>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Other Investments [Policy Text Block]</link:label>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:href="vtl-20230331.xsd#vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:to="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_5b23f6d5-4414-4ed7-b264-2fe174e1f044_terseLabel_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal and audit costs</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:href="vtl-20230331.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:to="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_e1e752b6-18e4-4b8b-a0c6-9db413a9a249_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:href="vtl-20230331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_December2020ATMMember_5a5fb1c1-b722-459b-9290-b0254d5da8cb_terseLabel_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:label id="lab_vtl_December2020ATMMember_label_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM [Member]</link:label>
    <link:label id="lab_vtl_December2020ATMMember_documentation_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember" xlink:href="vtl-20230331.xsd#vtl_December2020ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_December2020ATMMember" xlink:to="lab_vtl_December2020ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_ca35bbec-3854-4a62-b760-1703c988ef30_terseLabel_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical and related costs</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_label_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_documentation_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:href="vtl-20230331.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:to="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2f8d4d6f-da78-462a-86d5-734e9d76827a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2cec04ad-7edf-440f-8c04-e736ae495a59_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_465e3ead-c37f-4394-b05a-ed18415ee869_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2ed99633-3248-41f6-bb5d-fc482ca1dbd9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_341f9718-d35e-420d-83a5-ec7d302edbc3_terseLabel_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="vtl-20230331.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_d0d647fd-7620-4e85-adba-3fc3c4b23dee_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized, percent</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:href="vtl-20230331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:to="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_34f76ebd-7523-4661-84f7-e1121904a3c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4a841a8f-ab7a-4a0b-a3ee-a189f20929b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9e43d31e-e696-450e-b0ba-250d2cd2d433_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3ec9460e-d635-47fa-8be9-2955fe3d3416_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_a3cc1810-3cce-4972-af7e-9fa49f1fa560_terseLabel_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">common stock at a weighted average price (in dollar per share)</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_label_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_documentation_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:href="vtl-20230331.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:to="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_01e873a5-3cc2-45da-8a41-c078be16283f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a10d0083-2d35-4b40-90d8-07673f8a3d60_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_3f6913e0-fbfa-4b20-8d9e-8793e06d53e0_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, extended rent holiday period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedCompensationCurrent_d6fde363-c2b0-45ba-98dc-2b697756c993_terseLabel_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_label_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent" xlink:href="vtl-20230331.xsd#vtl_AccruedCompensationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedCompensationCurrent" xlink:to="lab_vtl_AccruedCompensationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_8429eab8-b163-4dfc-a686-135eaca876a5_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b5f8428c-51e4-471d-a0b3-fda7ac14b9d1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e6cb2c70-f3cf-46aa-b2e2-2fd49fb88a31_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NewYorkCityMember_090f5921-a173-4019-814f-dc796122663d_terseLabel_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_label_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City [Member]</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_documentation_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember" xlink:href="vtl-20230331.xsd#vtl_NewYorkCityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NewYorkCityMember" xlink:to="lab_vtl_NewYorkCityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2979c3f6-4c08-4e3d-a4fa-9e56cc801ff7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6f9ea34c-4e0d-44b2-a96a-e642151e6e87_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_c1877d93-96ed-4679-bbab-495c3be177c0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0257c478-3c8c-41ae-b519-b8c52ee73102_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d52678e4-d72d-4606-8bad-fa2641c9fc2a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_2638ba9c-ffad-48e3-98a3-6d27919368fb_terseLabel_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May not exercise of percentage</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_label_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_documentation_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:href="vtl-20230331.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:to="lab_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8f569c5f-5ff7-4256-bb69-d8e450a82166_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c5009341-2207-4f0f-b587-371d997f98d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_ff2c1a25-83fd-432e-b48c-0e847a5f62df_terseLabel_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial institutions used for cash deposits</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_label_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposits</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_documentation_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:href="vtl-20230331.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:to="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6a171402-9462-425e-bcd9-379fa1114847_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ea681b-6dc3-424e-aca9-f6e2ab030206_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_2e59b171-0fd8-48f2-b4af-910457aaa5c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a11080e0-c212-4ee8-9962-0a86c5812f57_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b700e9e1-94a2-40cd-a019-3a10fdc7c80a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9f064650-5070-4161-adc8-16f5a211db28_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40f52bd5-6798-41d7-9cea-ef5dfdee5e25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf76d091-b689-44aa-9bc4-fe83fbb99d08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_27573298-e2fe-4578-801a-7b3f891ed2c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_09b06c13-e0c2-4894-a230-aeab35300747_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_272f6ec6-05e0-4f97-97e3-db4d001bab99_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a90e2a21-aea2-4907-be69-0cdcfa92f709_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_96a2276f-6820-4efd-b93e-062d3634a658_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a78ee867-ff3b-4e9b-a6ec-e55e16e66d88_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6efa3995-c02a-4957-93a8-a97bab64beca_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dd7593f0-89f6-442e-a5ff-d3fd1f43f33c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3897f2d1-51dd-4328-84d8-ed2dedc25450_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0d9db131-dd1a-4a44-9b57-34292bd7e45a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_d206e6c6-2479-4b72-ac68-6f6519f85c05_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6a65651e-a187-4fba-975e-ebcf59dccfb1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_405e11c3-756f-4b08-a197-420b27f29ba4_terseLabel_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase or decrease not In excess of prior notice period</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_label_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period</link:label>
    <link:label id="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_documentation_en-US" xlink:label="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:href="vtl-20230331.xsd#vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:to="lab_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a58f3bc9-d380-4b45-840a-12e2e7898b20_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b0f923c4-382a-4b15-b31f-d4f3b8671caa_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_66030ff8-6a73-496a-a121-82126b617831_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ef7daf2f-eeaf-4f8f-a15d-27bb88d7e140_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock through At The Market Sales Agreement, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_02e27fbb-60c6-4f42-b021-935db0228a21_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d3910fa3-583b-4231-b57b-ce9a3b36bd93_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_610ddb2a-1f0f-42d8-82a5-0343036081f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50d8ace5-52f5-4731-a186-51fdab157805_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ccf4ce90-02c8-4b24-9d8b-7a75c0a58a12_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which compensation cost will be recognized, in years</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_85a677cb-cb51-4339-8c5d-8ef3a9d03af9_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d5a53207-0dd5-4823-ac89-b15f4025fc4b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_7ec8ef3c-44a6-4c45-aca1-ba77833efcd2_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, percent of gross proceeds from sale of common stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="vtl-20230331.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_20d83516-80fa-406b-9c55-927d9bb9d864_terseLabel_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and variable lease cost</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_label_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_documentation_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost" xlink:href="vtl-20230331.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingAndVariableLeasesCost" xlink:to="lab_vtl_OperatingAndVariableLeasesCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6e6fe165-879c-4a8e-8e47-d0829bda2291_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_51155ecd-6793-411c-a316-f2f2302f6250_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_69d30c6d-aaa2-40ce-bc99-bb0fa4a20bc6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 4)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_59000440-590d-48c8-8626-4c31de38c238_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a92e29a7-d3ad-4b5e-88c1-b2904b674614_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4b4a8c22-8ee7-47b6-95cf-aa0df0eabaf6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9a6148c-76b8-4280-94f6-3e9b7c3a1cb2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6af24a10-e6b1-489c-8600-cf2110198328_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c0d7eb56-7725-453c-a1ed-fb3d6ed45bf0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_71053334-426b-4f26-aa61-138c40cffd25_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_75fc07c5-09d7-4380-a172-0f5d27699edb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_dbb5c738-f2dc-4f4e-9f55-30fc61708cf7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_f70c6549-92d9-4346-a5ee-41915c758f13_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of March 31, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c5cac9a-3821-4608-8daa-2efd92329967_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_8141fed0-542e-449e-a56d-bf3f2a6a258c_terseLabel_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian research and development tax incentive</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_label_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_documentation_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:href="vtl-20230331.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:to="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_79db0dc0-8645-4831-8a8c-61aa889b603a_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration statement, amount remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_label_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:href="vtl-20230331.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:to="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_4cda94bd-e7e8-440c-8e95-ca9ba9c2d96d_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance, amount</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmount" xlink:to="lab_us-gaap_GovernmentAssistanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_93b2f38f-7bc8-44cc-8056-9fd2fe154dce_terseLabel_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options available for future grant:</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_label_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_documentation_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:href="vtl-20230331.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:to="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_017b8b51-1415-44f9-b785-265d54380ff9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1d539eb9-c508-4bac-a7f7-1a2571d56972_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f4b0d84f-6df7-4ae0-8c84-b78061cb9ae5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued from exercise of pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8579e582-3151-4bd3-9be4-b54fbbff4ae3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_b738bdaa-a3ae-4616-a5ef-fcfbe97ad923_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:href="vtl-20230331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_94c8e82d-29f9-4d8d-9511-7e1899be8015_terseLabel_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and related costs</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent" xlink:href="vtl-20230331.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedClinicalCostsCurrent" xlink:to="lab_vtl_AccruedClinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7934b029-a49d-43a8-be3a-02c05847e409_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_84b94803-bcea-4f16-a8c3-4aac2d331980_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_f53bd75e-c1be-4359-b132-408a5be7f0b9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_df2a8939-7bb7-4657-a7e8-d090899f25d7_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration, termination, prior written notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_label_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:href="vtl-20230331.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:to="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_ceef2b15-b3da-4faa-b20a-4fe0926a5f89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f8c14c6e-1629-42ff-b9da-1443ed8f1324_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_26cc79ad-f857-4f2c-968f-85c7fba3c18c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_afbe1fef-67b1-4904-93ca-6386e8503a86_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_085bc07f-5d02-4c0b-b824-6b540391d6a3_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5df00283-66cd-44d5-a041-959be79b4f1e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_bebe1bd4-cee9-40d5-8d00-f680c56b9df6_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_fbdb114d-fba1-44bd-9969-661f0f1e0e13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets and Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c5442ee8-5f65-43f7-a50d-baf12e048909_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0985b510-0a5b-419f-b484-728837650918_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1c4ad69b-bbb2-4048-96a8-44c3d47664dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_6da6767e-610a-4025-b8ca-1b9af9d4628c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_30b63337-ef87-403f-b461-cb322aa10736_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_93bedf5f-1f91-4529-af50-592ddf65054a_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6bd1aa10-3a71-4e59-b686-92fb069cae07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c80ee8b4-c045-4f0c-b709-ce2b4752c480_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_95de4628-82cb-4bb4-a01b-1a7f48ba9d2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_795bc3cf-5619-409a-ba03-f1e490f3f526_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c698c132-efb6-4d84-a320-f43ae566e0a4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_feeccf43-962e-4e14-bd4f-9c4c2480c85b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2c356473-7d90-4edc-a190-9217af14dd91_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5ad60a6e-245b-44fe-9e2d-c527cd3e9f01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_beab5ed0-2687-4a4d-95be-00b0d8610ccc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_50c6fc17-c81a-4498-8a6c-6e065c716ca7_terseLabel_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_label_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_documentation_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms" xlink:href="vtl-20230331.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfDevelopmentPrograms" xlink:to="lab_vtl_NumberOfDevelopmentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_50ed422c-e228-4386-9705-b9b1f05365a4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8a0d55b4-450c-49b8-9876-d0be05878541_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_0e585d39-017b-4dfd-babd-5207f5f17b58_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5f1004f9-3a10-4da2-a813-5243cd56a6f6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_4e7501aa-cbc2-48b2-a74c-3acf27f8c8ff_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5abcca48-a86a-406a-a5ec-ba3b76269e92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_332f4542-a346-45eb-8408-1892b371c4f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under the ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ba63e8f3-3395-44ec-ad13-ababe1baffd9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c9304ac4-b740-4808-9d3e-dde6c887f68a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d8ec717c-8ff8-4dda-bf80-0013e6976635_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f4e5e5d8-8fdc-4571-8697-959f6145a865_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_a6c47d3f-f9d8-467b-9c4c-360787c13d8c_terseLabel_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-statutory options</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:href="vtl-20230331.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:to="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5afa85c5-156e-4841-be19-4c610a371758_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_97fd4b5e-7bbb-4503-b9ed-3fea3f9432ef_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_60d2df29-a722-4f09-a59c-55292f16b650_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0202f62-7001-498a-bdf4-b8d32f023e4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_89ad19ab-6e44-473c-a09b-fdd7dd1c94fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9e8d4b10-4c41-4321-876a-c2a05387f3db_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2a1c32b3-2102-4ae1-be5e-2513401643d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AU_9e22c95a-9475-45e2-8ff6-8578081c233a_terseLabel_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_country_AU_label_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AUSTRALIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_72186e50-9225-4f1c-a45d-be52e3eb49a8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1efb1444-b2ea-4ffd-8b68-12ef1fdafa70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_a3d39f42-e0e2-4aae-a26f-32f797d2f131_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of investments - other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_11f9c899-3265-4ffa-b7eb-a4f9a5bf4118_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dafe4db9-bc6a-4f85-b740-aeb3a33bc096_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4f6609fb-3ccb-4dee-833e-73ca248056fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_fdb2f23d-eb3a-4702-99f7-4fc8522ef159_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_be44bab7-b5ab-4881-8cd6-6bfb33c2cefb_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_6467e7dd-0de0-4cd4-84f0-62496a8b4a8d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1fcd02b3-8ec1-439b-a5b7-95c3ce53c50a_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_b0a2095b-faaf-4d3f-a97d-3ec7f66a78e5_terseLabel_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee stock purchase plan</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:href="vtl-20230331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7239d619-a5da-4584-907f-bf6cf016684a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AustraliaAndGermanyMember_69a4f39d-8d8b-4014-b2ae-aeadb0c0bf07_terseLabel_en-US" xlink:label="lab_vtl_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany</link:label>
    <link:label id="lab_vtl_AustraliaAndGermanyMember_label_en-US" xlink:label="lab_vtl_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany [Member]</link:label>
    <link:label id="lab_vtl_AustraliaAndGermanyMember_documentation_en-US" xlink:label="lab_vtl_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AustraliaAndGermanyMember" xlink:href="vtl-20230331.xsd#vtl_AustraliaAndGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AustraliaAndGermanyMember" xlink:to="lab_vtl_AustraliaAndGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_207f4a40-847b-4d36-98e2-ea8a9bb0eb0b_terseLabel_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:href="vtl-20230331.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:to="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4cc18476-101b-4fba-b062-253ed9a519b3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_c18b44f6-8b92-47ee-90b3-1c0d3f30354d_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_e4f101ac-8030-4f1f-965b-39b08765024f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_1a966815-e974-41c8-acc6-a85a5bd19617_terseLabel_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_label_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA [Member]</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_documentation_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember" xlink:href="vtl-20230331.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_DuaneNashMDJDMBAMember" xlink:to="lab_vtl_DuaneNashMDJDMBAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d98624c7-cf63-4695-9987-e341bc5f7006_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_81fc4641-2785-4649-a1f9-daf2f8202051_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a4910b05-c574-41ea-a100-a7e4ed7afea3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e70c5441-11b2-462f-9e51-b38a8e8afb3b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ce950e83-4b6a-4394-af75-336180f28f87_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_54cca149-2432-4c2b-9d47-2e2add6efec1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_20aedd23-3e04-4a46-996a-dd6ec7748339_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_865bb837-f4bb-4f97-9818-c3c2f991f671_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PreFundedWarrantsMember_48c4c00f-fa3a-410d-ad24-0ded5ddd5af3_terseLabel_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_label_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember" xlink:href="vtl-20230331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PreFundedWarrantsMember" xlink:to="lab_vtl_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d7620b17-b00e-4974-9a0d-d7f8c3351c9d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_972c55cf-ec4c-456a-9cfe-7f33610cda12_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in private placement transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0a688697-de98-470a-b90c-b534719243e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dc1607e0-e7e6-448d-a6c6-c8ed6c57e6ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_83e1e08d-6f97-4504-a649-e0f581d1b0f2_terseLabel_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_label_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_documentation_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity" xlink:href="vtl-20230331.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SaleOfStockRemainingCapacity" xlink:to="lab_vtl_SaleOfStockRemainingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c67e9e70-22d1-449f-9f66-f7596438bde1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_1598aafb-d113-4190-a8cf-eb7023989923_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_be7526f1-f7dd-4310-8fb2-64452f2833a8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2d1b9fc1-b6e4-4baf-8693-0449f14f58b8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_af71fe60-e0e9-4ae5-89ef-9d33ba8f96f4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_3d357a1d-49fa-4b52-a594-e46b7390cbc3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6b25f315-e2ec-40ef-a453-bfb1d8fe8dd9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_cf2b7083-a985-478a-8a3a-8bec387f08a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of the stock, at discount from market price at purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_aacc91af-bfba-4c96-aefc-11bf850a6a8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2bf3d51a-2dfc-473f-9d7a-6ecf11be9810_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3bd77080-d5fc-41a6-8c8f-095a1ee2cec4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2ebc26db-6338-4ca2-94bf-87c9916037b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c38fa7b3-271a-4162-9153-5c342f097186_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_72861fd1-fbeb-46ab-9e70-2714d6702bc7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal option period (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_cb71a4b8-3f19-4c5d-89bf-5b92d1bf9f57_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_51491f1b-71a1-4ad4-84ed-fbaa80c3cbb1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_190defd1-8dee-45de-b802-d23a2541d10b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_c443b0d9-6040-4af2-961d-c0c8907501c3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0e144ee4-987c-43e9-b749-84b4cd936266_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_678b7894-cf55-4c28-a187-f8980d54aa85_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_e7d70114-8678-4a65-9986-d9a8b33405bd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_45b692fa-4ad5-4716-8e8f-ce1365f75f6c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e7c049e7-e297-404e-9499-04b02c0dbdc5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3f54002b-0622-4820-8aaf-e3a6fae8798c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5671fb55-b24a-4529-ac04-8ee7b45201be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_d25b2de5-6bdc-439a-a388-3c34eb822c19_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_eb679294-6271-4afe-b938-99a8000b29bf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2222142c-156b-4d77-afc9-a0c376fd3cbb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_f563b4f8-90d9-4d0c-b322-6bc3efbe6880_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_4d18104a-0833-4cab-8ccf-bf922cf7108f_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:href="vtl-20230331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4b1eefb1-91db-4f60-8f0e-9aa0969fc4a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_747634a8-2657-44b5-87e5-a7e1de76e654_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8e22fa81-0911-4a49-a544-33cbb4d2578b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76a9b928-9782-46d3-98ca-846ab8c85cd9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9447d0c9-6302-45eb-95bf-f9f3e6369184_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5e74a379-5eab-40ba-90c0-776d34c2d3bd_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4d688cd4-3265-4264-a73a-611863bbf171_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_257dbecb-8632-4b47-959f-5ac38f35902e_terseLabel_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and audit costs</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:href="vtl-20230331.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:to="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c58fe811-1753-4b18-8945-7839653a4d30_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_097712cb-9285-43db-9c32-d1559d9ad276_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ac571252-ec62-4edc-b501-ba98032b7dfb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a5c6bede-84ef-469c-a3de-db531c7fb3a4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_465eec5f-7b73-44a4-bc5c-76191a10db32_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_c24c7ec7-8db0-4357-8301-1a20e6f915ac_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c8460ac8-4fb7-4bce-a22b-cf939374216f_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_12c767a8-4dc4-41dc-a173-1243f5a12251_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbc48cc2-67dd-48dc-b7d7-bc1fad0f38c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9e371b2a-293b-4a4a-b686-ca7d130f528e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_1d31e899-358c-4fa0-8a6a-9d8d5d3d600c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_37df5c95-7d17-4ec5-8416-e5eb68888a64_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32b40d8a-78b3-4ffe-bdde-f78bfbb130e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_675ed8f3-b68d-4da7-8a54-76dc81ab2207_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f4a06515-6621-40f1-a9af-fcaf3f289fdd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9de4beed-c664-4fea-ba14-8c1eed1ea9da_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d8554eee-e1bb-4c8d-b44a-0dcd164fe020_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8603f757-a99a-497b-be3e-c60f41923939_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in period, weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a70e4515-29fc-4635-a29a-2fcd9d3fa1a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_a85c568e-b1f7-4514-b7a3-8e80aac43d22_terseLabel_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per each share of common stock</link:label>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_label_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Per Each Share of Common Stock</link:label>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_documentation_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Per Each Share of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:href="vtl-20230331.xsd#vtl_NumberOfVotesPerEachShareOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:to="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4c5a6fd8-97dc-45f8-9321-9a5ab3289e90_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_86cce38b-2b40-4f87-a680-d48f5336e880_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_86262874-4abc-4e32-b3b2-19d85cc532e7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_145e70b9-0109-4f7d-8ebd-5dd596fed98a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_397a9f70-40f6-4a20-ab35-31bcaa32423e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_87f12431-b639-499e-ae04-2f7fffe240e9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_421c6564-34d0-48ce-ac27-ca52baaf52e0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_51b8ccb5-3b7b-4a59-ae5e-1a332799b01f_terseLabel_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate on operating leases</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:href="vtl-20230331.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:to="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_e3543708-28dd-4c6d-9c95-e7d18ca909a9_terseLabel_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_label_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_documentation_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:href="vtl-20230331.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:to="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_de7e0ffc-68cd-4b15-a24a-2d22d255bcc8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued and/or Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d05cb755-ca38-4f32-b9dc-31e774154662_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_6353a5a4-12d5-4e44-9d38-a7c9bfe0a15e_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent holiday period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1db59b4d-f04d-4a94-9332-a32137ff818f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_b35d5988-207c-4896-8dec-da3171824d10_terseLabel_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_label_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_documentation_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:href="vtl-20230331.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:to="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_63d385c2-4f67-4aa6-9c71-e6423e6048e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3038c324-b234-4b20-931e-d637f4142092_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fb568a6e-c1ff-416f-9911-edb7d60f097a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2dec19a7-b488-4d3e-975d-34c336b274ef_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vtl-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:40f41647-d1d2-404b-8a31-83c86744a64e,g:f57fa659-71e4-427e-b4f1-2f0099ec97ac-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CoverPage" xlink:type="simple" xlink:href="vtl-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_de332a35-79ae-470f-97b3-db7b1719275c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_DocumentType_de332a35-79ae-470f-97b3-db7b1719275c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b9f48e10-ab46-4f84-9d8b-612502a94af5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_DocumentQuarterlyReport_b9f48e10-ab46-4f84-9d8b-612502a94af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d0e71910-a75f-4680-89cf-f69277429025" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_DocumentPeriodEndDate_d0e71910-a75f-4680-89cf-f69277429025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_aca40444-fce6-489b-85e9-59d413d529dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_DocumentTransitionReport_aca40444-fce6-489b-85e9-59d413d529dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3dba0edb-73dc-4469-9c0e-be1c384d399c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityFileNumber_3dba0edb-73dc-4469-9c0e-be1c384d399c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fa1f1bf9-56b7-43bc-9281-71f1bab7767c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityRegistrantName_fa1f1bf9-56b7-43bc-9281-71f1bab7767c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_12696c74-46d2-419d-baa8-9295b9f78a33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_12696c74-46d2-419d-baa8-9295b9f78a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d45e14a6-0ffa-4be1-a15f-dae8fb85c76a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityTaxIdentificationNumber_d45e14a6-0ffa-4be1-a15f-dae8fb85c76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_67d3d27a-b6f3-4550-90a4-a432d4747e0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityAddressAddressLine1_67d3d27a-b6f3-4550-90a4-a432d4747e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_ef26bc80-9cc0-4f55-a009-f178f730a977" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityAddressAddressLine2_ef26bc80-9cc0-4f55-a009-f178f730a977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b1591ca1-a9aa-451b-8968-fc72b9be4bbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityAddressCityOrTown_b1591ca1-a9aa-451b-8968-fc72b9be4bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_374dc1f8-9faf-42d4-a5fc-460d9b117cbf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityAddressStateOrProvince_374dc1f8-9faf-42d4-a5fc-460d9b117cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c3bf8457-0846-4563-82fd-7148bca664c1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityAddressPostalZipCode_c3bf8457-0846-4563-82fd-7148bca664c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c394429c-c81a-45e4-a2a1-e10138177bd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_CityAreaCode_c394429c-c81a-45e4-a2a1-e10138177bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5130324e-086f-433a-986d-c69f455fb60d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_LocalPhoneNumber_5130324e-086f-433a-986d-c69f455fb60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6fc13a43-8986-4fce-8878-6895cb640960" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_Security12bTitle_6fc13a43-8986-4fce-8878-6895cb640960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3c2c829b-8ee6-4e8b-a4e0-4b6c310e51b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_TradingSymbol_3c2c829b-8ee6-4e8b-a4e0-4b6c310e51b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4a5d13be-4733-4484-b2f6-0e9f1e8257c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_SecurityExchangeName_4a5d13be-4733-4484-b2f6-0e9f1e8257c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5294ba5d-a1d5-4f4e-9d9b-63560bd71902" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityCurrentReportingStatus_5294ba5d-a1d5-4f4e-9d9b-63560bd71902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fd6745e1-d579-488f-beb1-8d4adade3ac8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityInteractiveDataCurrent_fd6745e1-d579-488f-beb1-8d4adade3ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0f540a90-2cc0-4823-a6a9-5b685283d3c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityFilerCategory_0f540a90-2cc0-4823-a6a9-5b685283d3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a838b5fb-ccf5-46b6-bd30-d43bf7b2e812" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntitySmallBusiness_a838b5fb-ccf5-46b6-bd30-d43bf7b2e812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9cbb6355-4914-456e-8074-d82f8f3d7288" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityEmergingGrowthCompany_9cbb6355-4914-456e-8074-d82f8f3d7288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7bad518c-a28e-4add-bae5-fac0755c4e34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityShellCompany_7bad518c-a28e-4add-bae5-fac0755c4e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e2015346-af00-4136-934b-bbdcc89f64cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e2015346-af00-4136-934b-bbdcc89f64cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6fe39733-5e2a-4f26-b834-3b0362ef2e44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_DocumentFiscalYearFocus_6fe39733-5e2a-4f26-b834-3b0362ef2e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_41208e38-a100-4fd2-a718-6ea2effeaa93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_41208e38-a100-4fd2-a718-6ea2effeaa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5fa029c7-abac-4db6-916c-6dec8b4c065c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_AmendmentFlag_5fa029c7-abac-4db6-916c-6dec8b4c065c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_6bb97239-f250-41be-9e52-4dcacd62680c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_CurrentFiscalYearEndDate_6bb97239-f250-41be-9e52-4dcacd62680c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a686dfc5-489e-476e-9eff-e8a3f756f6ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_203456b3-8fcb-45c9-9d59-ff0e72a52e0e" xlink:to="loc_dei_EntityCentralIndexKey_a686dfc5-489e-476e-9eff-e8a3f756f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b783bb64-9c0a-461e-9cbe-654b718a6567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a8e970c1-8dda-4b15-8121-f7685235a4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b783bb64-9c0a-461e-9cbe-654b718a6567" xlink:to="loc_us-gaap_AssetsAbstract_a8e970c1-8dda-4b15-8121-f7685235a4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b0371bb5-e1af-4933-b475-0371212aaeff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a8e970c1-8dda-4b15-8121-f7685235a4db" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b0371bb5-e1af-4933-b475-0371212aaeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999bd2ab-c839-4833-92d9-c07f57203872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b0371bb5-e1af-4933-b475-0371212aaeff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999bd2ab-c839-4833-92d9-c07f57203872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_ae58bd60-b493-4e7d-b48a-d500190a1561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b0371bb5-e1af-4933-b475-0371212aaeff" xlink:to="loc_us-gaap_OtherShortTermInvestments_ae58bd60-b493-4e7d-b48a-d500190a1561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7675b97b-2900-4ffa-b663-e263c2c20e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b0371bb5-e1af-4933-b475-0371212aaeff" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7675b97b-2900-4ffa-b663-e263c2c20e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fcc2f263-7dd9-4d10-9c2c-5ef1daa1727f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b0371bb5-e1af-4933-b475-0371212aaeff" xlink:to="loc_us-gaap_AssetsCurrent_fcc2f263-7dd9-4d10-9c2c-5ef1daa1727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a2c0e18f-4304-41f7-812d-caab621057f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a8e970c1-8dda-4b15-8121-f7685235a4db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a2c0e18f-4304-41f7-812d-caab621057f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c42dcdf6-4c69-42a4-8bd9-bb6cd0dd3e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a8e970c1-8dda-4b15-8121-f7685235a4db" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c42dcdf6-4c69-42a4-8bd9-bb6cd0dd3e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_52a6e16e-b28d-40b0-aa08-b7bba237c1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a8e970c1-8dda-4b15-8121-f7685235a4db" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_52a6e16e-b28d-40b0-aa08-b7bba237c1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_222bd98a-624e-4798-a94d-29a7b6cd29a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a8e970c1-8dda-4b15-8121-f7685235a4db" xlink:to="loc_us-gaap_Assets_222bd98a-624e-4798-a94d-29a7b6cd29a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62890617-b9eb-4992-8c4e-e4e778fb7d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b783bb64-9c0a-461e-9cbe-654b718a6567" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62890617-b9eb-4992-8c4e-e4e778fb7d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ac7a4e22-639b-498b-a6b1-9e411c95df57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62890617-b9eb-4992-8c4e-e4e778fb7d76" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ac7a4e22-639b-498b-a6b1-9e411c95df57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b15719a0-85e2-4ad2-9ae4-f4bb54b93f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac7a4e22-639b-498b-a6b1-9e411c95df57" xlink:to="loc_us-gaap_AccountsPayableCurrent_b15719a0-85e2-4ad2-9ae4-f4bb54b93f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bab1ac22-f20e-4a27-a6df-4ab135b3951a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac7a4e22-639b-498b-a6b1-9e411c95df57" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bab1ac22-f20e-4a27-a6df-4ab135b3951a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e909890b-e089-42ee-a240-8b393f713fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac7a4e22-639b-498b-a6b1-9e411c95df57" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e909890b-e089-42ee-a240-8b393f713fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_27a2454b-5c87-4d81-b2e3-0fa52d54777c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ac7a4e22-639b-498b-a6b1-9e411c95df57" xlink:to="loc_us-gaap_LiabilitiesCurrent_27a2454b-5c87-4d81-b2e3-0fa52d54777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_e7257a05-5182-4847-a2c8-1af209862d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62890617-b9eb-4992-8c4e-e4e778fb7d76" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_e7257a05-5182-4847-a2c8-1af209862d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_15ebb586-ce11-4bbd-b1fe-dd47f2d32faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e7257a05-5182-4847-a2c8-1af209862d56" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_15ebb586-ce11-4bbd-b1fe-dd47f2d32faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_24c3e5dd-6b91-48f6-9f01-e3a1bddc8617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e7257a05-5182-4847-a2c8-1af209862d56" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_24c3e5dd-6b91-48f6-9f01-e3a1bddc8617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b7c56bca-7736-4a4d-866f-dfe722b7b1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62890617-b9eb-4992-8c4e-e4e778fb7d76" xlink:to="loc_us-gaap_Liabilities_b7c56bca-7736-4a4d-866f-dfe722b7b1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1b341e88-a3b3-44c5-a20d-42184ebc52c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62890617-b9eb-4992-8c4e-e4e778fb7d76" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1b341e88-a3b3-44c5-a20d-42184ebc52c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_7ee0ac5d-2b1b-41c8-86ad-d42ab87e95ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62890617-b9eb-4992-8c4e-e4e778fb7d76" xlink:to="loc_us-gaap_StockholdersEquityAbstract_7ee0ac5d-2b1b-41c8-86ad-d42ab87e95ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b66fd39c-937a-4d6f-b1c7-aebf6e20074b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7ee0ac5d-2b1b-41c8-86ad-d42ab87e95ff" xlink:to="loc_us-gaap_PreferredStockValue_b66fd39c-937a-4d6f-b1c7-aebf6e20074b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_96a7efa6-329c-49dc-9470-f9bea3822101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7ee0ac5d-2b1b-41c8-86ad-d42ab87e95ff" xlink:to="loc_us-gaap_CommonStockValue_96a7efa6-329c-49dc-9470-f9bea3822101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a96f476e-f3d4-4711-82ab-a980038f77b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7ee0ac5d-2b1b-41c8-86ad-d42ab87e95ff" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a96f476e-f3d4-4711-82ab-a980038f77b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78de82ad-3fcd-42b8-a9eb-d7aee2065ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7ee0ac5d-2b1b-41c8-86ad-d42ab87e95ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_78de82ad-3fcd-42b8-a9eb-d7aee2065ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a68b2017-059e-4898-85e2-59106bcce992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7ee0ac5d-2b1b-41c8-86ad-d42ab87e95ff" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a68b2017-059e-4898-85e2-59106bcce992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1801f952-0601-4818-992b-d3e032634424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_7ee0ac5d-2b1b-41c8-86ad-d42ab87e95ff" xlink:to="loc_us-gaap_StockholdersEquity_1801f952-0601-4818-992b-d3e032634424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e54cbbc2-e8e8-487e-99c1-933b0ca6389d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_62890617-b9eb-4992-8c4e-e4e778fb7d76" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e54cbbc2-e8e8-487e-99c1-933b0ca6389d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_21af6b9a-886f-412d-b1a8-845e06ed8bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bc31ac06-93f6-470b-b3cc-fc8df7fe6290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21af6b9a-886f-412d-b1a8-845e06ed8bf9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_bc31ac06-93f6-470b-b3cc-fc8df7fe6290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_961739d3-e22a-472a-b140-2517f3252b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21af6b9a-886f-412d-b1a8-845e06ed8bf9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_961739d3-e22a-472a-b140-2517f3252b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_fe0fed74-5d22-4783-9713-03025d408445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21af6b9a-886f-412d-b1a8-845e06ed8bf9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_fe0fed74-5d22-4783-9713-03025d408445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_81b19a4f-b856-4966-855f-27e9c6c4b6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21af6b9a-886f-412d-b1a8-845e06ed8bf9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_81b19a4f-b856-4966-855f-27e9c6c4b6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ef18dc76-545c-4284-8910-3e611e79e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21af6b9a-886f-412d-b1a8-845e06ed8bf9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ef18dc76-545c-4284-8910-3e611e79e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0453ff90-55a2-4523-bf18-667c78bf197d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21af6b9a-886f-412d-b1a8-845e06ed8bf9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0453ff90-55a2-4523-bf18-667c78bf197d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a81a31a2-b331-43f8-8f24-0fe1bc28fa64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21af6b9a-886f-412d-b1a8-845e06ed8bf9" xlink:to="loc_us-gaap_CommonStockSharesIssued_a81a31a2-b331-43f8-8f24-0fe1bc28fa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2f3e6a10-692a-438e-a73d-7a41908d1471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21af6b9a-886f-412d-b1a8-845e06ed8bf9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2f3e6a10-692a-438e-a73d-7a41908d1471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b4d3e2b7-daf0-4dd3-9699-7e3dc5eb5607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bbf91f15-b06b-4781-a38f-d3b12c9095eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4d3e2b7-daf0-4dd3-9699-7e3dc5eb5607" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bbf91f15-b06b-4781-a38f-d3b12c9095eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_893c69f5-d16a-419d-baa2-07645f6e3b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbf91f15-b06b-4781-a38f-d3b12c9095eb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_893c69f5-d16a-419d-baa2-07645f6e3b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8bb575fd-cdd0-4d86-9cea-4b9d4c8e38b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbf91f15-b06b-4781-a38f-d3b12c9095eb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8bb575fd-cdd0-4d86-9cea-4b9d4c8e38b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2e49982c-2c9a-4cbf-b519-15aea72af8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bbf91f15-b06b-4781-a38f-d3b12c9095eb" xlink:to="loc_us-gaap_OperatingExpenses_2e49982c-2c9a-4cbf-b519-15aea72af8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f1efd5b7-fb25-4186-b7cc-a5ba2424da45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4d3e2b7-daf0-4dd3-9699-7e3dc5eb5607" xlink:to="loc_us-gaap_OperatingIncomeLoss_f1efd5b7-fb25-4186-b7cc-a5ba2424da45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5571eabb-d985-4773-ad00-1578c88eb6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4d3e2b7-daf0-4dd3-9699-7e3dc5eb5607" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5571eabb-d985-4773-ad00-1578c88eb6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_13b3a480-4142-4651-8c18-4e0186208901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5571eabb-d985-4773-ad00-1578c88eb6a9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_13b3a480-4142-4651-8c18-4e0186208901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3bac69b0-2791-4b4e-b7ea-e12a88dcbf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5571eabb-d985-4773-ad00-1578c88eb6a9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3bac69b0-2791-4b4e-b7ea-e12a88dcbf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_11090d09-65b8-4584-86d0-b5382a3d1d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5571eabb-d985-4773-ad00-1578c88eb6a9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_11090d09-65b8-4584-86d0-b5382a3d1d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_459832de-f94e-4de4-8783-069680fc4017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4d3e2b7-daf0-4dd3-9699-7e3dc5eb5607" xlink:to="loc_us-gaap_NetIncomeLoss_459832de-f94e-4de4-8783-069680fc4017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_24c904cc-5b73-45f5-8618-aa4c820399c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4d3e2b7-daf0-4dd3-9699-7e3dc5eb5607" xlink:to="loc_us-gaap_EarningsPerShareBasic_24c904cc-5b73-45f5-8618-aa4c820399c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b15eeac4-3da6-4551-8b5a-1016661f2568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4d3e2b7-daf0-4dd3-9699-7e3dc5eb5607" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b15eeac4-3da6-4551-8b5a-1016661f2568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_47588be0-f1b0-4f44-aed8-d93af8a241bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4d3e2b7-daf0-4dd3-9699-7e3dc5eb5607" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_47588be0-f1b0-4f44-aed8-d93af8a241bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70924df6-c317-42cd-8895-d9a16daf182f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b4d3e2b7-daf0-4dd3-9699-7e3dc5eb5607" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70924df6-c317-42cd-8895-d9a16daf182f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_34ba3fa7-27ef-4324-96a8-11926ef21ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_154251e3-09b7-4819-9361-76130b2e9e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_34ba3fa7-27ef-4324-96a8-11926ef21ee6" xlink:to="loc_us-gaap_NetIncomeLoss_154251e3-09b7-4819-9361-76130b2e9e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0a0c3f43-b777-41df-8ced-b33e169ef050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_34ba3fa7-27ef-4324-96a8-11926ef21ee6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0a0c3f43-b777-41df-8ced-b33e169ef050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_773fa766-44cf-4531-a0d3-654325ddc4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0a0c3f43-b777-41df-8ced-b33e169ef050" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_773fa766-44cf-4531-a0d3-654325ddc4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c4979b92-2214-4715-bc48-d7ad204de45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_34ba3fa7-27ef-4324-96a8-11926ef21ee6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c4979b92-2214-4715-bc48-d7ad204de45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_93693a45-62f4-4168-809e-dbc3705a9742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5868e322-9a61-4333-a702-004a121f7456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_93693a45-62f4-4168-809e-dbc3705a9742" xlink:to="loc_us-gaap_StatementTable_5868e322-9a61-4333-a702-004a121f7456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b2a35a8a-9d01-4c8d-88c2-d466cf164b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5868e322-9a61-4333-a702-004a121f7456" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b2a35a8a-9d01-4c8d-88c2-d466cf164b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b2a35a8a-9d01-4c8d-88c2-d466cf164b30" xlink:to="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4021d909-5781-4da4-a874-7d429afc53d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:to="loc_us-gaap_CommonStockMember_4021d909-5781-4da4-a874-7d429afc53d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee2eb064-c5f9-407f-ad17-1f2d93859f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee2eb064-c5f9-407f-ad17-1f2d93859f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4db39620-743f-4a9e-a3f5-9e8bc02abd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4db39620-743f-4a9e-a3f5-9e8bc02abd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5d1bd522-d460-467a-87e4-11edba02e850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9e03695f-9cf0-4c75-85f5-1aceaa8c5aea" xlink:to="loc_us-gaap_RetainedEarningsMember_5d1bd522-d460-467a-87e4-11edba02e850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_102d5b61-53c9-4a5b-ac7d-1bd594acecdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5868e322-9a61-4333-a702-004a121f7456" xlink:to="loc_us-gaap_StatementLineItems_102d5b61-53c9-4a5b-ac7d-1bd594acecdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_102d5b61-53c9-4a5b-ac7d-1bd594acecdd" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_73c4162c-1fed-45c0-9c7f-0784bda33f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_73c4162c-1fed-45c0-9c7f-0784bda33f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e85f5f02-0153-4761-b688-33179c9e9a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockholdersEquity_e85f5f02-0153-4761-b688-33179c9e9a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5b2d0b7d-64ac-476d-bfec-d7c0697eb868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_NetIncomeLoss_5b2d0b7d-64ac-476d-bfec-d7c0697eb868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_db04b680-caf3-48d7-99ce-42e87cb750e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_db04b680-caf3-48d7-99ce-42e87cb750e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_83a8720b-e86e-4395-9dd9-ba2466cc3007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_83a8720b-e86e-4395-9dd9-ba2466cc3007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7fd52d62-5066-4251-9712-7a60744e4f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7fd52d62-5066-4251-9712-7a60744e4f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9ee43fab-32b2-4a75-a6e7-c7d5c49b4e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9ee43fab-32b2-4a75-a6e7-c7d5c49b4e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40d2423c-959f-472f-8ef2-b748150fb101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_40d2423c-959f-472f-8ef2-b748150fb101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_894de273-b802-4377-be40-82b51e4d20a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_894de273-b802-4377-be40-82b51e4d20a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5daf167a-00c2-4ca2-9141-911b433d6239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5daf167a-00c2-4ca2-9141-911b433d6239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c5c3693-a71e-47d9-87be-47388bb4d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_70f2e2cb-1f68-420e-99ae-a9b7ceafe76b" xlink:to="loc_us-gaap_StockholdersEquity_6c5c3693-a71e-47d9-87be-47388bb4d0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ada3a6ce-f1ca-409a-8105-bdd4dbe0d81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d428adf2-8a57-4500-a561-2eaacc6187f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ada3a6ce-f1ca-409a-8105-bdd4dbe0d81c" xlink:to="loc_us-gaap_StatementTable_d428adf2-8a57-4500-a561-2eaacc6187f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ca71e381-13e3-4766-a86a-69547fb119ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d428adf2-8a57-4500-a561-2eaacc6187f5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ca71e381-13e3-4766-a86a-69547fb119ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_581d2723-4dc4-4bab-bfaa-93360b794f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ca71e381-13e3-4766-a86a-69547fb119ff" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_581d2723-4dc4-4bab-bfaa-93360b794f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AtTheMarketSalesAgreementMember_0873ed12-00e7-4d15-ab93-176a333491c4" xlink:href="vtl-20230331.xsd#vtl_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_581d2723-4dc4-4bab-bfaa-93360b794f8e" xlink:to="loc_vtl_AtTheMarketSalesAgreementMember_0873ed12-00e7-4d15-ab93-176a333491c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_80a1cf8f-92b6-4231-8171-adfbb34a7778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d428adf2-8a57-4500-a561-2eaacc6187f5" xlink:to="loc_us-gaap_StatementLineItems_80a1cf8f-92b6-4231-8171-adfbb34a7778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_741c0922-23c6-4ac0-a542-0fd6167d231c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_80a1cf8f-92b6-4231-8171-adfbb34a7778" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_741c0922-23c6-4ac0-a542-0fd6167d231c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20230331.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1a383afd-b106-41c6-b37e-acc970f75d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_df1d8665-b367-4bed-9073-b07c3229c46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a383afd-b106-41c6-b37e-acc970f75d88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_df1d8665-b367-4bed-9073-b07c3229c46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f35b12d9-2a8b-42d0-841b-98024513a64f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_df1d8665-b367-4bed-9073-b07c3229c46b" xlink:to="loc_us-gaap_NetIncomeLoss_f35b12d9-2a8b-42d0-841b-98024513a64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a87de933-dbb1-4bd5-bcb8-7a2482fe0d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_df1d8665-b367-4bed-9073-b07c3229c46b" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a87de933-dbb1-4bd5-bcb8-7a2482fe0d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_03894d0a-24e8-4511-acc2-f09ed2434c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a87de933-dbb1-4bd5-bcb8-7a2482fe0d8f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_03894d0a-24e8-4511-acc2-f09ed2434c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_cfa792d6-2b98-48a0-8428-2a3b25ae66ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a87de933-dbb1-4bd5-bcb8-7a2482fe0d8f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_cfa792d6-2b98-48a0-8428-2a3b25ae66ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1b2e5f17-c0ca-4682-86a1-0bae0fa57796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a87de933-dbb1-4bd5-bcb8-7a2482fe0d8f" xlink:to="loc_us-gaap_ShareBasedCompensation_1b2e5f17-c0ca-4682-86a1-0bae0fa57796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_77999ab0-cd72-4c77-af0d-225394e033f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a87de933-dbb1-4bd5-bcb8-7a2482fe0d8f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_77999ab0-cd72-4c77-af0d-225394e033f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2f69893d-4d58-46b6-a02c-629c2575b55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_77999ab0-cd72-4c77-af0d-225394e033f1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2f69893d-4d58-46b6-a02c-629c2575b55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10b8096c-9e15-427d-acfd-cfef11c15e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_77999ab0-cd72-4c77-af0d-225394e033f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10b8096c-9e15-427d-acfd-cfef11c15e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eb325d5f-6aad-4c16-b400-b0bf7b4bc499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_77999ab0-cd72-4c77-af0d-225394e033f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eb325d5f-6aad-4c16-b400-b0bf7b4bc499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_697b8cc7-bef3-45ef-b9c9-28cab3dadbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_77999ab0-cd72-4c77-af0d-225394e033f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_697b8cc7-bef3-45ef-b9c9-28cab3dadbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad368571-09e1-4164-a833-b00300932e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_df1d8665-b367-4bed-9073-b07c3229c46b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad368571-09e1-4164-a833-b00300932e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9524071a-6f6f-41bb-85b3-933612628e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a383afd-b106-41c6-b37e-acc970f75d88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9524071a-6f6f-41bb-85b3-933612628e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_1183a276-e390-4154-b0c7-55c1db7b4ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9524071a-6f6f-41bb-85b3-933612628e9e" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_1183a276-e390-4154-b0c7-55c1db7b4ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8fd9e115-d6c3-4d5c-8c36-04a2f696dc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9524071a-6f6f-41bb-85b3-933612628e9e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8fd9e115-d6c3-4d5c-8c36-04a2f696dc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c2b94fb-46fc-42bc-b3f4-46fde2bb099a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9524071a-6f6f-41bb-85b3-933612628e9e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c2b94fb-46fc-42bc-b3f4-46fde2bb099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b2ab1595-ea4a-47ec-b463-ce82491698f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a383afd-b106-41c6-b37e-acc970f75d88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b2ab1595-ea4a-47ec-b463-ce82491698f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_89fe6273-06a4-4679-96d3-cf7b5ca13b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b2ab1595-ea4a-47ec-b463-ce82491698f4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_89fe6273-06a4-4679-96d3-cf7b5ca13b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_92eda212-19cf-447c-8ee8-32eba489325c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b2ab1595-ea4a-47ec-b463-ce82491698f4" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_92eda212-19cf-447c-8ee8-32eba489325c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_48fc749b-198c-4b95-829d-841d421b6087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b2ab1595-ea4a-47ec-b463-ce82491698f4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_48fc749b-198c-4b95-829d-841d421b6087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84107c3c-5d60-4957-9632-d96fc655b4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_b2ab1595-ea4a-47ec-b463-ce82491698f4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84107c3c-5d60-4957-9632-d96fc655b4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_493c5141-dc25-4354-8421-5794ce0a2ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a383afd-b106-41c6-b37e-acc970f75d88" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_493c5141-dc25-4354-8421-5794ce0a2ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_290e4847-d088-41dc-abcc-6d304c131c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a383afd-b106-41c6-b37e-acc970f75d88" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_290e4847-d088-41dc-abcc-6d304c131c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21929052-b067-4eec-9445-8e7c6cbdd915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a383afd-b106-41c6-b37e-acc970f75d88" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21929052-b067-4eec-9445-8e7c6cbdd915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e4a1fec-92b8-45c8-a0c9-a24042553a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a383afd-b106-41c6-b37e-acc970f75d88" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e4a1fec-92b8-45c8-a0c9-a24042553a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_da768bb6-15bd-403e-bdc4-d9a530d0bcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a383afd-b106-41c6-b37e-acc970f75d88" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_da768bb6-15bd-403e-bdc4-d9a530d0bcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_12386147-a0ab-4bcf-913f-27293e233f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_da768bb6-15bd-403e-bdc4-d9a530d0bcc8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_12386147-a0ab-4bcf-913f-27293e233f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="vtl-20230331.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d70880c7-4198-40ae-abb6-33cb0c8bfd17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9393ac42-c7dc-422c-b0b4-910486eb15c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d70880c7-4198-40ae-abb6-33cb0c8bfd17" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_9393ac42-c7dc-422c-b0b4-910486eb15c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtl-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5cbde8a6-9d31-4d3e-8d83-c721e42f4980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8f8b3b27-5f1b-4e42-8cfb-5fc018ed2e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5cbde8a6-9d31-4d3e-8d83-c721e42f4980" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8f8b3b27-5f1b-4e42-8cfb-5fc018ed2e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a724d11-f278-4ae1-af97-9797f42a9cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_2b72c3de-0897-4b16-b7bc-f48f494fa57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a724d11-f278-4ae1-af97-9797f42a9cc9" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_2b72c3de-0897-4b16-b7bc-f48f494fa57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6aa40cfc-5170-44a4-bc3f-729e35d3d742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7e800fb4-c6f0-4c0c-b2f9-421bb72a5f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6aa40cfc-5170-44a4-bc3f-729e35d3d742" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7e800fb4-c6f0-4c0c-b2f9-421bb72a5f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValue" xlink:type="simple" xlink:href="vtl-20230331.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7729e564-4b8c-4a78-8ca2-394fccc778cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ce8703a3-5c9c-4776-82ce-2bf10dd35526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7729e564-4b8c-4a78-8ca2-394fccc778cf" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ce8703a3-5c9c-4776-82ce-2bf10dd35526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStock" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_378efdfb-8e6f-435a-a138-761dc6b53975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6a48cafa-0bb3-484f-9a25-d9598d022bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_378efdfb-8e6f-435a-a138-761dc6b53975" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6a48cafa-0bb3-484f-9a25-d9598d022bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51114e9d-4c24-435c-9401-5f23419e70f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a88f9d27-e5f7-4e44-87c4-b8b6da2d4bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51114e9d-4c24-435c-9401-5f23419e70f5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a88f9d27-e5f7-4e44-87c4-b8b6da2d4bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtl-20230331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4a830e67-cb67-4dcc-bd81-3bab22089c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1bd9f683-ee2d-495f-9ac6-34db93d57375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4a830e67-cb67-4dcc-bd81-3bab22089c3f" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1bd9f683-ee2d-495f-9ac6-34db93d57375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="simple" xlink:href="vtl-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_791921b1-1c61-4c07-8a41-aa6878105334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9d5493df-9a62-42d9-a1a8-ad544ebc1727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_791921b1-1c61-4c07-8a41-aa6878105334" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9d5493df-9a62-42d9-a1a8-ad544ebc1727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtl-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e7376212-0183-44c0-9be4-5d9311d4e466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e7376212-0183-44c0-9be4-5d9311d4e466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4540ef9f-e392-4912-83a3-537e5039ca92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_UseOfEstimates_4540ef9f-e392-4912-83a3-537e5039ca92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5ef8c9a0-cd96-4a09-8e97-534c62177420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5ef8c9a0-cd96-4a09-8e97-534c62177420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_6e53eedb-c042-44ac-bcc1-76a630ec19e6" xlink:href="vtl-20230331.xsd#vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_6e53eedb-c042-44ac-bcc1-76a630ec19e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d9561282-7105-4b45-b08d-c31e39f0338a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_d9561282-7105-4b45-b08d-c31e39f0338a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6e66d0a2-940a-44ba-a62d-34fd7b3c9b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6e66d0a2-940a-44ba-a62d-34fd7b3c9b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_db750524-673d-4305-90d2-d2e7d3983685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_db750524-673d-4305-90d2-d2e7d3983685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_96935642-39b4-4c2a-9887-d35976223897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_96935642-39b4-4c2a-9887-d35976223897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c5719726-e170-40af-8fa7-1f38d98fbc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c5719726-e170-40af-8fa7-1f38d98fbc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_5e425765-c40e-44ab-ab60-f91e01f38a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_5e425765-c40e-44ab-ab60-f91e01f38a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock_d50ea57b-5e14-44cc-94f8-c72643658a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_GovernmentAssistancePolicyTextBlock_d50ea57b-5e14-44cc-94f8-c72643658a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_06de6a50-a175-49bb-a532-310eb9481347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_06de6a50-a175-49bb-a532-310eb9481347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_147c3a7f-a589-4f6b-bfd3-e1d00b81c8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_147c3a7f-a589-4f6b-bfd3-e1d00b81c8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_673b70bd-0ca4-4ede-a4f3-8cab5e8ac77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_673b70bd-0ca4-4ede-a4f3-8cab5e8ac77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e102105e-51e5-43c2-8170-7fcc29a0eb43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_e102105e-51e5-43c2-8170-7fcc29a0eb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_f986d5ab-44a1-45a3-8895-d77e818617de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_f986d5ab-44a1-45a3-8895-d77e818617de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_556710af-6cee-4926-a73f-2e2ae529bd38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_556710af-6cee-4926-a73f-2e2ae529bd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2ce3e4cc-f547-4ec7-86dc-434dbfe3ef1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2ce3e4cc-f547-4ec7-86dc-434dbfe3ef1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5ccde1d1-2eed-4e4c-9291-39533d9bf90d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf0bce8f-7b82-4767-bc4c-adb933271bfa" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5ccde1d1-2eed-4e4c-9291-39533d9bf90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vtl-20230331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_784f9378-8d34-41a3-b3f0-a003aa45d879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_154255bb-02e2-4548-aed4-207b6354297c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_784f9378-8d34-41a3-b3f0-a003aa45d879" xlink:to="loc_us-gaap_InvestmentTableTextBlock_154255bb-02e2-4548-aed4-207b6354297c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ca816c04-01d4-4261-90a1-7af517385a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_784f9378-8d34-41a3-b3f0-a003aa45d879" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ca816c04-01d4-4261-90a1-7af517385a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f0a40fb-67f3-4569-99a8-261d53773332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_b93ac1c5-d747-42fc-8f2e-57e3a7f38586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f0a40fb-67f3-4569-99a8-261d53773332" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_b93ac1c5-d747-42fc-8f2e-57e3a7f38586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_068c8d8c-8d3d-4198-8733-d22650bdce63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f0a40fb-67f3-4569-99a8-261d53773332" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_068c8d8c-8d3d-4198-8733-d22650bdce63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_59535694-b518-4856-ba99-13540eaef294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f0a40fb-67f3-4569-99a8-261d53773332" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_59535694-b518-4856-ba99-13540eaef294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8dc901a1-1882-4d34-b0e3-d0e15bccea6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f0c2d739-9430-41af-81f9-8cb589ec0770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8dc901a1-1882-4d34-b0e3-d0e15bccea6e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f0c2d739-9430-41af-81f9-8cb589ec0770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueTables" xlink:type="simple" xlink:href="vtl-20230331.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bebefcd5-d52e-4e17-bde7-7cd9e590756b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_15432270-582e-4559-bd92-1719e4d46b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bebefcd5-d52e-4e17-bde7-7cd9e590756b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_15432270-582e-4559-bd92-1719e4d46b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockTables" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6441dfeb-3801-4603-82fb-40387bf63b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_995b63c9-4f84-4b26-88ba-b26631273504" xlink:href="vtl-20230331.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6441dfeb-3801-4603-82fb-40387bf63b6b" xlink:to="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_995b63c9-4f84-4b26-88ba-b26631273504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f928a3b-53f1-400b-b988-2bb42fd8a207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0a781e7f-dc47-45c8-8bce-288af1efa110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f928a3b-53f1-400b-b988-2bb42fd8a207" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0a781e7f-dc47-45c8-8bce-288af1efa110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5795bbbe-ce7c-4c11-be91-b82e404d0e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f928a3b-53f1-400b-b988-2bb42fd8a207" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5795bbbe-ce7c-4c11-be91-b82e404d0e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a40457a0-be90-4f42-95f0-e0f8265e871e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f928a3b-53f1-400b-b988-2bb42fd8a207" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a40457a0-be90-4f42-95f0-e0f8265e871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_99d38804-4ca6-48dc-82e1-d199047b152d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4d84c469-bb7d-4f75-a0ed-27789472cd38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_99d38804-4ca6-48dc-82e1-d199047b152d" xlink:to="loc_us-gaap_SubsequentEventTable_4d84c469-bb7d-4f75-a0ed-27789472cd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_40560cf0-21d2-46ea-baba-496d69922259" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4d84c469-bb7d-4f75-a0ed-27789472cd38" xlink:to="loc_srt_StatementScenarioAxis_40560cf0-21d2-46ea-baba-496d69922259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0cce8969-cf8e-4e1c-86b6-db71cda91ccc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_40560cf0-21d2-46ea-baba-496d69922259" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0cce8969-cf8e-4e1c-86b6-db71cda91ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d2791893-ea63-4e73-9fb3-fda8229cbd24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0cce8969-cf8e-4e1c-86b6-db71cda91ccc" xlink:to="loc_srt_ScenarioForecastMember_d2791893-ea63-4e73-9fb3-fda8229cbd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4d84c469-bb7d-4f75-a0ed-27789472cd38" xlink:to="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_1025ed5e-d446-4a5a-aacf-928554732da7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_dei_EntityNumberOfEmployees_1025ed5e-d446-4a5a-aacf-928554732da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms_e60c35a3-879b-4382-be07-a72cb479c181" xlink:href="vtl-20230331.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_vtl_NumberOfDevelopmentPrograms_e60c35a3-879b-4382-be07-a72cb479c181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_491ffc1b-d528-4ca9-9dd6-a2c947b738b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_491ffc1b-d528-4ca9-9dd6-a2c947b738b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_68c4c35c-09ce-4ba4-995d-df505f41ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_68c4c35c-09ce-4ba4-995d-df505f41ab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b0da5fb-175d-4d87-9433-aadb1c603219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b0da5fb-175d-4d87-9433-aadb1c603219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_719aeaee-3755-4d6e-8ee4-cef9caa22c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_2df44592-5c9c-48f6-9cde-1f7a5afe825e" xlink:to="loc_us-gaap_OtherShortTermInvestments_719aeaee-3755-4d6e-8ee4-cef9caa22c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b3027984-65b2-40e3-a68b-2448411fa200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b3027984-65b2-40e3-a68b-2448411fa200" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_177cc11c-e36d-45d8-a2b4-c34bb0563330" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:to="loc_srt_RangeAxis_177cc11c-e36d-45d8-a2b4-c34bb0563330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c353be7-5804-4450-bf44-7c789b018777" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_177cc11c-e36d-45d8-a2b4-c34bb0563330" xlink:to="loc_srt_RangeMember_7c353be7-5804-4450-bf44-7c789b018777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_975e5d92-4a34-4d4e-a8c7-32606df77f94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c353be7-5804-4450-bf44-7c789b018777" xlink:to="loc_srt_MaximumMember_975e5d92-4a34-4d4e-a8c7-32606df77f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_26195474-4287-41a0-8af4-a8b493844813" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c353be7-5804-4450-bf44-7c789b018777" xlink:to="loc_srt_MinimumMember_26195474-4287-41a0-8af4-a8b493844813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7821d481-875a-456c-8f14-877fb69504d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:to="loc_srt_StatementGeographicalAxis_7821d481-875a-456c-8f14-877fb69504d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7821d481-875a-456c-8f14-877fb69504d3" xlink:to="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AustraliaAndGermanyMember_63f395a3-a8d3-46fa-a95f-3d12a6bf59a3" xlink:href="vtl-20230331.xsd#vtl_AustraliaAndGermanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:to="loc_vtl_AustraliaAndGermanyMember_63f395a3-a8d3-46fa-a95f-3d12a6bf59a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0fd45ed4-a5f5-4081-96e0-c3aa779356b2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:to="loc_country_US_0fd45ed4-a5f5-4081-96e0-c3aa779356b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_da2e5838-adc2-4224-8435-8c41e503862c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:to="loc_country_DE_da2e5838-adc2-4224-8435-8c41e503862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_12c76813-9a4f-429d-888b-a39d90dc8be5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7fb4e402-b0e8-423f-8a40-c542a4276a4f" xlink:to="loc_country_AU_12c76813-9a4f-429d-888b-a39d90dc8be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6e217d82-4783-4722-82e9-bb9551d0f802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:to="loc_us-gaap_InvestmentTypeAxis_6e217d82-4783-4722-82e9-bb9551d0f802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5d37e4f4-7a40-4d3b-8991-005b4e327f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_6e217d82-4783-4722-82e9-bb9551d0f802" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5d37e4f4-7a40-4d3b-8991-005b4e327f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_78d13da7-abaa-4afd-9f00-922bfa33d162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5d37e4f4-7a40-4d3b-8991-005b4e327f91" xlink:to="loc_us-gaap_MoneyMarketFundsMember_78d13da7-abaa-4afd-9f00-922bfa33d162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_46680a12-9d68-45b1-b2d6-08d0137f1ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5d37e4f4-7a40-4d3b-8991-005b4e327f91" xlink:to="loc_us-gaap_BankTimeDepositsMember_46680a12-9d68-45b1-b2d6-08d0137f1ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3514cf37-2179-4584-956d-fd0e6704a56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3514cf37-2179-4584-956d-fd0e6704a56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_22c8ece8-5a40-4d64-b851-157603753294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3514cf37-2179-4584-956d-fd0e6704a56a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_22c8ece8-5a40-4d64-b851-157603753294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_da5a15ec-b20e-44d1-9b18-469173be5365" xlink:href="vtl-20230331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_22c8ece8-5a40-4d64-b851-157603753294" xlink:to="loc_vtl_PreFundedWarrantsMember_da5a15ec-b20e-44d1-9b18-469173be5365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_feae31da-b51c-4d31-9238-710241fb80fd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_9d0be0e4-4ffa-4526-930c-62368aff154d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_InvestmentInterestRate_9d0be0e4-4ffa-4526-930c-62368aff154d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c3230dd-76dd-440e-bd40-759acdefe8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0c3230dd-76dd-440e-bd40-759acdefe8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_29e620b3-93d8-4f6e-aa34-a3cee45b39f5" xlink:href="vtl-20230331.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_29e620b3-93d8-4f6e-aa34-a3cee45b39f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_89a2fffb-a9d1-476b-8641-463585e4dbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_89a2fffb-a9d1-476b-8641-463585e4dbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e1ccb0ed-3ed2-4f00-b324-f6a87c895388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_Depreciation_e1ccb0ed-3ed2-4f00-b324-f6a87c895388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_529a02ff-0b34-46c2-9edd-a022f9c9ba23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_529a02ff-0b34-46c2-9edd-a022f9c9ba23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2f63f610-0962-4ad4-84aa-a322b9a54b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2f63f610-0962-4ad4-84aa-a322b9a54b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceRate_0cc488e2-e183-4a89-9952-e4032b2bd8d1" xlink:href="vtl-20230331.xsd#vtl_GovernmentAssistanceRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_vtl_GovernmentAssistanceRate_0cc488e2-e183-4a89-9952-e4032b2bd8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_12903f90-323b-4368-9d66-5cc0de48571f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_12903f90-323b-4368-9d66-5cc0de48571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8d73bfbc-a460-47ac-a21e-afe06a599516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8d73bfbc-a460-47ac-a21e-afe06a599516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_635658f7-2694-47a8-8a0f-09238c4c1e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_635658f7-2694-47a8-8a0f-09238c4c1e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_106dadb5-36b7-439d-9564-c324df8fe819" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_106dadb5-36b7-439d-9564-c324df8fe819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_296a4e08-45ed-42f7-bdd3-a0e44429e18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_296a4e08-45ed-42f7-bdd3-a0e44429e18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d956042c-dccb-4177-aff2-9bfbde067a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1a41a2bb-c5af-42d6-80a0-f287e452cf8d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d956042c-dccb-4177-aff2-9bfbde067a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#SummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_22772e9f-5400-4785-85f1-d33392a21f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_195e2bb7-1d1c-4ee6-abd4-30b4f10e1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_22772e9f-5400-4785-85f1-d33392a21f05" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_195e2bb7-1d1c-4ee6-abd4-30b4f10e1a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_650986fa-00e5-4737-a7c9-89ba19c0ffec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_195e2bb7-1d1c-4ee6-abd4-30b4f10e1a8e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_650986fa-00e5-4737-a7c9-89ba19c0ffec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9751989b-7c15-43ef-829e-3017f293dc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_650986fa-00e5-4737-a7c9-89ba19c0ffec" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9751989b-7c15-43ef-829e-3017f293dc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_dac63fb2-b664-4fd3-974c-2958d36f3495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9751989b-7c15-43ef-829e-3017f293dc24" xlink:to="loc_us-gaap_BankTimeDepositsMember_dac63fb2-b664-4fd3-974c-2958d36f3495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_ee06de3b-a112-49d7-9c45-d8d4e0aaf996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_195e2bb7-1d1c-4ee6-abd4-30b4f10e1a8e" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_ee06de3b-a112-49d7-9c45-d8d4e0aaf996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_a0177e2f-56bc-42f4-9542-3e0d590a2690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_ee06de3b-a112-49d7-9c45-d8d4e0aaf996" xlink:to="loc_us-gaap_OtherShortTermInvestments_a0177e2f-56bc-42f4-9542-3e0d590a2690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4dc2c43c-475a-4d0a-b5f7-f1dd28da5ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4a35730-42a1-4dcb-a19e-2a8b68e8166f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4dc2c43c-475a-4d0a-b5f7-f1dd28da5ef2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4a35730-42a1-4dcb-a19e-2a8b68e8166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bba0693-3ef6-43a3-8997-c31eab862ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4a35730-42a1-4dcb-a19e-2a8b68e8166f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bba0693-3ef6-43a3-8997-c31eab862ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fe570c3-3420-4daf-b4d5-7ca3333871b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0bba0693-3ef6-43a3-8997-c31eab862ad6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fe570c3-3420-4daf-b4d5-7ca3333871b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_7027e409-0279-40e2-8b19-06a61475033d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fe570c3-3420-4daf-b4d5-7ca3333871b0" xlink:to="loc_us-gaap_StockOptionMember_7027e409-0279-40e2-8b19-06a61475033d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c18c1329-1d2d-4ad4-a522-5620f5f9454b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4a35730-42a1-4dcb-a19e-2a8b68e8166f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c18c1329-1d2d-4ad4-a522-5620f5f9454b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f778c06-fa10-4820-9d3d-aab35f1528d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c18c1329-1d2d-4ad4-a522-5620f5f9454b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f778c06-fa10-4820-9d3d-aab35f1528d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aecb5cc1-f094-4e7f-98a0-d3fc86dc4157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_d105721f-fb40-49e4-9a65-6d6ad4c19ca3" xlink:href="vtl-20230331.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aecb5cc1-f094-4e7f-98a0-d3fc86dc4157" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_d105721f-fb40-49e4-9a65-6d6ad4c19ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_2d62da00-4070-49f5-8764-932b11a8e587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aecb5cc1-f094-4e7f-98a0-d3fc86dc4157" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_2d62da00-4070-49f5-8764-932b11a8e587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_a3398212-7458-4fe7-971b-18ead30ebd36" xlink:href="vtl-20230331.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aecb5cc1-f094-4e7f-98a0-d3fc86dc4157" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_a3398212-7458-4fe7-971b-18ead30ebd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5c76565e-d3fb-4b6b-8c90-d8198f9cb5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aecb5cc1-f094-4e7f-98a0-d3fc86dc4157" xlink:to="loc_us-gaap_OtherAssetsCurrent_5c76565e-d3fb-4b6b-8c90-d8198f9cb5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf763bdb-c7d1-4bee-9b9a-7a5f621a02ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aecb5cc1-f094-4e7f-98a0-d3fc86dc4157" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cf763bdb-c7d1-4bee-9b9a-7a5f621a02ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eccfcb24-edc0-44c6-8e3e-7ea6a6d44dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_ee609d47-381b-4b26-9b71-6c9b4642b0be" xlink:href="vtl-20230331.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eccfcb24-edc0-44c6-8e3e-7ea6a6d44dcd" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_ee609d47-381b-4b26-9b71-6c9b4642b0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_afa2bdf4-e621-415c-9ec2-847c214770c1" xlink:href="vtl-20230331.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eccfcb24-edc0-44c6-8e3e-7ea6a6d44dcd" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_afa2bdf4-e621-415c-9ec2-847c214770c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_30905577-b15b-46de-9395-a6ac53d0f999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eccfcb24-edc0-44c6-8e3e-7ea6a6d44dcd" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_30905577-b15b-46de-9395-a6ac53d0f999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_cb7b9093-5785-49b8-be54-f46a7532789b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eccfcb24-edc0-44c6-8e3e-7ea6a6d44dcd" xlink:to="loc_us-gaap_AccountsPayableCurrent_cb7b9093-5785-49b8-be54-f46a7532789b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64968566-1f59-471f-bd88-92ff5b32177e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_eb2983f2-cfad-4323-80ae-ff36d029af83" xlink:href="vtl-20230331.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64968566-1f59-471f-bd88-92ff5b32177e" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_eb2983f2-cfad-4323-80ae-ff36d029af83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_1bc42858-df3c-4bfb-a04c-ac0a740c84f8" xlink:href="vtl-20230331.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64968566-1f59-471f-bd88-92ff5b32177e" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_1bc42858-df3c-4bfb-a04c-ac0a740c84f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_292ed582-fb4f-469c-a68a-14844518af16" xlink:href="vtl-20230331.xsd#vtl_AccruedCompensationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64968566-1f59-471f-bd88-92ff5b32177e" xlink:to="loc_vtl_AccruedCompensationCurrent_292ed582-fb4f-469c-a68a-14844518af16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e0caa07b-e8f6-4e00-a5c0-2069030c03b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64968566-1f59-471f-bd88-92ff5b32177e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e0caa07b-e8f6-4e00-a5c0-2069030c03b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9b1c6e04-28ca-4a5f-bb55-1dfbe50d7145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64968566-1f59-471f-bd88-92ff5b32177e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9b1c6e04-28ca-4a5f-bb55-1dfbe50d7145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_681a3a03-0470-4a2f-9479-40a28b8841a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a09aab90-19aa-4c00-984d-a903e710fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_681a3a03-0470-4a2f-9479-40a28b8841a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a09aab90-19aa-4c00-984d-a903e710fcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_5c353ecb-4142-4f5c-b6f1-54fa90d04eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_681a3a03-0470-4a2f-9479-40a28b8841a8" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_5c353ecb-4142-4f5c-b6f1-54fa90d04eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b7ff7c4e-41a3-4e39-9b0c-b983abfe07cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_681a3a03-0470-4a2f-9479-40a28b8841a8" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b7ff7c4e-41a3-4e39-9b0c-b983abfe07cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_69ddfe7d-cf4e-49e7-bc3f-8febfd480c98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_681a3a03-0470-4a2f-9479-40a28b8841a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_69ddfe7d-cf4e-49e7-bc3f-8febfd480c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f3d97e2c-b1dd-4b4a-98b5-9021141efec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c6cd4f56-dd2b-4169-b68b-0a6e7aee3d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f3d97e2c-b1dd-4b4a-98b5-9021141efec4" xlink:to="loc_us-gaap_LossContingenciesTable_c6cd4f56-dd2b-4169-b68b-0a6e7aee3d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_32b2e0ec-e171-4cfe-b88e-920404318bbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c6cd4f56-dd2b-4169-b68b-0a6e7aee3d86" xlink:to="loc_srt_StatementGeographicalAxis_32b2e0ec-e171-4cfe-b88e-920404318bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_32b2e0ec-e171-4cfe-b88e-920404318bbb" xlink:to="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_2157cbf7-fa8f-4afa-9512-e4bc4781e0cf" xlink:href="vtl-20230331.xsd#vtl_GrafelfingGermanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:to="loc_vtl_GrafelfingGermanyMember_2157cbf7-fa8f-4afa-9512-e4bc4781e0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_9ae931a3-caac-4e99-9fa2-edf4fe767a10" xlink:href="vtl-20230331.xsd#vtl_NewYorkCityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:to="loc_vtl_NewYorkCityMember_9ae931a3-caac-4e99-9fa2-edf4fe767a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember_0ccaa770-fc7a-4620-9302-64d36a8325de" xlink:href="vtl-20230331.xsd#vtl_PlaneggGermanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_430f99e2-478d-4a58-9ebd-90bf25f018ae" xlink:to="loc_vtl_PlaneggGermanyMember_0ccaa770-fc7a-4620-9302-64d36a8325de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c6cd4f56-dd2b-4169-b68b-0a6e7aee3d86" xlink:to="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd116250-8cc2-40c3-b478-80a5b63da50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_dd116250-8cc2-40c3-b478-80a5b63da50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_b718addd-d181-4720-a5d6-2fec571383b4" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_b718addd-d181-4720-a5d6-2fec571383b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_5b902b63-1e61-49ff-9942-9d339f505e23" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_5b902b63-1e61-49ff-9942-9d339f505e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_508dc27e-1060-4ea5-a257-4d1bdf0296b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_508dc27e-1060-4ea5-a257-4d1bdf0296b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_570f6fba-136a-4823-88b3-36a4525e1bd4" xlink:href="vtl-20230331.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_570f6fba-136a-4823-88b3-36a4525e1bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_4ecdf868-3a25-4ebb-9b28-3805a5ca6e4b" xlink:href="vtl-20230331.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_4ecdf868-3a25-4ebb-9b28-3805a5ca6e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_da15107d-8258-4dac-96e6-8a5aac70ed46" xlink:href="vtl-20230331.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_da15107d-8258-4dac-96e6-8a5aac70ed46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_9940a9a1-eaee-438d-86d1-53ed4758e478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_23506815-b61b-4b5c-82f0-eca65cd8a801" xlink:to="loc_us-gaap_ContractualObligation_9940a9a1-eaee-438d-86d1-53ed4758e478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_50df8a61-d42c-4ef5-a02e-f22342c9562e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_50df8a61-d42c-4ef5-a02e-f22342c9562e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_aa9022b2-5246-4365-a696-477ccb62b397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_aa9022b2-5246-4365-a696-477ccb62b397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_107e315f-51b1-48b6-9fb5-665c08d5a3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_107e315f-51b1-48b6-9fb5-665c08d5a3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_634c7be9-7b48-4c91-942d-c655101329bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_634c7be9-7b48-4c91-942d-c655101329bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c9f90ccd-4ebc-4390-a508-687769c30ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c9f90ccd-4ebc-4390-a508-687769c30ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_6b23518d-a835-4be8-bb26-27819b65290a" xlink:href="vtl-20230331.xsd#vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:to="loc_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_6b23518d-a835-4be8-bb26-27819b65290a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03b7612f-42f2-4d34-b342-60533c33acf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_03b7612f-42f2-4d34-b342-60533c33acf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b9282386-a045-4ac2-b7ff-c1fffa193fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b9282386-a045-4ac2-b7ff-c1fffa193fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_de423253-68a8-41fe-8cc6-19af98c8874e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6838da98-25be-49c1-a248-92d4b07fc7a3" xlink:to="loc_us-gaap_OperatingLeaseLiability_de423253-68a8-41fe-8cc6-19af98c8874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4023b08c-ee71-4439-b451-2be26d65f508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4023b08c-ee71-4439-b451-2be26d65f508" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fbfc9716-0acc-4316-be48-df65be2f197f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fbfc9716-0acc-4316-be48-df65be2f197f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_72b98190-6017-481d-be28-47c21be3afc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fbfc9716-0acc-4316-be48-df65be2f197f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_72b98190-6017-481d-be28-47c21be3afc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ed6ab06f-724f-440d-aea3-39c6c9e183a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_72b98190-6017-481d-be28-47c21be3afc7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ed6ab06f-724f-440d-aea3-39c6c9e183a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8c850297-da41-4ae6-abfb-63e074faace6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:to="loc_us-gaap_InvestmentTypeAxis_8c850297-da41-4ae6-abfb-63e074faace6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b184a07e-0b2c-4214-8242-c0c112d52837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_8c850297-da41-4ae6-abfb-63e074faace6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b184a07e-0b2c-4214-8242-c0c112d52837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_45531ddd-ec1a-4b36-9e38-eff110aaee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b184a07e-0b2c-4214-8242-c0c112d52837" xlink:to="loc_us-gaap_MoneyMarketFundsMember_45531ddd-ec1a-4b36-9e38-eff110aaee0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fcc17cd-7adf-48ee-afca-15b685258065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fcc17cd-7adf-48ee-afca-15b685258065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fcc17cd-7adf-48ee-afca-15b685258065" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6c1918ab-01ce-46ea-9c62-713b5fd80d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6c1918ab-01ce-46ea-9c62-713b5fd80d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9ccbb7da-71af-456a-b686-a20c97525926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9ccbb7da-71af-456a-b686-a20c97525926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9bc49659-6781-4876-83c3-0af6720e8745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a571cb3-1812-443f-b8c9-b8a2551ee92a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9bc49659-6781-4876-83c3-0af6720e8745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83cde11d-9453-4da4-b489-25cef2b9d940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_71202caa-caa0-4507-b63f-56afa4cbf83b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83cde11d-9453-4da4-b489-25cef2b9d940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bafb95b-8995-451d-a2af-640008ec012c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_83cde11d-9453-4da4-b489-25cef2b9d940" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bafb95b-8995-451d-a2af-640008ec012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9d4189ec-bd2b-4046-9585-fc98258a7795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_8bafb95b-8995-451d-a2af-640008ec012c" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9d4189ec-bd2b-4046-9585-fc98258a7795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#FairValueAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63cde584-ffb8-4783-a3b2-070905c44ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9463ae74-1cb1-48df-bc3a-09e5a6741114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63cde584-ffb8-4783-a3b2-070905c44ff8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9463ae74-1cb1-48df-bc3a-09e5a6741114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6a6882b3-7468-43c9-bf94-56a4cfc200c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9463ae74-1cb1-48df-bc3a-09e5a6741114" xlink:to="loc_srt_StatementGeographicalAxis_6a6882b3-7468-43c9-bf94-56a4cfc200c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f55c810-771b-4a4d-bb6e-8ee56598545d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6a6882b3-7468-43c9-bf94-56a4cfc200c1" xlink:to="loc_srt_SegmentGeographicalDomain_1f55c810-771b-4a4d-bb6e-8ee56598545d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f29025ad-aa9a-4b6a-ac14-498dd5bd0184" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1f55c810-771b-4a4d-bb6e-8ee56598545d" xlink:to="loc_country_US_f29025ad-aa9a-4b6a-ac14-498dd5bd0184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_5a1427cb-f1f6-41c8-8d52-9b54e2e013d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9463ae74-1cb1-48df-bc3a-09e5a6741114" xlink:to="loc_us-gaap_InvestmentTypeAxis_5a1427cb-f1f6-41c8-8d52-9b54e2e013d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b4df338d-0735-45a0-8c74-b1ac91edeb35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_5a1427cb-f1f6-41c8-8d52-9b54e2e013d6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b4df338d-0735-45a0-8c74-b1ac91edeb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_abae56f3-3ea0-4b78-9891-2176b4d03c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_b4df338d-0735-45a0-8c74-b1ac91edeb35" xlink:to="loc_us-gaap_MoneyMarketFundsMember_abae56f3-3ea0-4b78-9891-2176b4d03c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266a7536-ac33-4b40-8dd4-448a2937cfda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9463ae74-1cb1-48df-bc3a-09e5a6741114" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266a7536-ac33-4b40-8dd4-448a2937cfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_bec48a8c-c8d1-4d6c-9584-2e22bb890ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_266a7536-ac33-4b40-8dd4-448a2937cfda" xlink:to="loc_us-gaap_InvestmentInterestRate_bec48a8c-c8d1-4d6c-9584-2e22bb890ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_41dbeb27-c4cf-48ee-88eb-01c1259c626a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_28a61d54-c569-491b-a04b-21c7c0cfdb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_41dbeb27-c4cf-48ee-88eb-01c1259c626a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_28a61d54-c569-491b-a04b-21c7c0cfdb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a4c796e5-d839-4453-8460-3c51aa2915c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_28a61d54-c569-491b-a04b-21c7c0cfdb28" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a4c796e5-d839-4453-8460-3c51aa2915c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4837df76-cb05-4b96-a890-e5490a5592fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a4c796e5-d839-4453-8460-3c51aa2915c9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4837df76-cb05-4b96-a890-e5490a5592fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_a6edbfc4-9387-44c5-9220-0cc9d9cebff0" xlink:href="vtl-20230331.xsd#vtl_December2020ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4837df76-cb05-4b96-a890-e5490a5592fe" xlink:to="loc_vtl_December2020ATMMember_a6edbfc4-9387-44c5-9220-0cc9d9cebff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_348b0c3f-7172-4d54-aafc-b5f0817cfe6f" xlink:href="vtl-20230331.xsd#vtl_May2022ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4837df76-cb05-4b96-a890-e5490a5592fe" xlink:to="loc_vtl_May2022ATMMember_348b0c3f-7172-4d54-aafc-b5f0817cfe6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_57e71e87-3f0f-46a6-a385-7ad29bc0ef8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_28a61d54-c569-491b-a04b-21c7c0cfdb28" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_57e71e87-3f0f-46a6-a385-7ad29bc0ef8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a3b4fb84-39e2-45ec-b134-68776f7417cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_57e71e87-3f0f-46a6-a385-7ad29bc0ef8a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a3b4fb84-39e2-45ec-b134-68776f7417cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_32ed9144-b760-4458-b5dc-b8fd00d96619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a3b4fb84-39e2-45ec-b134-68776f7417cc" xlink:to="loc_us-gaap_SubsequentEventMember_32ed9144-b760-4458-b5dc-b8fd00d96619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_28a61d54-c569-491b-a04b-21c7c0cfdb28" xlink:to="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_d45a4ff4-5ebd-42c0-bb39-eb027fc890d9" xlink:href="vtl-20230331.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_d45a4ff4-5ebd-42c0-bb39-eb027fc890d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_2d3d57c8-73e5-4090-acfb-e8598c0df7fe" xlink:href="vtl-20230331.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_2d3d57c8-73e5-4090-acfb-e8598c0df7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_534f18fb-098b-440d-bac0-592ff6374b4f" xlink:href="vtl-20230331.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_534f18fb-098b-440d-bac0-592ff6374b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_750f4533-d723-41f0-81f9-8a7bc71fa7fe" xlink:href="vtl-20230331.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_750f4533-d723-41f0-81f9-8a7bc71fa7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_765b1d48-b0b7-460c-ab3b-bd31780b0c14" xlink:href="vtl-20230331.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_765b1d48-b0b7-460c-ab3b-bd31780b0c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ecf87f6-d416-4003-9d69-5b454b7bdcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ecf87f6-d416-4003-9d69-5b454b7bdcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fdaeb2c6-19fe-416d-811f-9e0510c5077a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fdaeb2c6-19fe-416d-811f-9e0510c5077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_5edea55f-60b9-4340-aa1d-5dd44708c873" xlink:href="vtl-20230331.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_5edea55f-60b9-4340-aa1d-5dd44708c873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ffdb5ed4-107a-4da2-820d-08430322bdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ffdb5ed4-107a-4da2-820d-08430322bdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_cd8c83ea-1bc6-4f60-89c5-0be8dd8e4949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8a5ac17d-ca06-4053-979a-2b61f103d2bd" xlink:to="loc_us-gaap_PaymentsForCommissions_cd8c83ea-1bc6-4f60-89c5-0be8dd8e4949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockEquityOfferingDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_04daa3d5-6e09-4bf4-bd2c-bbc5fe277d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_cc600d06-c28c-4bd4-8b80-909a1e7ff144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_04daa3d5-6e09-4bf4-bd2c-bbc5fe277d1d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_cc600d06-c28c-4bd4-8b80-909a1e7ff144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f1f4649f-f3e0-4881-93f2-f397fa148fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_cc600d06-c28c-4bd4-8b80-909a1e7ff144" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f1f4649f-f3e0-4881-93f2-f397fa148fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200949c4-f005-4480-bf17-6428a8b3d5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f1f4649f-f3e0-4881-93f2-f397fa148fb4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200949c4-f005-4480-bf17-6428a8b3d5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_10ea33f7-5427-416a-bab8-4d714d989b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200949c4-f005-4480-bf17-6428a8b3d5ae" xlink:to="loc_us-gaap_CommonStockMember_10ea33f7-5427-416a-bab8-4d714d989b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_b517e62b-feaa-43b2-bbf5-0d53378d1c7c" xlink:href="vtl-20230331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_200949c4-f005-4480-bf17-6428a8b3d5ae" xlink:to="loc_vtl_PreFundedWarrantsMember_b517e62b-feaa-43b2-bbf5-0d53378d1c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_cc600d06-c28c-4bd4-8b80-909a1e7ff144" xlink:to="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ccbae900-11f2-4eb8-a2d6-6d28c00d03c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ccbae900-11f2-4eb8-a2d6-6d28c00d03c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0a154ab5-0eb9-4c7e-a7c2-1358da652623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0a154ab5-0eb9-4c7e-a7c2-1358da652623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_c8ae802f-5898-4333-8542-e43f9ed9ac44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_us-gaap_SharePrice_c8ae802f-5898-4333-8542-e43f9ed9ac44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_e654b97b-a9b4-4a6a-9c2c-0350d180a405" xlink:href="vtl-20230331.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage_e654b97b-a9b4-4a6a-9c2c-0350d180a405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_2784ad84-eb38-4a01-a7ad-ead25dd8222c" xlink:href="vtl-20230331.xsd#vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent_2784ad84-eb38-4a01-a7ad-ead25dd8222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_f40d4be1-a2b9-4cdb-9af6-1fdbfd40c113" xlink:href="vtl-20230331.xsd#vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8b73c893-2ffd-4e01-aabb-e5be19b0f365" xlink:to="loc_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod_f40d4be1-a2b9-4cdb-9af6-1fdbfd40c113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockCommonStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5902d3e2-dd1a-4dfb-96f3-0750a7e6e705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2f4c89a5-c3d7-4f4b-8a7a-fe3265f62f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5902d3e2-dd1a-4dfb-96f3-0750a7e6e705" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2f4c89a5-c3d7-4f4b-8a7a-fe3265f62f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_44782eb6-f1c0-413a-88b3-a88d320ed0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5902d3e2-dd1a-4dfb-96f3-0750a7e6e705" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_44782eb6-f1c0-413a-88b3-a88d320ed0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_bcc45df6-640d-4355-a8bd-e680a0b8dad8" xlink:href="vtl-20230331.xsd#vtl_NumberOfVotesPerEachShareOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5902d3e2-dd1a-4dfb-96f3-0750a7e6e705" xlink:to="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_bcc45df6-640d-4355-a8bd-e680a0b8dad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_b2c75dde-d0e0-408c-b47c-801d982d6f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5902d3e2-dd1a-4dfb-96f3-0750a7e6e705" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_b2c75dde-d0e0-408c-b47c-801d982d6f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_6edbf3ad-066b-43f9-b8b9-1815172443d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5902d3e2-dd1a-4dfb-96f3-0750a7e6e705" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_6edbf3ad-066b-43f9-b8b9-1815172443d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockPrefundedWarrantsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_765ac6ac-5dae-4338-a508-bb3b8f469e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_180fbe59-8c2d-449c-84da-4db25b012b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_765ac6ac-5dae-4338-a508-bb3b8f469e85" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_180fbe59-8c2d-449c-84da-4db25b012b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d6a58232-710c-4d39-9c6c-be9a0b856801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_180fbe59-8c2d-449c-84da-4db25b012b4e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d6a58232-710c-4d39-9c6c-be9a0b856801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26468448-f746-4e27-850c-df0cd6a9d527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d6a58232-710c-4d39-9c6c-be9a0b856801" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26468448-f746-4e27-850c-df0cd6a9d527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_81d2ad54-8129-483b-a55d-da0756b501fc" xlink:href="vtl-20230331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_26468448-f746-4e27-850c-df0cd6a9d527" xlink:to="loc_vtl_PreFundedWarrantsMember_81d2ad54-8129-483b-a55d-da0756b501fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_df68e6ac-99a4-4e66-94cc-edbc1668e322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_180fbe59-8c2d-449c-84da-4db25b012b4e" xlink:to="loc_us-gaap_ClassOfStockLineItems_df68e6ac-99a4-4e66-94cc-edbc1668e322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3a0b9835-ffce-42d1-8a5a-deed9e258356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_df68e6ac-99a4-4e66-94cc-edbc1668e322" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3a0b9835-ffce-42d1-8a5a-deed9e258356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f22109b2-355e-447c-aa08-875c82cb5a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_71b855f9-bdc2-4aea-af04-34f7fc76350e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f22109b2-355e-447c-aa08-875c82cb5a69" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_71b855f9-bdc2-4aea-af04-34f7fc76350e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6dcd8fb4-f586-4576-ab29-d67b115e04d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f22109b2-355e-447c-aa08-875c82cb5a69" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6dcd8fb4-f586-4576-ab29-d67b115e04d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d3c7e9c5-edab-45bd-b136-8f079d02eb60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f22109b2-355e-447c-aa08-875c82cb5a69" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d3c7e9c5-edab-45bd-b136-8f079d02eb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d7c7d920-d5bc-437e-8d3f-5d805b47faa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4a785de3-e24c-4ab2-b8c9-611c5b664e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7c7d920-d5bc-437e-8d3f-5d805b47faa0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4a785de3-e24c-4ab2-b8c9-611c5b664e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06920f69-25f4-4087-aa68-3add36d3933b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4a785de3-e24c-4ab2-b8c9-611c5b664e0c" xlink:to="loc_us-gaap_AwardTypeAxis_06920f69-25f4-4087-aa68-3add36d3933b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779c2be4-d29c-4891-9a51-9bb70af26e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_06920f69-25f4-4087-aa68-3add36d3933b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779c2be4-d29c-4891-9a51-9bb70af26e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c784a2ab-55ad-4b7b-abf9-fcf7eb3a1a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779c2be4-d29c-4891-9a51-9bb70af26e53" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c784a2ab-55ad-4b7b-abf9-fcf7eb3a1a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_f763a0d6-5f3f-4af8-bc35-8ce5df2a5ce7" xlink:href="vtl-20230331.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_779c2be4-d29c-4891-9a51-9bb70af26e53" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_f763a0d6-5f3f-4af8-bc35-8ce5df2a5ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_89c90219-0ec6-4553-99ef-f55f361c5b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4a785de3-e24c-4ab2-b8c9-611c5b664e0c" xlink:to="loc_us-gaap_PlanNameAxis_89c90219-0ec6-4553-99ef-f55f361c5b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_89c90219-0ec6-4553-99ef-f55f361c5b5c" xlink:to="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_24c893e7-9ab7-4f8c-b3de-fc7f2c7b6670" xlink:href="vtl-20230331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_24c893e7-9ab7-4f8c-b3de-fc7f2c7b6670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_5a9c5f88-fb9b-439c-a544-62757314a743" xlink:href="vtl-20230331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_5a9c5f88-fb9b-439c-a544-62757314a743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_c2aac1a9-e525-43b7-b71d-45bb3bda065e" xlink:href="vtl-20230331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_c2aac1a9-e525-43b7-b71d-45bb3bda065e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_73501882-3091-4e6b-99ac-205451fc0013" xlink:href="vtl-20230331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_20289d05-80d2-4aee-ae49-06fc091e5ee6" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_73501882-3091-4e6b-99ac-205451fc0013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1a3effe8-a62d-447c-af9d-bad66f79494c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4a785de3-e24c-4ab2-b8c9-611c5b664e0c" xlink:to="loc_us-gaap_ClassOfStockLineItems_1a3effe8-a62d-447c-af9d-bad66f79494c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_55a0be59-3e1f-4290-a42b-0a1c6cc82522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1a3effe8-a62d-447c-af9d-bad66f79494c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_55a0be59-3e1f-4290-a42b-0a1c6cc82522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62027abb-0bda-4f7e-a576-8eeb3acec468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62027abb-0bda-4f7e-a576-8eeb3acec468" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f01ee5eb-c4c4-44e7-a1eb-4fe023c9d454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:to="loc_us-gaap_PlanNameAxis_f01ee5eb-c4c4-44e7-a1eb-4fe023c9d454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f01ee5eb-c4c4-44e7-a1eb-4fe023c9d454" xlink:to="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_9bbdbdb0-9b75-4753-a801-1a2ff66b9db5" xlink:href="vtl-20230331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_9bbdbdb0-9b75-4753-a801-1a2ff66b9db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_1f78615f-6257-439b-861a-4a836ea09322" xlink:href="vtl-20230331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_1f78615f-6257-439b-861a-4a836ea09322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_1f535b33-ef49-44ab-89d1-c91501b1f2ed" xlink:href="vtl-20230331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_1f535b33-ef49-44ab-89d1-c91501b1f2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_48af5c74-98c5-4c8e-8b4c-229f5298eac1" xlink:href="vtl-20230331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_48af5c74-98c5-4c8e-8b4c-229f5298eac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_19cb4c17-57a3-4666-a8a5-9a43399518fd" xlink:href="vtl-20230331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0ff660fc-2add-4e91-a92b-e4c2a1373770" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_19cb4c17-57a3-4666-a8a5-9a43399518fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8e0c48e6-1ad4-47ba-b3ce-e638426f935a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:to="loc_srt_RangeAxis_8e0c48e6-1ad4-47ba-b3ce-e638426f935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b726d419-9860-44df-93b6-48a15b823433" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8e0c48e6-1ad4-47ba-b3ce-e638426f935a" xlink:to="loc_srt_RangeMember_b726d419-9860-44df-93b6-48a15b823433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1974e2e4-63bc-480d-afce-8987619ce4f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b726d419-9860-44df-93b6-48a15b823433" xlink:to="loc_srt_MaximumMember_1974e2e4-63bc-480d-afce-8987619ce4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_79d5cb94-e225-462f-be44-3383a9411de1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b726d419-9860-44df-93b6-48a15b823433" xlink:to="loc_srt_MinimumMember_79d5cb94-e225-462f-be44-3383a9411de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d18c5f90-d721-4519-9226-def472b17daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:to="loc_us-gaap_AwardTypeAxis_d18c5f90-d721-4519-9226-def472b17daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bb4527e-4cbc-4d36-b3ca-5294aa39dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d18c5f90-d721-4519-9226-def472b17daa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bb4527e-4cbc-4d36-b3ca-5294aa39dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_eb77d162-47e6-4283-84c0-e9ab6ac9aa7d" xlink:href="vtl-20230331.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bb4527e-4cbc-4d36-b3ca-5294aa39dbbd" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_eb77d162-47e6-4283-84c0-e9ab6ac9aa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_ee46f5f5-978b-4071-9b1f-ef0a94ce621f" xlink:href="vtl-20230331.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0bb4527e-4cbc-4d36-b3ca-5294aa39dbbd" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_ee46f5f5-978b-4071-9b1f-ef0a94ce621f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59b4bd85-1cca-48b3-be44-7c6b1690f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_e4e712ca-ed36-4e76-b41a-48a1b79926c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_e4e712ca-ed36-4e76-b41a-48a1b79926c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1bf735f8-0984-4e41-ad9b-45622b24dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_1bf735f8-0984-4e41-ad9b-45622b24dc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8cd5682c-7677-4531-b69b-26c22f871895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8cd5682c-7677-4531-b69b-26c22f871895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c553dbf-b5c1-4abc-be00-38d3a293d985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c553dbf-b5c1-4abc-be00-38d3a293d985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b31f2283-1826-462a-ade2-2619f0a11272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b31f2283-1826-462a-ade2-2619f0a11272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_91434baf-251a-4bfc-aae6-de6f6d7314a0" xlink:href="vtl-20230331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_91434baf-251a-4bfc-aae6-de6f6d7314a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f61f9c4e-3c25-4036-8cbd-3a30e3e2f05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f61f9c4e-3c25-4036-8cbd-3a30e3e2f05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4f5ae81f-50d5-4777-b1a3-337020b76ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4f5ae81f-50d5-4777-b1a3-337020b76ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3161ac1f-6422-4225-b974-aa5749fd2fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3161ac1f-6422-4225-b974-aa5749fd2fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e4dcc1ec-0496-440d-a1e1-cf152203887c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e4dcc1ec-0496-440d-a1e1-cf152203887c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2b5b894a-945f-4205-9edd-f14c97808473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2b5b894a-945f-4205-9edd-f14c97808473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ba09e160-9a79-4b77-83b2-17492e30693a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ba09e160-9a79-4b77-83b2-17492e30693a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f2c4f0c9-0673-49e5-9d67-7735f44a8de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8557727c-2bb4-43ae-aec4-1ae42cae4834" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f2c4f0c9-0673-49e5-9d67-7735f44a8de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5a6e2e2-c7d6-44f5-9c27-1765c257e2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb11e5d1-9ca5-4d2c-8ade-a2634a89d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5a6e2e2-c7d6-44f5-9c27-1765c257e2e7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb11e5d1-9ca5-4d2c-8ade-a2634a89d4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_621b9b7b-190c-4bcf-99a6-6ffb7808a392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb11e5d1-9ca5-4d2c-8ade-a2634a89d4c3" xlink:to="loc_us-gaap_AwardTypeAxis_621b9b7b-190c-4bcf-99a6-6ffb7808a392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df95c4d1-cb1a-4c06-a50d-9ba880c13991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_621b9b7b-190c-4bcf-99a6-6ffb7808a392" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df95c4d1-cb1a-4c06-a50d-9ba880c13991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d1506d92-d24b-4c4b-8978-e413c5cd2fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df95c4d1-cb1a-4c06-a50d-9ba880c13991" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d1506d92-d24b-4c4b-8978-e413c5cd2fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_eebf6708-03af-4db5-9e61-8d220d4f0046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb11e5d1-9ca5-4d2c-8ade-a2634a89d4c3" xlink:to="loc_us-gaap_PlanNameAxis_eebf6708-03af-4db5-9e61-8d220d4f0046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0aa84691-1167-4756-869d-52a2f7c5c9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_eebf6708-03af-4db5-9e61-8d220d4f0046" xlink:to="loc_us-gaap_PlanNameDomain_0aa84691-1167-4756-869d-52a2f7c5c9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_4223e56d-0415-46ad-be8d-98f3fe9ac98e" xlink:href="vtl-20230331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0aa84691-1167-4756-869d-52a2f7c5c9fc" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_4223e56d-0415-46ad-be8d-98f3fe9ac98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bb11e5d1-9ca5-4d2c-8ade-a2634a89d4c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2f8b5161-f953-4519-a1e9-c4be55046151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2f8b5161-f953-4519-a1e9-c4be55046151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_199d960f-4463-48d0-a073-27d470c39d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_199d960f-4463-48d0-a073-27d470c39d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3362314-5d88-41a7-89bb-e0b72318215d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f3362314-5d88-41a7-89bb-e0b72318215d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0afe23bf-de2a-4bbf-b895-511c7801580f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0afe23bf-de2a-4bbf-b895-511c7801580f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2805da67-2b84-4e16-a2a7-f29d7c411935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e89d056-a728-4da6-932f-a6d7a0182d49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2805da67-2b84-4e16-a2a7-f29d7c411935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_174592f6-368a-4fe6-af7e-70eb4572a9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_174592f6-368a-4fe6-af7e-70eb4572a9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e8528294-0d75-4a1d-917f-b2e7ec21e08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e8528294-0d75-4a1d-917f-b2e7ec21e08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4f6d3716-9f3b-46fc-8201-fbf4c286760d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4f6d3716-9f3b-46fc-8201-fbf4c286760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0bd49867-9e6f-4380-a171-d80087072901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0bd49867-9e6f-4380-a171-d80087072901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16d5fe64-f3f4-4058-8838-896872bdb91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16d5fe64-f3f4-4058-8838-896872bdb91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2cb15f2c-40cf-4791-b83e-f08a31b9bc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2cb15f2c-40cf-4791-b83e-f08a31b9bc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14412a0d-3618-4bdf-905d-6586d8589297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_198361d4-77d4-4b44-a018-38b0a9cf3998" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14412a0d-3618-4bdf-905d-6586d8589297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_55cbfd72-701e-46a7-991b-cace43d7d406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_55cbfd72-701e-46a7-991b-cace43d7d406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b87a8776-d1bb-4108-83f9-56a7e9385912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b87a8776-d1bb-4108-83f9-56a7e9385912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a83b9dc2-9c7c-49d6-84db-37f2837235ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bb691878-e5f6-46ca-8a7e-592f077111d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bb691878-e5f6-46ca-8a7e-592f077111d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a006c31c-a465-4f32-9134-e0dcb664170c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a006c31c-a465-4f32-9134-e0dcb664170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_53661138-7f09-474a-97b8-1c0dea6a12f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_53661138-7f09-474a-97b8-1c0dea6a12f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30e88f78-36a3-4e1e-9028-3c216c6b205b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30e88f78-36a3-4e1e-9028-3c216c6b205b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3e2f89d2-3f4b-441b-a638-f8327bc3d9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_3e2f89d2-3f4b-441b-a638-f8327bc3d9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6f98f214-a3bf-4129-b747-d04d3bf26bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_39f8e8b7-e59c-4c60-8c6e-942abb13f943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6f98f214-a3bf-4129-b747-d04d3bf26bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d7a27cc-c369-4040-99eb-ee29040ba3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52fe5ea9-49d3-483b-a2a6-421982924152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d7a27cc-c369-4040-99eb-ee29040ba3f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52fe5ea9-49d3-483b-a2a6-421982924152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_acdfb782-d221-44ed-bb56-64b714b21b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52fe5ea9-49d3-483b-a2a6-421982924152" xlink:to="loc_us-gaap_PlanNameAxis_acdfb782-d221-44ed-bb56-64b714b21b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_45397c8a-d0e8-46bb-95b3-c0050836f158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_acdfb782-d221-44ed-bb56-64b714b21b6f" xlink:to="loc_us-gaap_PlanNameDomain_45397c8a-d0e8-46bb-95b3-c0050836f158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_84fc9c63-281a-4b59-ba9c-fbdb1c41a15f" xlink:href="vtl-20230331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_45397c8a-d0e8-46bb-95b3-c0050836f158" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_84fc9c63-281a-4b59-ba9c-fbdb1c41a15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52fe5ea9-49d3-483b-a2a6-421982924152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6c06336f-6425-4061-a885-a96c9510258e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6c06336f-6425-4061-a885-a96c9510258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b38761c8-4542-4505-a4aa-37ead1d4c6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b38761c8-4542-4505-a4aa-37ead1d4c6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c2fa734-adea-46cf-9fca-d65cfd4cda22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9c2fa734-adea-46cf-9fca-d65cfd4cda22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e124a4b2-87a8-4200-bc84-182fe43b0050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_43303ba4-fa16-4f94-bad1-892338b7d58d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e124a4b2-87a8-4200-bc84-182fe43b0050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd328135-7abb-4f89-83ea-6e50b22b02db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_586180c7-d194-4682-a37b-c1fb8545f458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd328135-7abb-4f89-83ea-6e50b22b02db" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_586180c7-d194-4682-a37b-c1fb8545f458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5a4a27d6-5c3a-4e3f-8770-e2658d48464a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_586180c7-d194-4682-a37b-c1fb8545f458" xlink:to="loc_srt_TitleOfIndividualAxis_5a4a27d6-5c3a-4e3f-8770-e2658d48464a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3bab6fd3-c04b-4227-addd-fac331e0efb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_5a4a27d6-5c3a-4e3f-8770-e2658d48464a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3bab6fd3-c04b-4227-addd-fac331e0efb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_06ef8e42-c3b4-4579-a5d5-49d474852958" xlink:href="vtl-20230331.xsd#vtl_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3bab6fd3-c04b-4227-addd-fac331e0efb0" xlink:to="loc_vtl_EmployeeMember_06ef8e42-c3b4-4579-a5d5-49d474852958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d72c2d1-da62-4873-abab-4c5986cc111c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_586180c7-d194-4682-a37b-c1fb8545f458" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d72c2d1-da62-4873-abab-4c5986cc111c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_986d0e65-382b-4c09-ad71-04130bce02ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d72c2d1-da62-4873-abab-4c5986cc111c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_986d0e65-382b-4c09-ad71-04130bce02ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8d79f2bc-d0e6-4591-b620-8b52cc668712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_986d0e65-382b-4c09-ad71-04130bce02ef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8d79f2bc-d0e6-4591-b620-8b52cc668712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_62a15a7d-2b47-4cd3-b6dd-170759eca81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_986d0e65-382b-4c09-ad71-04130bce02ef" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_62a15a7d-2b47-4cd3-b6dd-170759eca81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6140ecec-33da-4375-9670-3c0856fc8f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_586180c7-d194-4682-a37b-c1fb8545f458" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6140ecec-33da-4375-9670-3c0856fc8f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fbf5dfd7-888b-4237-9f17-baf8af05a36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6140ecec-33da-4375-9670-3c0856fc8f68" xlink:to="loc_us-gaap_ShareBasedCompensation_fbf5dfd7-888b-4237-9f17-baf8af05a36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_265a5903-859d-435c-b205-3410d73becfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_265a5903-859d-435c-b205-3410d73becfb" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_73af79c8-b9b0-40b5-a887-4b6b22ac7f16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_srt_CounterpartyNameAxis_73af79c8-b9b0-40b5-a887-4b6b22ac7f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53e77b2-a1cd-4fb3-ba2a-c650bdde31e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_73af79c8-b9b0-40b5-a887-4b6b22ac7f16" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53e77b2-a1cd-4fb3-ba2a-c650bdde31e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_a2bf3a10-12b2-4742-8ddf-73e34be3c28b" xlink:href="vtl-20230331.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53e77b2-a1cd-4fb3-ba2a-c650bdde31e5" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_a2bf3a10-12b2-4742-8ddf-73e34be3c28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_89fb5326-bfed-497e-bc7d-3a01c8816ae1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_srt_StatementScenarioAxis_89fb5326-bfed-497e-bc7d-3a01c8816ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_338749d6-fb6a-417c-abcb-60ad5c714dad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_89fb5326-bfed-497e-bc7d-3a01c8816ae1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_338749d6-fb6a-417c-abcb-60ad5c714dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b9c1ef3a-a932-4985-b006-0be2fab8cd57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_338749d6-fb6a-417c-abcb-60ad5c714dad" xlink:to="loc_srt_ScenarioForecastMember_b9c1ef3a-a932-4985-b006-0be2fab8cd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_01ed394d-9135-479a-a79c-b549df1c5c76" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_srt_TitleOfIndividualAxis_01ed394d-9135-479a-a79c-b549df1c5c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_814b23b4-250d-462d-8d4e-85a540bd4100" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_01ed394d-9135-479a-a79c-b549df1c5c76" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_814b23b4-250d-462d-8d4e-85a540bd4100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_871e25e0-fa10-4e91-ba9e-3a4e982316a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_814b23b4-250d-462d-8d4e-85a540bd4100" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_871e25e0-fa10-4e91-ba9e-3a4e982316a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_17727a4e-80a0-47f5-8474-4afcff56d5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_17727a4e-80a0-47f5-8474-4afcff56d5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3ef4edf7-2843-4262-b21c-3fb36b317eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_17727a4e-80a0-47f5-8474-4afcff56d5a9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3ef4edf7-2843-4262-b21c-3fb36b317eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_1f69c5ba-5883-4d63-a056-eea94af4196c" xlink:href="vtl-20230331.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3ef4edf7-2843-4262-b21c-3fb36b317eeb" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_1f69c5ba-5883-4d63-a056-eea94af4196c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a3babc38-ca66-4bf3-a19b-cc1a05d2f9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a3babc38-ca66-4bf3-a19b-cc1a05d2f9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_05a8fafb-ed36-482e-adb9-c58feb51849c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a3babc38-ca66-4bf3-a19b-cc1a05d2f9a0" xlink:to="loc_us-gaap_RelatedPartyDomain_05a8fafb-ed36-482e-adb9-c58feb51849c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_2acc2868-9865-4f2b-b930-f0aa939c9580" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_05a8fafb-ed36-482e-adb9-c58feb51849c" xlink:to="loc_srt_AffiliatedEntityMember_2acc2868-9865-4f2b-b930-f0aa939c9580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b32a3826-8214-48ef-8cb5-83d9ba7b9165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_53970054-6852-418e-a101-a8578a245f07" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b32a3826-8214-48ef-8cb5-83d9ba7b9165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_64335a2a-eeac-4c9b-bb66-809de24e8ad0" xlink:href="vtl-20230331.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b32a3826-8214-48ef-8cb5-83d9ba7b9165" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_64335a2a-eeac-4c9b-bb66-809de24e8ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtl-20230331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_205f2f29-cd06-4cad-8793-31d1b3cd0d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_eeea5a02-de31-4e8e-be8e-eeee7d8b43c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_205f2f29-cd06-4cad-8793-31d1b3cd0d4c" xlink:to="loc_us-gaap_SubsequentEventTable_eeea5a02-de31-4e8e-be8e-eeee7d8b43c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4d31650-4c76-4c83-9f32-8f694cdfddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_eeea5a02-de31-4e8e-be8e-eeee7d8b43c2" xlink:to="loc_us-gaap_AwardTypeAxis_d4d31650-4c76-4c83-9f32-8f694cdfddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72c81c75-debb-4773-b42d-3b5d2b8e7106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d4d31650-4c76-4c83-9f32-8f694cdfddd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72c81c75-debb-4773-b42d-3b5d2b8e7106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LongTermEquityIncentiveAwardMember_66d2fddd-3311-4b36-a250-aa5fd7e14967" xlink:href="vtl-20230331.xsd#vtl_LongTermEquityIncentiveAwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72c81c75-debb-4773-b42d-3b5d2b8e7106" xlink:to="loc_vtl_LongTermEquityIncentiveAwardMember_66d2fddd-3311-4b36-a250-aa5fd7e14967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9380e3e9-c8d8-4482-94c0-6a633b8e608b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_eeea5a02-de31-4e8e-be8e-eeee7d8b43c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9380e3e9-c8d8-4482-94c0-6a633b8e608b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d9e6f304-3054-49ac-9c4b-ecd7bd5d9cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9380e3e9-c8d8-4482-94c0-6a633b8e608b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d9e6f304-3054-49ac-9c4b-ecd7bd5d9cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_69af1b62-3eb9-4ec0-aff4-007d445663b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d9e6f304-3054-49ac-9c4b-ecd7bd5d9cad" xlink:to="loc_us-gaap_SubsequentEventMember_69af1b62-3eb9-4ec0-aff4-007d445663b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_eeea5a02-de31-4e8e-be8e-eeee7d8b43c2" xlink:to="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e347fc5e-f762-4c76-bd81-32682615b9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e347fc5e-f762-4c76-bd81-32682615b9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0ff576d5-e17e-4bb0-85fa-ca71ad45ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0ff576d5-e17e-4bb0-85fa-ca71ad45ab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_53ebd4f5-adcc-40f0-a3c4-f49a5b185cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_665ac9e8-74b8-4a7e-9383-46217ec265a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_53ebd4f5-adcc-40f0-a3c4-f49a5b185cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>vtl-20230331_g1.jpg
<TEXT>
begin 644 vtl-20230331_g1.jpg
M_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B '
MS@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M]M8  0    #3+4A0("
M                     !%C<')T   !4    #-D97-C   !A    &QW='!T
M   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B
M6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $
M,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S
M4D="($E%0S8Q.38V+3(N,0
M                            6%E:(        /-1  $    !%LQ865H@
M                     %A96B        !OH@  ./4   .06%E:(
M &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:
M          !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M            9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M 5A96B       $P)5@!0    5Q_G;65A<P         !
M         H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \
M%  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "!
M (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
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M_)C]*?VZ_DO^W/]M____[@ A061O8F4 9$     ! P 0 P(#!@
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MTF. 0X,5XB0%_]H # ,! 0(1 Q$   #U]F*Y]XP           !'8]2*?(
M              'Z1J/4DGR                !''J2//X
M    1Z)D,P                !^D;>I&\@
M          ?T7?CRT=GP6G95H            S+@S::SX0
M  /HB,LXL^GLV$                #+V+-JG)@^>9                 S
M3BS:6RX0                .5&6,6?467"
M          !]"*RI[KX<V"T[*M            &9<&;36?"
M   !]$1EG%GT]FP@                9>Q9M4Y,'SS(
M&:<6;2V7"                !RHRQBSZBRX0
M            /H165/=?#FP6G95H $<RX8/GU;;T]\D        9EP9M-9\(
M   XIBGMVOM/4W>S\9  .N]>(3GU_KCU/-?9$!V-:?:^R *FW-&V]/>_D
M^B(RSBSZ>S80   !TF3%76SJ7!I6%3[FC;&GO    0S/KS/!L     9>Q9M4
MY,'SS(    @FQJ\$^?X3,L.?L_&0   13-@CN3%9NKN     9IQ9M+9<(
M _"G-ZNLO4W(%L:]K:FZ   !3F[HV3J[/=>,H    Y498Q9]19<(
M  _2)YL'$B8X=C\ !'LF'D3WN/+ ]C5XSJ,GBVM/=_@ _3\
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MS5F:NWI*KM\_653>-?9XTO.?O#0L=15-SFBSK.HR8-QT/1@ 9EP9M-9\(
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M?U?9Y^L:J-9<?ZGCGS9^GO?U,:HJ+K*-O2P'9U-V<_TH    Y498Q9]19<(
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M]?355<TAOULOPYNL]1K*HN>@R>,(7_.[)I;VS-7:    &7L6;5.3!\\R
M,L6U)J>INZ!L:RW]+=SM95=7[>I,L&>18\W]HK+9U+ZK[.]-"QPG?\Y*<.QK
M*HN.Q\^P   !FG%FTMEP@   #CF,PVM/J*IN<PVM1V/CWR/-=;.MW'CW"L^&
MZ]'=K;9U]&UMI)<67)=O3=SYG65/>    #E1EC%GU%EP@         #EAE"X
MI8_DQ?=Y]=AXR7EHV&&K_F_1_F.MS1:4]P:6_E^VIYWK[/SS'-$RK#FK3:UK
M@T]S/-C67'I[O0>_%9;6GW?C),\.>W]+>AV;!0MA7:#KK2J-O2L37V+\KK0
M         ?0BLJ>Z^'-@M.RK0    *GW-&H-W0NS0LK+U=L     9EP9M-9\
M(                'T1&6<6?3V;"                !E[%FU3DP?/,@
M              9IQ9M+9<(                '*C+&+/J++A
M   @VQK?),6)K;0                     ^A%94]U\.;!:=E6@
M   #,N#-IK/A                 ^B(RSBSZ>S80                ,O8
MLVJ<F#YYD                #-.+-I;+A                 Y498Q9]19
M<(                                   'T(K*GNHF=OZ\
M  #/$>M#SY                 _H@)/                 "!$^/P
M            @Q.0                #J,F+.=E5:CJ;H
M                     #^CL_&3D-9H            &/T[ 0
M       (1*;P                 @LIU                  0F4V@
M            !$\^OCV]YS=W-]6
M   ,CIY36:            !C].P$                 "$2F\
M       (+*=0                 $)E-H                 1//KX]O><
MW=S?5@                                   #(Z>4UF@
M 8ZEK+UX                 _2%DS                 (23<_
M         "&DR                 (MFU\FW?/[NYOJP
M                    !D=/*:S0            /$;J.0\VOH_RH
M          ?A^@                'X?H
M         ![X?-/K.[N;ZO)-YSWG'U?&>QO!_1[%U-W/*=#(%4%K@$9.(E8
M  !EQ.HT 0\[ D  ,3)UXBATU^:\1D=-G%\HS\G1:,YISFG2R,^&HC)Z='(T
M*BI"VRMR?GTF4TZL15Q:(!@I-H%5&^D8(3<(-+(  R.GE-9H
M'B+U'(>;'TCY3_*?T_4#[/.3X_6,  ?B?U  )('XG]0/L\^_C]>/Q/Z@?9YR
M?'ZQ@?B1^H^GS[X9\_Q,  #\3^H [/QDZKWX_0?J/Q/ZC^$]MX]]9[Q@#\3_
M  G^T?J/Q/X?H /P_I'&]<B/Y/Q/]('Z@?9Y]_'Z\
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M#^EY&U]*RV[SO3X/Z3E9YK;E&655.-?8OBLM\F7=!]$>:^V](
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M/YG]:W=S?5@          "L3[R?@                       R.GE-9H
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M/O5U^5ES.-;;Q]?<Q$-C6U!37W ]=/EP3;6W;0T]ZDK&JZ+WXE>'-EB[YP
M                            #WS^9_6MW<WU8  %5%J@   %2IMI &6T
MZ;1]( *L+3 *K.,YBT@1@J1.@$"JRU@   <1!B?  XCE        !D=/*:S0
M            /$7J.0\V/I'RD   6EI6-6[M< !WF+-J6FO\V6U)$=C5
MM31LJKWJT         6)J;]=[>@  !8VIO5QMZ7Z@
M                        #WS^9_6MW<WU8 &-$_6?*2T[HIDM<JPM(Z([
M4Z4SNGT]><LI[<QRD;$1#3A+]1FU/ :>1E]/?%.IWF\PE-%G0FE2N#I#/"=F
MHA1,C12,"IN<C1*#$B=7H^ LHHXM QTG:R)P3%&2$VX5"3HK@YC9J.[   !D
M=/*:S0            /,ZRJNAZ'F                 !T)WP
M      !T!WX                 .B.]                 .G]XKYK;;=W
M-]6 !B!/ =X1@ZI,W1QGTGQE&)U&B#G6F\$8'3R$K/Y*=3;Z. VJC&Z;.*1*
M%3I5' ;41A=-^&/$^C;S3"?O*?/E,]IU^C3:,*IXSJD]LCZ3D* 3M!%:'V'4
MEQ$2.O-.(QDG19@I.C$7FBD$W$70@  #(Z>4UF@            8_3L!
M              A$IO                 ""RG4                 !"9
M3:                 $3SZ^/;WG-W<WU8 'G2]:81/D4^F;DG1^']'\$#3]
M)\A\QHM&5$VD=RBMDRDKXMU%B%?G=$+*/3HE'\EAD#*%3?J)F<)0B;&1_!6R
M9$76CRU>MZHILNI%=ILY%5IG1W*.4JY/WDJ+11CQ.@44DF\4<I(SXR5    R
M.GE-9H            &/T[ 0                 (1*;P
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M[ 0                 (1*;P                 @LIU
M    0F4V@                !$\^OCV]YS=W-]6 !YZI[(EQF1-NHYR%IYR
M?H@Z?2=Y^(Q*F')B9Z@O.)DY/3K)&8DZ&1GQ.AD8O>O1%Y^<UJC R1W)MM&!
MD]H:2/.I-\(Z1,<-2(H4Z=,W1329V?:CO3ID[]>>8\U7KK2YD6H42<IU*>D)
M^B8%%IDB(<G^R?HBR?1UY &1T\YK%             R$G7J
M    !")3>                 $%E.H                 "$RFT
M          (IGU\?WO.[KYOJ@ /-)ZM1%EE7ETE&$N._(X5,GT7><+IFIH-&
M8$[-1E-,9+1*--+F:C2AG$G1$#<2,-I[\G)HQ&3$]8;#1@I-V%(%A EA^'7D
M*+3/C/B(:=H:R1EE/(2$BY"2P3M#@/X*T/M/A)8=T1@K]/H,\@#)2?Z-9H
M          &/T[ 0                 (1*;P                 @LIU
M                 0F4V@                !$\^OCV]YS=W-]6 !5I:0
M                     (83,          R.GE-9HQ#T7+ZUH^AQ1T/,:@I
M[V?ZNWD.]YW;O.]0/+CLN$^>8]3^,[P#!'2\E8NKNZDIKW[O/L   #'Z=@(
M                $(E-X                 064Z@
M(3*;0                 B>?7Q[>\YN[F^K  R"G2B)4 4(F^$40F,GT%\(
MR(GJ33*,UIT.9R-6(R>G=Z.<                        R.GE-9H\H^UX
M"9Z^U*\.>'Y]>E;"K[3QD_@FNOLYAN*/2-3==GX]]AY]Q[+AS9;4NNZ/H?[B
M:!LZC[_/NQ=7<TE4W="6510EG4^VGSWZ?]GGT,?IV @
M0B4W@                !!93J                  A,IM
M     ")Y]?'M[SF[N;ZL #RI>KD1&4]LC5J,Z)^DAJ?01YP\GN38R,4)^,W"
MC%:>8UJCS->O4-Y[$                        R.GE-9HHBRJO&OO?FWK
M-Q/T#)=WS\$V=3]!;6E8]#DPBO\ :U(=GUK%U=RI=VOT;577#/FX="R_#/=I
M3PW8UKGK[+*=U0>W'SWZA.=;:'G9O:'>7%"                 3&B2H
M              C"9/!,                 773WNC-&P
M   B>?7Q[>\YN[F^K  QLF%$83<"-BHQ.G:*,7IH).ND00MLQ*F]$?(?I1Z=
MUHS$G7*+30                       !D=/*:S0/P_0?/,?1$_+Z\_5Y]
M<$QS1/',?U#^T@ <$QSQ/RSY^J/0'B+U'(>;'TCY2
M                                  ![6_-OJ_IIS'7
M    1//KX]O><W=S?5@ #\/X.0  'RE3)N- '$<H!Q'*
M        #(Z>4UF@            >(O4<AYL?2/E.B*JZ^KS[S;;T0     M
M^OM:@L*H 2;#L6/J;M,6%9H&KN,\6M*+YK+CI\F.GM^K%^5=W0=I2 G7]#TF
M=K6FA.SIWY5W=!VE(  !<&A:4_OU81-]5ES;6EO9QM::S=3>S9;T6CZF\B6;
M7F&#9ZGWXH.TI0!9.GOZ#J[C&=_S6AJNXJ3>KN*8E>#9J[=KK1TK&X-"QKC;
MT[&U=R%[&K,]?9@.SJTYOU>T^?Z>$;&ME6[YZX:^TIZPJ_Y3?]7<4%:4P
M        ]K?FWU?TTYCK@                (GGU\>WO.;NYOJP
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MTG)           #VM^;?5_33F.N                 B>?7Q[>\YN[F^K
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MJ\VVM/<NCOR_7V[*T][B>H)MU^%NDY(           >UOS;ZOZ:<QUP
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ME@F $^C#SGQ-^DF1A!ZU.B\T8[3<)1IIE&<DPHW^@ #(Z>4UF@
M  >(O4<AYL?2/E(  '\/7]O(         _$_J
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M.F                !^D0)<                 0Z4RA^
M    '/K[=K8<P                $3SZ^/;WG-W<WU8 &?4U0746FC,"?@.
MU)D=N?I=:,#IU8CH$_P7<C)*;7/PBQ "XRY4923.BKR?']'Q%Q(A28V5,:$*
MH.,LLIXF)IQ&3$R$Z(U>BH4_6BB4SPK\M(I T,48:+1FM-UG\EYHQ<FY2<HA
MZ:,+2-$(  R.GE-9H\M.RX.W=&QH6SJ:UV]+:G/]-DN[Y^8Z^QMCG^GJ[<T=
ML\]T_B#]$^76UHV,ZUMJ*9]>F=^MM+3W_K\^O5_BN_   &/T[ 0
M        (1*;P                 @LIU                  0F4V@
M             !$\^OCV]YS=W-]6  !U)]A]0
M        !D=/*:S1Y(=Q\]T=4W.9+BD@6SIS/7VI%BS=9[Q[AYWJ<GW7/WQ6
MVV!^FY*[*ZTNC0LJ LZBKMS1N+0LNO\ ?CUPX?Z$   ,?IV @
M      0B4W@                !!93J                  A,IM
M           ")Y]?'M[SF[N;ZL "MSK4^?:?29YKQ.?$SA%4)U<C+B=_//E^
M]>JCR                           !D=/*:S1Y6=GP6P:+HZ[VM.P]7<@
MVSJ?W$\,Q0-G4>D'*=I),.;S+Z_B+BT+*IMZNNBOLZ1L:NX-"RSG:TOK-Q/T
M$   8_3L!                  A$IO                 ""RG4
M          !"93:                 $3SZ^/;WG-W<WU8 &$T_*20V@CJ#
M'R?E)P7PC(Z8RF!GJ \_<                           #(Z>4UFB'Y];
ML//N08LP      K#<T;/T]X   8_3L!                  A$IO
M          ""RG4                 !"93:                 $3SZ^/
M;WG-W<WU8 &-$BQ30R,+)LDX"OCOSZS4B,UIU6C^P
M        9'3SFL4            #(2=>H                 $(E-X
M            064Z@                 (3*;0                 BF?7
MQ]>\[NSF^J                                    &2D_T:S0
M      ,?IV @                 0B4W@                !!93J
M             A,IM                 ")Y]?'M[SF[N;ZL
M                         9'3RFLT            #'Z=@(
M       $(E-X                 064Z@                 (3*;0
M             B>?7Q[>\YN[F^K
M   &1T\IK-             Q^G8"                 !")3>
M       $%E.H                 "$RFT                 (GGU\>WO.
M;NYOJZ'LJG(=[SWH-R_7R[!L5,FV4"+$I (P<1+    "B4WL@"'GWDA !DY.
ME$4 F0E]H BI*C+R>8&DT5$FBR]"W$5H4FFQ3HSX34J(L2DBP)24.F^$5@6>
M    #(Z>4UF@            83SZ]S;M>                 (G*60
M            B,I?#\                 )%I[]R:^R
M!$\^OCV]YS=W-]7YP=7Q?A[]%^7?Z=/D'W&[:ZTQ F-)L%&94ZL16I(21G6D
M4.4O M!&*WJU$0(T*9E3WZ)^<I7199 BW"^4813+3,B?59Y\OGJST=V=:7&8
M63ZXO/FX]:R1E--OHIM,T1,#5B,@IH5-GHZ-.GT7RCR6>M#(E18)G9,P1M1&
M<$U =J;90   ,CIY36:            !XB]1R'FQ](^4@
M                                      >UOS;ZOZ:<QUP
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MG5XI\VOHV54;U:                     /:WYM]7]-.8ZX
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MN[KYOK?-CKN%DV#;W[S/65EMZ?-'O/EI37M6VO9^,F'>DY$
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MZNV#0]/@[IN._A._N8Z[K/4?/ZQPC/AU737U$V-9B+I./
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M                ")Y]?'M[SF[N;ZL "LS^#^SI$SA%>IJHV*C!3U8:+M1
MT]864CD.(Y3ITUT6"5(:^1G5/&6.B.I_LILO9%J$;,HI_@_2VS+R=D/,I*?3
M]A*4=,GXRU$?I7Z:7-!(@B8B7"?:C'SUZ#/-:G8D)36A>B!8Q5A3R;K19( !
MD=/*:S0            //;<TI;:T@                 C4S)8@
M        ",3,GB                 !;55=:"T]X                ")Y
M]?'M[SF[N;ZL  =:=D  #Y3Z@          =<?0?0?P?AR@     '7'8D0)*
M?4 =:=D     #(Z>4UF@            8_3L!                  A$IO
M                ""RG4                 !"93:
M$3SZ^/;WG-W<WU8 'F\]2U%PF@D9O3J%$.*O39J/Z(<GM$1I/>HQ*];D>?C3
M;*,W)N)%-)O%&?DWHC\.M(*GY"1'=(Z).5T^B+R**3.$5"FM#^R\2/';EM(S
M@G]._!=Z*033AKY'F:];?1:J*K3=R,H)M@[<Q2G=[S"TWJ@  #(Z>4UF@
M         8_3L!                  A$IO                 ""RG4
M               !"93:                 $3SZ^/;WG-W<WU8 &&$_$2,
MKY/.;.><0/7$6 CZ"C$VRC^#M3YR6$_+!122:'3?"*T-C(RJG^2)F@SY3&R;
MH1SG1)]!7D>43U>:($F9HU2C#3UJ%%>$(3P'2&O$8J39Z)L5PGT&><))EA%#
MK#?B,=)[XHM,W16Z>V/1EY   R.GE-9H            &/T[ 0
M       (1*;P                 @LIU                  0F4V@
M            !$\^OCV]YS=W-]6 !D9/:DQ.N*^-=HSDGK"SR%D&+/.$^0K8
MM$C!IU&&DVT5$6F0\FQ1J=!(G*.Z,TIMLJ ^$G)J=&)DW$486.=L0TT:B$)H
MTZLL\^DJHTPC,29N:Z1GM-)%O'8&@T4 FICL3X"5'8FFT   9'3RFLT
M       #'Z=@(                 $(E-X                 064Z@
M              (3*;0                 B>?7Q[>\YN[F^K
M        C1)0                 9'3%"3             SDG1J
M          !&92:                 $7E*(                 ",RDT
M                .BRX.MO^:W9S?5@ 9O3T!PG7DW(T:41D!.WD
M                      9(3R&LT            #'Z=@(
M    $(E-X                 064Z@                 (3*;0
M          BF?7QY>\YN[F^K  XS#B>0XC<J,,)[0^ W*@
M               #(Z>4UF@            8_3L!                  A$
MIO                 ""RG4                 !"93:
M   $3SZ^/;WG-W<WU8 'F>]:012R?L1%4Z"1UIFQ/J4\@
M              9'3RFLT            #'Z=@(                 $(E-
MX                 064Z@                 (3*;0
M  B>?7Q[>\YN[F^K                                    &1T\IK-
M            Q^G8"                 !")3>                 $%E.
MH                 "$RFT                 (GGU\>WO.;NYOJP
M                              !D=/*:S0            ,?IV @
M             0B4W@                !!93J                  A,I
MM                 ")Y]?'M[SF[N;ZL
M         9'3RFLT            #'Z=@(                 $(E-X
M             064Z@                 (3*;0                 B>?
M7Q[>\YN[F^KK?;TJ/L:O3E/>=YCRT"GY">HEAQF?$WLB8D0*53;Z*Q3])?Z.
MI(T3LXCE/X((3XJ9-LH  XB"D_  .(Y0"HDVZCB.4    %3%L@ XCE  !4B;
M;0 ,CIY36:            !AG-AN_<T                 /TB:96@
M           #H?/O0>GO                 "*QZGGCT
M !$\^OCV]YS=W-]7YP=7Q?A[]%^7?Z=/D'W&[:ZT\]7K9;SY<O6K40=.C$50
M;;1BQ,$3_1\YMQYG!3*<_&YT>3CUL!'='0D /PW.BCDTP6,=P8*3JU$8.$LT
M[HZ(QPG;Z(<3 Q GUM>?*]ZV,BJS7Z*83U97Q>!29?)GHBQ,"[#[2%&0$^J[
MSE%/8D&)>?(9O3ZA/( R.GE-9H            'B+U'(>;'TCY2
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M8^D?*9?K[6DZF\R#>\WQSYN^MN.L]XJCWZP =GXR:]H>ES'<4,GP[%2;]8
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M_D                 [71WK=U-L                ")Y]?'M[SF[N;ZL
M "L"3$@.,^LZL[(^$YCXSN ?$?&=D<YPG7'8G*<1\9]Q\A\QW!Q'Q'9
M$2):   #XRH4W4@       #(Z>4UFCQ[[OYS+<&Q_)V/GW\/KQ56[H?9Y];7
MY[IZ>WZVC[&KM'3WY)AS9^M*BPM7<FNOM>EW(]L    /$7J.0\V/I'RGT@Y+
MN<1]#RVZN;ZZK]VO[''F^3WA[3'FF.#9CF;7Q%T7*=YCR7E6W%PZ%E#<^OUG
MOQHVJN<_V=1R%S5]GEJYH+DT+2SM3;RS<T63KSF@
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MV^/)<6C94'95.CZJYH6RJ;GT+*N=K3[S'FZSWC['Q[I:QJ@
M         !<]?:_Z"OG'U?\ D                 [71WK=U-L
M       ")Y]?'M[SF[N;ZL ##:?Y.]-DH@9028F3$NU&;TZ*1A5Z]-WD>=+U
MI!%/G6$A!52?0AYR>FIT]H?IIQ$0+[1EM.U$9&3&2XS/A,SHCL#^3;:,,)Y#
M[RO4_8CN3NSL#H2A$Z219!RF-DWRCD-F(      R.GE-9H            'B
M+U'(>;'TCY2                                   +GK[7_ $%?./J_
M\@                ':Z.];NIM@                1//KX]O><W=S?5@
M973^%A%SHQVF1G?%>G;'"3\K<XC8:,P)$J.\17"8(:91F%-V'(<!#SL#2Z,F
MI&LD9M3V14!>I2A;!VQ\Q>",EIL ^DX"ORQ"QD9338A2J=(HGR*23!"\CD+=
M0     !D=/*:S0            //'=T9+;48                 C:9(@
M              #@QY]FU%W^                 '0X\EA8\@
M      $3SZ^/;WG-W<WU8       'QGV
MR.GE-9H            &/T[ 0                 (1*;P
M    @LIU                  0F4V@                !$\^OCV]YS=W-
M]6                                    ,CIY36:            !C]
M.P$                 "$2F\                 (+*=0
M    $)E-H                 1//KX]O><W=S?5@
M                #(Z>4UF@            8_3L!                  A
M$IO                 ""RG4                 !"93:
M    $3SZ^/;WG-W<WU8                                    R.GE-
M9H            &/T[ 0                 (1*;P                 @
MLIU                  0F4V@                !$\^OCV]YS=W-]6
M                                 ,CIY36:            !C].P$
M               "$2F\                 (+*=0                 $
M)E-H                 1//KX]O><W=S?5@
M           #(Z>4UF@            8_3L!                  A$IO
M               ""RG4                 !"93:                 $
M3SZ^/;WG-W<WU8                                    R.GD-7H
M         &0DZ]0                 (5*:P                 @\IQ
M                0R4S@                !%,^OD&]YS=W-]6
M                            ,C)C)+0            9P3H]
M          BDI7                 "*2E<                 !%I2F
M               '19L'27W-[JYOJ@
M     !DI/]&LT            #'Z=@(                 $(E-X
M          064Z@                 (3*;0                 B>?7Q[
M>\YN[F^K                                    &1T\IK-
M    Q^G8"                 !")3>                 $%E.H
M          "$RFT                 (GGU\>WO.;NYOJP
M                      !D=/*:S0            ,?IV @
M     0B4W@                !!93J                  A,IM
M          ")Y]?'M[SF[N;ZL
M 9'3RFLT            #'Z=@(                 $(E-X
M     064Z@                 (3*;0                 B>?7Q[>\YN[
MF^K                                    &1T\IK-             Q
M^G8"                 !")3>                 $%E.H
M     "$RFT                 (GGU\>WO.;NYOJP
M                 !D=/*:S0            ,?IV @
M0B4W@                !!93J                  A,IM
M     ")Y]?'M[SF[N;ZL                                    9'3R
MFLT            #Q]O^;R%W'SL                 ?*GZD
M      6G67/O9\[^G@                "$RFT                 (GGU
M\>WO.;NYOJP                                   !D=/*:S0
M      /$7J.0\V/I'RD<;UR/(   ")3    _8G\F !WV+/T.7!QO7]O/[$I@
M  =WBS=)EP@               "^Z;H/],WRC[*                 (3*;
M0                 B>?7Q[>\YN[F^K
M        &1T\IK-'DEV_SV5X=CLO'OFB>DR8N*7)#TNY+MXCGUO)[M> TS47
M>1;SGMGT'2X?Z+E_=GYO]5     \1>HY#S8^D?*=M<[UG%/G.MK2W?76F:+>
MDO.MM=%U5UCN^YKN<>7N\>6K]S1M_1LOX>8/L:VPZ+HL6=!S/9^/?U1Z[3'F
MTQ4W5/[U=&<VO6FYHV/J;M2;NEK*DOL7=!S'I]Q_=51NZ--[]=',VM7.UHZ
MK+C.EK37]66]=[6ELSG^IPMTO(3#7VH]EP377V_B]>*"M*8
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M*;0                 B>?7Q[>\YN[F^K
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MOE'V4                 0F4V@                !$\^OCV]YS=W-]6
M                                  ,CIY36:            !XB]1R'
MFQ](^4@                                  "^Z;H/],WRC[*
M           (3*;0                 B>?7Q[>\YN[F^K
M                       &1T\IK-             \DKSG\U=EP0
M          !/P'WH                 L6NM_;W@OHP
M A,IM                 ")Y]?'M[SF[N;ZL
M             9'3RFLT            #'Z=@(                 $(E-X
M                 064Z@                 (3*;0
M B>?7Q[>\YN[F^K                                    &1T\IK-
M           Q^G8"                 !")3>                 $%E.H
M                 "$RFT                 (GGU\>WO.;NYOJP
M                             !D=/*:S0            ,?IV @
M            0B4W@                !!93J                  A,IM
M                 ")Y]?'M[SF[N;ZL
M        9'3RFLT            #'Z=@(                 $(E-X
M            064Z@                 (3*;0                 B>?7
MQ[>\YN[F^K                                    &1T\IK-
M      Q^G8"                 !")3>                 $%E.H
M            "$RFT                 (GGU\>WO.;NYOJP
M                        !D=/*:S0            ,?IV @
M       0B4W@                !!93J                  A,IM
M            ")Y]?'M[SF[N;ZL
M   9'3RFLT            #'Z=@(                 $(E-X
M       064Z@                 (3*;0                 B>?7Q[>\Y
MN[F^K                                    &1T]T=0
M"MRR                  =:=D                 =:=D
M    #K3L@                #KO?BM-S0MS0L@
M              !8!>J
M
M                       !_]H " $"  $% (0Q&289)ADF&289)ADF&289
M)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289)AEQ&289)ADF
M&289)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289
M)ADF&289)ADF&289)ADF&289)AE&$)<8C),,DPR3#),,DPR3#),,DPR3#),,
MDPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3
M#),,DPC*C 91ADF&289)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289)
MADF&289)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289<1DF&289)ADF&
M289)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289)ADF&289)
MADF&289)ADF&289)ADF&2891A"5&(R3#),,DPR3#),,DPR3#),,DPR3#),,D
MPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#
M),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,D
MPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#),,DPR3#*-T)OW>U&_?U''\I
M/4D_]L.I/_?U)(_;^"H_FF_=[4;]_4<?RD]23_VPZD_]_4DC]OX*C^:;]WHR
MI)IT34Z>6'L9OW^HA#$<,G@\LTN/HD)^N*M*9-,4)3IX]!4DPQ/01HC*H^HC
M^4GU<J4:;&--GP$?<%B(R6/J2)CG+ZN?^V'JY*29.A-1S94$B4RH\PGZ#>HD
MISSHST,V1#U?_O\ 5\,GB9*-+CV(V3ZF539TR$R4:5'U<C]OL\U.>4)28\V'
MHRI)IL9LHTJ(BDF0+(23)\$B(RF$.IH_FF_=Z-N?.EU2?+/6DL#*2T(\(I$!
MU1N"Q/"7(,<Y:+B98B[,;@)RFE4LTR,VD1@1$C,K-*H9C"72#A=3SI(^B;]_
MJ)'[ZVLFRIZV9VE'*HLR9">A,29P;",^0:0:71S?I.C,EFUWO-4E3)9S4,Y(
MK:89-"5*FQ3HT1U9IE'C^E)3S*"SZ3$I+?\ W0]1'\I/JZ#WB?4Y\J;<)(?J
MJJ R@RVF&3%24\R@LZDQ*1&B,J-/IT"$1H3JHQH\3P"<Y2'E+3*4WJY_[8>K
MI\PQ$=&J$V9-ILN$M:>CF.=6E,E.6D1A!=3SI(IZ;&816D[/&728_I64\Z;H
MDKYDDE%4'4$AZO\ ]_JH?G7E<R5-G38JT2=,=0B/13?I3R#*#%HT#1BE/"9&
MCX1ER33#<&]\^0:0:$<(S:G.FFK\<2>KD?M]F-^532F4QJ2LLLJ.GG4PFTJ,
M"=A-DHTIE1YI/T&M[Y]4_P#*DI$\5$Q8IA-DT^5-F%H?[$R<T\W!L8Q3G@>-
M'_3&AH\9M2I^3%-2C3"*J4:21)3SJBEH1C Q8EB6D1+!:A.DB2DQ@52GC(-[
M/'\TW[O1MSYQ5B62:6J,I4UR9$Z@L<M!3S1).A@2H2Z2<DY?/+/GW',C&:DI
M\9Q*3)DRXVY[ILN8:,VX#Q,H5QQ1>B;]_J)'[ZM,3%FKZCVF%2F1@EMTL,V*
M=*:*Q1+5J*Z:)E":,<RN]YN'YMQ'C$\B.*%-W%-_Z$)8_I"6G9I*;)E$);W[
MH>HC^4GU=![Q-4I)<Q<L,K/<!X_J2QQ0I:?&<2F29,LM+6DD044J!2)2$[$B
MBF2S%)RGF"G=U]7/_;#U=+B2"0E3DIH4*,8J5IXGFUZ/Z@:EDE0J)"E22E$E
M5*FTTR:;5Y4B9.GSY!$PDR33C+)I4,KU?_O]5#\ZQ,3EF+JEGE*>)4%O&PGR
M4QI\V4BD2IE24=G63$$I>:WY?Z9O9TL8UA410<):P9/"J2"SI?JY'[?9C?E-
M70D17H8HSGERNR()J9&:BFA-A3(12RA;WSZ.:$T4XD4<M%W.B?LH7[+>+"!9
M<A*6*VH$BIFHY50-1I<2*E4,9UQ1C"90(_J%'/$DBEQ_3/F2X&75*4GF3EJB
M3V>8>34PK2&2G]GC^:;]WHT=61-,-'&*69"7,J4\L^<@7$(229(D-29IYR@T
M]%&-21%2GK"HBF:C5RC24:I,C%&5$33"1P-55)5$Z>K(=-Z)OW^HE&_2:K*B
MJ9H6JR39*!9%),F2D<R*@TLIU"A,N$Z;)+,JJ@JB=6%9%,RL*R*3R59"I9*L
MA4M-7$E%,5))@F52ILA,K3)2TA61-&'J(_E)]72E)4\Z>>!SQ%75D4F3JR$3
M)5<J9(2JTR6",L@T(J9*64@7$(3(1D$?SDP)$TA0DE2U1918^JG_ +8>K3+"
M$3"E*2IYT\T#GJ2PDZ"N>F717+94V024EFEJ*TDR$Y0G7A45.0HI2R0GEY:*
M(/"$(^J_]_JH?G659%4P=K)V2DJ2IIU/702SO_$DG6*I,]2F,E2&2U$TF=,E
M(YD5.7^J4:!3&E(ID:C4"3">KD?M]FB*JL(H@1=+GR$JV6>2:4DEP23HR9EQ
M3H%Z*.J(FFR)\9,RLU(BH)E9")Z8K)(+2U9$Y:8M[(<TA'&/ZI.:G[(F/(7_
M *%%0@G,#K)"XAUDI++0JR29**;"5-6*H&GJ)J9;%5"06&2C/&IK8*YGL\?S
M3?N]6B6F2&X@G"Q8=4;UAOW]1Q_*3U)/_;#J3_W]22/V^UI9T),Q8IBIF=6Q
M_--^[VHW[^HX_E)ZDG_MAU)_[^I)'[?P5'\X1P&9$9D1F1&9$9D1F1&9$9D1
MF1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1^N(S(C,B,R(S
M(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B
M,R(S(C,B,R(S(C,B,R(S(C,B,R(_7& S(C,B,R(S(C,B,R(S(C,B,R(S(C,B
M,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S
M(C,B/UQB,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S
M(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B,R(S(C,B/UQ&9$9D1F1&9$9D
M1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&
M9$9D1F1&9$9D1F1&9$9D1*C$YJRC@AG9D1F1&9$9D1F1&9$9D1F1&9$9D1F1
M&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9
MD1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1
M&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1&9$9D1F1_ 4>I(=2_#J-
M-\RZN\_\+CU)#J7X=1IOF75WG\30A&(RS#+,,LPRS#+,,LPRS#+,,LPRS#+,
M,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPR
MS#+,,LPB0PRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS
M#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,($B,LPRS#+,,LPRS#
M+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,LPRS#+,,L
MPRS#+,,LPRS#+,,LPRS#+,/T1&6899AEF&6899AEF&6899AEF&6899AEF&68
M99AEF&6899AEF&6899AEF&6899AEF&6899AEF&6899AEF&6899AEF&6899@F
MEQS+J[S^)K3[Q@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!=7>10::1
M?,TBG"Z1"1-_$5I]X]&)X0C[# \(Q]")X0CZ1C0+"$<?5QF%A'TSS"D]I,>!
M?P%=7>1:DTLN=VR4*J:!E'XBM/O JA3SU:B,ZES)Z@D@J6J2%4:EWU54)24)
M%\I4)BZ5+BEJ<E5%74)24$4RU4NFFER$\VL)Y0ES"S(3*TF(9,LEJ87!.-*3
M4)4?&LK8I9-OFF0-*4DFQ[23,2Q@5?(N$D9YE$A7/F+)<LR:JR%)JEWU2KEI
MH)*C)5=!S'J"I B.EBJJDA+&MSR3T:4T"R9=:33#3U!)$)=1DS)BJJR$T4ZH
MB@L^KIY!JKESI$R>1.1)4I*J(01[4K52CJED)DZGJ;@--C,HZWM<BNJCXRJC
M,DT^129DV76$L9R6G*>TR>FXIQI28E$.:%=.9.DH:TYA)G&BO+^NI**>C.F%
M"G'F1N2<:5(N*<>7(6H)R*7-6&FHD%*.HE)9,9)%U-,I-3T4Q2>3.EHX+%4E
M9(SB)Y:>L)YYK@_>J6RTL$JV4JAU_=7>?Q-:?>!5"3#K22SE656;$ZQ="<I-
M4^^K54B3-33/U+XI2**A6Y19$Y?)F)U*95)4RD'\91*?*[-1L>QIJ@F*CH\@
MTE/<O=5W_AS)W_F+:-\^C?/C_))._HI)8KZA+*18K3$45"XI!9$*EWU5-B==
M.+-G3Q4:+!2:F5"<6;;DDLXE:2DD)*U-C!.M_6HDUF!X(92.6CEVVG*>2FEP
M35"48U*C7S$,BK".9.+3ZA*4G%L>^7/ES9B^GD-!75N](X]B6(H=IA1))9R.
M<AGTJ$I255(M>,8I5TR>6&>O"&8H-&Y^ZR:;/PN?NM5DF3P1S835R^B9QZ34
M9IYEO?NNGN]SP_\ 'JTI1*+4BE*DIM.GS)!"Q+ 4+YRU*534+BDEEI%<Z1*D
MUE3F$N#]]53S"SZ:MDJOP!=7>?Q-:?>!.1'.KK5/,J+4*?,FGEG6S#+$)YJA
M2BGR5"= HBIGRYIE\M!/53E)E9#T^FS)14M-F2T5-3F3R2)(H4B)&LA*HR\R
MR7649E<A:@[2GHE.,CETY$=/-.B4)9Z.F3R*4Z$Y%2A"HDJ%*&9-GU"7,.O,
M@4+9BQ">:I74^;"=(,L.<3"K9)Z?3ID)LM"I0'4(5"A,MI?:9!9B_"KH9BN1
M^G&$A$JIXIU./+/,*N,551C11JX*"!(BG3)XHT.SSR(3P5U6GGG'7H3SYU=I
M9UI2(LI.G0SY*6=*7*BJX%IZ2BI^SI^FM(C+)!3+RPJJ.8L30E0B2D468BGF
M@NDFIM./*/.IT]-.X>H6GK2(ZN4L304RI*&=V-++7)Y::,R)!3$)T\PZ$\5E
M91F5R*C39DXBY$K7EJJ$ZDRN*HAZ:@F2YG7]U=Y_$UI]X]01"4L[T9TDLXL+
M?EP"9,1,3U,4!(SO9#(B&F^FL1$50_#5U=Y_$U+J44$S6)QK$XUB<:Q.-8G&
ML3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C
M6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)Q
MK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$X
MUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<
M:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.
M-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G
M&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3C6)QK$XUB<:Q.-8G&L3
MC6)QK$XUB<:Q.-8G&L3C6)Q*NXYS75WG_A<>I(=2_#J--\RZN\_\+CU)#J7X
M=1IOF75WG_A<>I(=2_#J--\RZN\_\+CU)#J7X=1IOF75WG_A<>I(=2_#J--\
MRZN\_P#"X]20ZE^'4:;YEU=Y_!I:(68D3R(SSJ*1(2J*E*E2IL@L#GN.GRT<
MSH34U*E3*J<E.DZ;=ILI8*0F33HGA"$>KH]20ZE^'4:;YEU=Y_!MIJ('A;U/
MB56FGP6U";3B**BIJ:8D^X$G:E:^HR*8>MI)4@+ZB24ED?Q<U.2%,H4@ATM&
M3RDJ6BKI2N%J2"33VNF)./3%:92=,I3)Y\BGRY-17RBE75M)*BLJ<R**)HPC
M'J>/4D.I?AU&F^9=7>?P;2%?99]5.1'*M^."HZPJ:I+:&3/K*PJ=95*%&H3;
MD5RX$JQH</D&APNFRRU%"B2D1)Z1$B]'1J>6GBT#0@>TC0A,MF,(*BQAQ)2J
M+(J2VCD@HN.5!0KI<E0C"PQ33>A!3SK3Z44C2BD:44C2BD:44C2BD:44C2BD
M:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C
M2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:
M44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2
MBD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD:44C2BD0M12-**1I12-**1I
M12-**1I12-**1I12-**1I12-**1I12-**1I12-**1I12-**1I12-**1I12-*
M*1I12-**1I12-**1I12-**1I12-**1I12-**1I12-**1I12-**1I12%Z Z(W
M4:;YEU=Y_",31CT0-&'H0C&'1". C''THFC'HB:,?0M/O'XMNSO'4:;YEU=Y
M_$UI]X"ZKRT9TE;DJ#^LD5 LV;Z"B>602G526NA&,"P05B4M-T25\3J4U0A/
MF=".H1GSNF9<,J!DBHBH@65",B=Z<ZH0E3NFF+XK(:DDQBC72U995;DS)PGU
MJ3)G+JE+1P25F6H/!>8JGT%JZ6C*2XY,8_F$E8E*9JE1!.1//A/)/7$DS!(7
M$G3%%>E29B&J2E@45Z5)F(:J16917I4F8BJLI9$YOT0-<TDD$U=ESS@E0@:?
MT4ZH15&]HNSO'4:;YEU=Y_!M$HT5YC2J7 RA/ DV:F/*%JIR380AB)B<\L+I
MB>*8TLQ80EFC#+-A,D'E@R<Y2^LM/O 5F@5?79A%$VK5.:EG'63T$J/$/T$K
M93)5*A;)DJELZ0C0S5:@Q%BA>:FKIAYB96I7BI5"8EE)9:HATZV9-441>97+
M3U8QC2CK5)*6O[;*K'=J?'L<ROSXEE4N1"0LIRT\^<9<>"Q+_(4]:>=/2U!4
ML-3E\V$ZD][EJU"\U-73)AYI/UEI-1A38*%9$\J2==/)4C1,H7+YF;VN>CFU
M2I3D\^*J<ADE[?,))K4)B5)%9,@I6GEJIZR=/4(X38%J\Z,E/1I64FMR<27)
MHF$Q3-DQB(+B1DPE1A"L%.F4(JC)6PKT<J8#*998]LE IH&@0D%E0F2RS(51
M5V21-2\-+68XIJ1W:J=\%+[Y3IA2+('+/J,JHRT:Q%4):R$A=*2K4\8+EHNG
MNICQ)*0+5BXDI:<RN>19-/25\R<:@?O]HNSO'4:;YEU=Y_!M(C$M/%"GJ"!)
M*4395H_E;$@LN6HN.:H)6/X^M=P1_P 8C502T]!4NV):+4S50L881]7:?>!4
M4Q%"Y+3Y*85'OMSRXQD&JLB$N5+-+IT)A)Y*_ L$:7Y='1RHA"C3R9BU-(_3
M+GREJ=,8R-53N_+5'"U$:<:73J<D33Y5,3R9)*QW::DBHI])G1J<]'W^FSRR
M%4E4114$O\A2.\T%;+E3)4R"JH4J&*JC(Y484]&GE3)TV$HLY6E4RTT@\RGH
MZK)C(J4R$Q0OD$@NC34L#*_Y"YI)IB:55),95$_21.K(6F17=_6I$RP] 5GG
MDKI/UI:5,S$]"IDE3+E2BRH48D#S"?KB*X6!3GJ$HDQ7"5%;<?\ Z^B;14\T
MW $HDR2R2SIO#ELZKIY1:U$RV:LI"J?+E*^T4ZEKY)$]5G%@JEKI4R-+[XF0
MRE2Q.EEIX(9Y)2R6IES8H993K9,.'+!=/=9OR+=[K(_D9!XKYMO_ *.T4#]_
MM%V=XZC3?,NKO(ER338]@G Q8EC^";?K)4@F4RGP-2*@G+"F3DR"%LK92>%N
MU26G@L0HTY*FME3$4A2F7I)RU*1(9;*C3J2LERD=KK):8QOS]7:?> 9,0QP=
M,0YHPQ$**F@:N)YDZ1,6$F$IU-RTQ2P+!539*F*9'+30-1DT33TDN>5+3Y*4
M$3$(90CEJ.B;1D\PTJ26469++,++E%EE3I2)X%3$*=53I*F)$<LABIR%/+3$
MEFI5.+-@G2RT\):8DLRFFR5,4R.6FA&&(-14T8E+ L.#IOU'3$.90F(H@GI4
MA/$R<ACQAB(T5-^H\HIRR*3(D&.F(<ZBER%!I4DLDIR0/"ARIB>7(3$D0$I,
M25'LI/USDQ)T5*"4I"9#*3"8G.H6>A.DEG0DTA/*C!,2!P5#*+#@J83:=)FP
MDTN1)-+3$EF(F(0PG4N1.,GI\E/$B8A#3DI)T1/3DGEB2$829!9)8)B0.HI<
MB>:4EERHR4Q),?:+L[QU&F^9=7>1:'SQ5N\?B*T^\?BV[.\=1IOF75WD4JIQ
MIY]8G"J?GS/P2G3G4&G2C2C>HA#'HPZ(0QZ%*&:F]3)GGDQXG/'$YXXG/'$Y
MXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/
M'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXC4YXXG/
M'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YX
MXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/$
M*G/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'
M$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXXG/'$YXX
MG/'$YXXG/$Z>>='J--\RZN\_@VU94)9;<-FJT\LL:G7DY%4BVD4%$ZX3DG)"
MDAPNB0Q4W.6!5(7S^$2;DED/(D7)"3&[4TL@6SN$2+BEDF)YL.V4WJV/4D.I
M?AU&F^9=7>?P;2/X^UN])OY2G*(15&D1I*.J_P =++^JE4(L8JJO*DS5M01I
M"EFK8465<*<JJ53:^5(6Y4$)I9BN%$DW!(*KDTC^/ZMCU)#J7X=1IOF75WG\
M&VK-A,+3%?#I\JLE(KXG^E57*UQ +*P6>EH]=BA@6X$R<*5!E!RFB6)K@3JB
MU2N=I)"MI)D:O73+@:X)"HM5KD%,N9'L=-ZMCU)#J7X=1IOF75WG\&IE)TQI
MTXTXWKE2^:JAU;'J2'4OPZC3?,NKO/\ PN/4D.I?AU&F^9=7>?\ A<>I(=2_
M#J--\RZN\_\ "X]20ZE^'4:;YEU=Y_X7'J2'4OPZC3?,NKO(I=,,O/H^:%,B
M,B9^(DZ4Z@W!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'
M!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X
M(I'!%(X(I'!%(X(I'!5(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!
M%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(
MI'!%(X(I'!%(X(I'!%(X(I$**I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(
MI'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I'!%
M(X(I'!%(X(I'!%(X(I'!%(X(I'!%(X(I"A,=/'J--\RZN\BT/GBK=X_$5I]X
M_%MV=XZC3?,NKO(DJ#R(\54 YXGC^(K3[P#*2%/&.$"+9<R6B5E52_4)5LM5
M#T3UM,0TN869 *U,$TL]1ERY13P-"8>$N"94127HJ"XJ,DY421 2E1)IE*R6
MF@FJ<A3%.OA-F],8PA#CB;$IH&@5;*-,,:!82)Y9Y5"DB<LNLICQA'$*5LI-
M!-59"B)SP)"76DQS*5<M-"%<2QZ9:V5,.%%4D)S<=2B3.+.*K62TI81QZ%*\
ML@_5EV=XZC3?,NKO/XFM/O 4_P A/_91.X4:>60B)5E)RK:F5,0U6G)HU6JP
M003U&>:$ZJ*I):PJ-,2TU6J+(2U/!.F5%G2I%<A%.>JJ))9<R$PMQ3S?ID4N
M1)(>,FE235544M25%4HE"DJ=#<TZ9D=M50(A7D@ED5%3-Z%\<Y;<GY"B]XI4
MF%1FGILDQET<A;TUTYI\V%,D0(0A$,J$HTB6I- TJW.ZW1\B=3)$TM#F&3S*
M(G*N-7:;+F2:E-F*T"7LB^7<T80++.C/$+$T5!$"4B9>)B:7,C;R:6<*:QV:
M:M7G(G6JCR2EJTZ3,K'>>K+L[QU&F^9=7>?Q-:?>!4)D)*Y;-+*E4>7$B"86
M,:6EFEC*K>)E"FCS5!*Z3],:FM[')6RE)DT/XVB]VMTD#RX*C)D]<3=FD3:7
M.G%1IH)Y=R0C*C+FEFEN.<69+G32E(D)$M,JO\=<?<YGR*)*+-0SH3J,6$<0
M?_TU*YO_ $RRS"F+08YLVW)D)!IDXLN-:_\ 4H$^GJ#FEEB4M9-V95 \(PKZ
MK.DSTZR;)I"J,Y';O=;G^0<\"0HT.U3[9F0EEKJLLA/2R032*]3I2<E;-&=*
METV1+BL13IITLHTHDG^2Z+:$J'_]&Z.[U-?,DFJ\B;*C6.\]679WCJ--\RZN
M\_B:T^\!8BEJRDMR3")Y4#%3HB294+;D0"E!+42RV_+@%:$BF,^06>4MNR80
ME)"2Y:*C2TAD2$B2$RD2IDZ?(+/+"W94!+) D)DHLTNF9 +3Y194+;DB>C)-
MESZ;+G29Z0D^6DI$M- E,E%D2Z!**85PD9)YDHLXNFI(D)R2"KJ/)612T.2G
M.0O:EW2H3D4%A;,B A2I13B33)<HT+9D0$RD2YDF%N2,94HLHJVC259DU!DR
M3+D$M865;TDIE].(M+"W970K2E4DTU(QDRH2BA&@(D!4)"SER$BPBZG2UA2V
M_)"A"2>?JR[.\=1IOF75WG\36GWC\6W9WCJ--\RZN\_B9$NF(SZH5#5"H:H5
M#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H
M:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#
M5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:
MH5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5
M"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H
M5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"H:H5#5"
MH:H5#5"H:H5!:N.L-U&F^9=7>?\ A<>I(=2_#J--\RZN\_\ "X]20ZE^'4:;
MYEU=Y_X7'J2'4OPZC3?,NKO/_"X]20ZE^'4:;YEU=Y_X7'J2'X)3QP/=?>?^
M%QZDAU+\.HTWS+J[S_PN/4D.I?AU&F^9=7>?^%QZDAU+\.HTWS+J[S_PN/4D
M.I?AU&F^9=7>?^%QZDAU+\.HTWS+J[S_ ,+CU)#J7X=1IOF75WD(T,Q6;3BL
M3I1I1OQ%(3'GQX.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!
MU(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.
MI'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U
M(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I'!U(X.I
M'!U(X.I'!U(X.I'!U(X.I'!U(/2U$N&4891AE&&4891AE&&4891AE&&4891A
ME&&4891AE&&4891AE&&4891AE&&4891AE&&4891AE&&4891AE&&4891AE&&4
M891AE&!BQ+U(F^9=7>1:'SQ5N\?B*T^\?@BJ_(ZD5_GU&F^9=7>0AJ$Q$;5"
MH3YT9Q_P2CI4U61!3)JZ*U!,1F1()BPRZF349E],FH0@IDU=$T,(D)$\2VLI
MC"*&9";I94%28R8Z:W%,\JM(=*?U5I]X"E41,67<B8T81QZ%-0R9QJB0L[T)
MDR$LL+F31"97+4EA421G]<U7Y'4BO\^HTWS+J[S^#;8[M: J\.WHZ7_X".[?
MFWE^ZS?W3OW4521.HG4N=,5J%I%=0JB%=,FTU,><LJU-5K9J^1-DS/56GW@3
MR06KYLDLTM07=CA.7*D(J4<5DQ::"M496<]-J$T\V;4)ZF:@FSC07_)H,(12
MSI4$"XJXT5G;5"J9,6F2R(J%T"2UT9\A4J6I"U&J=GDI.UE//7S9TY(OFEG=
M857Y'4BO\^HTWS+J[S^#;8[M: MF9!1+N2="5&[XX3+B1'7R[<1G0DI]<[&6
MGSR519/4K2J[A19BJCI%A)ZE40M2J2)29;=\PL9OJK3[P%4R"!=-7RI1:W"!
MYT^CRC%J!?TK)O\ (YLQ<HI18%6T.:63-E*238K_ )-#GD(ES(5)9+_D5-.E
MSC+%$Q=3Y-.ESB*ID*6DJJ7+30DR9Z:2:8@4)DL#*Y%+E2YW6%5^1U(K_/J-
M-\RZN\_@U-49J<J1?-2A,J.F-/4GGG5KYJN*2K3TD%=6GJX DR,N,+C58%63
M"S#W$J-")HQB6X512S)D9D?56GW@3TY)Y95!2RXSTY)Y95 2RXS$A)AXI"1F
M*Z1(5&D4^5(,LI,A7%*CEI2G) \(6^E@),DLF$$A(3)U"333$DE(4UO)8QBE
MEQ)*H2:6)]/E3B(Z5)2164V2K".E24D>L*K\CJ17^?4:;YEU=Y_$UI]X_!%5
M^1U(K_/J--\RZN\_B9"O.C/JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI
M2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*
M1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JE4-5*1JI2-5*1JI2-5*1JI2-5*1JI2
M-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1
MJI2-5*1JI2-5*1JI2-5*1JI2-5*1JI2-5*1.N-1.+VDP[28=I,.TF':3#M)A
MVDP[28=I,.TF':3#M)AVDP[28=I,.TF':3#M)AVDP[28=I,.TF':3#M)AVDP
M[28=I,.TF':3#M)AVDP[28=I,.TF':3#M)@>9$_4B;YEU=Y_X7'J2'4OPZC3
M?,NKO/\ PN/4D.I?AU&F^9=7>?\ A<>I(=2_#J--\RZN\_\ "X]20ZE^'4:;
MYEU=Y_X7'J2'4OPZC3?,NKO/_"X]20ZE^'4:;YEU=Y_X7'J2'4OPZC3?,NKO
M/_"X]20_!*>&,RZN\_\ "X]20ZE^'4:;YEU=Y_X7'J2'4OPZC3?,NKO/_"X]
M20ZE^'4:;YEU=Y_X7'J2'4OPZC3?,NKO/_"X]20ZE^'4:;YEU=Y_X7'J2'4O
MPZC3?,NKO/XFMU'+4SM/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*
M-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1
MI]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-
M/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I]*-/I1I
M]*-/I1I]*-/I1I]*-/I1I]*-/I1I]**S1D\A/U)\.HTWS+J[S^)K3[Q[5*G$
MF^K/.*2/45P=UZD^'4:;YEU=Y_!MM2BF36E+*:-R)2');J<DJ7=<HI)MWRRD
M-:$LIS3?<9#-ERIE)K4%LTU-E1J$ZI&D*JVCDRU:3LTQ-ZNT^\"IJYLZ=IN5
M@EEF32XW&FA&*@D"2*Y(G&FW"4JH]2E%ER*O)GS5-<D)S(UTM66E2Y)3GKR<
MI9-4DS95.N(ICK*C*201U24KBLJTE*:95Y633+CEY5),GFS#UU.2")?+6%4U
MR1(,D6RU9;<$Z.!*-2"JY$B?-IZB9+D]L5U>2F,F5D4$F7$F)&6I),(:X$Q8
M+JG*1A6NEJU"Q=+2%25:2J,HJ,I.:56Y$R6DJ\E2;VVX.Z]2?#J--\RZN\_@
MVV.[6@*5#MZ*K?\ A)KN^9>)8XV=#WH4:6=!?*DIYE*KTN?,GT0T%LRO2I4^
MX:?%).M[N?J[3[P$YLNHU!%.F1I"W,235\Q1)1HXK:>GJ9I$9O\ )71#%.:4
M5+)MF46"=,6$FH4'YEL2"P)2RP(LM^'_ ,A9LV*XR=1/4*4\Y(H3+I:R3:\/
M_%I'>K;D%Q0$@1<6I_J/;\8YMN"?^RV.ZUS_ .11-_D9LF>AGU&HEGHD"<DN
M31X?H+;"8A4R$L)JZJ2"D6*IDPR]5(4JIE23EGKJQ3C*B)*KF3/;;@[KU)\.
MHTWS+J[S^#:162(I5#JQ$ HM4[!,JM2[;.KM6+4#)KBES)2BX9<J6*<K*FF2
M:TB3QA7IG:3UE$<ZVK=LGR;A2R2U*?)G']5:?>!4Z458(I5YH2*.66FETY7E
MR*?-D)C4U0K-4*;-F3E]/FJY$88B52U**--IL4\:;3S)34A 9&1+3S25!:8H
M3S5E,F1FI92N)Y\E84]-IO924VFJ$44* TB=2:>9'"0@-+4RJ:I2&I=,,D/2
MZ>9()A?U%24Q8E(@I.0<]/,95.DK"F2T8LN1+0K9!4=,@EDTE%%')64R;"="
MCSCSJA3#39DB4L,:<@-,4KI4X\)%.G39WMMP=UZD^'4:;YEU=Y_$UI]X_!%P
M=UZD^'4:;YEU=Y_$U 7RT<[5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"
M4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2
MC5"4:H2C5"4:H2C5"4:H2C5"4:H2C5*4:H2C5"4:H2C5"4:H2C5"4:H2C5"4
M:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2C
M5"4:H2C5"4:H2C5"4:H2C5"4:H2C5"4:H2BK5].ID=2?#J--\RZN\_\ "X]2
M0ZE^'4:;YEU=Y_X7'J2'4OPZC3?,NKO/_"X]20ZE^'4:;YEU=Y_X7'J2'4OP
MZC3?,NKO/_"X]20ZE^'4:;YEU=Y_X7'J2'4OPZC3?,NKO/\ PN/4D.I?AU&F
M^9=7>?\ O$L_Z#5*H&73/_\ D7__V@ ( 0,  04 C&!89Y!GD&>09Y!GD&>0
M9Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&86,,\@
MSR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/
M(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#.(#32E&>09Y!GD&>09Y!GD&>09Y!G
MD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>0
M9Y!GD&>09Y 6:4PSB#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(
M,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@S2X9Y!GD&
M>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y!GD&>09Y
M!GD&>09Y!GD&>09Y!GD&>09Y!GD&>0&FE+'/(,\@SR#/(,\@SR#/(,\@SR#/
M(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@
MSR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/
M(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\@SR#/(,\G0I_9[47]
MG4D_\^HT_P"[J3_Z^I%'[OP6I_9[47]G4D_\^HT_[NI/_KZD4?N_!:G]GHSU
M!)$"U5.:/L9?V>HC' <73"7,+,AZ,P\)94:LJJ6F5RU,.@ZR669Z"Y>5'"/J
M9_Y^JG3BR2PJR>(A[PA7E5P]2=5+(?U:?]WJYZV4GC)7R9\5JPJ0DJ9"87U$
M]3+D0D+Y4^/J_P#Z_5\73"5.+-AVXN=ZF94Y$N,J<6:7U:C]WL\E22<)JJ7*
MCZ,Z>23"3.+.*(+943J%DN1%8N*EC&&'4ZG]GHW3\B;29$V705D2I37#+P65
M&6D+QZ!(S%!)9#5[])4*^"LD+CEF+-JY)995:+&8O7%1EG7 0@FUN7A3ZD1;
M#T2_L]0I^70$4J;(02^RK9U=ERC)Z@69*C7?<GGE4%F5POZBKBJY%O\ =J1.
ME32%N"6<J"JD5FG3I4%*Y>1&656X1,LJ14QD]9*>9<O[8^IG_GZJXN[)J5(G
M2;:.;]-'J)4Q$%6*J,LJ94QI%9*:8N7D1E3U.)SK:@1)"%;@2(4D.<DY 1*J
M]6G_ '>KJ4LLQ=7:=*ER:I.C-02ZV67+1+"*R'K4(QI]2(M@IJL)9T2SM,)M
M8A^M#4B*^B=3Y4X]=2D3'C^?JO\ Z_5&_*VT<J;)D28(URE41,N)7B_K4J"I
MR'KL20*K)&7"MXPFSRRB1KGND3RSRQAC"529$HMN0P/ZM1^[V8OYTI65+"EH
MS33+:D1+&36(1/"H%SUJLJ67)F9A;G[O2/\ Q)ZU3V:4C2Y,^I3I4LUP?O5*
M"IR\=PA!02)(5O\ 5"X%_P"B52:EGP55@DHZ2L$GG65.6D.:X"EB0\#P-6H&
MBAJ!%D#UB$3)5,%!/:%/[/1NGNYD2N>6>D*E26_*@1.;_P"2HU,L#R(XS*;,
MJY)B>GR#2$]K2BEDK*E"0>L*)\R%T?)FRRPDV]+*20B]R[T2_L]0I^7192HT
MFG4R"6-+E%,LN@\82BJ518(TTU$FMXL"IE4(0EV_W:V/DVP2$):C_P!-05=_
M5?\ R5 T/U!74LF959\Z8>YOVQ]3/_/U5Q=VD)5DV53T)49+:)"!5D,%ZNI0
MDGJL^?,-5T!U$4U8B:8KF3.WKH*E<M(0Q)0J7>_5I_W>KJ\#Q6'I4]7&X2P@
MEIY($E6Y#](A5SSA2IASK)J:>DG2ZJ55)HLY1+DIT\\ZH3IQ9)44DR^=ZO\
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M/TQ$N2:9Z7Z8C#HP$(8B,,!@(0Q$(8B,(PZ/TQZ(0C$?IB,,!"&/2268_P"
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MJ_EV;W3\%1$/:_A_Q%7\NS>Z?@J(A[7\/^(J_EV;W0+JC*1%U4B$B<6<08#
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M1P!S*. %.\*YD=<YE' ',HX YE' ',HX YE' ',HX YE' ',HX YE' ',HX
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MP!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*.
M.91P!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S
M*. .91P!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*. .91
MP!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*. .91P!S*.
M.91P 7<DX)XLHZ:9Z;-??QA]JNC_ $'U&C[QM)^C^H]Y?A,L^?U&F_T7U')_
M?LO\'/P2E^=L8\%WW\8?:KH_T'U&C[QM)^C^H]Y?A,L^?U&F_P!%]1R?W[+_
M  <_!*7YVQCP7??QA]&Z+OH=D(D+^-K4I_L=T?Z#]1.G2T\N&XIKHBC5NG7&
MC]&L5.51*<U;GTMW+5;]SK7=1%T5)T;5H]T^@[;Q4AFTIR_H-Z:/O&TGZ/\
M57%<M)M"GR-P;8J9DF)5,&B>*D/.A]357%M:AUWU>\OPF6?/]5=CH6A8:BV'
M;LB]%;K.93F@MFBU657:=ZB[KZMRP$ED/18;DJ?5IO\ 1?JOR@;<0UY(T"XJ
M3=:*#OTF+B>HA",8W+N&;*SUUOW'2KM0>JD_OV7^#GLQ2Q/&V+ZMZ]3W&X-L
MV>NC")8^A<]V46RD-N7/1[P00AB)#I6<JKM[.I:C<*71>"DM*LF$C*/TE+$\
M8PB6/MZ7YVQCP7??QA]'?_"$6VKNV5K[GMK9XXZU SBO>W;JA(Z;Y6PS])/O
M%36_.KEZ4.W+?6;Q2I*6T;P2W:I/._;*^E71N6HUM(K<W5H9UR/&[E-92CW)
MO.H=*-<&["UY9&6?>@/>C]&Z/]!^HO/Z<V9-+8UXMBSM#DM%N'N7=]:ELU&R
MWHIMPV9S>F4([%O6C.31*WNVI1JS1G?HKQ6%L@+ S,;:+FLN[+<0;T;7KB!G
M=QE%=RHW1<EE)'@=MY+:96E47=BDC4G1?NEMG5[-W1H*S=&^J&%&G_,]-'WC
M:3]'^JWQ>#EF[<FQN^R]A-67PI&V-\*.UU$:#<A1G5JSHOW26SJEH[I4%4N=
MW'AH3,TVR7\67!7W:>BW&912-V":BU"(ONDURNT&ZF>HK//5ZO>7X3+/G^J?
M2A4VY=Q.[AB;&MJP-PM>779MIIF[&F42WVM<VA/%0*ANJDKUC-/O0'KDWYN,
M1VS<C5NA+=!-<&Z)!"MM&^]!=XXNEC[+OFY=W]@T%M+A40A";ZI-_HOU2KNV
MR)K;+O6Q;0MM(RFY6_' H;8;E*5O!I1*Y?U[TALZ%4=WL^D)$KE6TLM)-NV.
MJ2W#=M'M2B1W>FF(K+O.C.%1%$@JJ3:^W-M;.I&QQ-+1U_U4G]^R_P '/9DG
MS]NKE45HJ?M\:VLW36G8?B@-.IMG<^A4W!+>FF0<EV7.I;.VO;E7C<-(WZQA
M!LMM4?Z?<AU[_3M99[4-^HLERWZN:R+=JF]*!BW X=\T-MZ7,W>F1HTU\V^L
MMM/NX,O2[T'7BELK;V^<R^95_P"Y^B6G7VVW.T.^;@=!^+=:&L+MZM(IAJ:O
M2UA(MW6I*M4&@>B@/2DJFZ20KJS>7VD<FA>S)?G;&/!=]_&'T=_WALK:A^K^
MI%>;BC-,S6RBA(*$TRV62Y=UCXTM)<+>3(SKAV@7!NFH5<;MC;*J;=-;]ORA
M($-D.F_21O*YNDNUP;D3?<%+":W];H5.16/L&I2-"TS5R2(]S'HW1_H/U%Y_
M3NUB@O/4[ 8Q@)33K-OE IZY]]_]05ELA-?#[(4[26+>;)--LDIB6E,_?J>3
M+MC9!X,;!_H/8%2D4BUKRE%0[IW!_P!/N'*EW!NA5RI:\CE/[)LJY=P-TWY<
M=Q[\?XJ?\STT?>-I/T?ZK?!A_3MM-\_MUVDRS145DZ!L,I2*73'*E%1;GW,?
MM/8MQ;C+JOZY*KN6:"X7$G-_N=75&Y7.J]T'W*/$D?!Y+2;ZFU*BVJ-P7CUZ
MO>7X3+/G^JW(IKA5OS5=N;C.[/WIII*!F&<I2*@67LEE$ITY%N5KM[JMOE1K
M54W W-8KDLQ?]M;B::Z]B[4[A=*VV\LFQW.K3TBZ;II-D4AI+;JVXR^XQQ]6
MF_T7ZI3W;:;17?J5HLOM[.W=96TA#5]U^_E*16UEW./0VTLBY7B=2\K5V]6#
M+=7;=;[W7YMKIV^VN1JEDDOA]I$C:2V=TM7;$/<''VDT=RU^VF\ZY85Z>JD_
MOV7^#GLR3Y]KL[4G)2L6\U/?.UZ57KV+N#>^VGO?*C;P*>MLM1N,4R7FOTWZ
M<=^_ACNTIRJS"O\ 5A,^UYNY A=Q>\G^?WK?4>_%4N45:MWB^]91LXQ->2LI
M;3M.!M;I.[RM)+@8YMU<U/8.P)))G6;OJD$IY]VE(15QU-R".546LMVMKJ?M
M8V[W([=LMVSUA.)*=VB4AR]HLYKW3H;QT#V9+\[8QX+OOXP^CNU:^XG<LM%*
M,G2N70UESVAMULJKMTW+ZLG<M<N>[:?N!>ZF;I+8MFP&<0V9N41H]N[PU5Z+
M>VG-E<+362[+77U2')=ELWM?*5NX;*X7<M*M(YJVC;5F[KK4MM9377%1'O\
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MC<C^!ZD+]7]1WY]-?;L,4S1>C7DSB)]QU+;QQWJ<&UFVKE*>E4WCF,3>K67
MZ]R5-19#J,^YSM-7>U'ONSKR?"Z*Z[S87M0G$<=LWP?2N#=?8KKN36;6O=]N
MW55O;5KJF?MJ3F?@I8$ANS:V[[^HE[[;:A,8';*V%5:ZR+0LAV]L<]IZJY%;
ME6I9#M[9E;355R:V2P-IYJTQU+6[@*58LNR'/?"^Q/;ISF$O*QFROUQG JC;
MUQ6^0W%-I=U6NAX[)<-\&RF2R3B6+9SP[8)%/H#@NU9-@H-Q%H6<Q#%U>V]O
M^VE*[%F4QC6VKEB7#;+:5REO7?;5U^OO;<K<N0T;@-I<KOW-6[(;:N4-XG*;
M"OW,\+L-_?MKNQN%=R^&Z;61F9;ZM+=J^Z;=OA^+EJ[EW&\5K5]B6QN]+>3"
M6<ZK&*FB:FX+.=C;VVM=;M98385ZWWFN9KJ]57SJ%AN<SCHLXV3I)W?JUCN@
MTCIN\U%ZI;SM.]7SNBMN"V]^V$Y=7:]Z75O_ -#8V8IF9=SQR]JO+_2?4EB=
MWZC<C^!ZD+]7]1WY],_;H\(?1HK4TZAWYU=5&^H-;N/V78OX+NYXY"H;KZI;
MKX7Q=B2Q+>L?<PYCMM4P]PWG=-EW=49](H6QEZ;L>NU^B_'Z>-U79;U[GKHK
MX=.]Y];Q9<VYJ_G;LR12YJF>B]3>7^D^I+$[OU&Y'\#U(7ZOZCOSZ9^W1X0^
MB\-WWO<SG632JU1*)T[F7A5L,WLH^81MW@5WRX5\. \=0K[%/S4G$JUV7,@L
MJB,O>3@6\SMU;@GB91.\#Q4-FK/KSS[@K&I%:=V*FP[MW O*RJ1PKX7VO;-W
M[@'H95&F4REDGK'8OX+NYXY#[D5FJ:(LWL/6GJK(W_:2UC=K=O/C7FZVIV*P
M;M5MN]ESC0:5D&>8UP]U=N[2G'O>_P C.L;<%TO3=7NWG6]>EPSMX&[Z\*]0
M7KW1WO>KN/%NO:6]6;4_<=O"O6C0_N#7U<%D4-_FT>%K[?O^P7@<1MKK>>Z;
MQVH,Y<-57[;=IKCW=)8)@Z&C?9+3Y,Y.EZ+R_P!)]26)W?J-R/X'J0OU?U'?
MGTS]NCPA]&X]N**K;E+L+<;I.,Y%JUO9W,?.+A76^S2M0G:&F_<7,8C"RMPK
MQD)M!KM7N=U9\^6EE[;/UNNY6\96HNY$E32D4G>U5YUWV[NCI\DMS+4DM>G^
MW<JG3F*WM5N=<EKRT^DZ#N<>6XW%H%(EI)2'K'8OX+NYXY#<PW$75;3;I3*^
M]U[;U)4R>R]-:ZL.9M":S=W6SMMM7:^IN,PVWO=[(VX6CL/;2YE5Q;;$L^7N
MENM)/CO+?2KU/;;N2=)Q;C>]U]S$NM[>7^W4O16=Q0^YNDGJJ#]RI)/4VOOW
M3S9[*+$T[E+L5OJQ?>T1I]T-;4M7L:N)<WK([@;J:EY9;8H*Q2K0Z-Q[PT!E
M'W\QYI!YCS2#S'FD'F/-(/,>:0>8\T@\QYI!YCS2#S'FD'F/-(/,>:0>8\T@
M\QYI!YCS2#S'FD'F/-(/,>:0>8\T@\QYI!YCS2#S'FD'F/-(/,>:0>8\T@\Q
MYI!YCS2#S'FD'F/-(/,>:0>8\T@\QYI!YCS2#S'FD'F/-(/,>:0>8ZT@MC[A
M+54J3YCS2#S'FD'F/-(/,>:0>8\T@\QYI!YCS2#S'FD'F/-(/,>:0>8\T@\Q
MYI!YCS2#S'FD'F/-(/,>:0>8\T@\QYI!YCS2#S'FD'F/-(/,>:0>8\T@\QYI
M!YCS2#S'FD'F/-(/,>:0>8\T@\QYI!YCS2#S'FD'F/-(/,>:0>8\T@N_[A#5
M5NE^8ZT@\QYI!YCS2#S'FD'F/-(/,>:0>8\T@\QYI!YCS2#S'FD'F/-(/,>:
M0>8\T@\QYI!YCS2#S'FD'F/-(/,>:0>8\T@\QYI!YCS2#S'FD'F/-(/,>:0>
M8\T@\QYI!YCS2#S'FD'F/-(/,>:0>8\T@\QYI!YCS2#S'FD'F/-(/,>:0,T\
MEOOE4>H[\^F?MT>$/HKI1X[JK]N/EI>UWW9H&\275Y1^:,?<-DS)[%)ODL!*
MF$?3<MN2M*^+X9S<JSM^JVL@9V'SW)OJDV[V.Q6Y%CK#F[GTJURK(N3?@WE:
MM]!69.P[;PQ.Y!DK*478_EO6S9CO;Q6N<^R&.LQ>W3>=8[%_!=W/'+HA"$.F
M6DD2I@GH4RD_2H2R59,(0$Z1+4DERR2B^A^0E)9,@XEHD\F;T_=(^O\ \6_;
M8^E>H[\^F?MT>$/I&+ T)4HDDOI+9<^:G85HI+(67TED2R'Z9<B5*-UEL7\%
MW<\<O:OND?7X:#;+=+TT5Q]J+@-G1O676S=0M&Q_0LRTE]^UY[MOUVL O3IY
MJN:\NV&]6(I?1<C-)Z U%_,U4&^M?H<MET]@6%T1C@*/LIO953W$;VN-77PV
M+,)W!L;T[:9JH7/871[P_P T*!D5)]B%_29#H-+=;-5:XMJ5^6TWPM+:K?EY
M6(S[%76]\]R=KESMU;\]H$*YH_0:UH[K>:KU/8S?\E/,QE!R-L-\-5:%C6<O
M<*X;TM-=8=?M-HJY>=J"[&BKEF6I9>SB\[VMAVMOE[LH6R-G-YWS;#M[>*XS
M=.L?9W>5]6N[&W2^6834Q!,JJRG[!K[JT^^MHMSM_0A4V9J%+;D'-^@KVLLG
M:2G>T?;8^E>H[\^F?MT>$/X*V+^"[N>.0W:[IY.WBFH*_O(FT^R;RFU>T*#?
M-MW5,^XE>5P6JMGSY::70KUMZZ)C041UTCLI:[35RJ97:;)6PK5.BKH=XT"Y
MYB&\[?J=0]9]TCZ_#;T]34]KVSRB5IN[.VT,)9KK6+2FR;K<->J>9M>/7*CM
M/JB![+ L_;O?;@-ZU=CW\_+O6ZR#:4ZMMVUNWBCOBU%K4:UK^;QG=O$6&9>U
M7>O._P"X&=N.A7RU=K6<U6[!GJ.SUTWKMQ04FF70GVX-=<&X)GS,?>6V'Q<>
MF4=[[2V:6@AJEY[@KN7W^P3UM30+$L-(T] G,"X?^77J:J@6&V[ALNRS+H7K
M9NR9S?[CC?I8ROMXU>W6EOFTEL4&W*'4BT:I[DV-6[H5UEMU<+DWM<])VU6+
M7F-2(4#4-(TEIDLJ2WC8/I:&WYAK$<5MI+?6,_M]KS[8;;K=U;4Y]NO,X\MA
MK<7V$T] N)E[4;1OK :MS9UDJ:OMLM>1>3I[J;CFW4[&^FU:O7[ZW;%66TSU
MNW8B1&4-+6Y-_P"IT$U?M<56^YS6.FQ]^,1/V=)H7=;$HT3D0V)<]33_ -:W
M@%B-13I]6J<YFMK=$JZ^V5VWMN)CP.10'&)NEK6ULIB._N8\6F \ OAN \ W
MNHJZLL$II=6;W:C<;&W<]K!.FR=ULFJN]H+O=S;Y>:2>P>WK\Q]O*64KSH:.
MFK5[/*U; [?Z]76HH%-8FU*LPMJ4/<@T5J6?1=Y?T_[1]MCZ5ZCOSZ9^W1X0
M_@K8OX+NYXY#<M+D57=2-WMGMC7(.3<37VA>7W,._P#W!+LK-Q7/9&QJR6UN
M+;)"$-TNU*$(;GG.A_\ L5S; 4NGNG>!AOZ2>7=2P=-VFU%/,C.E>K^Z1]?A
MC;YKS<[;[_>>^G3*R$,=NNP"M($+D)-N[AJ+LN6O4BYMVTVCW&W]P;,IM04;
M@7!CEW5NC=.]TIG?<UU+VM1K;]<N75:S:UWLBZU^HZ<][-O;#';BT]C0W8-4
MF?&F5[=:^3D.XWU]/Y>E^WM<>V'Q<MYRI+9[JMQMHHMJS:.=_F)]+2K%\,G=
M#?5UMMJ3A_Y=W.^"N\AJ;JN6W;CHBUI=K&XJ9DLANJ=2^$2MYG/=&[[6MNWE
MUVU:W6Y>=L+KOJ[J!;&Z5T=O3A(W'8VB++::=FKKN!3MLE/V]:NC-P2!=KFP
MFXZ?;KP7#MZ<)%>&[4]9N!TVUK%0W52&B-^K;(U#F.PRU$WDMQ;=@U[:'5R4
M1Y=Q5'-0'-WA/^XC97/<-PU2ZENZ>HJJ/:M3+;D@VT%:HJ5&I3+7O6[6;=5=
MTG;WL5/"CFD^^7;FZ9U[1I?.0](N6Y:G>-5M6WINYC;G:NVYS[QJFT^-.9"R
M6PW-,Q8%SW&V\&UW9[AF;OZLN?MVMFL+66K;37O;2'<!X!WR[UY-*PMZ7_<K
MC+G:M2N73M^KECW):\EX*S4:-MXNA3-W*[?_ ,Q]O/QGMOQ%WQPP>Z\C1)M0
MO"G2=O%G;V>.?U1O+^G_ &C[;'TKU'?GTS]NCPA%>N:CVM(_N*P0A7IJHG$^
M?+2R[><2U+M4"EUFGULE3JJ*BIQQ9#VT4NK(:XG*Z%FG4PC T)[LV.EFT.XZ
M3<Z?^S[-[24T#PZ:O7J9;Y.BKN/;]"N;T9TXB<E(K*"X$?J:.X]O5ZY?5W\X
MUOMC3_66HXUOWM4/1V+^"[N>.0WK;6JP[YZ,_>Z:=3]RS+.C4%K^VN[^X11O
MZ:N[W(6;X-OUU.$I:UWW_<BY& :R[K:W#W98;M;>7NMAJ'EK;[(&KN^5NPW'
MM9=UTOQ]PIK;M<ZGI"1ER/5_=(^OPDO6OH:$*9>M?HM'DSIB>8HW3.ZKINT6
M]K5L1QZ(U==MJOO>^9[D=Y6KG+Y]@/FX#6R;Y<Z[G-GI=T;N(J99SC72WU1<
M%YKY=:%2O6OUFCV6YMVMP/TPC"@[H'9MFG7!<=6NQ?1*VOMNH5JMU"XZA>5^
M7&XBU=>U?J=$L![[]:Q/5',NVN4]9>M?J%#N&];@N2D[C7OJEIK;V<"Y7(J%
M8O:OW#3+!?5P6M3WPYEVN6HES#R3I=U+OHT"M6HJ$^7N>=J52J3?-PT*GV??
M%Q-\OO3<2YCB(D=ZU^GT,IHD,3=,[LNFTFX:K0:E=^XMS;]IB"]J_2J+9&X-
MR6W07%<E6N^H4RIJJ(MW<W);3CW-=E[5^_%7YBX+UK]UICWY<<RWK<O>X+/D
MV"[U[-;&_79O-T9E#O6AMPP?H6[<M7M!?<NY!TKP0J+YN%5;\80-"H.Q>=67
M<TSPBWGKO^TE=RO^Y5Y4VK7K7Z[2JK>U?KM)%M[@'+LZFWH\U^.,CJ=ZU^M4
MBV;]N2S$\(0+"T;SKU@U*34E:=9=%U5B]JFHO6OJZ#9NX)R6^I=P7[<MV(;C
MO>X+PD^T?;8^E>H[\^F?MT>$(^YOX<#;7#!J1=M*YJ7EN;9BT==2[D'+G-"V
MNUVQI^U9RON(P@9BY'RU!8<X8^W&6!6,V0;<6O<IH-G/:K2KVQ[;PV3A-78K
M<VNV-/V4[=&Q<IK]D1C4HU\W,HLZA[.-QEX7 BOS=U;-CW6XU^V?>%I.N\"-
MJI=B;GT]P74['^D@X6YA!:MR,^_%(=N=<>Z,LJN[V-PE?I;,U;<]6%=-:AQ;
M$M9C2[VJ76:4IW?T&OE;-Z+;=6T%V\-0G27\\LF4W.R!^KHO:R[YW-I:%<;.
MOI1'D)7]VB7C.UMPJ*Z;[7+6)MOTG;WN<O-9<CN/_16H6V+NC0UZYQ?^[BV+
M$NN+]TJA6!SBRJ$=U7@0M8GL?=!(K=TO$^-!9A/NIW"R+WMUUW;MMEZ'-WC2
M[9F.J[-*:6C7[>"1OK:W=[CJN5BV<=JK..(QA""C=]*K*BWGUM>[K 0;TT%W
MTMLW*H#N6S/WD(:E.V3W;2+]N;T=B_@N[GCE[5]TCZ_].$HD(^R%+ OJ(1A'
MUN'J,/7QC"'4OVV(XVKU'?GTS]NCPA&XY@$FXFW_ "NJ$&[L^6WUL!@5!;2?
MX;L;HKUSN?N3<5TEA-_=42UO;_(^7/\ ]A#[<O@;LR9]P;X:QH&>MQD:!LOV
MM-TZ;9639E*;RA[7MIEIO@TFS.[#5&RAL"A&%C-;242C<KO1_C7H>RJ6377+
MDNM_:3L?Z2&V:0\%07M^S;DP=9<V3F,%6MW#JTM[=I]UPPMAL31+L?VY4Y(C
M:7[=2),C8/;C>5.;^%/OU_'<M7:!"'+!L(\ MIR9YEU!L!G'(HSB?;Q(F_H5
MEY"=/N5&TB$878TL9:O<IOOEDTJ&WI"%3N9WKPKBFY'(;+<$Z5KW:YE:99 [
M,EV/[%KT>U;LM_B=/,L5]LI5N#W)R*:I:>_IJ^.V/<T:!6B=R$>1NBPPI^XI
M54$35[<*8^DMK*6T%S-2V>U)$G0,PQ<]93&3V?ID*5D]I:=.EOST=B_@N[GC
MD+SO:AMY2;;N2FW?2_43)A)1?S!YA9?1,F$E%_,6([5H.;-]0ZEJT:[MQ/\
M0+:#^@6T'] MH/Z!;0?T"V@_H%M!_0+:#^@6T'] MH/Z!;0?T"V@_H%M!_0+
M:#^@6T'] MH/Z!;0?T"V@_H%M!_0+:#^@6T'] MH/Z!;0?T"V@_H%M!_0+:#
M^@6T'] MH/Z!;0?T"V@_H%M!_0+:#^@6T'] MH/Z!;0?T"V@@P+:0%FL6W"M
M/_0+:#^@6T'] MH/Z!;0?T"V@_H%M!_0+:#^@6T'] MH/Z!;0?T"V@_H%M!_
M0+:#^@6T'] MH/Z!;0?T"V@_H%M!_0+:#^@6T'] MH/Z!;0?T"V@_H%M!_0+
M:#^@6T'] MH/Z!;0?T"V@_H%M!_0+:#^@6T'] MH/Z!;0?T"V@OUC&Y0T6+
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M;<Y[K_<JV[EJVZJX=KEYWW-5'A3]W>_2JHTMO"[7%O\ <5SVYMZY+8W2+O\
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M*>GJR6RFV?9@$#+,.LM$64VS]L13+U8.MNDULNG[G;A3[@6=N*]:DZ;'/9N
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M:Z"R:**E9M O7==:[>6K9!V=_P!,[D))=N$ID*HBIS:[U6>L]!9^ZBL52I-
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M9M/X3Q@6NZUAD"#J/X@_U QAGM'*C*() J=7\6& )/(L,P0=1]&,Q.'7H1,
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M@B43I",W$8BQR=*.9ER$P*M4)HL&M)- $9PG&35 JB(T%2:!$Y4XS(J!7F]
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MRR\CQGL[.0;?Q.;M_#&T(?5C(EM!L:]#+@,,!HU[586>3<SIAIB5@A5SS!T
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MY*H E^77R^C/^/>HQG:,#MK8FO(I80!;&@;2%"6>'%C!G>3: HR^E*!$@TB
M.:SUL63_ .@[%#[B$<8B&,=(Y1RJ1RQAE9B!#2Y'U_H#Y1^I_EEV>B&<&PQB
M0=;E]ZB<NR<2"']?5E'/RB!F1#,>$C5UH8A"(>VTDD<BR\T,T7?G1^XR&EB
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MV?@G/M<AN3UL_B,)AP:A,)Y@C_2)6(0RPP'X7U[<0&'D;_2C.[P#;1RZ_P
M1F[ @MK;7R?IOY1^I_J /81>RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R
MX!>=RX!>=RX!>=RX!>=RX!>=RX!>=R$< M(%3N7RC]^8[1UKY1^_,=HZU\H_
M?F.T=:^4?OS':.M?*/WYCM'6OE'[\QVCK7RC]'?Y$)$D5#:C;T6H0%20+U'*
MS)G"0Y-&JUZ,<DO&QB@#I(ZU&.6&!#U?3R^F.?\ < RQ: ^F@#$:%+/R01J<
MG6!K_@G]0.P#6MK4O\B6%J6MM1:FC]G([1UKY1^CIY$J$/V2[%+%_P#MO?0=
M#E8I6@DL#:& +=2.4S1L) LI$'I*_P <Y8P@@.-$N2S0>59>7K'0Y?H0R898
M( &)ZV\Q<MK67]UEQ#$AXZ#WA9HY5#-, 1)FCH#@G5HV*6T_W!">$/9:UO$U
M5FF0!(>TC_:C]UF 2-K/M8 ;3I4YPA@DWO-0U8]:GC -@J'TE9@F ;-(I::(
M_;1RQA +$]YJOIZ5_B0RW#L9%B<7.*:.Q?3 &%B0#:!8_7180 V.-FC1H67!
MA&) =K-)6&.3&66UI:_9SWIQ^RL=HZU\H_1T9Z'8[#8=ZS,V)]Z;#G;#9S6J
M'/U%&4C86!.V([4?N)S @^(ZWU#1:?Y+*S#0"W821VKZV5*+2 ?FL<-6S8H?
M;99?#7F##GJZROE_M*(Y3_<%] $"0WXAS%9N4)"4F)DU X+#H1^V=I#?B!V:
M%*$I@S(<@4 '\U-]0ZRLQ]0ZRN:2?_>A*1L8!]H7^3F3 @X/*X:SU]JA D!X
M@/JM*/UYQ.6!827Z3HVJ1APDEMCV>G!!G8FWD7=O]B[M_L7=O]B[M_L7=O\
M8N[?[%W;_8N[?[%W;_8N[?[%W;_8N[?[%W;_ &+NW^Q=V_V+NW^Q=V_V+NW^
MQ=V_V+NW^Q=V_P!B[M_L7=O]B[M_L7=O]B[M_L7=O]B[M_L7=O\ 8N[?[%W;
M_8N[?[%W;_8N[?[%W;_8N[?[%W;_ &+NW^Q=V_V+NW^Q=V_V+NW^Q=V_V+NW
M^Q=V_P!B[M_L7=O]B[M_L7=O]B[M_L7=O]B[M_L7=O\ 8N[?[%W;_8N[?[%W
M;_8N[?[%W;_8N[?[%W;_ &+NW^Q=V_V+NW^Q=V_V+NW^Q=V_V+NW^Q=V_P!B
M[M_L7=O]B[M_L7=O]B[M_L7=O]B[M_L7=O\ 8N[?[%W;_8N[?[%W;_8N[?[%
MW;_8N[?[%W;_ &+NW^Q=V_V+NW^Q=V_V+NW^Q=V_V+NW^Q=V_P!B[M_L7=O]
MB[M_L7=O]B[M_L7=O]B[M_L7=O\ 8N[?[%W;_8N[?[%W;_8N[?[%W;_8N[?[
M%W;_ &+!-G9[/R2.T=:^4?I)O19_!9Z+/P6_@^679^KA\([?R2.T=:^4?J?Y
M9=GH$)"1)#^Z'7TPXEJD&_%ED@$&.DBP[/X3.5 '*)RWLJ#5.48Y;V6VAK.3
MTRR&X0"^UMZGE@$8"SD6'9Z<S*(; UNM_P" B E-JF,7 YT,R%#Z,O+ ?&3;
MJ9OP(Y)!)D'<"P5K=_!*;-$2(B=8&E%HS+%G$;.M8LLN.D;0CD!\0)%HL)%?
M0,@OB) L%@)HZ&-W-  Y*^FTHR-!(,^Q?0D QCBB=>L'UI_#BS"PZ3L"]X2B
M#0RC9V^@Y4'</L+%BR.9*@#E"<:$.%'*D[S=M5FOT2RHN\&?5;J1RVD2*L'[
M41 VBH-A1RVD3&K!^U&,8R#!_>#(Y9$B15@_:C&!M%00Q1)T6IS&8VQ]J$!&
M8?28V=?H.0Q<!W;W=&_TSB0V"6';_J1\([?R2.T=:^4?HXF1:(J=)Y!VKZ=K
MTQ/)KZ=#(PA[P!(!%KW)YQ(V@A9F, L!4/K3!/*)&T$*(RX$2L>3,]EMNETY
M!8Z66)BVO0G8MK3R!#ZP0L1B0-;%K_Q?EEV>C+)L]P]JRH91!GB>RUAR]?,H
M0RQBQ V:SHMT#6I9GW!C(V81&RTZ*+ZCQ=GP-T/KY^='[EJ6-_NHWKH7US*-
M 3%J \NE?6<&5A! L8D:-A4<V6&,#W>\S6'GKL4OH$0A$MB(Q&1'8I9&<V.-
MKBD@=*E/*E&(!($2');^K4ZC8,<B(_[034[%_P!LHRBV@82#VA9N58T0,-FD
MC3K1^IQ1)C+U]:+-S)>7"P:R16WUJ%]6)C%[1 A[-#GE]66-F+D$:B%/X2LK
M,I'-@(GXA0]72AE0XLPX1L-=W.IY<:1A$= 6;"5($ =*&19AP/RNY69\,>Q9
MN7)F@0!TJ4,MAAD09D6 : !I/*C]M]PV(!Q(4D/7M6?MCVJ1R"(0B6<C$9$=
MBED9P&.#6BD@=*,=8(7^-]P,)!+2[I?E[>I'-L( >S2^\KZT3 /:($:-%NL^
MK+[<R#&UQJ+!PA]OD-B(<DTC'?[-:C#/(E&982 PD2Y1J4<K* .*)8?[GJ3J
M%2I9GW)$FX<-E=%-?0OJ P#VB#=#ZU+/:V+@Q_W;K0HYN*!!8F+:#JEK67E!
ML,@2>9T<C)(CA ))#DOJ";.8EZC2-'.IR&H]-G:H#_:#?;VJ6(@>_*I U+-S
M,O@+#D)Y.F]9V;#BR\W$+R^_F7U]&'%T4[%E9L^+,S<1V6,.WG4/NA'%&(8@
M5%;>E/ED$C0>(+)S1HFW,?0QD =H7%&\)Q:I8[1EBP<MF\]"PR (.@J4QH##
M:; LG/U63^>TW6BY3^$K+^$=2R/F]&?\JSG('#78A+*M$8^^133[/4+..82'
MPM83HY$3EEVK81UK..86?"UR&?E#W(AC)FQ&V^O1L]!VCK6(5$7Z$)PPQ J2
M.,O:VH#KZ)9);"(@C6]B. QA$4LQ$\NH*>5G-B@1:*$%9W_H>W_4CX1V_DD=
MHZU\H_1TS&K3ZMWHE'[>()+6GN]EJG#[L N+&;LU:%F;!VJ?W$@YB[<C!S>I
M9>8 1+DX5E?+_:5E?+_:5/GZPHYI D8T?7B(!YG4LW.B#@)+:#A&(*>7F@-R
M:B]G-^+\LNST9<)AQ@-EZ_ZX@<NF]9/S=2$A;AD)'9:.U?5Q!F>MNQM?(IDQ
M?$26U D6\S.AE3^X!A99APR(% 2I"-&BVQPRC\(ZE+*S92C.,C9B,7&L>NI&
M67+%)K7EB8>H4ON?M\S!)B?=-DCJ,=9]0H#[E@9C38Y&D:M?.HY&7,SA(&PE
MS!N59WR]2S):,R!(^,>O2CECB(Q':XD>BQ1ECD+ XQD,=-CV(C(+@DVN]NFU
M3^$J+5C$2&T>QT,^0LA$ ?&:GKZ%F_#'L6=&9 )((>QQ;O"Q0+@0(?02-6M9
MGPQ[%G[1VK-RY$ F9(>QUCR[1"+$BCV[^@K/VCM4LK-E*,XR-F(QLU@*4LJ6
M*3,?>Q,/4(SE0!SL"><HF/*1_,'I68(OAQ/%_P"D$$]5[J,S(!@'MH0*-5?;
MRC0N1L("?.)C&<;"#AM&A_6H4<4R2XP@S>W8ZROAEVHX;6()V!#,Q!FU]#:^
M13S,YA&<B;:,;.E1G]M.PR ^F^(%]7KSK*V2ZBB<6&<;'!:0V^O.I"9Q89$"
M7]04P-3W%U _[1U*4LR()QD:>188  #0%GQ-#,CK7_\ 76\=?_Q\7M60!03'
M8OI2D!*K&RNHFQ99^W;$_OX:8>5K*.ZRH#3,>O3Z#*4 2;37>N 7G>A" 8"@
M1S)\&8&?4;-W2L1F.8N;@LO[:!;ODZFHXOZ$8RS<0U80':T;%)ZQB8GF]C*
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MMC%.WKC4'UHMJ'HA]" (-9-UM_4H9THX9EG&FT.7V6*,,G+#6#_<;M-ZC.(
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MR.X6E\,O7I1C(."F!GA_IQ6(0@& T+%,,1I!8K';(BAD7;8C+NY0;YI>O1_
M83#@IGDVK%8HY@#8 T1W171KM]$Y1?W^(/9II>F!GXO8AD%\(+UMTZ>=>]BE
MR&19",0P% %CDXE_5$L4)EY$4,B[+#F"EHT$;$)2,IM02+@<R$9O87#%EQ3\
M7HP2) Y"Q3O-]>+V(0#V!K;3Z)8']XN7UHY]N(AN1E@F[.]G(@)O9:""Q&Q
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M!S2[4IV)LN1 U5'2FS)$C50='HQ1+$4(38N@/U+ZHD<6O2FQW  WLGTK#CZ
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M]^8[1UKY1^I\.8'#'L7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7
M+SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7
M+SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7
M+SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7
M+SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7
M+SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7 +SO7
M+SO7 +SO7 +SO7 +SO4IPB 0+"YUCE_1,=HZU\H_4_RR[/\ 5G"06+%M!U?A
MB)(!-!KV?D<]G:/T3':.M?*/T=F$@&NC_:LPD L!7G4/N<L "08M>.T*?W.8
M'$; _3V!08 .-7*H80!8:<RGB -@KSH[2A+,&*(J-=EG2OHG+ B06;0VNQE]
M'NN[<V+#>A]M'+&$L*5!TC0P[$(#W8EC)NZYMZ+5F?0C9$2#D6DX:Z_Q/EEV
M>@?:Y!PDAY2_I')ZZ0N*>+^K%:FS98F?WC99R[!I52VMBUZ^H2,+.^AD(1)M
MHX(!V%8<7_6 7]T\5O(^KD0S2?=D0!8=*.5 N1=95BL!+D5 !+;5BRRXZMH6
M9](DG%[SZ#;3I6+%I(8 O9R:N5'-B7B*V%QS54QFRLQ>Y[IX>8;*H?4-:"I/
M,$8P-HJ"&-Q6"1+Z@"3T+ZP-E*'BU$,A]>1Q6]T\U RS,S)D2209 O8[T<#E
M3XM)#,7<5LU<M%BRR^O6-H1@2214 $MM6/++A9O_ *%'84,R4IN7I+E4<C,D
M9PGPDU!U'UTC8HDDX\-@[K6^U8)$DZ@"3SLOJ0+CUUIG):I )%Z^I$O%G<*)
MQ<5+#9:UNI#ZAM- +2>99$LLO:7UBE0L686U:SL"P1+2U$$'I6"98L9<P1S
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M4"H%0*@5 J!4"H%0*@5 J!4"H%0*@5 J!4"H%0*BM"H%0*@5 J!4"H%0*@5
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MK*$TY%'[C(#0GH'=D*CUU2T*$P!B,RY:VATK+G'+C.4PY,AB I8W/ZZ(F$!
MVXL-#1F&C2LK  'RXDL&<ZRB)@$896$/J1$XB0$26(<:$,G,R8#%8\1A(?9Z
M]2&0?> F!;I#Z>:JEEC)RRQ(X49B(B^@6 +#++A.UWD'*RYC)RSCCB/NTI2]
M?6R\MA*0B!$68F%@'2A&65B)#B)8Z#S:[D8PC:2?= I[ L<X$#F/4[<ZS_\
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MBW$96V#37U+;5])I-3&XO:C=/(A]L]AT_P"UG>[I"_QQ&3NPD]6UAF#\B&2
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M'(Q&<B0'/*!5R:.C#ZOOQ?NG"2*BNNQZ>C-S=,B(<U3>#T+-_P#.78N=?;_
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M_.H;1^2G\DE\)ZE\Q[/T=E;!_<LK;+_BI_:FDN'^Z/\ \20H_;]V )E=B/\
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M+'^?Z@_;4S&Z?XO5/S2/]UZ*_A#4/R[/M(U\8G^W%^_CG5O[3<]I+G]96/\
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M]$AU/#P%!44@G;D4$J.-0:7DP+@]?;+/1;8L%@(6[<7U5KT 34I2BE5%0XP
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MJJ2P)*+=:HY<*&5$I2MQP\E()!V"IXSB)NTUYIV[:2O]PV0DW)*2T\HUHD+
M30JI1)H4E7)K6F-&@_\ VS,_Z,+_ .(_V_:&OC$_VXOW\<ZM_:;GVN\'_P"6
M6_Y;%DB772ML2_<;3#+TMAD-2>D<:35P.I((74YJ\9X=F-4:&DRE3+5I^\%B
MWNJ).5"\X4E)_NDI"PGB)--AQJ33YA3[WJBY:EDNPK/;&2Y(<;0FBG5&F5"
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M8W9H92$-I@R$H0.!*1T@ 'WALQNL_B0?ZV<;LOXH/RC6- Z:AQD36)-Y>?\
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M?MNBOX0U#\NS[2-?&)_MQ?OXYU;^TW/:2Y_65C_:3.'?^-7]OM)+_P#+V/\
MM1SVD_J/]F-/?'7;]I2/NR[:+LUP%JEW2,J*)BFR[T:%D!SD@I)S)JFM=E<6
MS=]:W.G;M[:@Y(RY"\\XHK<<*=M,Q.P5- ![6H^_BQ_G^H/VU,QNG^+U3\TC
M_=>BOX0U#\NS[2-?&)_MQ?OXYU;^TW/:2Y_65C_:3.'?^-7]OM)+_P#+V/\
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M'A4=_'G;'A4=_'G;'A4=_'G;'A4=_'G;'A4=_'G;'A4=_#Z42HYHXPH_C4;
MEU))X>( G%#+8K\:GOX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\
M[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*
MCOX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\
M[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*
MCOX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX\[8\*COX6
MZ)4?*+6@'\:CAZ=1[N/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.
MV/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H
M[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.
MV/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H
M[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^/.V/"H[^+R
MA$I@J-NE@ .I_P#!5[N&_K:;_L_H78_S_4'[:F8W0?%:M^8L?=>C2DT/T+/X
M/CT8YQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ
M]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./O
MXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXV*/OXYQ]_'./OX
MYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'.
M/OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]_'./OXYQ]
M_'./OXYQ]_'./OXYQ]_'./OXYQ]_%"H^_CG'W\<X^_CG'W\<X^_CG'W\<X^_
MCG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<
MX^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'
MW\<X^_CG'W\<X^_BN8U^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'
MW\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_
MCG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<X^_CG'W\<
MX^_AOZVF_P"SV+=JS1C$)^9+NK<)Q,YMQ: VIAUPD!M;9S50..E*[,?HW3_5
M9/:<:?UK>4--SKK;8LQ]# *6PMUL*4$!140*G94G[_L3=Q:XT86>/I1B_)DC
M/Y07W)A8*#MRY,HKS:UXR/99W%JC23>'K"YJ 20E/DX81)$<H)KFSYC7FTIQ
MU^PN;V@VHS^HTQ'S;FIJE)CKDA!Z(.E-"$%5,U"-G&.'%L?WAM16-3+B,FY-
M05*5'1)*1T@:*B3E"JTJ3]\\/VK1,C2<U<)RY:[T]:YA0$GI8DIY27FCF!V+
M'#2A[A'V%S?W;,Q)&J$1G#;FIZE)C+?IR X4D'+]XC[XX<6Y[6;4=F_JB,*N
M#412E,(DE Z5+15M* NN6NVE/L9FY32^J)^D=.Z?L$6ZRY%K;8,N7+F/+0TG
MI'D+"&6THJ0D56JH.RA3"M-]N"[K<(S#;3\]QI#2Y"TBA<4ANB$E7"0D4KP8
MM6ZK=I9CJ7>-?4+?BV_I@Q'BQ&U95S)CU"6V4FH309G% I3RJ8_>75.G-*:K
MM:"%R;=IIZ8Q<6FZC-T/E=6Y"DBIR\A2R*)%3B1J>\K\EM\.*Y,D+=%.B:;0
M5K*AQ94@UQ>;+O L[5BNT=F%>;7';*B9%FN*"J,\<RE54*<LB@Y:>2#7%]WK
M:;C1YEQM0AEIB7GZ)73RV6%9LA2K8EPD4(V@<6&9*@ 7&TK('%F%<0-Q"(L8
MV:7I1Z_*DG/Y0'VY98"!MR9,HKS<U>.FSV-=1+Y%C1AI;5]ST]%,?/\ C6(F
M3(XYF)_&'-RLM$]P8D:^T+:M#)L2;A.ALQIS]Q;E*$5XMG,I 6@$TV&FWN#%
MXLVI;2O3^M-,31;[W:ENAX-.J3F;<:=  6RZFJFU4XCPBBE:SM^Z>!HMFQZ5
MU'-T^DWA=P$APQ2.6>AJFB@H'@&VHXJF=_UV;TXV^%M^0?N\J6I)10])TWE(
M&VM,N7W:\6+AK+05KT,FP1KK/MS,>>_<6Y2O)'2W52FPM%33AIM[@Q>[)JBT
MJL&LM+S_ *-O5M+P?0ATIS-NLN@ +:=34H-*[#PBBCB\72P1I,9NRWR?8GDR
MDI"EO0E)"UIRJ5R%9A2M#PU ]B=(W,1K=+U>GHO(V;JI:8I!=2',Y04FH;S%
M/*'*I4X:5/"$RBVGI0V24!=.4$D[2*\%>+V-U6B+1.6Q8;ZUJ55RB)2DID&)
M"2XP5$@J&19)&4CW:^QJ6/K:+;&=(-+B_NZ]$6M4IU!;/E'E(42D$+IERA.R
MHV\/V&M-%;GH&CT6;2$^-!6N]N3TOO%Y@.U!8JGNCFBFSAX<7/<?ODLC-@U[
M;82+FR(<@R(-P@K7T?E$9Q24K 2ODJ0L5!XZA03<-RFJ+1$8T6+FBQ0;NVM8
M=%R7#3*::>S**3TPS(0$I2<P J=OL:>W-Z.M,6=8GKO9[-?KD^7,S$N[%:FF
M&<I"<Z&4=,K,%<*4T3PG3^Z;=-:XMVUUJ5,IZ/\ 2#JV8,.+$2"[(D*;!6H5
M4$I0C:HUVUH%1K)O:MNFKGIV6ATJN^GW9$9<-:$9D)>C2E+4XE:AE"FU;"05
M  ;?L;'^?Z@_;4S&Z#XK5OS%C[KT;]2S_ET>QRB!]\XJD@_>]EV='CO.1F*=
M,\AM2FV\W!G4!1->*I%?LJG%4FH]S[&IV#%1M'L<D@_>]ENXNQWD1'5%+;ZF
MU!M:D\(2LC*HCC .SV DD5/ /9=GQX[SD5BG3/(;4IMO-P9U@94UXJD5^PJL
M@#W<5201[GL(A6]EV1(<-$-,H4XM1X=B4@D_U#"FG4E*TDI4E0H01L((/ 1]
MG51H/=^PD7J)#D.VZ(I"9,E#2U,LE9H@.+ RI*N*I%<440#[IQ4&N.40*]WV
M*J-!BHVC&7,,W<KMP^;-#D3!%95(D>3M+<Z)E/.<7E!RH'&H[!BHX/L*J-!C
MG)]\8S$[.[BHX,9:[>YBJR!]\XJDU'N8V&M,54:#W<54:#W<420?O'%3CG)]
M\8J-HQ11 /NG'.3[XQ5)J,54:#W<5'L.K@1WGTL(Z1TM-J6&T#\)92#E3[IH
M/Z!-_6TW_9[%FAZ?A29SZ+\TXIN*RMY02(L@9B$ D"I K[N/1V[]0D? QI"#
M/:<8DM66"AQIU)0M"@RD$*2JA!'&#[%U_P#+B+^U%8WK:<U/J:Z1] VNZVSI
MK-!E.L+E.N0$Y4*D(4'&HR152FFBGI7"DK-$44=RNFKA.DZ%U'IMV]Q;?/E.
MRS;YD20EE88<>4I8:=0NI25'ECN81I24]>Q#GZ+EWAU3=ZG(=$A5S""$.AWI
M$LY2?Q*5!NM#39C0/\NUFU,YI"RZA=DM7'4,N8HR8MKM[06ZA$IY2E)?D*4E
MIMU1)23[HHYO3_EHWC)_?.SO,2EVY>I'K@U>& ZD/QGF'W702M!4I*D)"DJ%
M13A&YW3V[2]R=/2=0F_)=D(6K\7&5;T+>7T=<BGD,E?0%8(0]E4*4KC>)-T#
M.O7E,S3<]QQV;=),I:7H\1XAYM3BR6W%%1*U(RU(3L&44:U!&FR6[K^X]D>\
ML0\L/](IB.5+Z4'/F42:FM34UX<3]Y6L=5WR7O38M;ES8OD2X2(K$.0RP76V
MHL1I:64QTD!)2I!6X,RUJSJV6K>]_,#?KI<;W?8#,F"Q:9LBVQ+6VI(R*CM,
M+2%2%4SNNNYP5'(E(;2*I:UK.5=+S8KK<[$_/7^4DB#(4VVXYW5EO+F.TJ/*
M)*B<3M-VV[S+"_+0E'TE;RA,EA(6"LM*<2I*5*2"G-0E.;,.4!BZ:VW-;QG8
MV]*S)3*B+.J7K@],>:6G.Q(CN/N-NAU-4J3D&WBH"DN:DT])7;[Q)D6%QMUA
MQ;>5;TQBHS)(5D)510XT[,7;7EPU9J"1O5APY%R;U&BXR&$(ELH4\EMJ&A?D
M[<7,,@9"#1O85%7*Q9+ZY=)-AO&HK)#?D7"VA"7F'5I27E,YPI*2JB@DT.0*
MJ-H&+MK#=)O(?B[T[,UY5#>.JGKA(E2&"DJ8?CN/N-N=**I4C(-IX* IQNHO
MLM*4/S=>:-DN)3P!3KA60/<!.-#Z\5+?_=/6,=[2-QCK=5Y.U.J9$!U+9.4.
M.J"F:BARCW<;O-PNGY+\=CREW5FH%1G5M+%OMW)8:64$$MR)"LBA7\$8U3HK
M^:>\S;7&;\B&B[>[<Y%LMS\1;'XY]EQEQI#LDO$A86LK2:)0F@V:OLFGKM=)
M9M]@N;D2?-F*>F)2I*W$#RC8M0;!"&U$E00E(*B17&[:7+N%S@:-F*LB-8W6
MVK<\K9MJX8*U*=15U#:W,H>=1RPD\/*-3KW<;?9DVR2XICN1F;V]<K>XLE"@
M\4O./%#Z0FE4J3L4H*22=E3BY[Z-\%SNSVGIETG1=.6*#<),&+$A0WE,!UP1
MEMJ=?=4A14I:B *!.R@2SN 3=9]VT)J>RR+K9$722N3(M\J&X$OQFWG*K6RI
MLYTA2B4&@'X2E:NT0](OXM\/3=HEMK3?K@E\K>>="@MX.](M/)3E2I12DU(&
MW#<5K,4-H2A.914:)%!4FI)]T[3C?/J&YG-.MB-/6B&%<YJ(J*IU03W$N.)"
MS[NWV+/N-T^M2+QO%N\>PYF^>U KTMP>IQI0PDI5[CF-VN^RS,IC6)1&@[R&
MQ1*(4RA@J538EMA]&TGB4!C67_#;/VG&Q%^(;_TC%E_\N)7[3/L;X?\ S/O_
M /\ DL2=*76W:BN-V:OEY<#-ILLN8ES/*64I;=;1T14>X5BAV&F-;[_MX=L7
M8KMKN;#5'M#R@I^+ MS)8C=/38'G 2I:1S=@.WDIWN0]V&AF]4P'-X5X<>E+
MO4>WEMWD M=&ZA150!*LPV<JG%CZ2WD:?1IJ\=,XCR!$]N>.B33(OIFDI356
MWDTV4Q?W=&;LINJK'%U%?G_I&)=8K94ORA14D1*+D'+3:4H-?P:XO&_Z9=8=
MVO6\26W=)9MP6(L5#".A:AHZ0!94P I#BEA*BNH*>34R])WM<E$&:A*'51)+
ML5X!*@H9'F5)6@U YJA45!V$XU'JV2]>4S+%KZ\,0T-WF:ADIANMJ:Z9I#B4
M.J/_ *13B5%P;%U&S%KW9Z?U%.L>GYFAG7[V(;ZT..0T7(!2(^W*V\ZOHVU/
M 9TLEP)/%C6=MW:SKM%0IZ'+;<>N4E]YE:Y<9M26GG%EQ""$[4A5*J5_>.(J
MM7:GN.G-,6]:G[D(,\6Y$I! "42)0*7$-).TA"T9JT)X,:"A?RQZT^D6+]=U
M6B_V-%\=NK#L=YE2D2,KKKI;6TM(HI)%<P3P9@=RGQ&K_P!G(]C?3;YTI]Z+
M#N&GDQF7'5K;92NW%2@VDDA 4=IR@5/#C>8UO#U'=7M"VO7=VCQK%%FOQNED
M!MDJ+[[2TNF.A!0&HZ%I;"\ZU [,:J_EVA7&;<-()LD'4=G:N$AR4] Z5Y4=
M^.EYPE:FU+&=(43E^^5%6-\</5,>[OO3;[;W&A;+7*G"B(0!"E,(6$DD[ HB
MO%B3_,KJ"QSM-:8MUA.GK#"NK703Y?2O].]+>9VEI'X#:%&JARJ#;C^82T:=
M*D:FM=]L=ZL;K?Y1NXP(/3,]'7@4NA:KW%X8_F/N"DMVQ%F7<9C22*HD,)*7
MHZ?\0?2II/=53NXW-:@UMZ6ZQWL6O5%Z!J,DF<%J0T :E(99Z-K+6@*33%AW
MM[F[G'M>\+2WE"(@G)4N%-BR4@/19 3M2E5 4K2"4FO <JT1]SF^[3LK16\"
M2AQ4-A]:7X%Q#7.,*6GDK-!7(=HX*J5L^RL?Y_J#]M3,;H/BM6_,6/NO1OU+
M/^71[&K=[-TTO9]17>!?8T5H76.ET=$ZEE.4$@D 9U* %-O#C5\)>C[;I'6&
MG[<NZP[C9JML+2D*.1UO8*%2:*KFY*LR<I3M:T[HJW2;I='DE:8\5LK5E'"H
M\24CC4H@#NX1>-?Z>EP+<LI3Y5R'64J5S4K6TI003Q!5*XWR?_5G^H8<_P"G
M=BF71IE00Z^T@)80HBN53JRE 53;2M<,QMXUEE6OR@J##KH2IETIVJ"'4%2"
M0#4BM<6R[V*RS)L6]278=N5'1TAD/,BKB4I2:T0 <RB D4.W9AFZ;PK!*MT%
M]24(DJR.-9U"H0I;:E!*CQ)403AYG=S9)-T3&(2^ZWE0RVI0J$J=64H"B-H%
M:TQ;;1K>PNLW9N3%DLV^:@*;E@/ )2""4N-N*3D.4D<(P[9YFDV=-ZFF^11&
M[#!"*=(ML=&04Y4E3@(-: =W@Q/8L6EISJK8^[%E*7D;0EYHT6VA2U)2XI)X
M0@JQ(L>H(ST&XQ'%-2(\A!0XTM/"E23M!_\ QC#6I;7I&X+@/)2MHK#;;BT*
M%4J#2U)7E(V@Y>##%KW@VJ1:9<EHO,MR0 5MA64J%"=@.S%BL>J83%QMSB)J
MUQY38<:4IN,M22I"MAH0"*[*XT[ONW7VYJV:=U F3!F1(R0EIBX1'5H7R4T"
M2L)4*  'HR:5.+?8[\!^[MO0Y=;PM1(0(<49E)61P!Q65!VC8HGBQN_UQN^L
MD.R1;[;9DDMPV4M9V@MLLE82 "0E5:D5Y6+5?=26]Z';[XP9-M><IED-"E5)
MH2?P@=M#0@\>#O(%O=_=@2_(#/Y/1B12O1\.:ONTIQ5QNP@1$*=?>OL]IIM.
MTJ6M;X2D>Z2:#&E]2Z<T]=G]X$R5(1>H)6A26&DJ=#9#>P)J$MFN8US>]JVR
MZPW;I7;KHVA;U[GMH+MO2*(JV1F-*[10IHHUV\&(^J+#9Y<VV2K@+3'=CHZ0
MNS2G.&4H3RBK**\%/=PC4NNM.RX%J64@R3D<0V5[$ATMJ5T9)V#/3;LX<;XA
M_CMG^I./H#0%JDW6>E.=;<=%0VBM,SBC1*$UV541AIW>)8I5MCOJR-2%97&%
M+I7+TK94C-3\$FO<]C2N]V/I2V:HU1J]]X.3+TR9$2$VG-D:#?!F(3LVI4I6
M<DD )%NFV[2%NTUJ6.ZYY=(M Z*++9* $#H/P%I4":U.P\X\2[QH#3TNX6YL
MJ3Y5R&F5*3SDH6ZI(61QA-:'9C3FF]8V^3:[JR99<C2FRA82J&X0H5V%*AP*
M%0>[B^V^W,N29DB^3VVF64%;CBU25@)2E-2HD\  PK55YTG<&K<V@N.*2$..
M-H J5+:0I3B0!M-4[./!L6BX+EQGI8=DEEG+4--"JU\H@4 _MH,,[T+Y8I<3
M3#Y;#<QX)14.FC:BV3T@2NHRJ*:&HIPX^F]":<F3;:<P3*5D9964\(0MU20N
MAV<FNW9@Z>UW:Y5JN(3G#4E!3F1P9D*VI6GW4DC"=5Z0TS-EVE:2MJ0>C:#R
M0:5:#BDE8J*52"#Q87;K7HUK4^HH\>9%=L=Q0$EM2:=(LAP$)6WEIM' H@<.
M';#HNTO3;M(>?=\BA-U#0SDJ'<0A!.6JB -@KAF7O%L4FVQ9"PVU(44.,J60
M59,[:E)"J G*36@/<Q4\&-"[KHF9J?JYUW4]X' I::)\F0KCR@*1LXE-XM>\
MY_1]BU#>9NHY,!U=VC)</1T60<U"KDY  ."GNXU9O+L>EH6D-8Z-R/.*MBBF
M)*:6,^539H 2D*'!F2H)(44J*<:]USO,L<*\0[0BV5\K80Z6F7EN)=*,X.79
M11IM.7AQ=])VU&6RNJ3/M="2GR23RD)23PAM69NO^'%YWU[R[:Q=+-;I,*RV
MN'*2%-2+C.?0W7*H%*BTE:=AJ.63PIJ)6Z)$=NVZ9<DI?=BQ &DE#4),A;:
MFF3I% @Y:4!.6F+INXD[J=+'25KFOVY<5R+T=Q+;+A05F0:Y5J S#DGA'+X\
M6R?;FE1]-WJ<]:7H3J\X\BGK*&FG3P+Z,ENI/"4UQJ'0* 1'ML]UN,5<)CK.
M=D^#4G["TV354&/<;>J-.<5'E-AQHK;844DH54&AVBHQ*@(W5Z*4F/(=:!,,
M5(;64@GD\.S$%G4MJA/6R9])R_HY307%;/1+<0A+:JC*V=B :T &+/OQW3QD
M1]$ZF267(S*:-PK@R2EQJ@V)SE"M@V9T.4V$8TYJYB!&3?']4RV79R6DB0MI
M/3 (4Y3,4@)31-:;!C1&K+5I&T:EU+K*,Y,EW2^,&3'9&5"TL-MU !RKH**2
M>0M1S5H+?>;!I2%I>]M(?3<S;%98DJN7H5(9H.C4BB\W#7,-IIC=PK3EOC0%
M3M)19$HQFDM],ZH))<<R@9E&IJH[<2K9JJWQ;E#18ISJ69;276PL*; 5E4",
MP!(!X179B9#U3;8MTAQK/<I#<>8TEUH.-K0$G*JHJ 2!4;*XMNZ[>!NQT]"B
M7MPPF9EG2J/(8=4%%"ZI )%1P@@IX>4!3$#='<PBZ6B)JAF"H2$A0?8+@*0Z
MG@)RD!8X":\6+_H*W;L-&R8MHGNQ&WG820M:44H5!*:5/N8G:KBVR'9FIJTK
M3 MZ,D9G*@)HVGBK3,?\1.'[#-T1IW4;KLE<GRR[,=(^D%(2&P:'D)I4 4X3
MC0NI[7NVTC*?U7:?I"2V]!0$LKR-JRMY4U(Y9X=NS#V]'1VD$0K/<[@S:V(M
MF9I&3,#*1T3:*YJJ SK- D$DDC%JM-ZT.W>]1OPY#T6R3E-+;?:4A04ZE8*T
M MY3M-:4(X<3K3I6R//7F5,E.FUV]DJZ ](HK0E(YK;1.6I(  X<*U1J[3$R
M-:FTYWI""V\EE-:5=#2E% ]U0H./&]BG_P!IDG_0[@V?=W:)-UDLMH4]T( 0
MTE6P%QQ1"$UXJG;MIP8:M6\6T2+5(D)4ICILJD.A- HMK05)5EJ*T.RHKP_T
M ;^MIO\ L^RN=Z5%?%N5N]C,)E%I?0ET7)2B@.4RYZ&N6M:;:8WSS)L9]F/*
MO-G7'=<:6A#J4V\));40 H [#E)IQXTM=FXSRH+>C+JTN0&E%I+BI;1""NF4
M*(!(!-<6'?CK*-/_ '/EZ2F:?<G0H;\Q,>8)B9*$NHCH<< <0"$G*:J]P*(W
M=?S5Z&L4V_0=,.RW9]E7$*9K]JN;(:=<;BO *4ZT '$-$!2J\5,,0-'Z:N]Y
MO3SC;8M\+2LI+[94JA+BGV6FD)1PK47*  D5QN6GQ(SSD2(YJHR'FVEJ:9"[
M7E1TBP,J,QV)S$9CL&-;Q(;3CS[NG+LAMII"EK6I41P!*4I!*B3L  J<-6)B
M')7<_P!Q[(SY(EE9?Z1+$8%'1@9\P(-12HH:\&+I%:;6M]5@DH2VE)*RHQ%
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M^_RTQ6+/NVGSA'U/ Z-1N"9@*0D2'E+7F;S! -.&K9!R**1OH2K:#;((/_\
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MBE)4*;K7"#D.C(@"N(D)14?]HQ-/$-.W"I[G+:Q<''D](R+%="I(-,R>D14
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M4I2$YE[2=@VKRJ*LJ<IW@;K+J))O.IE0C +;04U1A0*ND749>#9L-<2_Y?\
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MI2MPE*$J(!40*T XS05V?8V/\_U!^VIF-T'Q6K?F+'W7HC^$K_\ .(WM+/\
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MH ;2V4I2FBJ)VU.\MR\Z6G:/W97AV'<;=;;MY.R&7G8ZT7+(EAU:&VEE*5D
MA*0=E-H$O1VZ3=7?-4:&+3\%,BSV)AJVOH 4APLN2%M%P @U<2DU5M"B=N$2
M[Z$37H^D;Z&5OH2X6PSY4VWES T+:$A*2.  4QH*ZQ849J:YI>T9WVV4(<56
M(W7,I(!-2*FIVG:=N-[&\J]0TS+Y U4["A+D?C&XR%Q65N+9;5R4NN5"5N 9
MLB4I! S!6K4W* EVVV^TVB_,6LG_ -G_ $F_TC!F*C?DU/)0CDK*312UKY]%
M#0\W3["(C^I=-7N)<RPD(3(1$R/LEP  *4E7 H\JE$UH,;Q]<7K0-]UM/LUQ
M9T]:GX#,)YBVQ([04MMM,E]HH<>6HN+4D&H(&8 D&R[S-*;O[YHVRS+1/MVJ
M';BB(RS*R)#D%?1QWW IU+@*"LC-D(3S:XUUJ+5T-,]ZPVG3CT!E_EQT/O-/
M#IU-'DJ=;"2&E*!R9UE/*((W9WG3;#<.3J:TZDM]V+"0CREF&PW(8Z0)IF*'
M#4$[: "M ,2H#]OAKC'=HEXMJCME)<-W%5D9:%9K3,>5396F$1HJ$MLMI"4(
M0 E*0.  #8 /8TIHJ]Z7NFLK'I_3LG4;-FMJ&' J>Y)$9$E]N0XTVM#" 0BI
M)2XL$"A5C25_T#NGU-8-8:?O\"7&NTABW,-HB%P(ELNK9DK66G&B0I%*&G%M
MKIG^8"T:;<UI8K+:IULE6B,4*FPUR'$."=#9=(2ZX4HZ):0I*\M,M?P;M>]W
M\.(F:X^TS?84F F-.;?9J&TS6%I"\R>5D*LPV'*HT-(<FXVV$^]]+7M.=R,T
MI5!<'J DIKLX!W!LX,;\XD!EMAAM_2X0VRA*$)'T>O@2D "IVG9M.T[<;U]Y
M]UA(EW^/KJZVZ*Z^ XB,R&V'%%E"JA#CA71Q8Y2DH0FM :[Q4S("7+=96K)>
M(-L428#5QGQE!^8(Q_%].0WR7,M4YED<H@BR/V!@1%ZET;<$W-+-$(D+B24*
M9=<2-BG$BJ<YY66@K08=C1M,2M4[S9\-E<MBQVQ,^<U#1R6U2'%%*&&S^"%+
M3FV'*:@XUD_"TM<='1KEI*!)FVFYL,L+D2$2E-"46F5N(H4')6M2<]14XWY1
M9%MA+8CRM+!ELQFBEL&WN5RIRT34BIIPG:=N(5AO6D[KK.S:2TPBY0+1;6XS
MB&Y\N1T9F.MR'6D*R-@-M\XH5RD@<.-!ZOW>[K=1Z;U'8]0Q#+NLQFWL-*M#
M]6IK#JF9*UJ24*"@"DY:$IVG;KJ[:N83-3H*TV6W69B2G.TPJY-.2)#[:%52
M'%9<F>F;+R:T&-T>\+3EN:@7NZWZ1%GN1@&T2$LQ%J;4XA-$J<3F("Z9LIRD
MD!-/L+'^?Z@_;4S&Z$%-5%K5M%5.S_D6*[..OW7HE)3ROW2O]%5X/^8C<7M+
M/^LYGRGM(_\ &Q_ED>TJ_JI'RZO:2\UV_P#LZ7\BK#9;3E'TK-V5K_<^RUIJ
M?<P["E3;=I^P>66.X$M,7-ATO I3( )8>;*<S2RE222I*QE)QI[>3OMM,+2^
MFM'+>EVJQQIZ;A(E7!U&02)#R$(;2AI.UI"1FSUS;#C5>]*8VT+!=K':8$58
M=!<+T5;I<"D<( SBAX\:BUGN-M-OU5I/6$P72X6.7/%NDP[B4A#KT=]2%MJ;
M> "EI6,P4 $T J94[>KIVSZ9L(8"8D./<5W">I_,*J<=0AM@-Y:T2D%>;CIC
M66NMU.G;;JFQ:Z-MDK\INB;<Y;I41DL++@4VX76U Y^0,WX.SA,'^8?<:B!-
MU$FV?0UZLMP>5'9N,,.=*V6GP%!I]I=<JE)RE.P\&54%G4VBK)I73;:BJX.R
M+V;E*=1D-$QD1VFT)5GI4NDC+796F+=_,9N0C0[K>$6M5BO=CFR?)$SH72],
MTME\I4EMYISC6DA2-G%16B]8:KM]JT_9=-ZLM=R&G6IR9;W0LK)>F/RPA*%+
M0GDLL-)X'%E:R0GV+-IS2%E@WS=G'2B9=[8[=1;W+C*0M1;8?66W#Y,BB%E"
M?RI)"B,J<6ZTW;=O8K;8P\PP^['U$E9CQLP2I3;28P"LB-J4"E:!-1PX7<[W
M8[9,F.4SO2(3+KBJ"@JI2230"G#B/O-;T_9?W%1H]=J6SY.Q^D#.Z4*\GR4K
MT6SI.&G)P$( "0* #@ Q9M2;EU,-Z^TS<Q-MJY"PV@MOLKCR6RH[ %-N5X1M
M0,6K<OHHLHU5IR+:I5K>6L)0+G <0\5YJ4'2+#@)_P 9X,(MVMRRO5UWGS[Y
M?G&"%-KGW!]3KF4C80E)2BO'EQ<M&;I].V[6N[N7/DW&U,.75-KFVPREEQR,
MHNMN-NLI626R*+Y2BH\ $^X[X[3:+&''&_HZ!;I;DQYMNAZ3RE\I0VI1-,O1
MI  K7;BZ:3W3Z?MVM=WDZX2;E;([MT3;)UL5*67'8Y4ZVXVZR%DELBB^4K,>
M+$^Y;XK1:+$A:V_HZ!;I;DU]M !Z3RE\I0VI1.7)T:0 *YN+$;<EO72(-\C7
M"Y7&'.@NA;T"4Y/?D1I+#J<I"T!::@$5!4@D5Q!2];K!<-<VF=Y/-1(E+0Q>
M(#:"D/LN('_+2'"4J*7$E%4KV)"DI&D=;;U].6[1MAT5*?N#,=FYHN<Z9*=9
M+:0'6FFT-,)X5I-5.43L_NXU'J[<5:;?JS26KYINLZQRYXMLB%<E)RNNL/J0
MMM3;U I:5)S @!- *JMV_3?Y%@6;]W(TF-IS3L"29OD[DQ(1(E29.5"5NJ0,
MB$MI"0FAV*!S6G>RRVU^[L/2<VT.N%T=)Y2],;=2D-\)3D03F_J]C0V^S=5!
MB7>_Z+DW +M4N2(@EQ;C'Z!T(?4E24+10*3F%./;3*JWVNZ66%:-5?3]LGO6
MU%P$AMF-$FI<-9&1"5KZ--2$II4T%<*9=2%(4"E22*@@["",2-VN[/3=NUQN
M^;DR9-D+EW3;)T!J0XITQGNF;<0ZE"U'(M.VBJGB0G5&D]]4.UZ=5?H<FWPH
M]HDNRW8S$AA32E/O+2A"W I51T:0G+L.TXM>XNW:9T[$<M,-JT,ZL7="[$$5
MA :0^+<&P\I[HP.2I:4*<Y2J))2(FX+7J68MU7:KI;)18<#[:/+'7\JPH9<W
M)<2JG$>3Q8LVZ/>-IBVPK%INUHMR;Y%NP?,WR5*6F"W%#25MYD"JRXOA&P"M
M!O$O>HFVD1=2:F5=+>6W0LJCF,TV"L#FG,@[#C5&]26VR-/W:P6JWQEI=!<+
MT5QQ3@4BE0**%#7;C0>]:VMLG3^G[;>HTY:W0ET.3&@EH(12JJD;378/^V^;
MV=Q%NM^H[-JU,9R]Z?FS/('D38R.C3)BR%(6V M'Y5"QM5M%?P5RMY&F+-I;
M3#;"TICHNBKC<'9&89%!;3;;"&@G-F!S+KEILKC76\RXMM)L5^MUBC05I="G
M%+A(=#V9'"D K%.[C=IO,M#;*K%IEG4*+DM;H2X@SXB&F<B*575::'@RC;BW
M_P Q.Z&RP]3..:==TU<K3)GIM[@;\I$EI]I]:%HV*&522*Y> '-5-LGZ>BP8
M^]2_S;9;+?:P52V539+J2\TE7(*TMM!PEPA*1ES&FS"/*,O2Y1GR\W-3;2O%
M7%@W\;E'(1UII]B1;W[?<5*;BW.W22%+84Z@%3;B%C.TJF7.>7L&+?#NFA+)
MIBS)?;5<I<R^_2+BF*_C$QFHS3='".:IQ62O",(F[MM-VC5>E7HR$JB.7(VV
M>Q)2I6=72NH<9<:4DIR@ +!"J[*8U5OWWL1H%JONIV8,-FSVYXR$1(T)*@GI
MY&5 >>63M4E.5*0 -G)2=SC.G+9<="IO4Z8QJ,70-.-PI;RY&14(MJ6IY*E%
M%0L(_J&8[T=X][0PFRZK>L:[8I#H4XH0HBFGLZ*<BBB*5.W&\"5JAMIM&HM9
MW&]P.B=#F:(^TRAM2J<U1+9JD\&-?[T+DVR+#J&!8H\!:'0IQ2X3*T.YT4JF
MA5L[HQIC>W$0S^[MIT_<K=)6IT!WIY#B5("6Z5(H-IKC5N]7=78(&L;)KANW
MN3(;]R1;9<*3 9+*,KCB%H6RI))I3,"=E GEW??7OA1:6V;OIEBWLQ[6ZI28
M2FY9<3%)6 IY01RUO42DK44(3E2,:OWF;H].V[55HUTQ:U2&I-T3;G($NWM*
M8"E9FW.D:6E68A S5V;*<JT_S$;E4V]_6$*V*LMVM$]U;,:Y0%N=,$(> );=
M:=Y2%*30B@5L3E5 CZ@T19-*Z>0X%7)^3?/I*0XUEVIC(C--I2O-3E.'+2NR
MM,/[_P#<A!AW_P"F[?'MFH+!,EB$I[R4GR>5'D*2I"5H2<BDK%"G@J553H3>
MQO 8M5FL^G;PX^G3L.2)"XT=<=:5R'Y92D/OJ7E2EMI(;0C;4J4NGV%D+:<B
M?+[_ +*D_P#]ZF5VG&Z#XK5OS%C[KT1_"5_^<1O:6?\ 6<SY3VD?^-C_ "R/
M:5?U4CY=7M)>OJZ7\BK#?UM-_P!GV5\WO1Y,A=ROL"#;WXZRGH4(A%90I%!F
MJK.<U21LV>U]KW@W:()%]LC,IBW/K6HB.)82'E(17(%K2D)*Z9LM4@@$U^Y;
M'^?Z@_;4S&Z#XK5OS%CV&OY?]4V:/&M<MYMJ)<4O*+BP^SG85E(R\IS\61Q*
M^]MNFM+L?^4M<-^6X*TS!I!5E![JB*#W3C4&\O0FEXWT]#FMP[;&:4M\/)J@
MOKR$H*BVE>P [379LH8%ZWO6Y-JU,Z7@_&2@M\A+A#:BV2HH*D@$I)]W96@N
M=V@D)DQ84E]HJ%0%MMJ4DD<8J.#%XO6\26W,F0[EY.RM#+;-&RTE="&P :$F
MFRM/9N^Y+^7]^':&+$70\_(;;45B.I*'7'%N(<HDN+"$I0BM*$G;LLVX[>Y=
M($AIQ"O*FX<=G(XA49;R%=($(4%5 K2@XJ?8:3&[R8U$%SDR4RNDCMO9TM=%
ME3RP:#EJK2A/=&+&K</8$7DREN^7K+"GRUE".C3D2M)2E>91*^++2HQ&?NC2
M6)BV6U/M).8(<*05)!XP#45^U:(_A*__ #B-[2S_ *SF?*>TC_QL?Y9'M*OZ
MJ1\NKVDO7U=+^15AOZVF_P"S[*R?R^;L;TG3"7[%+U%=+NF&U+D!AJ0B,TS'
M0_5I)4XKEJ4E1RTRTIMAVG6=U3>[PP@HD7%,9$7R@YCE464%24'+0*RFA()
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M"$NOH>;2EU(4I*5=%W?ZL2=Y-^#DJ(V&D1(T49WIC\@A+#+(XU.*(IW!51V
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MV_=VZ.>6..J4_G;Z<(5TA.:J0!0UJ*#&L]9QY<J[Z@MDBX.03+6N4I);B-+
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MS9H*\%=G![&H&XZ%N+\KLY"4)*E&ESCDT J<-U_N)_LQOR<6A24+F:6*5%)
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MY"F6Y4HI4D=&VX 5$I5T>8#E*6E()(V:NUAO#N+MG&GY$)1N"5\AB+EZ1_\
M%T(6M:04(KP**: G8;#H#^7N)=K%%R2G+W+NRP]EBLY2E] SJY:A4924IS*3
ML !P-W9MNI# 5($(:H,T"JRK)TW0\ :S;<V2N7E9,1_Y<S.JS+<#[-RZ,5,
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MQ!4ATI:2EU387F12BJYSPGN4]VU[]][EMNFHW+_/>APH$"3Y)'C(94M)4^\
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MI;: 59%5H% $!0H:5%6]*ZW:7!O>K-1IG0X,A)0^F.T6UE:D':G8T":@$!Q
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M](:KR"E17W2?88TWI75=TM]JBI*6(K#J0VV"2HA(*305)/\ 7ANS:^U%<+O
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MHA8_U?'^!CT0L?ZOC_ QZ(6/]7Q_@8]$+'^KX_P,>B%C_5\?X&/1"Q_J^/\
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MHA8_U?'^!CT0L?ZOC_ QZ(6/]7Q_@8]$+'^KX_P,>B%C_5\?X&/1"Q_J^/\
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M.5=,PJ$@XN&GHE6[1J]!*D 43TDMKITJIP><(4D'B"S]IT1_"5_^<1O:6?\
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MQ8TQNBM^H;MJ#1&N;?=76H=[DJFR+;*MK0?*VI*_QA:<2<N11-%&M=@QIO\
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M/Z%V3HJY?+]0<ZE?TU,KP>[C=!\5JWYBQ]UZ(_A*_P#SB-[2S_K.9\I[2/\
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MKG&T<JW-RF5,,M](69<TJ2[T[J1MZ()0VKD@G:L1]ZFCKU#W=V&9%0]9[>N
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M1MKLT]N<W/L1)"M0V&:]GF('107FWT)\N=4.4I#+>:C0ITCBD)X\6ZSZBU3
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M$$@TIBYZDFZONM_U5/@GZ*D3-1RIKLY]=#TG0-N]$IN@S*/1AI">&FS$:O\
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M9<P;13,HE1  %1PGA(&%S[CHZ[!AM)6M33(>(2.$D-*6=GWL*;<24K02E25
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M1VB\MZ0Z.C;!0.<A*E!2_P# %8TYNW"$IEP82%32BE%3'OQL@UXQTJE!/^$
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M,-Z.LEMAQ+"TT66X#+#:(R6U5)0&@ C*2344VU-<(U-:-$V"/<VU]*V^W;V
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MEF>GNUSFPH\=!-$YE16ZJ4>)*0"I1XD@G"MV5\WHH8UTVKH'O_9ZOHQJ5P=
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MI?2=,B6XE(/]U+8/1A%-@1ERTV4IA$JX%$C4VI9L:,I3326TJ>6$,)5D3L%
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ME3T.4G*HG-LQNOGW70=MB7QF/J46ZVMZC0MJ:%1&P\770R UT*2%)!0KI"2
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M2*T&&Z)RC]Q+'R>Y^(C;,6S4%EEL2K4_!9>:E,K2IE3?1@YDJ&RE/>QO,OL
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M'H'),E>5.97-2D;2I2OP4I!4>(''[J:'O[;]Z+9>;AR6)$1YUL;2II,EMLN
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ML5"5OM!IM"G%=$E:2M:4EM.8 JJ:8A:ITY(3*M5QCM2XCZ 0EQEU(6A8"@"
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M=<=)VK<6352U;:T[@IIN\6V&@7"^P42KG)<_&.R7*J0D.+54E*$ (0CFH0*
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MTOY%6&_K:;_L]AC4.\6?]'V^3($5ISH77LSJD*6$T:0LCDH4:D4V<./2;_\
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MJ47-/:8BNR[D$[4Y^B\H="J=U*66O<4HC&M_CV/D',:Q_.+=_H>QHW\ZN/\
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MA'3.)1FIPTS$5IA,6'.C.O*KE0V\A2C3;L -3["I$E:6VD J4M9 2D#A))V
M8,JS2F);(.4KCNI<2#W*I)%?MEOT!/G-M:@NK$B3"B$*SNM1J=*H$#+R<PJ"
M0>Y7;]I?NUU?;C0HS:WGWWEA#;;: 5*6M2J!*4@$DDT Q,L.[2_,76?!;Z9Y
MIMMYL]%FR=(@NH0'$9C3.V5)KQ_<5C_/]0?MJ9C=!\5JWYBQ[&A/S>-\^.-
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MLMH<<>0V% ".D+ +SBFTYJC%TMMF8N%JO]D=0U=+->(QBSHI<&9M2VR5 H6
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MG$X:(C;OE6 /K\A-P>NHE%BO(+P:1D"Z<[+LKP8>UEO&EQ8$:W0Q(N4A*E=
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MXL\)40E*:G@2E*1L 'VZQ_G^H/VU,QN@^*U;\Q8^Z]&_4L_Y=']"=)?6T?\
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M36F&G9>]2UNL)6E3C8TDRDK2#52<WE>RHV5XL1-2[J-:JTX_'CF.] EV]J?
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M"H\J5 L+,:Z/,*%"@/ATMMK4-A<0WF'"-N(^Z&V04'2T>WFV>2.\L.1U(*'
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ML-AJQL.="JX7"4W$CJ='"A"W#51%:'*" =A-<,;I+E;&TWA+;-P>:5,82VY
M+J4K=;>SY% I) RG-6NRHQ+;W(V6.WI+R>.6$O71A*@Z4?C=C[O2 9N[L[F-
M%Z$WP66V6NUVIA]FU/P5-..R$LH;2LNK;6L5"2BM G.3F-3AJU1[,A"'8$>Y
M&8]);1$;8D5Z/I'R<H6:'\6*K'#2FW"-.;Q;>84EYLNL.)6EQEY -"6W$U!H
M><-BD[*@5&(^J[7;H\*TS4A<1^YS&HHD)(JE3:5$K*5"A2K* :U!IAW2>\.W
MKM]QZ$O(2I25H=;-0%MN()2M-014'8=AH<;N/X*@_P!N+:R\D+;7.C)4E0J"
M"ZD$$<8(Q<-WFF+!IE^R1&(3B&YEL2M2NE92M044J3LJ=E!L&+QOMW<61C3.
MM]*J2J^VN"*1)+"AF+K2  $G+5:2 #R%H7FY*L7:U0+9;5[O%WQI,FXK"?+D
MRBIM80CE5R5"*JRU )2#2N%:MTW"CQ[$'"RB=<I3<1EUP&A2V7#59!%*@9:[
M*U!P]HC6<-46\L=&2RE27<X=%6U(4V5!877DTX>#AV89N!M,6&](1TC,*;.8
M8EN)I78R34'W%%)'&!A6@[_ >A7],AN*J(^ A8<=("!4[**J"E0.4@U!IB\1
MV[,VV+(HMON.R6T-NK#8=*(ZO_2D).TCD@\DG-LQ*=T!;P["@^=39+J8\9HT
MKE+B]A53:4I"B!M-!C?/I_>! 5#>D6N ]'=0M+L>0W1T9FG4$I6!6AXQ7:!7
M#EAW?6Y<Y]A'2R'"I+;#"#6BG75D(0#0TJ:FAH#3"-5ZE@L/V):PT;A;I+<N
M.A9- EQ39J@D[ 5 ))V5KAW5.BK8NX0FK@Q:R&5IZ4R7P"D!!-<H!!4LT2D;
M2: TM>[B5:$R;]>&7)$5J'(;=1T;2LKBG'*A+8;) 45$#:*$U&%:NU/&A.V=
MMY$9^1 G,RDL.K-$H="#F22=G!2NROW=IO\ .S_H5[2K^JD?+J]I+U]72_D5
M8;^MIO\ L_H78_S_ %!^VIF-T'Q6K?F+'L:$_-XWSXXT!^=7+_YKC2^_%)+-
MEOR6A<5)2<M$I$:5L'#1I3;E.$J]W;C7G\P\NJ[;:V9$.U+/ .E0IEDI_P"&
M.@Y@.-VO'C6R$ E1D1P .,] YC65H6K++#EO=+9V'* \DG^H[#W-F-&Q M/3
M]/<5]'7E9<K(K3N5V8L]IW/:-8OUI7:8SC\EX.%2)&U*FZ)=;RY4A)VUK7W,
M37][MG3I>_N/R(K+<?,"&2TG(\ I:R%!2E <K\$'97"]Y4_6K^K8MC6B0]"N
MZ'@ @K2DE&=]T*J3RD\BJ:T-=AG:YU988BE6]PZ=5:([8;AR7%-)Z-*44(;:
M+:JK3MRA*LOX(Q+WTV1Z)"B3 NZ1]/H4Z4N1&RI8HI2B*A->B0LJ)3PK"C3"
M8K5LCVF78%HM[T>$CHXQ3DS(<:1^#F%<R:GE FM%#&[C[]K_ &FK[9HWZEG_
M "Z/8TE<;)5;&GK](1<TI',4XZ^E*U4X*=,V-O$O[V(.C]:;N+?J.Y/S0VJZ
M/S7&G"E]P)2"V&U#D T%"*^X=N$;NMR$ V^6^;:NVQXKBD='*=0%9T+4:MT4
M,Y-:(H5;,6I6NMZ[*-X4*[Q')$:%"F3#Y274DLKEU S+)R+S<%3G'%BY[QI$
M,RH4*2WY2PU3.428*&W%HJ0,XS9A4BIV5%:XU#O@_EIU9].1$H?GW>S2BXQ=
M&&'2IQQ*J[7DC;SP,P% I:AMO:DJ5MUBW0YCP?\ +?\ 9B9,1RG&M/W%P9MM
M2E31VXARM=3GYCE^O4-$\K<5E6EZ2E! 37*$I2:( %$C8,3]+2E+;M%DAP8U
MNAI-&66UL)<)0@42"I2N&E: )X ,::U#JMQ4BZ6?4;MNM\EXE3JHQ#J2C,=I
M  "=O_A#N#&Z3^#VO]+.--Z)=F._0,?3T*6B&E12T7W"M*G% <Y5$@ GFC@I
M4UW07R[NKD7')<8_E+A)<+;=4)25<)HE"!_W1C=#12A_]B#%:*.W\3'X>[C0
M=CU=JB5I6V7R;+GS%P[<N;Y=)2ISD.A"T$)0 .$D'(D4Y.-:;IK-K"=J95]0
MR_;8C]G=BMQ9;)J%(*EK2G.0DJ/)IDXZXLG\O^\^].Z1O&G94AZVW);72V^3
MTZE*I( ( 4,Y&913EIF2O:I.+%I76DA$P./V]ZW3HSRW&'XAD)""TI6U*0:@
MHXN*J2";KE4H?^S[=P*(_P#0_?QN8J23]%W3:37_ ,#&@M#IFO)L)TM"G*AH
M44MKD$EOI%@<XA*0$YJA.VFTG&["ZWIU4B7'N-PBH?=)4L,HZ5*49CM("4)'
MWDI[F+%J#^8W7[6F_I""VJS6QYF3<I;<-('1U:0:,H (H!L'-YP*1NH>M=T5
M?6$V>8PU=G&EM+E--H9"%*0LE:?O*->[C=Q_!,'^W%K_ #^+\LG%Z_-+;\V1
MC?#KFZ)I9C9$VY*U\U<A33XRCB)'2MCNU4,7])X1K",/^QC&E]R>O[ZYH_4^
MEB^W;I<A'26R6'E;.EH0$+X!F44Y2%$*5GRC3>@=ZF2:Y$9>N,*0AU3K$AMB
M.XJ,XTI>W*E:=B2.2I-.*N-0:MO4R0+PW=98;=Z507'##RD-H;(/(#82 D)I
MP8W+:[NR G4-XMEM7<%$ +<*'XZT+539M+BZ??IQ8FZ8D3GD6NR1XB8,=I:F
MTMF0PEUU=$D56M2J%1VY0$\ QNST]I]Q3$#4$J9-NG1$IZ=Y)4H)<(X0"> [
M#D3_ '1C>WI:YS7I%KM4&,J$PZK,&.GSEP()VA*B@'+6@-2 *G&?4NH9&EHF
MH-2.-7&?#A*F.O\ 1*6EN,M*%(4$*2V%5K3A%.6<:TTG$UO<-0P=2V=V*W;%
MV1V,TF4$JZ)Y)*UI"JD"M$\ -=@QO#O^EI)B73Z7BQDR$<]M,A##3A0>)651
M"5<*2:C:!BX/Z^3-DZ?OEID6>4]&<4J3%0^H*+K537A'*RG-MS"I30S-Z>Y;
M5#&J]WZ'FT3^AS,RHQ*AT?E3' K*5 9B$J%<V0 U'W;IO\[/^A7M*OZJ1\NK
MVDO7U=+^15AOZVF_[/Z%V/\ /]0?MJ9C=!\5JWYBQ[&F]=V.YPH<2S-LMO-2
M$N%Q71R"Z2C*"#4&E"4[>/&FE::N,.!]"/2G'O*TN'.'^AIER [4]&:@TK4;
M1B/IJV2&(=Y@2T28DF0%9 ,I0XA64%0"DFNP'E)3@[OI$AF3=9+DF1,E,I4&
MUNO#*FF:BJ);2A.WA()H*XO5KU+<(D]RYR6'FS$#E$):0I)S%83M->(?UXE[
MS/Y;=3)L+\U;CCD1Y3C8;+JLRT(6A*PMHJVA"T430"IH*0]X_P#,MJ=.H'8"
MFUM0F2MQ*RVK,E"UK2A*&PK:4(1RMM2-M<2=*Z:O+]ANQ=8DQ9\<K"FW6%A:
M0<BDJRFE#0[.&AI0IT;O$U_"DZ;"TJ6,SJBL((*2M"66RX1P@.+I45K7;A>X
M&')>;:4Z)OTD4)+IG @].I%0"*#)DK^3Y.;-R\+W5V77=N;T@6G(R4_C M+#
ME<R$GH"XD&I&5+E!6@-,73=_H&[%O55S:>=7>%MT"9:F\C:DHY65MN@H.4>%
M7":8@:PU5KJW3;S;.C\CE.![.ST3G2(RT: V+Y6T<.)5NWQ:A;U'=79BGF)#
M:"D-LEM #=2E!/*"CP;*\/VO1OU+/^71[%PLLB Q?='WI.2Z6:6:-NBF4K0H
MA02LIY)J"E0IF%0DAK54/1>IQ,9>2^W;3.1Y&E:"%)%>F*LH(X*G9Q8B_P Q
M,.VLQ94%^,MB 7"M):806BA;E 2I:"H%02*$[!LPO?/I_2%\E:RD3/I!5NN$
MII-J:EE84I[\62XLYJK2GF9^$)'!==ZFK].RKEI*[-!ERW./AF4V?)T-!Y"T
M*RAQ"DYDC-2FPFNW%\1_+]9;^O4FH;:NV.S+^^R6HC+IY8;0T3G5P$5'"$U5
M0%)O.XK?):;C<=+W*:W<6'[6ZA$AA] 178LI&TMI((/]X%)!J+OKJPVBX_NK
M*M\J! A%YMR4V'@W13BUG*:E*B:$TS #-3"9,=9;>;6'$+2:%*DFJ2/=!VX@
M7S^8;3MZ9UE!BIC/W'3SS2$3DM\WI4.$93P\1RU(2O+0"S[NM!VD:>T#IU"Q
M;K>7.D=<=6**??4-A6:F@JJA4LE2BK&BK-9X4F(YI>QHM4A4@H*77$I;!6WD
M).7D'G4.T;-F+=J>PPI,%B%9XMM6W**"M3C)62H9"1E.8 5V[. 8T/NCB0Y+
M,_2RIBI,EPHZ%X/J41T="5;*[<P']>-.:9WT:=O,O4NE+>NWP9%LE(:8D-Y0
MEOI2I04D#(BHRJH02"0<N%;B]^]EDWO234HS;=)M[P:FP'E$E71YB$J352B!
M4<Y0(4" )=FW26"_O7F06PU=;[+;'DZ4K"E]&PR<JBH IY0V UKBWP-Z&G=0
MQ+_!CEF1*L4IKH9Z@HE*W$/*JA9! 44@<'#Q"T7+3EO^A[%IJ%'M]FB+7TKB
M&HZ@I*G5\:B0-@- D 5)JHR-<7#3EYB;S)$!B)TB)2/HY+C5!TI 5G51-0D9
M144!%1FQH/=U;(DF/-TE#F1I3SQ06GE/]'E+64E5!D-<P'",:<N-DA282+)8
M8]H=3)*"5N-*4HK1D)Y.W96A]S&E=RC$*2W<;!.ERI$I:D= ZE\NT" #FJ X
M*U X#PUQ9)^_2P7_ />ZPV]NW=+9)#*&)S37-#A<(4BIJ30525*RJ(H!I+3.
MFK$=/ITVS-C>3(<#D9+3I0EE+2JYU94(&=2P"5$T&-+/66')ABP6"/:'A)*#
MTCC1J5HR$\GN5H?<Q$N2TE:8TAE\I!H5!M840/OTQ(WB:ST;J>3=Y"&4.(3<
M&F6%!E 0@%*'=@H!6GW\1MU.[ZR1M)[OH;H?1;(RRXX^Z#4+D.D JH>53C50
MJ4HI32Y[BG(<DW6=?6[JB8DH\G2V@-\@@G/FY!X!3:-NS%O:WC::U%#OT&(V
MQ*79)39C7!QO877 \K,VIS\/+E'<.+/O=T?#1:6M-,QX=GA+47 F*QF!0\H4
MS=(%*2NG D@ DC,7=YFL=':A:U))=3)FVN%*:%NE/\*U*45)4$K/.H$9JDE)
M)-;?O&OD5$2W6IV&B!;(RJHCQ(KH<#2"0 5*H254 J=@"0 +IO)LD5^'"GHB
MH0Q)*"ZGH&$MDJR$IVE-10G9@;A_Y@+/.N>FX<LS+3.M;B4S(2U%14D!92"F
MJE$;3L44J21E(U7N3W<Z4E6RQWB&&H<QYU#LQ^2H_C'IRRK@ "0VAO-E&;@J
M +KN:WM69V_Z"NSR98:C.AJ5#DBGXUA1(&W*#3,FA%:D*4E4^#NTT]J2=>Y<
M<M19M\EM(:AN*I^,2VR>6I/%F%#W<:GW*R(<ERYWVY19K,I!1T#:&2T2E8)S
MU/1FE!3:."F+A"WQ6*7>+5.8;0R_;W^AF0G4+S=(UF(0K,.2H*_[>#%ZW/\
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@:([<'Y"X*G%Q\TR<_*HVIQ*%D .@<I(VC^O_ /;W_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821933469152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunic, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,403,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821929977376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 92,761<span></span>
</td>
<td class="nump">$ 106,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">4,351<span></span>
</td>
<td class="nump">9,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">9,470<span></span>
</td>
<td class="nump">9,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">106,582<span></span>
</td>
<td class="nump">125,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">1,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">108,872<span></span>
</td>
<td class="nump">127,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,241<span></span>
</td>
<td class="nump">4,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">10,183<span></span>
</td>
<td class="nump">7,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,302<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,352<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">1,352<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,654<span></span>
</td>
<td class="nump">14,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of March 31, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,403,838 and 39,307,286 shares issued and outstanding as of March 31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">429,955<span></span>
</td>
<td class="nump">427,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">3,811<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(342,552)<span></span>
</td>
<td class="num">(317,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">91,218<span></span>
</td>
<td class="nump">113,684<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 108,872<span></span>
</td>
<td class="nump">$ 127,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821933408176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">44,403,838<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">44,403,838<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930251072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 22,963<span></span>
</td>
<td class="nump">$ 17,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,288<span></span>
</td>
<td class="nump">3,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">27,251<span></span>
</td>
<td class="nump">21,435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(27,251)<span></span>
</td>
<td class="num">(21,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,272)<span></span>
</td>
<td class="num">$ (20,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in USD per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in USD per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">43,664,783<span></span>
</td>
<td class="nump">28,127,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">43,664,783<span></span>
</td>
<td class="nump">28,127,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821933406736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,272)<span></span>
</td>
<td class="num">$ (20,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">776<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (24,496)<span></span>
</td>
<td class="num">$ (20,866)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932140096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 127,115<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 324,237<span></span>
</td>
<td class="num">$ (252)<span></span>
</td>
<td class="num">$ (196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants</a></td>
<td class="nump">29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,240,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 137,961<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">355,949<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(217,681)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">39,307,286<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 113,684<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">427,925<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
<td class="num">(317,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">44,403,838<span></span>
</td>
<td class="nump">44,403,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 91,218<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 429,955<span></span>
</td>
<td class="nump">$ 3,811<span></span>
</td>
<td class="num">$ (342,552)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930952656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_AtTheMarketSalesAgreementMember', window );">At The Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932134640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,272)<span></span>
</td>
<td class="num">$ (20,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency loss</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">123<span></span>
</td>
<td class="num">(2,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">986<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,072<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">51<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(19,513)<span></span>
</td>
<td class="num">(20,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Sale of investments - other</a></td>
<td class="nump">5,439<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">5,335<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock through At The Market Sales Agreement, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of pre-funded warrants</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">29,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">143<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(13,984)<span></span>
</td>
<td class="nump">8,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">106,745<span></span>
</td>
<td class="nump">86,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">92,761<span></span>
</td>
<td class="nump">95,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of use asset obtained in exchange for lease liability</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930885824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Financial Statements</a></td>
<td class="text">Description of Business and Basis of Financial Statements<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company currently has approximately 73 employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); and the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $342.6 million as of March 31, 2023 and $317.3 million as of December 31, 2022.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2023, Immunic has raised net cash of approximately $355.6 million from private and public offerings of preferred and common stock. As of March 31, 2023, the Company had cash and cash equivalents of approximately $92.8 million and investments - other of $4.4 million.  With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial </span></div>statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821933394080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S of approximately $69.2&#160;million, Germany of approximately $27.5&#160;million and Australia of approximately $0.4&#160;million as of March 31, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of 4.7%. Cash and cash equivalents in Germany are earning interest at a rate of 1.5% to 2.75%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,351</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,351</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.87% and matured in January and April, 2023, respectively.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNDU2Mg_39b56566-c533-42eb-a49d-8d8409f1a003">three</span> to thirteen years. Depreciation expense was $32,000 and $21,000 for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance.  </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC, PMS and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to one million Euros per year.  We recognized $1.8&#160;million and $0.7&#160;million of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_78b0eeb2-f243-4b7a-92e7-d8188a462216"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_a04b00e1-dad3-420e-abd4-51c63bcf0717">other income</span></span> related to research activities performed during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:73.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930891312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">Balance Sheet Details<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expense consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.287%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.389%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_e9a3cedd-15f8-4c7a-8ef7-0f175db48d87"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_ebd123b0-afec-4aee-8416-c7a76f3dc937">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930216736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesOperating Lease<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#228;felfing, Germany office and November 30,  2028 related to the new lease of a research laboratory in Planegg, Germany.  The Company formerly leased office space in Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025.  The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a five year lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions of $544,000 related to the addition of new laboratory space in Planegg, Germany in February 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $195,000 and $130,000 for the three months ended March 31, 2023 and 2022, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of March 31, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:83.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company has non-cancelable contractual obligations under certain agreements related to its development programs vidofludimus calcium, IMU-935 and IMU-856 totaling approximately $4.4&#160;million, all of which is expected to be paid in 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821933375456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 4.7% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of March 31, 2023. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div>The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930955920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of February 17, 2023, there is $75.0&#160;million remaining on this shelf registration statement </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 2, 2023, $8.4&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.  As of May 2, 2023, $80.0&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three months ended March 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2022, the Company raised gross proceeds of $30.6&#160;million pursuant to the December 2020 ATM through the sale of 2,904,113 shares of common stock at a weighted average price of $10.54 per share. The net proceeds from the December 2020 ATM were $29.7&#160;million after deducting underwriter commissions of $0.9&#160;million.  During the second quarter of 2022, the Company raised gross proceeds of $10.3&#160;million pursuant to the December 2020 ATM through the sale of 1,300,000 shares of common stock at a weighted average price of $7.90 per share. The net proceeds were $10.0&#160;million after deducting underwriter commissions of $0.3&#160;million.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, are immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the </span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. Through March 31, 2023, no cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-funded Warrants</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of March 31, 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at March 31, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,116,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821931591536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued 83,109  shares life-to-date under the ESPP.  The Company recognized $46,000 and  $28,000 of expense related to the plan during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board of Directors (the"Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MzAz_cd4f286e-f982-4745-9e25-2b9dea81d824">three</span> or four years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the quarters ended March 31, 2023 and 2022, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423,482&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the three months ended March 31, 2023 and 2022 was $1.15 and $8.48, respectively. The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:72.529%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, there was $15.8 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 3.06 years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital Therapies, Inc.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 12, 2019, we assumed the equity incentive plans of Vital Therapies, Inc. (&#8220;Vital&#8221;) following an exchange transaction (the &#8220;Transaction&#8221;) with Immunic AG.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the Transaction, holders of ordinary shares of Immunic AG exchanged all of their shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary. Following the Transaction, we changed our name to Immunic, Inc.  Upon completion of the Transaction with Vital on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain 43,311 shares available for grant under the 2014 Plan as of March 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the three months ended March 31, 2023 and 2022, </span></div>respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930936544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821931591536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appointment of Richard Rudick, M.D. to Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, the Company announced the appointment of Dr. Richard Rudick as a member of the Board of Directors of the Company, effective as of April 26, 2023. As a Class III director, Dr. Rudick&#8217;s term lasts until the Company&#8217;s 2023 Annual Meeting of Stockholders . Dr. Rudick is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr. Rudick and any other persons pursuant to which he was selected as a director.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with his appointment as director, Dr. Rudick was granted a long-term equity incentive grant in the form of an option (the &#8220;Option&#8221;) to purchase a total of 32,000 shares of the Company&#8217;s common stock on April 26, 2023. The option to purchase 32,000 shares vests in monthly increments over a period of three years from the grant date. The Option has an exercise price per share equal to the closing price of the Company&#8217;s common stock on The Nasdaq Stock Market on the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Additionally, Dr. Rudick and the Company entered into the Company&#8217;s standard form of indemnification agreement for directors and executive officers.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932601568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial </span></div>statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock', window );">Cash and Cash Equivalents and Investments- other</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S of approximately $69.2&#160;million, Germany of approximately $27.5&#160;million and Australia of approximately $0.4&#160;million as of March 31, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of 4.7%. Cash and cash equivalents in Germany are earning interest at a rate of 1.5% to 2.75%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,351</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,351</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr></table></div>The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.87% and matured in January and April, 2023, respectively.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNDU2Mg_39b56566-c533-42eb-a49d-8d8409f1a003">three</span> to thirteen years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div>Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC, PMS and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div>On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government assistance</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to one million Euros per year.  We recognized $1.8&#160;million and $0.7&#160;million of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_78b0eeb2-f243-4b7a-92e7-d8188a462216"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_a04b00e1-dad3-420e-abd4-51c63bcf0717">other income</span></span> related to research activities performed during the three months ended March 31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and/or Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342957-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Other Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930940800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of Investment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.665%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,351</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,351</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:73.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930143264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets and Prepaid Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expense consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,628&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.287%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.389%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_e9a3cedd-15f8-4c7a-8ef7-0f175db48d87"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_ebd123b0-afec-4aee-8416-c7a76f3dc937">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821931683024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Obligation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of March 31, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:83.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,001&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930916944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930926352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Shares Reserved for Future Issuance</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at March 31, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,116,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930143136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the quarters ended March 31, 2023 and 2022, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423,482&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952,888&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Used</a></td>
<td class="text">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:72.529%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821925923312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">107 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>employee </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfDevelopmentPrograms', window );">Number Of Development Programs | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (342,552)<span></span>
</td>
<td class="num">$ (317,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">355,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">92,761<span></span>
</td>
<td class="nump">106,745<span></span>
</td>
<td class="nump">$ 95,710<span></span>
</td>
<td class="nump">$ 86,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">$ 4,351<span></span>
</td>
<td class="nump">$ 9,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932243440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 10, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>lease </div>
<div>financialInstitution</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,761,000<span></span>
</td>
<td class="nump">$ 106,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits', window );">Number of financial institutions used for cash deposits | financialInstitution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_GovernmentAssistanceRate', window );">Government assistance rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases', window );">Number of existing operating leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement transaction (in shares) | shares</a></td>
<td class="nump">5,096,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Australia and Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Germany | Time Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Australia and Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_GovernmentAssistanceRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_GovernmentAssistanceRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Number Of Existing Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeasesNumberOfExistingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Financial Institutions Used For Cash Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfFinancialInstitutionsUsedForCashDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_AustraliaAndGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_AustraliaAndGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821933329808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">$ 4,351<span></span>
</td>
<td class="nump">$ 9,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">$ 4,351<span></span>
</td>
<td class="nump">$ 9,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932471552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock (in shares)</a></td>
<td class="nump">5,595,841<span></span>
</td>
<td class="nump">3,423,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930220032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_PrepaidClinicalAndRelatedCostsCurrent', window );">Prepaid clinical and related costs</a></td>
<td class="nump">$ 3,902<span></span>
</td>
<td class="nump">$ 5,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">843<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent', window );">Australian research and development tax incentive</a></td>
<td class="nump">2,823<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,902<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 9,470<span></span>
</td>
<td class="nump">$ 9,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_PrepaidClinicalAndRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical And Related Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_PrepaidClinicalAndRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Incentive, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ResearchAndDevelopmentTaxIncentiveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821935335904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accounts Payable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ClinicalCostsPayableCurrent', window );">Clinical costs</a></td>
<td class="nump">$ 4,919<span></span>
</td>
<td class="nump">$ 3,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LegalAndAuditCostsPayableCurrent', window );">Legal and audit costs</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total</a></td>
<td class="nump">$ 5,241<span></span>
</td>
<td class="nump">$ 4,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ClinicalCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ClinicalCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LegalAndAuditCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal And Audit Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LegalAndAuditCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821926039424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedClinicalCostsCurrent', window );">Accrued clinical and related costs</a></td>
<td class="nump">$ 9,628<span></span>
</td>
<td class="nump">$ 6,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedLegalAndAuditCostsCurrent', window );">Accrued legal and audit costs</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 10,183<span></span>
</td>
<td class="nump">$ 7,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedLegalAndAuditCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal And Audit Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedLegalAndAuditCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821933291936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 649<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total<span></span>
</td>
<td class="text">Total<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932540752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod', window );">Lessee, operating lease, extended rent holiday period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingAndVariableLeasesCost', window );">Operating and variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember', window );">Grafelfing, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod', window );">Rent holiday period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal option period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember', window );">Planegg, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Increase in operating lease, right-of-use asset</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingAndVariableLeasesCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Variable Leases, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingAndVariableLeasesCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932577952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">2,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of obligation</a></td>
<td class="nump">$ 2,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821926274048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 69,058<span></span>
</td>
<td class="nump">$ 85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">69,058<span></span>
</td>
<td class="nump">85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">69,058<span></span>
</td>
<td class="nump">85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">69,058<span></span>
</td>
<td class="nump">85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930869056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">4.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821926100864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Shelf Registration Statement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>d</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 02, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationStatementAmountRemaining', window );">Shelf registration statement, amount remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Commission, percent of gross proceeds from sale of common stock</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="nump">$ 30,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">2,904,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SharesIssuedWeightedAverageSharePricePerShare', window );">common stock at a weighted average price (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="nump">$ 10.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 29,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Underwriter commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember', window );">May 2022 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember', window );">May 2022 ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Aggregate Offering Price Of Securities Under Shelf Registration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SaleOfStockRemainingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SaleOfStockRemainingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SharesIssuedWeightedAverageSharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Weighted Average Share Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SharesIssuedWeightedAverageSharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationStatementAmountRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Statement, Amount Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationStatementAmountRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration, Termination, Prior Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationTerminationPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932587232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Equity Offering (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 10, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement transaction (in shares) | shares</a></td>
<td class="nump">8,696,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="nump">$ 4.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage', window );">May not exercise of percentage</a></td>
<td class="nump">9.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement transaction (in shares) | shares</a></td>
<td class="nump">5,096,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="nump">$ 4.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent', window );">Increase or decrease not in excess of percentage</a></td>
<td class="nump">19.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod', window );">Increase or decrease not In excess of prior notice period</a></td>
<td class="text">61 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821929842400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfVotesPerEachShareOfCommonStock', window );">Number of votes per each share of common stock | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, cash dividends declared (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, cash dividends paid (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfVotesPerEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Per Each Share of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfVotesPerEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821926014928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Pre-funded Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercised (in shares)</a></td>
<td class="nump">5,096,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821925949360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821926280096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Shares Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">6,116,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">5,595,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options | 2021 Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">116,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">43,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">313,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932415456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">39 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2021</div></th>
<th class="th"><div>Apr. 25, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation cost will be recognized, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of the stock, at discount from market price at purchase date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares issued under the ESPP (in shares)</a></td>
<td class="nump">83,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted-average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 8.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Minimum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember', window );">2019 Omnibus Equity Incentive Plan, Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent', window );">Additional shares authorized, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821932372144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details) - Outstanding stock options - 2019 Omnibus Equity Incentive Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,791,688<span></span>
</td>
<td class="nump">2,157,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,815,314<span></span>
</td>
<td class="nump">1,301,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(11,161)<span></span>
</td>
<td class="num">(34,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">5,595,841<span></span>
</td>
<td class="nump">3,423,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, Ending balance (in shares)</a></td>
<td class="nump">5,595,841<span></span>
</td>
<td class="nump">3,423,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, Ending balance (in shares)</a></td>
<td class="nump">1,888,367<span></span>
</td>
<td class="nump">952,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (usd per share)</a></td>
<td class="nump">$ 11.33<span></span>
</td>
<td class="nump">$ 13.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">1.41<span></span>
</td>
<td class="nump">10.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (usd per share)</a></td>
<td class="nump">13.29<span></span>
</td>
<td class="nump">12.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (usd per share)</a></td>
<td class="nump">8.11<span></span>
</td>
<td class="nump">12.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)</a></td>
<td class="nump">8.11<span></span>
</td>
<td class="nump">12.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)</a></td>
<td class="nump">$ 12.66<span></span>
</td>
<td class="nump">$ 13.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 7 months 28 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 7 months 28 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">7 years 8 months 1 day<span></span>
</td>
<td class="text">8 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 161,428<span></span>
</td>
<td class="nump">$ 1,464,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">161,428<span></span>
</td>
<td class="nump">1,464,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 1,980<span></span>
</td>
<td class="nump">$ 215,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930184464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.97%<span></span>
</td>
<td class="nump">1.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="nump">97.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821926378816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,979<span></span>
</td>
<td class="nump">$ 2,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">903<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,076<span></span>
</td>
<td class="nump">$ 1,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vtl_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930869056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember', window );">Duane Nash, MD, JD, MBA | Forecast | Board of Directors Chairman | Executive Chairman Agreement | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="nump">$ 30,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SalaryCostsMonthlyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary Costs, Monthly Base Salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SalaryCostsMonthlyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139821930133056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Long-term Equity Incentive Award - Subsequent Event<br></strong></div></th>
<th class="th">
<div>Apr. 26, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option granted (in shares)</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock option vested (in shares)</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_LongTermEquityIncentiveAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_LongTermEquityIncentiveAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>vtl-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vtl="http://vitaltherapies.com/20230331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtl-20230331.xsd" xlink:type="simple"/>
    <context id="i09350f81250c464d865db34f18f61a93_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i388fe32242894fcda0ee04da0a4a7628_I20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="ie2ca6e9222044db0b2b0c86717d4704f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9320051a944145d6816da95e5465e3c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifac372e93e304225887151b04d10d097_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4155178cdc7140cea775b3cb724f22e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88a78d905402443da1f001d06d684730_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7525d297b7a4cc7892a3e0337f40706_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ca9c2ca745541f18b5bfa39907baf2d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b147340b42946ed8ca10d452b403ebd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i51a8f285fcfb4ccdb68607df5a39ef94_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i37e69ee3daf843cfb2cc88838d672346_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i070ed8b98474469aaa446823ba89a721_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaf37e7e42a624bb69e55ab937f3c9269_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2ba80912a12245ab9ea6a2e70d9fcaab_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic6dad41e267c41f9a02c026710ea4d78_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic1de0f235b8444c6af6405b255d75604_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4656bcc3b5664116bbc2110cb69413a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cee35bd9f1448618979791eff9cb402_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80d5e7c542364e6b91f404a68cce14b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5c1dfb8586a4e62b290f57d6b21e26a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25dc5ed916e5432d902a28c2209cb1cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib9bda424319e448ea9036287dc26278f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8d6bb7eeb17b42b6b560d2d0c4e347ca_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4fe801d7b5694d349caf6bc6c0349f78_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief4990a110a04802be1e5c3f245e10cf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b791530e898489c8c22614be6c3f978_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1e51941010cc4d6998cdc6318cacc80e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib0b6c17ec488454d8d2239bc02df935c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i67dc7d2117dd4e95a74b60a330d24d53_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i691582ba1b7640458a1c80bf290a4a95_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i971971525ba148019837a545259b6684_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1c1ce43c473547e99f3821322556a079_D20140417-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2014-04-17</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib8c1a45128834deeb7c989373a0d3a57_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i170f226050a64272899ebe618949d15c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i97e9633735014256ae003a713d8ab86d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i00dbb5ea0444479bb49ade8df06bec2a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i883c7dc6250c4a088e84c151079c3725_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iea3055f090434c34a36eb882151b2a4b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i68a332d0cac3410a9bf57d9923328244_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3c7e38a236f14a20b7ca1838765c36ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a7d9669b6d842baa047cfedec92e62b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec0275452bd148d5ac1ac3d3ab914a50_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i98492f22019748cd8f198e6e858d4908_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieede7680228b4ced8b38713bf5d0aae3_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1bab50058db432a95481b3b7f2efba9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic8ab2a7b7c1b48578feac81bbc5e3e28_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1b55fff4633243a0adf3497ef994823d_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="ibbacc1604fd34d488c15218cae45490d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iec03675d217d4626a6ad2990f79e3eb7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i89ddf70d08824b6aa7e7f010c23a3377_I20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="i20527b0f049e4fc49cf34f6e19f78f53_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i805e70466a81410da29a22178dd65ce1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9a80cba888e746d6bd629ae229623ef3_D20230201-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="ibf9be709dcc341ec81501791438f59e7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia456402de7a84422945fba2d356a2128_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieed67899138440fca6e702a05a6fe016_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i54c299796fa64dfcb61bc9a98dffb9ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6756bb299bd64a4c8756ee0392611ce8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7caa4e1db0ad42d798b24b3737f23fc6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i040bb11041164505a47e1dcaaf723bb1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8cde7bfdcbc64b08a49fea0cfd6c4e66_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9dce7e6602844c5d9fae5f312b27e08c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc410b5e83414c3aa3d99f8cfd2413d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2fed83fa3cd84a30b2fbc0c3d3a7d5f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibfd52b7f358e4ee28cc0c52c348d53e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40bc641f88774d5fa4e4a507ac82f713_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87d89dc42f6849f8bf05f2e1420914fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81bb32c6f29a45bbbd7f764bbf7b6bd0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13e792ced17e4aac8f2baa208d221702_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a93cf1f6efd47c68682b156780ea43f_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="iebae0eb40a444df390db58fc0a4f5613_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i5a10625444a64e53bdfa92e91315ad3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30b5afb1f0ff4c47b8c3bc25cc38daed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i82a88f6ec9b74cc5a1e1440f7bbdd771_I20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="icbd443fc4f014d7bbdc8e6eea80617c5_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="if2a13be659d44aba86b85693c76e9613_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i46a98a2bf0d84695bd517c220ad9693a_I20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7adc4e97d78648e5a2e35c0c4f324c4f_D20221010-20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="i9a7ff65586d1477a96c00b182f10e2cc_I20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="i95409047e69d4309b31a843a98de93fb_D20221010-20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="ibb7897fe5a4546198de6a00c37cae9e1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i239a3919cf64453b8bbede15f2c98d15_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1d5a0313e25e42cba4239ba45c3be9ba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie21c8c85594c4ad8acb51bd91760547e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if6f016a323654ddd9934856d79e1aff3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic8ec42d4c505493aa4e52b6dc975c57c_D20210425-20210425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-25</startDate>
            <endDate>2021-04-25</endDate>
        </period>
    </context>
    <context id="iaf59c539b0384772b43fdb06eff0b23d_I20210425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-25</instant>
        </period>
    </context>
    <context id="idd619ffa1b7c439ab600c4800cda19f8_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="ief8ab69f94cf44e4842f469e423648c7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i87843dae4e154ef4b4771cc451754b9d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie3f47deb3c97419e8cb5ad85105d41f3_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i18240f287ce143488e8e2fbd786ce30c_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="idb0e3c9196e14a1f9b8819f2efee359f_D20200101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id29dd56a8d2343fa923b6c1b453533a6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifa554797e5fd4c1abf0e6346028845b6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7e8e321395104641a2c172c323a23d47_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id849626157e04b04b98545bea26e1a7f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i01801c5e4d9a456585f4460c4186beac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i90b7b2db1cbc453baca9109f8891d37e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i852628a8fa954ea88ef5db4e6f88f6c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if5e4d9d710764b0db319b9d428403670_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9bac232d450542c29d7d8a2d9b455e83_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1e6755fc97ea425cb1262657c7ed624c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieae0ab47bf4b483788aa093a0ceca4cf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic16d1c96118c4a888e6a5395e0e4dc9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i781801a508af47b1a07f6605aa4e43d7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7ef55c12c6414e5eb8e4e206bc43438d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibb1cbf03fbb447069ee8da6cfe57e37e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8d852c9c8633413dac4a33c96a487447_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i76cd333d69ab4f47b9c2c6dc6ce0348f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1948e072c9f494ba65be7555fdc7188_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0c71bdc1a2f64a69a40ac91eb07d2ad7_D20221228-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:LongTermEquityIncentiveAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>vtl:employee</measure>
    </unit>
    <unit id="lease">
        <measure>vtl:lease</measure>
    </unit>
    <unit id="financialinstitution">
        <measure>vtl:financialInstitution</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="vote">
        <measure>vtl:vote</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGFibGU6NDhjYWI4MTY4NmNiNGNlY2I1MTQzODA5MmJiYzMxYzgvdGFibGVyYW5nZTo0OGNhYjgxNjg2Y2I0Y2VjYjUxNDM4MDkyYmJjMzFjOF8yLTEtMS0xLTQwODc0_9bf216d8-9c79-4cb6-8c30-c128fb4c7026">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGFibGU6NDhjYWI4MTY4NmNiNGNlY2I1MTQzODA5MmJiYzMxYzgvdGFibGVyYW5nZTo0OGNhYjgxNjg2Y2I0Y2VjYjUxNDM4MDkyYmJjMzFjOF8zLTEtMS0xLTQwODc0_0a9a29a1-71df-4c2c-ab8d-b66655e3308f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGFibGU6NDhjYWI4MTY4NmNiNGNlY2I1MTQzODA5MmJiYzMxYzgvdGFibGVyYW5nZTo0OGNhYjgxNjg2Y2I0Y2VjYjUxNDM4MDkyYmJjMzFjOF80LTEtMS0xLTQwODc0_58651050-a69d-4c42-acd0-d83ad5afda6c">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGV4dHJlZ2lvbjplN2M0YmM2ZGUzMmU0NDEzOGUzNmZhZWVhNjI2MDNhZl8zOA_68e41c74-e59c-4a76-8bc8-f8ad6a30f3b1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80L2ZyYWc6ZTdjNGJjNmRlMzJlNDQxMzhlMzZmYWVlYTYyNjAzYWYvdGV4dHJlZ2lvbjplN2M0YmM2ZGUzMmU0NDEzOGUzNmZhZWVhNjI2MDNhZl82Nw_ae5af24a-1dfa-4139-a46c-2c150ead2c95">0001280776</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iec0275452bd148d5ac1ac3d3ab914a50_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNDU2Mg_39b56566-c533-42eb-a49d-8d8409f1a003">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_78b0eeb2-f243-4b7a-92e7-d8188a462216">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_a04b00e1-dad3-420e-abd4-51c63bcf0717">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_e9a3cedd-15f8-4c7a-8ef7-0f175db48d87">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_ebd123b0-afec-4aee-8416-c7a76f3dc937">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7e8e321395104641a2c172c323a23d47_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MzAz_cd4f286e-f982-4745-9e25-2b9dea81d824">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF84Mw_18578dea-1d06-4bbb-ad4e-1cb078575e4a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MWE4ZjM3NGQwNjhkNGRjNGJmZmQyNTkyYjM0MjgyNDQvdGFibGVyYW5nZToxYThmMzc0ZDA2OGQ0ZGM0YmZmZDI1OTJiMzQyODI0NF8wLTAtMS0xLTQwODc0_8d7c889d-9c11-4df3-b64a-78a30dc0bb08">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xMDk5NTExNjI5ODky_b0bb7e1d-6659-4427-9e13-8d495b2d155f">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6NTlmNzAxNmIyYjM4NGQwNjhkNGNjZDMxMDQ3NjJlZGMvdGFibGVyYW5nZTo1OWY3MDE2YjJiMzg0ZDA2OGQ0Y2NkMzEwNDc2MmVkY18wLTAtMS0xLTQwODc0_5d229bf7-fd88-4b4d-9fe9-454c1f8965c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8yNDA_c284f1ae-d97f-4ca1-abb4-b79c730a37c1">001-36201</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8yNDU_dc52c30b-6005-428a-8988-f99411e29a6c">Immunic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF8wLTAtMS0xLTQwODc0_da602159-55d8-4a2b-b2c8-2dbb4b85e9dc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF8wLTItMS0xLTQwODc0_9b299a27-36ba-4881-af34-35367ea70f61">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF8zLTAtMS0xLTQwODc0_e7d3f82b-1fb9-4f7b-ae1e-95475c21b17d">1200 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF80LTAtMS0xLTQwODc0_49b9f81c-1bdb-49bd-9bae-c8a9a8225262">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF81LTAtMS0xLTQwODc0_55ce6ab9-a06e-4456-be33-ec32b0c7353d">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF81LTEtMS0xLTQwODc0_e71f8d3b-8fea-4cb9-b50c-271a57cd80c6">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6YjM2ODQwOGZkZDc2NGU2OGJmMzQ4NTBkY2IwZmU0YjQvdGFibGVyYW5nZTpiMzY4NDA4ZmRkNzY0ZTY4YmYzNDg1MGRjYjBmZTRiNF81LTItMS0xLTQwODc0_d1810375-8024-4935-b04c-88bff10e6f93">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xOTYw_46573e52-538e-4e65-a061-4760419986ae">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xOTYx_18c68d2c-65c5-4f87-a714-3754a38dfa0b">255-9818</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGE5ZmYxNjBkZDJlNDVlOTgwMDIzMGY5OTk3NWJlYjIvdGFibGVyYW5nZTowYTlmZjE2MGRkMmU0NWU5ODAwMjMwZjk5OTc1YmViMl8xLTAtMS0xLTQwODc0_fb4e9e79-d0d0-4aae-8f38-457509d02f67">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGE5ZmYxNjBkZDJlNDVlOTgwMDIzMGY5OTk3NWJlYjIvdGFibGVyYW5nZTowYTlmZjE2MGRkMmU0NWU5ODAwMjMwZjk5OTc1YmViMl8xLTEtMS0xLTQwODc0_87dfe6ab-e5e4-48a7-a007-a991854522ab">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGE5ZmYxNjBkZDJlNDVlOTgwMDIzMGY5OTk3NWJlYjIvdGFibGVyYW5nZTowYTlmZjE2MGRkMmU0NWU5ODAwMjMwZjk5OTc1YmViMl8xLTItMS0xLTQwODc0_c0253517-f3ca-4d43-aa51-d6b6d22137c8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF83ODk_0719b273-7b46-435f-a560-902d6eb89acf">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xMTI2_987237a7-e591-4aa3-be33-c5d3f3a26c40">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGRkNjYwNmUzMzc1NDExYzk2ODU4ZTZjYmM1ZGMzNjYvdGFibGVyYW5nZTowZGQ2NjA2ZTMzNzU0MTFjOTY4NThlNmNiYzVkYzM2Nl8yLTAtMS0xLTQwODc0_fa1a4777-ffb2-4feb-895a-f451e54c1db5">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGRkNjYwNmUzMzc1NDExYzk2ODU4ZTZjYmM1ZGMzNjYvdGFibGVyYW5nZTowZGQ2NjA2ZTMzNzU0MTFjOTY4NThlNmNiYzVkYzM2Nl8yLTMtMS0xLTQwODc0_244d8342-7600-452d-a85b-7bfb548d70ee">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGFibGU6MGRkNjYwNmUzMzc1NDExYzk2ODU4ZTZjYmM1ZGMzNjYvdGFibGVyYW5nZTowZGQ2NjA2ZTMzNzU0MTFjOTY4NThlNmNiYzVkYzM2Nl80LTMtMS0xLTQwODc0_ed56c5c2-0a07-437c-ae78-7e8f815028b0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xODcw_fd7c006c-6bd4-46c1-8fbb-41503d22a88f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i388fe32242894fcda0ee04da0a4a7628_I20230502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xL2ZyYWc6ZDExMTU1YzA3ZTkxNDdlN2I2MmI0M2QyYWQ4NzJiOGQvdGV4dHJlZ2lvbjpkMTExNTVjMDdlOTE0N2U3YjYyYjQzZDJhZDg3MmI4ZF8xODk4_2345edd0-2116-4791-82d8-6cf8c342ec8d"
      unitRef="shares">44403838</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNC0xLTEtMS00MDg3NA_c3819a31-1c91-4b76-b7e6-29156581fb3c"
      unitRef="usd">92761000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNC0zLTEtMS00MDg3NA_8f782362-1562-4726-9604-f0ff74d875e9"
      unitRef="usd">106745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNS0xLTEtMS00MTcyOA_099f2814-86bc-42e4-be6b-ee441a5826b5"
      unitRef="usd">4351000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNS0zLTEtMS00MTcyOA_4ec60bff-b584-4046-9af5-70cbbc25ccad"
      unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNS0xLTEtMS00MDg3NA_af26ff9a-456a-48eb-b241-192d1f2b9ed5"
      unitRef="usd">9470000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNS0zLTEtMS00MDg3NA_2502fc23-a0d4-472f-ab2a-62ff5cda6c95"
      unitRef="usd">9490000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNi0xLTEtMS00MDg3NA_5fa5d027-233a-400a-a2d4-c6c741ecabd7"
      unitRef="usd">106582000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNi0zLTEtMS00MDg3NA_eccd8128-24ec-48ef-afb9-e48bdb77ff67"
      unitRef="usd">125864000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNy0xLTEtMS00MDg3NA_3558571d-a42f-4896-92d1-a797638b72ad"
      unitRef="usd">288000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfNy0zLTEtMS00MDg3NA_faacef58-b005-47f7-bffb-c6d4ac0c84a8"
      unitRef="usd">294000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfOS0xLTEtMS00MDg3NA_b59ffb80-6f51-44fa-a1f8-7cf2f190eb92"
      unitRef="usd">1959000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfOS0zLTEtMS00MDg3NA_6d06c48c-df1b-4b4a-9a15-98e5148235dc"
      unitRef="usd">1552000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTAtMS0xLTEtNDA4NzQ_e2e9ffff-7e70-4e64-8752-22f8e5ce9c3e"
      unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTAtMy0xLTEtNDA4NzQ_8652e48f-a5ca-48b0-9a4b-f8850cc3a40e"
      unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTEtMS0xLTEtNDA4NzQ_ef3e7987-ee92-4daa-ba62-cf46eee9b415"
      unitRef="usd">108872000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTEtMy0xLTEtNDA4NzQ_d4d0c1eb-79bd-45e5-bdba-516bdbe9bac6"
      unitRef="usd">127753000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTQtMS0xLTEtNDA4NzQ_ae02cf9e-2957-4c36-80e4-a0cd076115f5"
      unitRef="usd">5241000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTQtMy0xLTEtNDA4NzQ_58099939-c3d1-4a8c-935b-509efbae0a42"
      unitRef="usd">4281000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTUtMS0xLTEtNDA4NzQ_4e385b0b-a6ee-4c2f-addc-144eee1869ce"
      unitRef="usd">10183000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTUtMy0xLTEtNDA4NzQ_f4dff87f-db9c-459d-9a60-b78bc0d5b159"
      unitRef="usd">7986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTYtMS0xLTEtNDA4NzQ_679d9d6e-16a0-46c6-8340-f6732e50e7cc"
      unitRef="usd">878000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTYtMy0xLTEtNDA4NzQ_79d910c3-cccc-461b-96dd-5874e4800dde"
      unitRef="usd">810000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTctMS0xLTEtNDA4NzQ_117c648d-a440-4234-8b1b-72163e7385dd"
      unitRef="usd">16302000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTctMy0xLTEtNDA4NzQ_fddb3641-86b3-40b5-9338-391cdea5ff02"
      unitRef="usd">13077000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTktMS0xLTEtNDA4NzQ_a4a21c87-91ad-42d0-af29-9e24d5c887d1"
      unitRef="usd">1352000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMTktMy0xLTEtNDA4NzQ_50fda20b-37a4-4a5e-9ef9-4bf0aa4b8e03"
      unitRef="usd">992000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjAtMS0xLTEtNDA4NzQ_e1bbddc4-c427-4171-a980-802de356a291"
      unitRef="usd">1352000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjAtMy0xLTEtNDA4NzQ_8bbe3392-542c-436d-b42c-b726abec9c54"
      unitRef="usd">992000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjEtMS0xLTEtNDA4NzQ_e4821378-2bce-4a71-9239-39253433ed2a"
      unitRef="usd">17654000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjEtMy0xLTEtNDA4NzQ_cc458772-a295-49d1-a3f2-a84a4e040614"
      unitRef="usd">14069000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjItMS0xLTEtNDA4NzQ_dd415815-9f82-4e00-97b2-9d1ef320afdf"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjItMy0xLTEtNDA4NzQ_8f0a7361-243a-4bf1-95c2-a58af28eb612"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV8yMQ_4689f2ac-9aaf-405f-aa1e-a065da3317d8"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV8yMQ_600d209e-66f9-4d80-96b9-4c7a3acca4dd"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV8zNQ_4c681fff-b28e-4d29-ad2f-9629800cd4c4"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV8zNQ_e93a258a-d4d6-4198-9c76-6c6645c64aa7"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV81Mw_33ae33b6-244b-47c0-a82a-1a8bd2f53868"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV81Mw_bab0ed99-a0b1-4856-88dc-f53c9e30f89a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV81Mw_ca6e6e7c-3de0-44bb-a623-d09b101624db"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjpmYTA1OTY0MzBmODI0NjRjYmNmZTg3NWViNjk5OWMyYV81Mw_cb4864c7-c93e-4426-a474-d1cd8c2510ce"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMS0xLTEtNDA4NzQ_93df23dc-1cdf-4cbc-a5ae-e17e0144073c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjQtMy0xLTEtNDA4NzQ_37844a12-2ae5-44c9-8688-29e213024742"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF8xOA_54a0f569-9a48-4b22-a278-b0eb01825c75"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF8xOA_68c68434-4f4a-4a66-8853-7b6cc0915651"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF8zMg_082f5670-c550-4760-8912-68e0a7856016"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF8zMg_137e2b6e-9708-41c4-b5ca-348f107ee2eb"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF81Nw_375f3394-1b07-415b-b7cd-8bae8469fc62"
      unitRef="shares">44403838</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF81Nw_84adfa37-3261-4370-bd3c-5f6a48155ac7"
      unitRef="shares">44403838</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF82NA_9a80e0ff-05e0-4f2a-9011-20789d8e8edd"
      unitRef="shares">39307286</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMC0xLTEtNDA4NzQvdGV4dHJlZ2lvbjphNzU2YmFiNWJmMjc0MzM1OWU4ZDY4M2I4MmFiOTBmOF82NA_ad653254-2ac5-4b6f-a6eb-423d268119b5"
      unitRef="shares">39307286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMS0xLTEtNDA4NzQ_9c9cdc83-7580-4c7d-b29c-6bdce1fee60b"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjUtMy0xLTEtNDA4NzQ_e88e24d2-d42b-471a-b918-744bb2b890cb"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjYtMS0xLTEtNDA4NzQ_0be0feeb-5609-4c6b-8a5b-e0b486361f9b"
      unitRef="usd">429955000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjYtMy0xLTEtNDA4NzQ_fea22acb-5eba-4596-86e3-f43821c05fb4"
      unitRef="usd">427925000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjctMS0xLTEtNDA4NzQ_0bd4d0f5-5d9c-49d8-8550-8e3733f59b25"
      unitRef="usd">3811000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjctMy0xLTEtNDA4NzQ_6b8f2201-cc22-43a2-b5de-2d9a6c77425d"
      unitRef="usd">3035000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjgtMS0xLTEtNDA4NzQ_fe718bc9-0772-4370-ae4b-90ced30a5af4"
      unitRef="usd">-342552000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjgtMy0xLTEtNDA4NzQ_743a4d4f-a74c-42d8-acce-fb0a0ff0c15d"
      unitRef="usd">-317280000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjktMS0xLTEtNDA4NzQ_d9beaf7e-9d8c-4686-a370-22a73c3b99f1"
      unitRef="usd">91218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMjktMy0xLTEtNDA4NzQ_e3cd0138-2965-4249-a123-f7bf8c69ddf5"
      unitRef="usd">113684000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMzAtMS0xLTEtNDA4NzQ_32e45bc8-56c0-49c7-9516-54059da8fee0"
      unitRef="usd">108872000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xMy9mcmFnOmNkM2QzNzA1YjQ2NDRiZTBhM2QzNGRmMGMzMTY4MmVkL3RhYmxlOmQxZDg3YmU2M2Y3MDRiYjdhYzA3NzM4MGI2MzRkOGI4L3RhYmxlcmFuZ2U6ZDFkODdiZTYzZjcwNGJiN2FjMDc3MzgwYjYzNGQ4YjhfMzAtMy0xLTEtNDA4NzQ_7529600a-ce93-400d-8bc5-5518d8bf7d69"
      unitRef="usd">127753000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMy01LTEtMS00MDg3NA_0fa193e8-03a0-4faf-984a-5102bef21deb"
      unitRef="usd">22963000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMy03LTEtMS00MDg3NA_4e94d165-1976-4ac6-8df1-caabb3ea9941"
      unitRef="usd">17445000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNC01LTEtMS00MDg3NA_2a9c80fe-33f4-46d5-8d80-b05818ae400e"
      unitRef="usd">4288000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNC03LTEtMS00MDg3NA_5bd635fd-9e2c-473e-ae7b-8be1afadfcad"
      unitRef="usd">3990000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNi01LTEtMS00MDg3NA_4e1473e9-8872-4278-af20-20cd6cc39c8e"
      unitRef="usd">27251000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNi03LTEtMS00MDg3NA_70ec626d-6dd1-4c32-9b7a-5f4b89cd723d"
      unitRef="usd">21435000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNy01LTEtMS00MDg3NA_8ef55275-ae0c-4b95-be53-d8bb1832e806"
      unitRef="usd">-27251000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfNy03LTEtMS00MDg3NA_3e5d2d67-b53e-4045-a561-78ae04684fce"
      unitRef="usd">-21435000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfOS01LTEtMS00MDg3NA_47f854ee-9e48-4442-987f-b2229b287d0d"
      unitRef="usd">800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfOS03LTEtMS00MDg3NA_bde8d0f9-f5f8-4f54-b595-184439ec2141"
      unitRef="usd">7000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTAtNS0xLTEtNDA4NzQ_a1b97087-a62f-48ed-9159-61fc8b5a28cd"
      unitRef="usd">1179000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTAtNy0xLTEtNDA4NzQ_9218f540-7a16-4a5e-9bf0-f4fb735f24f5"
      unitRef="usd">620000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTEtNS0xLTEtNDA4NzQ_fb9a6fc7-e491-42b7-bf08-5e5f1f6d21e2"
      unitRef="usd">1979000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTEtNy0xLTEtNDA4NzQ_b7e622e3-4b60-47a2-9bdb-e5cfc89e1211"
      unitRef="usd">627000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTItNS0xLTEtNDA4NzQ_a496a62c-8d27-4527-968c-a2a980e0b52b"
      unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTItNy0xLTEtNDA4NzQ_fdea558f-73c8-410a-a04b-3dfc2f07bb1f"
      unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTQtNS0xLTEtNDA4NzQ_a62a9f8f-fb58-475f-92b1-5a85e8cf8989"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTQtNS0xLTEtNDA4NzQ_af8c8ad6-aa41-45be-9e97-1edefe2c9c12"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTQtNy0xLTEtNDA4NzQ_4e512b1a-83f2-4de9-85e9-d6a10a6cb078"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTQtNy0xLTEtNDA4NzQ_dbfe888a-37be-40d0-8a17-10a8c44e8a72"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTYtNS0xLTEtNDA4NzQ_3d13bfd9-bbce-464d-a4c0-e4ad39ad07d2"
      unitRef="shares">43664783</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTYtNS0xLTEtNDA4NzQ_cd678802-affe-4bd0-bf21-afc5b8bb8aa0"
      unitRef="shares">43664783</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTYtNy0xLTEtNDA4NzQ_90b64933-dff4-4cda-992a-afd9d6a92c25"
      unitRef="shares">28127288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xNi9mcmFnOjY4YWYxNjljY2Q3OTRiZDdhMGY3Y2I4MWJmZDQ1Mjk5L3RhYmxlOjgyMTFjOWY4ZGM2ZDQ0N2E5MmM1YjhkYmVjYzQ4NGZkL3RhYmxlcmFuZ2U6ODIxMWM5ZjhkYzZkNDQ3YTkyYzViOGRiZWNjNDg0ZmRfMTYtNy0xLTEtNDA4NzQ_a4351bb5-1106-4f44-adca-996aaf6ef607"
      unitRef="shares">28127288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfMi01LTEtMS00MDg3NA_a496a62c-8d27-4527-968c-a2a980e0b52b"
      unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfMi03LTEtMS00MDg3NA_fdea558f-73c8-410a-a04b-3dfc2f07bb1f"
      unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfNC01LTEtMS00MDg3NA_6f08a813-6b9c-429a-8293-7eab1d360ebf"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfNC03LTEtMS00MDg3NA_8e9e136c-1434-43ba-ad76-c5280072add7"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfNS01LTEtMS00MDg3NA_f388ca93-58dc-4ee4-8abc-7d2d2bf99dac"
      unitRef="usd">-24496000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8xOS9mcmFnOjk1ZjM4MDFiMDM5ZjQ4NThiMmU4OWYzZDJlMDBjZTIwL3RhYmxlOmNjMDM3ZWUwZGI1NjQwYTI4MGFmYzI4NDI1YmU4YzEwL3RhYmxlcmFuZ2U6Y2MwMzdlZTBkYjU2NDBhMjgwYWZjMjg0MjViZThjMTBfNS03LTEtMS00MDg3NA_8ac49506-9167-4c28-9a1a-2a546046ba00"
      unitRef="usd">-20866000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4155178cdc7140cea775b3cb724f22e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy0xLTEtMS00MDg3NA_f94dd559-5071-4088-ab80-6472e08ad378"
      unitRef="shares">39307286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4155178cdc7140cea775b3cb724f22e5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy0zLTEtMS00MDg3NA_9c0a0159-5c39-4df6-999e-b4a7a2d2a223"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i88a78d905402443da1f001d06d684730_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy01LTEtMS00MDg3NA_4f35a880-9d35-4c38-9171-caa0f05a7bdc"
      unitRef="usd">427925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7525d297b7a4cc7892a3e0337f40706_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy03LTEtMS00MDg3NA_a471f9ac-f1bf-4345-ac94-9aab388109e0"
      unitRef="usd">3035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ca9c2ca745541f18b5bfa39907baf2d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy05LTEtMS00MDg3NA_b2ce9c59-c2ce-41b7-b383-b0436446326e"
      unitRef="usd">-317280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfMy0xMS0xLTEtNDA4NzQ_93b88882-ce10-45ea-938f-287fdacbafa3"
      unitRef="usd">113684000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5b147340b42946ed8ca10d452b403ebd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNC05LTEtMS00MDg3NA_bd8bdf48-0676-4fc6-9d1d-a6852654a753"
      unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNC0xMS0xLTEtNDA4NzQ_aece4413-54d4-406f-a0f6-90f64fae0936"
      unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i51a8f285fcfb4ccdb68607df5a39ef94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNS01LTEtMS00MDg3NA_c3cee257-9edd-4b9c-acb6-daf945cc0466"
      unitRef="usd">1979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNS0xMS0xLTEtNDA4NzQ_deb251d0-0d69-4180-b14f-375469477514"
      unitRef="usd">1979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i37e69ee3daf843cfb2cc88838d672346_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNi03LTEtMS00MDg3NA_dedc8d17-a7c1-4f0d-8100-aa927070e252"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNi0xMS0xLTEtNDA4NzQ_ee4252d2-0983-40b4-a6de-fd463807e629"
      unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i070ed8b98474469aaa446823ba89a721_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNy0xLTEtMS00MDg3NA_6b2a22af-8498-4c89-a5b2-9dae90991118"
      unitRef="shares">5096552</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i51a8f285fcfb4ccdb68607df5a39ef94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNy01LTEtMS00MDg3NA_a347426e-c461-41a8-b850-2f045719f756"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfNy0xMS0xLTEtNDA4NzQ_60172a6c-561d-44fb-832a-71f9f3d9004c"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaf37e7e42a624bb69e55ab937f3c9269_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS0xLTEtMS00MDg3NA_e2e29fc4-0932-40da-9008-842436a5e3ad"
      unitRef="shares">44403838</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaf37e7e42a624bb69e55ab937f3c9269_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS0zLTEtMS00MDg3NA_f237eb99-2e63-4147-8930-4e917546a47f"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ba80912a12245ab9ea6a2e70d9fcaab_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS01LTEtMS00MDg3NA_5fb015f1-cfd5-40fe-967c-93750155e8b4"
      unitRef="usd">429955000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6dad41e267c41f9a02c026710ea4d78_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS03LTEtMS00MDg3NA_c6c0de54-4d46-415c-a64e-952f4e859dd8"
      unitRef="usd">3811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1de0f235b8444c6af6405b255d75604_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS05LTEtMS00MDg3NA_3e7fe657-66db-4bdc-acf6-75290e59a873"
      unitRef="usd">-342552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjZiYThjZDMwNTIyMjQ3NjY5OGMzZWYwZjUwYjZjN2JjL3RhYmxlcmFuZ2U6NmJhOGNkMzA1MjIyNDc2Njk4YzNlZjBmNTBiNmM3YmNfOS0xMS0xLTEtNDA4NzQ_c36de0fd-cf55-4413-b907-900e60e47d7d"
      unitRef="usd">91218000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4656bcc3b5664116bbc2110cb69413a6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy0xLTEtMS00MDg3NA_b26b108a-c47d-4a2b-99c6-de1510c749c6"
      unitRef="shares">26335418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4656bcc3b5664116bbc2110cb69413a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy0zLTEtMS00MDg3NA_ec19ba92-d178-433c-9621-e050340fed8f"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1cee35bd9f1448618979791eff9cb402_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy01LTEtMS00MDg3NA_f523296c-1ef6-4304-a159-39c60647e15b"
      unitRef="usd">324237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i80d5e7c542364e6b91f404a68cce14b0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy03LTEtMS00MDg3NA_2c8ad3b9-a558-4047-b972-5ff2b8b8d837"
      unitRef="usd">-252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5c1dfb8586a4e62b290f57d6b21e26a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy05LTEtMS00MDg3NA_af13c68f-b635-43f1-8545-38df83f33d44"
      unitRef="usd">-196873000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25dc5ed916e5432d902a28c2209cb1cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfMy0xMS0xLTEtNDA4NzQ_230e2361-6293-41b9-b6de-ed60835261dd"
      unitRef="usd">127115000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib9bda424319e448ea9036287dc26278f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNC05LTEtMS00MDg3NA_0a09f92a-84ce-4467-a59c-00b7729ede43"
      unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNC0xMS0xLTEtNDA4NzQ_6c2858fa-4e37-4caa-b70d-5d8f278222b4"
      unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8d6bb7eeb17b42b6b560d2d0c4e347ca_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNS01LTEtMS00MDg3NA_44895851-8a0a-45eb-ba9d-d9fa34f04349"
      unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNS0xMS0xLTEtNDA4NzQ_786de5bf-b315-4abf-b82f-b0050cabaf23"
      unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4fe801d7b5694d349caf6bc6c0349f78_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNi03LTEtMS00MDg3NA_3e20f13d-4d15-4f7f-9f7b-d44202650d4a"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNi0xMS0xLTEtNDA4NzQ_7a4c3e1f-2a68-497a-b6b2-8328b637c047"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ief4990a110a04802be1e5c3f245e10cf_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNy0xLTEtMS00MDg3NA_36b7936e-e7c1-44df-b2ae-aa28250cb88d"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8d6bb7eeb17b42b6b560d2d0c4e347ca_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNy01LTEtMS00MDg3NA_d0868181-638e-4e7f-84d6-6815492086f1"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfNy0xMS0xLTEtNDA4NzQ_98f4f66f-0724-4b9c-aa90-d21fbc1d3323"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i8b791530e898489c8c22614be6c3f978_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0wLTEtMS00MTg1My90ZXh0cmVnaW9uOjZkM2E2MzdhOWM3ZTRhNjE4ZjdkZWU3ZWY5ZDNjOTQ1XzU0OTc1NTgxMzk4Mg_e9482a98-56cc-4df2-ad6d-977a1c2fb238"
      unitRef="usd">918000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ief4990a110a04802be1e5c3f245e10cf_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0xLTEtMS00MTg1Mw_726565c9-9547-4d97-8f57-61f60d2d92c9"
      unitRef="shares">2904113</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8d6bb7eeb17b42b6b560d2d0c4e347ca_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC01LTEtMS00MTg1Mw_f5335747-754a-4849-97f0-3a533878bda2"
      unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0xMS0xLTEtNDE4NTM_2bd1bb7c-b31f-4118-9de9-58499c9dcf9a"
      unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1e51941010cc4d6998cdc6318cacc80e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0xLTEtMS00MDg3NA_2ccee734-f1a7-4a9c-ae14-06c7b02d0310"
      unitRef="shares">29240383</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1e51941010cc4d6998cdc6318cacc80e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0zLTEtMS00MDg3NA_4c34140d-5441-4f01-8f8f-380f0fef6bf1"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0b6c17ec488454d8d2239bc02df935c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC01LTEtMS00MDg3NA_dbe15817-e954-40b7-8124-182db75edc1c"
      unitRef="usd">355949000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67dc7d2117dd4e95a74b60a330d24d53_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC03LTEtMS00MDg3NA_6b93f686-2998-4dee-beb2-e90ebfbc6d5b"
      unitRef="usd">-310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i691582ba1b7640458a1c80bf290a4a95_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC05LTEtMS00MDg3NA_755f8441-8c31-4a6b-a1d4-95441567f383"
      unitRef="usd">-217681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i971971525ba148019837a545259b6684_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yMi9mcmFnOjg5OGZkYWQ1OGJiZTQ3NzJiYTYxMDZlZDllYzIwMTJlL3RhYmxlOjUwYzFkYzMwYzhmZTRhYjA5ZmQyYjg1ODk0OTRiZTdjL3RhYmxlcmFuZ2U6NTBjMWRjMzBjOGZlNGFiMDlmZDJiODU4OTQ5NGJlN2NfOC0xMS0xLTEtNDA4NzQ_4816bbf2-8ad7-4bbf-9751-c9aa23e2ed4f"
      unitRef="usd">137961000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMy0xLTEtMS00MDg3NA_bc3d1e90-3f9c-4aca-a010-07a014f4fc03"
      unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMy0zLTEtMS00MDg3NA_62d7e6a1-2a22-49af-8451-736f5725eb94"
      unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfNS0xLTEtMS00MDg3NA_d6a13b9f-1a4e-4e52-9ec6-6650ab9d6d86"
      unitRef="usd">32000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfNS0zLTEtMS00MDg3NA_3bceba05-f1b0-440f-8a4d-ed06f6aff678"
      unitRef="usd">21000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfNi0xLTEtMS00MDg3NA_f3a8a6d1-38d2-4772-836d-ff4f3aed11e4"
      unitRef="usd">-516000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfNi0zLTEtMS00MDg3NA_0e34699b-c960-49e4-9a54-44d4f5d8b4fb"
      unitRef="usd">-149000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfOC0xLTEtMS00MDg3NA_a875b342-5671-436b-91c9-dc2b0076e508"
      unitRef="usd">1979000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfOC0zLTEtMS00MDg3NA_2f7a3ef1-943d-424e-9a78-f4349771f21e"
      unitRef="usd">2069000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTEtMS0xLTEtNDA4NzQ_f7bf1a86-fbb3-4097-987b-fdc544279933"
      unitRef="usd">-123000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTEtMy0xLTEtNDA4NzQ_b391019c-542a-489a-8822-919d166f3733"
      unitRef="usd">2267000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTItMS0xLTEtNDA4NzQ_9c542d81-4fbf-4e09-bc43-475c4ef15d61"
      unitRef="usd">986000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTItMy0xLTEtNDA4NzQ_7d969e99-e007-4c3d-a393-ef53dc30ad4c"
      unitRef="usd">-350000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTMtMS0xLTEtNDA4NzQ_dd073c42-0765-434b-b595-9a2fd434f89d"
      unitRef="usd">2072000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTMtMy0xLTEtNDA4NzQ_15edeea6-e8a5-40ff-91d6-366e8d952000"
      unitRef="usd">558000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTQtMS0xLTEtNDA4NzQ_1e5be543-3acd-4d71-975c-fc47746480b9"
      unitRef="usd">51000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTQtMy0xLTEtNDA4NzQ_c01563fb-cda5-49b7-ab4b-fd33f27ebb57"
      unitRef="usd">-53000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTUtMS0xLTEtNDA4NzQ_ea9cfa26-867a-4be4-b249-a04fa4689784"
      unitRef="usd">-19513000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMTUtMy0xLTEtNDA4NzQ_906e7b59-96ce-44ab-a4a6-77acae6d26fa"
      unitRef="usd">-20681000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjAtMS0xLTEtNDUxMDc_61db040f-e8e9-4623-a54c-4812fca48cb4"
      unitRef="usd">5439000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjAtMy0xLTEtNDUxMTI_4c080a72-fc86-4f04-9929-13468ee3bf56"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjAtMS0xLTEtNDA4NzQ_a0b20a55-1451-4524-aaba-e24a3ea9e2a8"
      unitRef="usd">104000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjAtMy0xLTEtNDA4NzQ_7f307204-ae46-4928-94f1-6fcd01d0ac4d"
      unitRef="usd">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjItMS0xLTEtNDA4NzQ_bb60b431-d849-4d53-965d-fc7fa20a0532"
      unitRef="usd">5335000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjItMy0xLTEtNDA4NzQ_cf7dc61c-b439-4aa5-8899-f76daa890a74"
      unitRef="usd">-12000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjUtMS0xLTEtNDA4NzQ_ecf73b28-0865-4394-8e4a-fb39ddba00f6"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjUtMy0xLTEtNDA4NzQ_21f0739e-2f9c-435e-9df2-1d93fdc2ca37"
      unitRef="usd">29638000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjctMS0xLTEtNDUxNDM_c3d1ef31-1793-48e5-a670-ca579ab215b8"
      unitRef="usd">51000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjctMy0xLTEtNDUxNDc_256a6e34-2e13-4e0a-bfa5-8a81d6888e64"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjYtMS0xLTEtNDA4NzQ_d24796ce-5253-4d73-97af-6f3a6420a7ec"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjYtMy0xLTEtNDA4NzQ_59eaf773-4e52-42ab-a290-e72574fe2ef5"
      unitRef="usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjgtMS0xLTEtNDA4NzQ_11ebe760-6b18-4585-9a2d-201887fe7683"
      unitRef="usd">51000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjgtMy0xLTEtNDA4NzQ_a46b3805-df27-4d3b-b6f1-8fd9743f93a5"
      unitRef="usd">29643000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjktMS0xLTEtNDA4NzQ_b21ea866-8cb2-4ddc-9e86-064857cdb2e6"
      unitRef="usd">143000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMjktMy0xLTEtNDA4NzQ_ba45ab18-4696-4bb0-89d6-2f0323b1e552"
      unitRef="usd">-103000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzAtMS0xLTEtNDA4NzQ_aa64d8f2-0bd8-4842-ae1a-f545e3e0e3a6"
      unitRef="usd">-13984000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzAtMy0xLTEtNDA4NzQ_a4159d37-dfb3-468f-9a7d-3b7602b0092d"
      unitRef="usd">8847000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzEtMS0xLTEtNDA4NzQ_2e6453fd-d2c0-4d50-9b14-4e098f0ae7cd"
      unitRef="usd">106745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i25dc5ed916e5432d902a28c2209cb1cb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzEtMy0xLTEtNDA4NzQ_2d37598c-e0ce-4238-bafe-af6b38bbb465"
      unitRef="usd">86863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzItMS0xLTEtNDA4NzQ_e014acb0-c78c-4afd-b9ca-5995cbb32d4f"
      unitRef="usd">92761000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i971971525ba148019837a545259b6684_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzItMy0xLTEtNDA4NzQ_3995e74a-e4bf-4c0b-a9ba-d080a4ab20fc"
      unitRef="usd">95710000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzgtMS0xLTEtNDA4NzQ_f2f6c77f-122c-4869-8c9f-3d571ca2da5f"
      unitRef="usd">544000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8yOC9mcmFnOjgxZjVjM2FlYWUzMTRiYTU5ZWJiMmU2MWY5M2EwZmIwL3RhYmxlOmMzMGYxMzViYTE2OTQ4YmZhYTdkNzAzZTRjMzI4ZDA5L3RhYmxlcmFuZ2U6YzMwZjEzNWJhMTY5NDhiZmFhN2Q3MDNlNGMzMjhkMDlfMzgtMy0xLTEtNDA4NzQ_dabc6f54-edf7-4c64-9668-c5ffbbfec9fa"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTY2MQ_461a6074-2f61-4c23-b770-9fb6cea75bba">Description of Business and Basis of Financial Statements&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#xe4;felfing near Munich, Germany. The Company currently has approximately 73 employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#x201c;MS&#x201d;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis (&#x201c;UC&#x201d;); and the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#x2019;s disease or irritable bowel syndrome with diarrhea.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $342.6 million as of March 31, 2023 and $317.3 million as of December 31, 2022.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through March 31, 2023, Immunic has raised net cash of approximately $355.6 million from private and public offerings of preferred and common stock. As of March 31, 2023, the Company had cash and cash equivalents of approximately $92.8 million and investments - other of $4.4 million.  With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial &lt;/span&gt;&lt;/div&gt;statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfMTY0OTI2NzQ2MDA0OQ_ca5f8040-1441-42e1-9500-6cec6827011d"
      unitRef="employee">73</dei:EntityNumberOfEmployees>
    <vtl:NumberOfDevelopmentPrograms
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTQ5NzU1ODIyOTEz_c2cb3399-77f5-4a51-be61-ab8d2285788e"
      unitRef="lease">3</vtl:NumberOfDevelopmentPrograms>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfMjIwOQ_2f60970d-1391-4efe-892a-303485ec6db8"
      unitRef="usd">-342600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfMjIzNw_21e31704-16f0-455e-a0de-90e0d7b670e3"
      unitRef="usd">-317300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i1c1ce43c473547e99f3821322556a079_D20140417-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTQ5NzU1ODMyMjc4_4641a744-9ada-4293-940e-31b6f4e263a4"
      unitRef="usd">355600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfMzE1OA_940b8e57-4568-4ed7-b1ca-0389aadde451"
      unitRef="usd">92800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherShortTermInvestments
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTQ5NzU1ODI0MTg2_67c3e77b-32a9-450c-86ab-c9c9241cdd9a"
      unitRef="usd">4400000</us-gaap:OtherShortTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNC9mcmFnOmRjOGM0ZjZmMjdjYzRlNjdhMzJiOTExZjJkMjI4NGM4L3RleHRyZWdpb246ZGM4YzRmNmYyN2NjNGU2N2EzMmI5MTFmMmQyMjg0YzhfNTY2NQ_bc582966-16a7-49f4-a240-388c14d6b3c6">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial &lt;/span&gt;&lt;/div&gt;statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODM_99beb41c-8a78-4a25-a80b-43aab7a0896d">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments- other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S of approximately $69.2&#160;million, Germany of approximately $27.5&#160;million and Australia of approximately $0.4&#160;million as of March 31, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of 4.7%. Cash and cash equivalents in Germany are earning interest at a rate of 1.5% to 2.75%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments - other consists of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.87% and matured in January and April, 2023, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNDU2Mg_39b56566-c533-42eb-a49d-8d8409f1a003"&gt;three&lt;/span&gt; to thirteen years. Depreciation expense was $32,000 and $21,000 for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC, PMS and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to one million Euros per year.  We recognized $1.8&#160;million and $0.7&#160;million of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_78b0eeb2-f243-4b7a-92e7-d8188a462216"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_a04b00e1-dad3-420e-abd4-51c63bcf0717"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODA_927cfbeb-db68-4baf-8125-2163e9823869">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5NzM_615e8eb1-fcfb-4986-91c3-eede5976f505">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA1Mw_d201b127-545c-40b1-9853-ad4a9a4e478a">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments- other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments-other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S of approximately $69.2&#160;million, Germany of approximately $27.5&#160;million and Australia of approximately $0.4&#160;million as of March 31, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of 4.7%. Cash and cash equivalents in Germany are earning interest at a rate of 1.5% to 2.75%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments - other consists of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The time deposit accounts are held in our bank in Germany and are held in Euros and are earning interest at a rate of 0.87% and matured in January and April, 2023, respectively.</vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib8c1a45128834deeb7c989373a0d3a57_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA1NQ_7cdfbc18-1fe2-48da-847b-aaf3dad96267"
      unitRef="usd">69200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i170f226050a64272899ebe618949d15c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA3MA_d8f3961d-bad6-4b9b-b377-4c19592fd34d"
      unitRef="usd">27500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i97e9633735014256ae003a713d8ab86d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA4NQ_10834f4a-f73d-4a71-a1af-f947e4977c9c"
      unitRef="usd">400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <vtl:NumberOfFinancialInstitutionsUsedForCashDeposits
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODM3NTA2_98dd0bac-5291-4d17-99c6-c55391ead651"
      unitRef="financialinstitution">2</vtl:NumberOfFinancialInstitutionsUsedForCashDeposits>
    <us-gaap:InvestmentInterestRate
      contextRef="i00dbb5ea0444479bb49ade8df06bec2a_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA0OQ_1f1c1e7e-2e19-4dd6-9dc5-70bc2a6d1b52"
      unitRef="number">0.047</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate
      contextRef="i883c7dc6250c4a088e84c151079c3725_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA1NQ_65521475-efeb-4918-8eda-93550b4b4120"
      unitRef="number">0.015</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate
      contextRef="iea3055f090434c34a36eb882151b2a4b_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA2MQ_24b03c08-174c-4d3a-b313-6dd2605987d1"
      unitRef="number">0.0275</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentTableTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzA5OA_54b61336-3b39-4367-80b8-3d3a804d83e1">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments - other consists of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentTableTextBlock>
    <us-gaap:OtherShortTermInvestments
      contextRef="i68a332d0cac3410a9bf57d9923328244_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmM5YWUyMDUzOTcyMjRjYzk5NjcwZjE1MGMwYmYzMWE4L3RhYmxlcmFuZ2U6YzlhZTIwNTM5NzIyNGNjOTk2NzBmMTUwYzBiZjMxYThfMS0yLTEtMS00MTk5Ng_87271994-4346-4389-ba5e-27e254911a77"
      unitRef="usd">4351000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="i3c7e38a236f14a20b7ca1838765c36ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmM5YWUyMDUzOTcyMjRjYzk5NjcwZjE1MGMwYmYzMWE4L3RhYmxlcmFuZ2U6YzlhZTIwNTM5NzIyNGNjOTk2NzBmMTUwYzBiZjMxYThfMS00LTEtMS00MTk5Ng_97d8dc39-db42-46db-a4ad-1db87a335a24"
      unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmM5YWUyMDUzOTcyMjRjYzk5NjcwZjE1MGMwYmYzMWE4L3RhYmxlcmFuZ2U6YzlhZTIwNTM5NzIyNGNjOTk2NzBmMTUwYzBiZjMxYThfMi0yLTEtMS00MTk5Ng_12ef7e11-429d-4cd4-bec6-fd6e6e59a8b7"
      unitRef="usd">4351000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmM5YWUyMDUzOTcyMjRjYzk5NjcwZjE1MGMwYmYzMWE4L3RhYmxlcmFuZ2U6YzlhZTIwNTM5NzIyNGNjOTk2NzBmMTUwYzBiZjMxYThfMi00LTEtMS00MTk5Ng_3fa2ff6f-17b6-4453-b1cd-a7c7bf35f027"
      unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:InvestmentInterestRate
      contextRef="i1a7d9669b6d842baa047cfedec92e62b_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODM3OTg2_164b7d32-45be-42b7-bd07-a5ce0f5a4e09"
      unitRef="number">0.0087</us-gaap:InvestmentInterestRate>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODQ_fc6c1e72-9a75-4f09-b56d-49a6f3f108b7">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5NzU_dd955382-940c-457f-9123-7b5006b097dd">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNDU2Mg_39b56566-c533-42eb-a49d-8d8409f1a003"&gt;three&lt;/span&gt; to thirteen years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i98492f22019748cd8f198e6e858d4908_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNDU2OA_c02ef43e-8865-48dc-be50-6c62ff4ec071">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODY1NzM0_904fd63e-c777-4c33-ae1a-6f76a47657a0"
      unitRef="usd">32000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODY1NzM4_f614c30d-13ac-4449-96a2-ee2124d0b3a6"
      unitRef="usd">21000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODE_a1b8b08a-409b-4aab-a086-7528486ea9b1">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTAxOA_64f24589-b419-4466-8533-9a1a6c122c59"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTAxOA_b0d1bd02-f33e-4e24-a687-e1fbae86227c"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTA5OTUxMTY4NTE0MA_7d3567dd-df57-4343-9665-2c3e78fe1492">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ieede7680228b4ced8b38713bf5d0aae3_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODcwOTA4_541e5668-9428-4e02-9d02-fd75faa8a608"
      unitRef="usd">33000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5OTA_52fdd616-6a15-454b-8e7f-0ef53850f643">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC, PMS and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODU_475726bb-262e-4e1d-af9b-7d07c38e9cbb">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the US Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzEwMg_aaaf1543-4cec-488c-b242-37a9bf2cf70b">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to one million Euros per year.  We recognized $1.8&#160;million and $0.7&#160;million of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_78b0eeb2-f243-4b7a-92e7-d8188a462216"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyOTE4_a04b00e1-dad3-420e-abd4-51c63bcf0717"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <vtl:GovernmentAssistanceRate
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODUyODA5_0fb0717a-5adb-40ff-bfd0-14f4ea559fd4"
      unitRef="number">0.435</vtl:GovernmentAssistanceRate>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA2OA_02a33004-ad18-47ae-810a-9e720331b009"
      unitRef="usd">1800000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5NDA4Mg_eaab70bd-509d-4449-b8fd-4e7371953c3c"
      unitRef="usd">700000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODY_7195f43e-d854-4507-9d7d-e8f446cd79aa">&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5NzY_7311d728-e3c9-43a5-b48a-a32de846b27c">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODI_2dfea6e1-e25a-4e62-934e-c9e09b1c9771">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id1bab50058db432a95481b3b7f2efba9_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODU4ODQ0_951e854a-c3e5-4b0b-b380-3417754ee19b">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ic8ab2a7b7c1b48578feac81bbc5e3e28_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfNTQ5NzU1ODU4ODU4_1979db7a-d73c-4199-bc2f-e70e86093b75">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzEwMw_3361e7fd-49e2-42ad-b9b1-b5ea4bc3b45e"
      unitRef="lease">3</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODc_85ec4fab-1007-437d-a7be-60164c032dc6">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5OTI_4c5684c5-4f11-4378-99df-d3339e845702">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzEwNQ_a2c835ff-e1ba-488b-b734-15b8476adeb9">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i1b55fff4633243a0adf3497ef994823d_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTY0OTI2NzQ5MzEwNw_4c961808-9ba6-4e0f-a6eb-0642fa6014ca"
      unitRef="shares">5096552</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5Nzc_84a9175d-5ccd-4cea-a353-18fc140a5f77">Net Loss Per ShareBasic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5Nzg_f7f811a9-e597-4036-ab20-55893195ad0f">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibbacc1604fd34d488c15218cae45490d_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmRmZGJhZmI2NzJjNTRiMTM4MDJlYzhmYzI3NTFlMGUyL3RhYmxlcmFuZ2U6ZGZkYmFmYjY3MmM1NGIxMzgwMmVjOGZjMjc1MWUwZTJfMi0xLTEtMS00MDg3NA_ca5e3a8d-954d-451e-a979-27a73f8fb673"
      unitRef="shares">5595841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec03675d217d4626a6ad2990f79e3eb7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RhYmxlOmRmZGJhZmI2NzJjNTRiMTM4MDJlYzhmYzI3NTFlMGUyL3RhYmxlcmFuZ2U6ZGZkYmFmYjY3MmM1NGIxMzgwMmVjOGZjMjc1MWUwZTJfMi0zLTEtMS00MDg3NA_f6929ee2-c334-4ca9-b810-cd6660e6ef03"
      unitRef="shares">3423482</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV8zNy9mcmFnOjIxMDZhMGJjM2E2OTQ4Zjk4ZTA5ZjE0YWY4YTlhYzQ3L3RleHRyZWdpb246MjEwNmEwYmMzYTY5NDhmOThlMDlmMTRhZjhhOWFjNDdfMTc5ODg_773c22be-44a1-474f-ac9f-464eb37624cf">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RleHRyZWdpb246OTY0YjBmZWRjOWM1NGJkZjhmZTc0ZmMyYTc4OTM1YWZfMzU1_21c596ff-0958-4afe-9c2c-d638429e2fff">Balance Sheet Details&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Assets and Prepaid Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expense consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_e9a3cedd-15f8-4c7a-8ef7-0f175db48d87"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_ebd123b0-afec-4aee-8416-c7a76f3dc937"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RleHRyZWdpb246OTY0YjBmZWRjOWM1NGJkZjhmZTc0ZmMyYTc4OTM1YWZfMzUz_9d4d6ea4-4987-4ecc-9e75-9e1c2f64c24a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expense consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfMi0xLTEtMS00MDg3NA_5b73cfb1-4286-493c-8c87-08f40add691a"
      unitRef="usd">3902000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfMi0zLTEtMS00MDg3NA_f20bb3f9-bbc6-4efd-8faf-9bc94d69c5f1"
      unitRef="usd">5608000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfMy0xLTEtMS00MDg3NA_2f5e6026-1849-4c28-a8ff-90cb11d7b6a8"
      unitRef="usd">843000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfMy0zLTEtMS00MDg3NA_c73282ff-be90-495a-b01b-6cd1ffbd931e"
      unitRef="usd">296000</us-gaap:ValueAddedTaxReceivableCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNC0xLTEtMS00MDg3NA_653b2918-aab8-4c59-a462-4d382773d9ff"
      unitRef="usd">2823000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNC0zLTEtMS00MDg3NA_8f11643a-4a97-41e8-9ba4-33d63eeb53cd"
      unitRef="usd">2361000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNS0xLTEtMS00MDg3NA_6d16ae1e-dd14-4ec6-80c1-496fa30af509"
      unitRef="usd">1902000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNS0zLTEtMS00MDg3NA_10ff75a2-7f96-4833-aadd-895c00d082e1"
      unitRef="usd">1225000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNi0xLTEtMS00MDg3NA_9c978448-8135-4f42-ace6-a564f8d94410"
      unitRef="usd">9470000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmNiZTIwOGMxYjYyYTQ5ZGI5NmU0YmY2NjAzN2ZhNDk0L3RhYmxlcmFuZ2U6Y2JlMjA4YzFiNjJhNDlkYjk2ZTRiZjY2MDM3ZmE0OTRfNi0zLTEtMS00MDg3NA_ee690171-012a-4249-98a1-0c5b3c8afb0e"
      unitRef="usd">9490000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RleHRyZWdpb246OTY0YjBmZWRjOWM1NGJkZjhmZTc0ZmMyYTc4OTM1YWZfMzU5_9efec160-d3c4-49c3-a3e3-c75e7eb64d7b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <vtl:ClinicalCostsPayableCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfMi0xLTEtMS00MDg3NA_ea67449f-de04-4469-8f83-a1d545e9155f"
      unitRef="usd">4919000</vtl:ClinicalCostsPayableCurrent>
    <vtl:ClinicalCostsPayableCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfMi0zLTEtMS00MDg3NA_d4aad6c0-58c7-4191-9f48-0dd6ca3c3262"
      unitRef="usd">3749000</vtl:ClinicalCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfMy0xLTEtMS00MDg3NA_04a8c908-f84d-4130-894c-a2f60ded64ca"
      unitRef="usd">54000</vtl:LegalAndAuditCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfMy0zLTEtMS00MDg3NA_e4c2505d-a746-40d3-b663-b7c436244e51"
      unitRef="usd">288000</vtl:LegalAndAuditCostsPayableCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfNS0xLTEtMS00MDg3NA_537c8b35-0f2e-4fac-8a42-a65570167973"
      unitRef="usd">268000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfNS0zLTEtMS00MDg3NA_4ab6546c-cbe8-442a-ae13-b8c6a44d28ae"
      unitRef="usd">244000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfNi0xLTEtMS00MDg3NA_29301c11-31a8-42ee-9af1-889c483abe7c"
      unitRef="usd">5241000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOjAwMzg1NmFkMTM4YzQxZjdiYjkzZjRiMzFmYzQ2ZTliL3RhYmxlcmFuZ2U6MDAzODU2YWQxMzhjNDFmN2JiOTNmNGIzMWZjNDZlOWJfNi0zLTEtMS00MDg3NA_12401a96-9e33-45e5-9c23-c6483f3351d6"
      unitRef="usd">4281000</us-gaap:AccountsPayableCurrent>
    <vtl:AccruedClinicalCostsCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfMi0xLTEtMS00MDg3NA_33d2de0f-e825-4100-a946-35707a03eade"
      unitRef="usd">9628000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedClinicalCostsCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfMi0zLTEtMS00MDg3NA_75c88c03-dbe3-42cc-b004-621de32c9d6c"
      unitRef="usd">6807000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfMy0xLTEtMS00MDg3NA_67bc33bc-90c5-4704-8080-1c254ca8c1bd"
      unitRef="usd">137000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfMy0zLTEtMS00MDg3NA_4893d1da-6939-4481-aa15-564d26a67623"
      unitRef="usd">169000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedCompensationCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNC0xLTEtMS00MDg3NA_36b9384d-778d-4440-9751-438a4047895a"
      unitRef="usd">336000</vtl:AccruedCompensationCurrent>
    <vtl:AccruedCompensationCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNC0zLTEtMS00MDg3NA_3ab36cde-f16b-48ab-b602-51f2beb97a5a"
      unitRef="usd">890000</vtl:AccruedCompensationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNS0xLTEtMS00MDg3NA_6353a546-950d-4021-8f33-d082f62d1e36"
      unitRef="usd">82000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNS0zLTEtMS00MDg3NA_724c66e1-c47d-420b-91d4-7f854c8d3b0a"
      unitRef="usd">120000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNi0xLTEtMS00MDg3NA_54de8acd-ef77-400b-ba80-efdf3ab86183"
      unitRef="usd">10183000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmM4NTAyZmYxM2UxZDQzNmNhOTI4NGFjMDczNzY2NjgxL3RhYmxlcmFuZ2U6Yzg1MDJmZjEzZTFkNDM2Y2E5Mjg0YWMwNzM3NjY2ODFfNi0zLTEtMS00MDg3NA_ac991eef-dd8d-4e16-b657-846dc9755718"
      unitRef="usd">7986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RleHRyZWdpb246OTY0YjBmZWRjOWM1NGJkZjhmZTc0ZmMyYTc4OTM1YWZfMzU3_9334ac4b-075e-4740-bf41-fc93ae467abd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_e9a3cedd-15f8-4c7a-8ef7-0f175db48d87"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0wLTEtMS00MDg3NA_ebd123b0-afec-4aee-8416-c7a76f3dc937"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0xLTEtMS00MDg3NA_45f1e059-31f1-4fff-929c-5e97e859c132"
      unitRef="usd">649000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMi0zLTEtMS00MDg3NA_a9437c7f-2ff7-4678-b070-e07ff5d09972"
      unitRef="usd">571000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMy0xLTEtMS00MDg3NA_47bcd048-ce22-4fe8-a4c1-10189357cad7"
      unitRef="usd">229000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfMy0zLTEtMS00MDg3NA_a8ca203f-29bf-470d-b142-a84bb8c5dbc3"
      unitRef="usd">239000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfNC0xLTEtMS00MDg3NA_6736ab46-6d2f-45ed-973a-2aec7acff7d9"
      unitRef="usd">878000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9320051a944145d6816da95e5465e3c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80MC9mcmFnOjk2NGIwZmVkYzljNTRiZGY4ZmU3NGZjMmE3ODkzNWFmL3RhYmxlOmUzZjFhMjY3OTQ1ZjQyZTBiMjliMmM3Y2ZmNjA5NTI3L3RhYmxlcmFuZ2U6ZTNmMWEyNjc5NDVmNDJlMGIyOWIyYzdjZmY2MDk1MjdfNC0zLTEtMS00MDg3NA_0772b66a-4c44-48e4-80f8-cb9a39e2bb15"
      unitRef="usd">810000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfNTMxNw_3996461c-d7b7-4440-bdbd-a135452d88f9">Commitments and ContingenciesOperating Lease&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#xe4;felfing, Germany office and November 30,  2028 related to the new lease of a research laboratory in Planegg, Germany.  The Company formerly leased office space in Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025.  The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a five year lease for its facility in Gr&#xe4;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#xe4;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions of $544,000 related to the addition of new laboratory space in Planegg, Germany in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Immunic&#x2019;s operating lease costs and variable lease costs were $195,000 and $130,000 for the three months ended March 31, 2023 and 2022, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of March 31, 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, the Company has non-cancelable contractual obligations under certain agreements related to its development programs vidofludimus calcium, IMU-935 and IMU-856 totaling approximately $4.4&#160;million, all of which is expected to be paid in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daiichi Sankyo Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i89ddf70d08824b6aa7e7f010c23a3377_I20200407"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1MzUyOA_f7f5caa3-b9b8-448f-b307-bd187b6d4923">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod
      contextRef="i20527b0f049e4fc49cf34f6e19f78f53_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1MzUyOQ_d08de07a-6248-4608-95db-15cba37c8b63">P6M</vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod>
    <vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTA5OTUxMTY0MDk3Ng_b3bac2be-9d4e-4f7a-aa86-4c78a362650e">P3M</vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i805e70466a81410da29a22178dd65ce1_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTA5OTUxMTY0MDYyNA_008a7662-3c70-4d4d-bb1e-55d5d7f64b83">P27M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i9a80cba888e746d6bd629ae229623ef3_D20230201-20230228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1NDQzMg_92cca5e7-c726-4166-b315-d2fddca3e47a"
      unitRef="usd">544000</vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <vtl:OperatingLeaseIncrementalBorrowingRate
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfNTQ5NzU1ODIzMjc4_b9feda2f-05b7-430c-a0ad-9f425f10c85f"
      unitRef="number">0.06</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingLeaseIncrementalBorrowingRate
      contextRef="i805e70466a81410da29a22178dd65ce1_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfNTQ5NzU1ODIzMzEw_edc4bd6b-9161-4543-90dd-d84df0aa7708"
      unitRef="number">0.08</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1NDQ0Mg_69e106df-dfb8-4deb-a70e-2e6653fcba1b"
      unitRef="usd">195000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="ifac372e93e304225887151b04d10d097_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1NDQ1Mg_9de7b730-f787-4202-82b4-a95c4b103ffe"
      unitRef="usd">130000</vtl:OperatingAndVariableLeasesCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfNTMyMA_b2d3fee4-dc50-4b1f-a209-b44823bdcc20">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of March 31, 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfMC0yLTEtMS00MDg3NA_2284e582-bd39-4caa-afdf-c7f0b361e2bb"
      unitRef="usd">506000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfMS0yLTEtMS00MDg3NA_0ef7b832-8766-4e27-8701-e2aac33f3e78"
      unitRef="usd">820000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfMi0yLTEtMS00MDg3NA_be00dff1-8e65-45f7-a7e5-3d7d9bbee7c5"
      unitRef="usd">495000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfMy0yLTEtMS00MDg3NA_5a143bb6-b019-4aba-a2f1-e2bda5bcbc17"
      unitRef="usd">140000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfNC0yLTEtMS00MDg3NA_6ebe1655-26be-4581-bb25-40c8b0675085"
      unitRef="usd">144000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <vtl:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfNS0yLTEtMS00MDg3NA_10c970d1-c946-4e7d-86cd-c88e72919eb4"
      unitRef="usd">136000</vtl:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfNi0yLTEtMS00MDg3NA_a5fe08ab-3116-40a8-bfe7-05b437127af4"
      unitRef="usd">2241000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfNy0yLTEtMS00MDg3NA_2169fefc-8ec5-4069-91b3-4f69cadf492e"
      unitRef="usd">240000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RhYmxlOmYwN2Y3OWQxMWE2MjRlYzk4MDYxZDQ5NmY0N2FjNTliL3RhYmxlcmFuZ2U6ZjA3Zjc5ZDExYTYyNGVjOTgwNjFkNDk2ZjQ3YWM1OWJfOC0yLTEtMS00MDg3NA_b5f524ca-f704-423e-ba59-9f25e9833340"
      unitRef="usd">2001000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractualObligation
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80My9mcmFnOjljNzVkZWJjYzVkMDQyOWY4OGUzYTZiY2M0ZTEyMmYwL3RleHRyZWdpb246OWM3NWRlYmNjNWQwNDI5Zjg4ZTNhNmJjYzRlMTIyZjBfMTY0OTI2NzQ1NDQ2Mg_3edb0fe7-23f4-4796-9996-02a512c63ff9"
      unitRef="usd">4400000</us-gaap:ContractualObligation>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RleHRyZWdpb246NWZlYWMyYzc3ZjllNDdjMmJmZjFjNGU1ZjJiNTNjYzBfODcz_0364440f-4338-4d46-aeef-19f7e05045e2">Fair Value&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 4.7% in a U.S. Government money market fund.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of March 31, 2023. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.&lt;/span&gt;&lt;/div&gt;The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RleHRyZWdpb246NWZlYWMyYzc3ZjllNDdjMmJmZjFjNGU1ZjJiNTNjYzBfODc0_9c126703-aeb8-4a39-acec-3e6d73733e46">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf9be709dcc341ec81501791438f59e7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfMy0xLTEtMS00MDg3NA_f1caaaaa-02cf-4d5d-9054-6adee812961f"
      unitRef="usd">69058000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia456402de7a84422945fba2d356a2128_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfMy0zLTEtMS00MDg3NA_2634c361-4fb2-4b64-9c59-5890c465005f"
      unitRef="usd">69058000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieed67899138440fca6e702a05a6fe016_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfMy01LTEtMS00MDg3NA_3e27752b-09b0-491e-bbcb-bc411d34dd55"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i54c299796fa64dfcb61bc9a98dffb9ea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfMy03LTEtMS00MDg3NA_9e58ad80-1d85-4e00-9813-88855e8d22b0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6756bb299bd64a4c8756ee0392611ce8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfNC0xLTEtMS00MDg3NA_5d6d9f16-c609-4be0-b860-efe16e102692"
      unitRef="usd">69058000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7caa4e1db0ad42d798b24b3737f23fc6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfNC0zLTEtMS00MDg3NA_91c9df34-19ce-46ea-a96f-ee2897a09a93"
      unitRef="usd">69058000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i040bb11041164505a47e1dcaaf723bb1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfNC01LTEtMS00MDg3NA_db898f51-adf9-467d-a53e-bcd5e0852339"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8cde7bfdcbc64b08a49fea0cfd6c4e66_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmU5NjVlYjVhZmM4MzQ3OWNiZmMyMTMzNDJhZDE1MmFlL3RhYmxlcmFuZ2U6ZTk2NWViNWFmYzgzNDc5Y2JmYzIxMzM0MmFkMTUyYWVfNC03LTEtMS00MDg3NA_bf3ce315-f2f7-4fe5-83b7-0627d23e12ae"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9dce7e6602844c5d9fae5f312b27e08c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfMy0xLTEtMS00MDg3NA_7348a4d4-9e0c-4f32-a1fb-1b2554249fdc"
      unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idc410b5e83414c3aa3d99f8cfd2413d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfMy0zLTEtMS00MDg3NA_1301b097-18dc-4dee-aaa2-60e9442ee6fd"
      unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2fed83fa3cd84a30b2fbc0c3d3a7d5f8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfMy01LTEtMS00MDg3NA_2766a990-10e7-450b-babd-9effbbcd3661"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibfd52b7f358e4ee28cc0c52c348d53e5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfMy03LTEtMS00MDg3NA_1623710b-61d1-48bd-934f-0bd7d09b9963"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i40bc641f88774d5fa4e4a507ac82f713_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfNC0xLTEtMS00MDg3NA_ac5b13d7-65ca-40c8-8a25-51a4c14751d4"
      unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i87d89dc42f6849f8bf05f2e1420914fe_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfNC0zLTEtMS00MDg3NA_27de326e-6f3c-41f6-b1a6-036fbadc49f4"
      unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i81bb32c6f29a45bbbd7f764bbf7b6bd0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfNC01LTEtMS00MDg3NA_8d032d6e-9b53-41d9-9134-4825bc3365f0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i13e792ced17e4aac8f2baa208d221702_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RhYmxlOmVhYTZkZTQwMGM3OTQ1ZTlhNDAzNjc1YWY4NWQyNTQwL3RhYmxlcmFuZ2U6ZWFhNmRlNDAwYzc5NDVlOWE0MDM2NzVhZjg1ZDI1NDBfNC03LTEtMS00MDg3NA_6b94ed1e-6a78-4266-8ffe-9f58445053ff"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentInterestRate
      contextRef="i00dbb5ea0444479bb49ade8df06bec2a_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80Ni9mcmFnOjVmZWFjMmM3N2Y5ZTQ3YzJiZmYxYzRlNWYyYjUzY2MwL3RleHRyZWdpb246NWZlYWMyYzc3ZjllNDdjMmJmZjFjNGU1ZjJiNTNjYzBfMTY0OTI2NzQ0NDMwMQ_9b74860e-9b2d-4c35-a4d6-3356c014fa1d"
      unitRef="number">0.047</us-gaap:InvestmentInterestRate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDYyNA_9d96bd36-bcc4-46d6-91a3-08ffdb079562">Common Stock&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of February 17, 2023, there is $75.0&#160;million remaining on this shelf registration statement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of May 2, 2023, $8.4&#160;million in capacity remains under the December 2020 ATM.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.  As of May 2, 2023, $80.0&#160;million in capacity remains under the May 2022 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any ATM activity during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended March 31, 2022, the Company raised gross proceeds of $30.6&#160;million pursuant to the December 2020 ATM through the sale of 2,904,113 shares of common stock at a weighted average price of $10.54 per share. The net proceeds from the December 2020 ATM were $29.7&#160;million after deducting underwriter commissions of $0.9&#160;million.  During the second quarter of 2022, the Company raised gross proceeds of $10.3&#160;million pursuant to the December 2020 ATM through the sale of 1,300,000 shares of common stock at a weighted average price of $7.90 per share. The net proceeds were $10.0&#160;million after deducting underwriter commissions of $0.3&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;$60 Million Private Placement Equity Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) for a private placement (the &#x201c;Private Placement&#x201d;) with select accredited investors and certain existing investors (each, a &#x201c;Purchaser&#x201d; and collectively, the &#x201c;Purchasers&#x201d;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Shares&#x201d;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase Common Stock (the &#x201c;Warrant Shares&#x201d; and together with the Shares and the Pre-Funded Warrants, the &#x201c;Securities&#x201d;), at a purchase price of $4.34 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.01 per share of Common Stock, are immediately exercisable and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentages not in excess of 19.99% by providing at least 61 days&#x2019; prior notice to the Company.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. Through March 31, 2023, no cash dividends had been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pre-funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at March 31, 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,116,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="i3a93cf1f6efd47c68682b156780ea43f_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIwMTk3_f1ba99f7-04eb-4132-9693-12fbfcd35cfc"
      unitRef="usd">250000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationStatementAmountRemaining
      contextRef="iebae0eb40a444df390db58fc0a4f5613_I20230217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIwMzc2_7780d88c-6fd5-4513-bb57-63828d20c7b7"
      unitRef="usd">75000000</vtl:ShelfRegistrationStatementAmountRemaining>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="i5a10625444a64e53bdfa92e91315ad3a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIwNTcy_33903cf2-f9df-4825-a894-ba1da8ca238b"
      unitRef="usd">50000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice
      contextRef="i30b5afb1f0ff4c47b8c3bc25cc38daed_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIxMzU2_eb5d891e-a8df-40bc-ba72-2d7d37bd0c3d"
      unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity
      contextRef="i82a88f6ec9b74cc5a1e1440f7bbdd771_I20230502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIxNTMy_70def97d-fe60-4f83-bcf9-7514e1aa094f"
      unitRef="usd">8400000</vtl:SaleOfStockRemainingCapacity>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="icbd443fc4f014d7bbdc8e6eea80617c5_I20220531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIyOTA1_f3cfdef4-b7f3-4216-8fdd-8707cf480995"
      unitRef="usd">80000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice
      contextRef="if2a13be659d44aba86b85693c76e9613_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIzNjQz_7e8556d5-2f19-4fdd-abc8-ae1f732088ab"
      unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity
      contextRef="i46a98a2bf0d84695bd517c220ad9693a_I20230502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODIzODE5_2114f52b-6db4-4f35-a9b6-fa64211c9f83"
      unitRef="usd">80000000</vtl:SaleOfStockRemainingCapacity>
    <vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMjcyNQ_b19bf41a-9f97-43f0-9c01-3d4407773b55"
      unitRef="number">0.030</vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMjk3OA_8189f0ba-bb4b-49da-aa30-b5ba89c99a4f"
      unitRef="usd">30600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzAzNQ_8c41fbb9-7d85-4093-b321-0d6d22e9d200"
      unitRef="shares">2904113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzA5Mg_a00f061c-394c-44e4-af36-ca0e9baf0099"
      unitRef="usdPerShare">10.54</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzE1NQ_87d22944-0b04-4ca6-9f9f-392331207c4c"
      unitRef="usd">29700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="if07d36129a11471fa781b3dc29c0deb5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzIwMQ_8e33224c-a0b9-40a6-b055-04e67af987d4"
      unitRef="usd">900000</us-gaap:PaymentsForCommissions>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzI3OA_8fb6416b-8994-4468-9a6f-06a422746a56"
      unitRef="usd">10300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzMzNQ_f8b394da-86c9-4d79-926d-196f5319cd71"
      unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzM5Mg_8674882b-7604-4330-ab05-f7f901ccfacf"
      unitRef="usdPerShare">7.90</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzQyOA_fff0d3db-31b6-4c3b-8d7f-063a82455fed"
      unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="i0d2b2fd267bb4cca859ec3d0efe07536_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzQ3NA_b9961477-18b6-4a39-8dc9-de84d4964c7e"
      unitRef="usd">300000</us-gaap:PaymentsForCommissions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i7adc4e97d78648e5a2e35c0c4f324c4f_D20221010-20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI1NzA0_716a75f9-d9f2-4ebb-b7f1-49846f9383d3"
      unitRef="shares">8696552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9a7ff65586d1477a96c00b182f10e2cc_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI1NzU2_06ecef17-76c4-4e8f-9a97-fdcd78129837"
      unitRef="usdPerShare">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharePrice
      contextRef="i9a7ff65586d1477a96c00b182f10e2cc_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI1ODA5_0e57bd2f-97c3-4d44-a61a-f968461a9365"
      unitRef="usdPerShare">4.35</us-gaap:SharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i95409047e69d4309b31a843a98de93fb_D20221010-20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI1ODMz_19f3ad3c-b2d8-41fa-9845-e5f6a3f5648a"
      unitRef="shares">5096552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2MDMy_dfddbb58-c392-427c-abd0-ac099be64d55"
      unitRef="usdPerShare">4.34</us-gaap:SharePrice>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2MTEw_cb50d3a0-1383-4a1e-aada-b51fdba5bdf6"
      unitRef="usdPerShare">0.01</us-gaap:SaleOfStockPricePerShare>
    <vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage
      contextRef="i9a7ff65586d1477a96c00b182f10e2cc_I20221010"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2MzY3_835e2523-9440-4cb7-a6e2-5451d6efbdd7"
      unitRef="number">0.0999</vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage>
    <vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent
      contextRef="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2NTY3_6e333bda-6469-4863-a72d-48852d49d6df"
      unitRef="number">0.1999</vtl:EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent>
    <vtl:EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod
      contextRef="if7df5b43a0ee46f69fb6590cf17f65aa_I20221010"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI2NTkz_cf76aa9a-0744-4661-bfd9-39cd099534c2">P61D</vtl:EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzcwNA_3fa4dee7-d1e2-4fe3-b94b-ceb12d42853d"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzc0NA_507ac777-e963-4ad3-af90-e8d603a4922c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <vtl:NumberOfVotesPerEachShareOfCommonStock
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfMzk5OQ_b5108e99-9865-4590-ae26-fb9fa40c268a"
      unitRef="vote">1</vtl:NumberOfVotesPerEachShareOfCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDIwNg_19011198-35c7-41fa-8387-e4bce16ee926"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDIwNg_8578b056-2d3d-44dd-90b1-164f715f2b92"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i1b55fff4633243a0adf3497ef994823d_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNTQ5NzU1ODI3NDk2_4c961808-9ba6-4e0f-a6eb-0642fa6014ca"
      unitRef="shares">5096552</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDM2OA_b43f2a7b-d147-4caf-be47-e3f19edf261e"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDM4MQ_b57dbe0e-bdf8-43a9-a843-4158af7d96ff"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDQ3MQ_3ced29a2-2b5e-4e14-97e5-5cc01803da0e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RleHRyZWdpb246MzMzNWUzNjZmMTgwNGViY2FkN2ZlNGUwOWM1ZTE3ZjNfNDYyNg_bc081e0f-a879-42d5-b444-294cee5bc2db">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at March 31, 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,116,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibb7897fe5a4546198de6a00c37cae9e1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfMi0xLTEtMS00MDg3NA_8d15216c-5ceb-423b-8ffb-2c045a511c31"
      unitRef="shares">116891</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i239a3919cf64453b8bbede15f2c98d15_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfMy0xLTEtMS00MDg3NA_ad5273ae-267d-4028-b218-f7f4a7dd44db"
      unitRef="shares">5595841</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1d5a0313e25e42cba4239ba45c3be9ba_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfNS0xLTEtMS00MDg3NA_89b6f9a0-462d-4755-af70-8aa7083eff1e"
      unitRef="shares">43311</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie21c8c85594c4ad8acb51bd91760547e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfNi0xLTEtMS00MDg3NA_c20cff41-7aff-4f43-8d23-cfb4f6a34c56"
      unitRef="shares">46250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if6f016a323654ddd9934856d79e1aff3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfNy0xLTEtMS00MDg3NA_3295cbeb-fc73-4ce6-ac49-3c20c7cd8402"
      unitRef="shares">313988</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV80OS9mcmFnOjMzMzVlMzY2ZjE4MDRlYmNhZDdmZTRlMDljNWUxN2YzL3RhYmxlOmRjOWQzNzIzM2E2MTQwNzI5YzdjYjRjZWZhYjhiZWM0L3RhYmxlcmFuZ2U6ZGM5ZDM3MjMzYTYxNDA3MjljN2NiNGNlZmFiOGJlYzRfOC0xLTEtMS00MDg3NA_17d6652f-89a1-48ca-8fcd-48a2443408d2"
      unitRef="shares">6116281</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjIzMQ_40a42b91-38a0-4dfa-a23e-8ef75a9af2a8">Stock-Based Compensation Plans&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#x2019;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;       &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued 83,109  shares life-to-date under the ESPP.  The Company recognized $46,000 and  $28,000 of expense related to the plan during the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company&#x2019;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which was adopted by the Board of Directors (the"Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#x2019;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#x2019;s fully-diluted outstanding stock, with a maximum allowable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MzAz_cd4f286e-f982-4745-9e25-2b9dea81d824"&gt;three&lt;/span&gt; or four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Movements during the year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the quarters ended March 31, 2023 and 2022, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted under the 2019 Plan during the three months ended March 31, 2023 and 2022 was $1.15 and $8.48, respectively. The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, there was $15.8 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 3.06 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Equity Incentive Plans Assumed from Vital Therapies, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 12, 2019, we assumed the equity incentive plans of Vital Therapies, Inc. (&#x201c;Vital&#x201d;) following an exchange transaction (the &#x201c;Transaction&#x201d;) with Immunic AG.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the Transaction, holders of ordinary shares of Immunic AG exchanged all of their shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary. Following the Transaction, we changed our name to Immunic, Inc.  Upon completion of the Transaction with Vital on April 12, 2019, Vital&#x2019;s 2012 Stock Option Plan (the &#x201c;2012 Plan&#x201d;), Vital&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) and Vital&#x2019;s 2017 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There remain 43,311 shares available for grant under the 2014 Plan as of March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, Vital&#x2019;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#x2019;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recorded for the plans assumed from Vital during the three months ended March 31, 2023 and 2022, &lt;/span&gt;&lt;/div&gt;respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ic8ec42d4c505493aa4e52b6dc975c57c_D20210425-20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODIxNjQ1_a990311b-fb32-4748-a61c-eae5ae0261ac"
      unitRef="number">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="ic8ec42d4c505493aa4e52b6dc975c57c_D20210425-20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODIxODU4_7316e13f-cc4c-4a80-a758-4c00eb04161e"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iaf59c539b0384772b43fdb06eff0b23d_I20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODIyMDY4_393f5004-9e78-438b-9df1-4cd7d20ecc83"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idd619ffa1b7c439ab600c4800cda19f8_D20210801-20210801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfMTY0OTI2NzQ1NDc0NQ_3af3e9b0-1377-4438-91c3-df359a3668db"
      unitRef="shares">83109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief8ab69f94cf44e4842f469e423648c7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfMTY0OTI2NzQ1NDczNg_989dc8a2-99cd-44cd-9410-8acabf62e53d"
      unitRef="usd">46000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87843dae4e154ef4b4771cc451754b9d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfMTM1NQ_0a8eabf9-7c72-437f-af76-1948c7c089a0"
      unitRef="usd">28000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie3f47deb3c97419e8cb5ad85105d41f3_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI0MjI3_e6c7da5f-a419-46c4-991c-1779829d7d05"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
      contextRef="i18240f287ce143488e8e2fbd786ce30c_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI0NDA1_3cd1cd97-6a65-461f-b3c9-66fc643e673c"
      unitRef="number">0.04</vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i18240f287ce143488e8e2fbd786ce30c_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI0NDk2_aa5e7631-9f42-43a5-9362-543cc2ff6bfd"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="idb0e3c9196e14a1f9b8819f2efee359f_D20200101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI0NjU1_f86c5d43-f72a-4006-9f1e-370ffb60bd19"
      unitRef="shares">4408871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id29dd56a8d2343fa923b6c1b453533a6_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MDkx_17e0b1e5-b85c-4f4e-a6e5-1a6cd53e060d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifa554797e5fd4c1abf0e6346028845b6_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MTYx_20c46d12-80a4-4a9a-bd14-7603bc56065a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id849626157e04b04b98545bea26e1a7f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI1MzEw_867bd2c2-38e5-434e-b8a3-05ff8606f07c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjIyNA_122e5720-8a65-4a2a-b5bb-58bd5d18df34">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the quarters ended March 31, 2023 and 2022, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i01801c5e4d9a456585f4460c4186beac_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMS0xLTEtMS00MDg3NA_79d84a5a-3839-4d9b-a78e-1d0684002a68"
      unitRef="shares">3791688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i01801c5e4d9a456585f4460c4186beac_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMS0zLTEtMS00MDg3NA_bb5865bc-75b8-4ccd-9151-9f148d198725"
      unitRef="usdPerShare">11.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMi0xLTEtMS00MDg3NA_c42f421e-58d5-4d9a-9f45-543e12818010"
      unitRef="shares">1815314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMi0zLTEtMS00MDg3NA_8f8183e2-9dfc-4065-810a-0b6241f177ae"
      unitRef="usdPerShare">1.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMy0xLTEtMS00MDg3NA_82aa3fd2-a4f7-4288-8645-eba42f3c2cb9"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfMy0zLTEtMS00MDg3NA_9d54e652-93db-49a9-b3d3-ccf740285438"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNC0xLTEtMS00MDg3NA_9a0e818e-8ba0-4d9b-8b71-dfe67c25330d"
      unitRef="shares">11161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNC0zLTEtMS00MDg3NA_03579926-acbc-4584-83d6-d5f873860809"
      unitRef="usdPerShare">13.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNS0xLTEtMS00MDg3NA_a2e19251-d13b-4caa-826b-44df0e854312"
      unitRef="shares">5595841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNS0zLTEtMS00MDg3NA_81974e78-bfab-4a9a-83ca-63fb6f4ab3d8"
      unitRef="usdPerShare">8.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNS01LTEtMS00MDg3NA_75cfb84e-2839-441d-a292-c944f7065195">P8Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNS03LTEtMS00MDg3NA_4b70c091-b7ed-471f-a6a2-99811bdc519d"
      unitRef="usd">161428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNi0xLTEtMS00MDg3NA_93c946a6-4ee8-44f0-8782-2e9c761c5224"
      unitRef="shares">5595841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNi0zLTEtMS00MDg3NA_2c524395-3875-4183-b7e0-e9110b40ec40"
      unitRef="usdPerShare">8.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNi01LTEtMS00MDg3NA_3415fd8f-e594-4b30-a053-a31c5768517d">P8Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNi03LTEtMS00MDg3NA_fa2706d0-6ca7-4706-af3e-b7096b3b7654"
      unitRef="usd">161428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNy0xLTEtMS00MDg3NA_775893aa-346c-41b2-b123-ce26075f9173"
      unitRef="shares">1888367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNy0zLTEtMS00MDg3NA_4699a077-52cf-42da-873c-96e38d27c297"
      unitRef="usdPerShare">12.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ib90ba78255724c8e82ca6503e839396d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNy01LTEtMS00MDg3NA_dc62f6e1-bfcc-4014-b3a2-bc9a74cff05f">P7Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i90b7b2db1cbc453baca9109f8891d37e_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjdhOGNhYzc4NGI0ZjQ0MGNiYjYwYmU1NjRkMjA5NmIzL3RhYmxlcmFuZ2U6N2E4Y2FjNzg0YjRmNDQwY2JiNjBiZTU2NGQyMDk2YjNfNy03LTEtMS00MDg3NA_6e72ed41-9c06-47b4-be58-e545504575d0"
      unitRef="usd">1980</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i852628a8fa954ea88ef5db4e6f88f6c3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMS0xLTEtMS00MDg3NA_05a84555-e0c8-4d8a-8b39-4955d737749d"
      unitRef="shares">2157460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i852628a8fa954ea88ef5db4e6f88f6c3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMS0zLTEtMS00MDg3NA_dfc34f36-ffc5-4339-889a-027f5579ef35"
      unitRef="usdPerShare">13.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMi0xLTEtMS00MDg3NA_5b65922d-2ce6-4337-b3c7-2678ce56229d"
      unitRef="shares">1301513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMi0zLTEtMS00MDg3NA_eea583dc-e8be-4d4f-9638-a44c60b901fe"
      unitRef="usdPerShare">10.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMy0xLTEtMS00MDg3NA_2958564a-005d-468d-a5ae-8280b06bf080"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfMy0zLTEtMS00MDg3NA_b70608c4-aed9-4f9a-bd31-48e98eb8ba4e"
      unitRef="usdPerShare">5.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNC0xLTEtMS00MDg3NA_77e646a1-106f-4f63-9cfc-8bc01b83b2c7"
      unitRef="shares">34639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNC0zLTEtMS00MDg3NA_51a8af7e-e67d-40c2-8222-00a29870f470"
      unitRef="usdPerShare">12.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNS0xLTEtMS00MDg3NA_88fdbe37-9a79-4637-9e61-63ec2b51cbbf"
      unitRef="shares">3423482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNS0zLTEtMS00MDg3NA_f47a2f60-24e1-4305-8f36-480a9f9a708b"
      unitRef="usdPerShare">12.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNS01LTEtMS00MDg3NA_41ae656b-74bd-47f0-a261-f524e56d8f67">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNS03LTEtMS00MDg3NA_11bf08bd-4eab-4851-af64-46d7e4a067d7"
      unitRef="usd">1464329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNi0xLTEtMS00MDg3NA_52ec82f5-5e8d-4530-b90d-b03ee60d4cc3"
      unitRef="shares">3423482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNi0zLTEtMS00MDg3NA_82bdac1e-e517-4351-88d7-0864a0fb0bc1"
      unitRef="usdPerShare">12.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNi01LTEtMS00MDg3NA_ecc464c2-9cb5-4c1d-b386-7c5d6bf13ec7">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNi03LTEtMS00MDg3NA_287caa0c-24db-4ab1-9f7d-3512943944df"
      unitRef="usd">1464329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNy0xLTEtMS00MDg3NA_216cc72d-6da3-4198-b5d6-9cc5aada376f"
      unitRef="shares">952888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNy0zLTEtMS00MDg3NA_912aede6-fa0d-474d-b08b-fc314496a647"
      unitRef="usdPerShare">13.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i5fb79376b0324c32a644473dc8c4135f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNy01LTEtMS00MDg3NA_3fbcdd58-2f00-49aa-aa5e-043755c457af">P8Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ic32c6086fc3f486288c72dbc3bb25a4a_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjIyNGZlNjkyMTk1NzQ4N2Y5ODZiMmVkNWRiNTFmM2JkL3RhYmxlcmFuZ2U6MjI0ZmU2OTIxOTU3NDg3Zjk4NmIyZWQ1ZGI1MWYzYmRfNy03LTEtMS00MDg3NA_54803f5f-2cbb-4c2b-b292-ba366cd0cd98"
      unitRef="usd">215617</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfMzcyNw_a579b711-0b93-44dc-97e2-a7059c71a277"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI2ODE1_26c48520-edf6-4e78-8e2c-2a657f4da572"
      unitRef="usdPerShare">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNDYwMg_8caaa766-7373-4c19-92e6-66adf95f4c7d"
      unitRef="usdPerShare">8.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjIyOQ_4e848378-dfb4-4fd3-a719-876acdb76a42">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfMi0xLTEtMS00MDg3NA_84d0cb2d-9670-4d42-b525-2cdb30a844e9"
      unitRef="number">0.0397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfMi0yLTEtMS00MDg3NA_e8db1f40-0444-4b1d-a9d2-4abba82a0919"
      unitRef="number">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfMy0xLTEtMS00MDg3NA_c3cd8793-248d-40be-9ea6-1838651a8129"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfMy0yLTEtMS00MDg3NA_1bfa87c0-0fcd-4d13-b373-ead1c056fff1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfNC0xLTEtMS00MDg3NA_363d860a-49b4-4f32-993e-b113c3ff765f"
      unitRef="number">1.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfNC0yLTEtMS00MDg3NA_f941012d-7ca5-4252-b716-238f3dd0a30b"
      unitRef="number">0.974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfNS0xLTEtMS00MDg3NA_fc0e480f-d184-46d6-bb8d-fa73d7d45979">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if5e4d9d710764b0db319b9d428403670_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjE1MzdlMjJkYjNhNjQ2ZjU5NjlhMzNmNGIxZjc5YTdhL3RhYmxlcmFuZ2U6MTUzN2UyMmRiM2E2NDZmNTk2OWEzM2Y0YjFmNzlhN2FfNS0yLTEtMS00MDg3NA_3d42c12b-5bd6-42c8-aade-63c4ad617b14">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjIzMA_a4e8dfb9-5e4c-4adf-b499-5319c03c9a65">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i9bac232d450542c29d7d8a2d9b455e83_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfMi01LTEtMS00MDg3NA_2c28285a-2bfa-4f74-accf-3c9c235f46ee"
      unitRef="usd">903000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1e6755fc97ea425cb1262657c7ed624c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfMi03LTEtMS00MDg3NA_a05439b1-2efd-437f-8a97-c36989f5af06"
      unitRef="usd">796000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ieae0ab47bf4b483788aa093a0ceca4cf_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfMy01LTEtMS00MDg3NA_fd1caff3-d858-431f-b411-315ccab90893"
      unitRef="usd">1076000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic16d1c96118c4a888e6a5395e0e4dc9a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfMy03LTEtMS00MDg3NA_5f5cb429-ce6d-49b9-b016-e5d56d1fc5a7"
      unitRef="usd">1273000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i781801a508af47b1a07f6605aa4e43d7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfNC01LTEtMS00MDg3NA_cd2a952e-3c12-4341-8562-a2febc319bef"
      unitRef="usd">1979000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7ef55c12c6414e5eb8e4e206bc43438d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RhYmxlOjQ4MTZkYWEwZjAwMTRlZmY4YjU0NDZjYWI2Y2JjZjg1L3RhYmxlcmFuZ2U6NDgxNmRhYTBmMDAxNGVmZjhiNTQ0NmNhYjZjYmNmODVfNC03LTEtMS00MDg3NA_e75a41fe-0349-46f9-a31b-7564e5fa7778"
      unitRef="usd">2069000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie2ca6e9222044db0b2b0c86717d4704f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTA0NA_a43aa7e8-3817-4e63-90c3-0375becb59af"
      unitRef="usd">15800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTQ5NzU1ODI3NTAz_c31bdea9-12d4-49fd-bf56-5e06ab2b4b77">P3Y21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ibb1cbf03fbb447069ee8da6cfe57e37e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTU4Nw_6873da97-c076-4955-89a9-69851d2b2c48"
      unitRef="shares">43311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8d852c9c8633413dac4a33c96a487447_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNTgxMA_10367027-e601-42ed-b8a3-9fc6ec3d29e3"
      unitRef="shares">46250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i76cd333d69ab4f47b9c2c6dc6ce0348f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjA5OQ_2186aee7-b6b4-4a11-922b-98b614f112dd"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie1948e072c9f494ba65be7555fdc7188_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81Mi9mcmFnOmUyNzkxMjdjMWYzYzQ5YjY5Y2I3ZTdjZjViMzcwMGIxL3RleHRyZWdpb246ZTI3OTEyN2MxZjNjNDliNjljYjdlN2NmNWIzNzAwYjFfNjA5OQ_51554057-97c8-4fc7-928b-557e6d8d1b8f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81NS9mcmFnOjA0ZTdhNjMyZTUzNTRiNjhhMGRlMzQxOWRlNzk4OWMyL3RleHRyZWdpb246MDRlN2E2MzJlNTM1NGI2OGEwZGUzNDE5ZGU3OTg5YzJfMTY0OTI2NzQ0NDAzNw_06180d45-a7b5-4b00-aca3-5c0a765133db">Related Party Transactions&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Chairman Agreement with Duane Nash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#x201c;Executive Chairman Agreement&#x201d;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#x201c;at will&#x201d; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company&#x2019;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <vtl:SalaryCostsMonthlyBaseSalary
      contextRef="i0c71bdc1a2f64a69a40ac91eb07d2ad7_D20221228-20231231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81NS9mcmFnOjA0ZTdhNjMyZTUzNTRiNjhhMGRlMzQxOWRlNzk4OWMyL3RleHRyZWdpb246MDRlN2E2MzJlNTM1NGI2OGEwZGUzNDE5ZGU3OTg5YzJfNTQ5NzU1ODE2MDU4_09e06d09-1b9e-492a-a2c6-31dbe519bffa"
      unitRef="usd">30250</vtl:SalaryCostsMonthlyBaseSalary>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i09350f81250c464d865db34f18f61a93_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81OC9mcmFnOmUxNzUzMzJkYTI5YTQ0MzNiZmMxOWU3Y2IyN2IwOWEyL3RleHRyZWdpb246ZTE3NTMzMmRhMjlhNDQzM2JmYzE5ZTdjYjI3YjA5YTJfMTY1Mw_1639a521-2eb2-49c2-883d-b2c16027ba25">Subsequent Events &lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Appointment of Richard Rudick, M.D. to Board of Directors&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 27, 2023, the Company announced the appointment of Dr. Richard Rudick as a member of the Board of Directors of the Company, effective as of April 26, 2023. As a Class III director, Dr. Rudick&#x2019;s term lasts until the Company&#x2019;s 2023 Annual Meeting of Stockholders . Dr. Rudick is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr. Rudick and any other persons pursuant to which he was selected as a director.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with his appointment as director, Dr. Rudick was granted a long-term equity incentive grant in the form of an option (the &#x201c;Option&#x201d;) to purchase a total of 32,000 shares of the Company&#x2019;s common stock on April 26, 2023. The option to purchase 32,000 shares vests in monthly increments over a period of three years from the grant date. The Option has an exercise price per share equal to the closing price of the Company&#x2019;s common stock on The Nasdaq Stock Market on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Additionally, Dr. Rudick and the Company entered into the Company&#x2019;s standard form of indemnification agreement for directors and executive officers.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81OC9mcmFnOmUxNzUzMzJkYTI5YTQ0MzNiZmMxOWU3Y2IyN2IwOWEyL3RleHRyZWdpb246ZTE3NTMzMmRhMjlhNDQzM2JmYzE5ZTdjYjI3YjA5YTJfMTY0OTI2NzQ2MDc5Ng_980fcbe7-17c2-44b0-941f-b99bd5ea60f2"
      unitRef="shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81OC9mcmFnOmUxNzUzMzJkYTI5YTQ0MzNiZmMxOWU3Y2IyN2IwOWEyL3RleHRyZWdpb246ZTE3NTMzMmRhMjlhNDQzM2JmYzE5ZTdjYjI3YjA5YTJfMTY0OTI2NzQ2MDgwNA_3a8eb9dc-2004-467c-909b-cd562ecfa137"
      unitRef="shares">32000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMDZkZTA0ZTEzNjQyNzE4MjU4OWY0ZWJkY2RmMTgxL3NlYzowMTA2ZGUwNGUxMzY0MjcxODI1ODlmNGViZGNkZjE4MV81OC9mcmFnOmUxNzUzMzJkYTI5YTQ0MzNiZmMxOWU3Y2IyN2IwOWEyL3RleHRyZWdpb246ZTE3NTMzMmRhMjlhNDQzM2JmYzE5ZTdjYjI3YjA5YTJfMTY0OTI2NzQ2MDgxMQ_a763ebb9-102b-4469-9f03-acb07d55de95">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<B&X+Y3Y -[/I-2[&_,/BE/Z_G]02P,$%     @ E3:K5H@K\!6T!0  VQ<
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M3XS8SHPMU$< 3BD/AX'OC1$:Q#PGF*DP24^.Q$Z.6U$4O*V!FYI=E#H/6)D
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M(7*/"7?C[+<7+SQ<%TQHPF&.4*_50PY5WF7*CI%Y<1V828.7BZ*9XOT/E W
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M+!K=%-Q4<:(EOBT0IY.QX!G6!#*"*R58D5&-FXG&!Q9+*R)F^*K$*Y*;VJV
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MY<]<B"L%?'0Y_((MTSBMNB 3H'[//]GS3QI4YP3J._:0%D5:/$!\9K2(87Q
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MJ(IJ ?A]R7GU]%+?YMI?*)S] U!+ P04    " "5-JM6;; A>T4"  #1!
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M]DT[&H%@EO3FH/$!=+[4VNT<GZ!_Q;*_4$L#!!0    ( )4VJU8O190;&P8
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M%4K1\IP)(U0FS&N/J2+GLEMW/=^_-XS6KQ6W5"DFR+X;7O6;Z<YO.TYYW3:
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M!WR?L@FT;.O&:,H)@ Z\VN'[*!S.II1A7H$/WG%2/=+N4$M^-IX/+QHW^!(
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M]VKH8ZN)A9ID[KX(3_ +$?-J2MHY\258IPG@TM,_&CQTCE:7Q%+&#WBT-L6
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M94VNO-?Z1 SN:RSCE$W$@\.?<"OB5,/C]YP. W2XPYS%#EO('>*B]DF5'.^
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ML_'590*N'6SM(M@Z#I.-#32:XFM%WP+H6(#.M]:&XX(OZ+\N%G\#4$L#!!0
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M,W+IRI &P;;Q,SVW 1_]^%KAEL5.#+"^L#:L!Q)@<V^;_0-02P,$%     @
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M01X4R,<;8))5HW WP+$F*EJR TI>7H+1A:")U2L]))\Q$*6/@,M/X\FFP<8
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M(9&^U>6MJ\^XF&ZX3])K $Q<;, Y1>P04<+FZ("4=%4L4@!5LPK0]FU#'R;
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M7:-P4)W*MKL=[.^5[Z7'2:231D:J:M4:&Q+XDW:4I(W[Q$8?LI*CFYJ" #"
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M40S[[B/<Z:L*[:J='@XRTVCJ6JSW]@/JLNO+?\>[Z<:IKZ1V7*B"H='9^3
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M=-SI#]H3KR^Z:,T>E&V)?*7E?0!OB[G"!(L8]59/]+]Z!OWC?M1M3_Y1SWL
M=I52V.IV!>J%[^D&$E5*6S6^9K=Y-J95MWPQK]X<^L,++@T(S,BU<W+>#T!7
M?;Q:6+7TO3-6ECJQG^;T]*%V!G2>*66W"Q>@>4PG?P!02P,$%     @ E3:K
M5O?G&&++ @  6 8  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULC57?
M;]HP$/Y73IDT;5+4_ (*#"*U7:OUH2LJW?8P[<$D!['JV*GME/:_WSD)&94
M[87X[.^^^\Z^.V9;I9],@6CAM132S+W"VFH:!"8KL&3F3%4HZ62M=,DLF7H3
MF$HCRQNG4@1Q&(Z"DG'II;-F;Z'3F:JMX!(7&DQ=EDR_7:)0V[D7>;N-![XI
MK-L(TEG%-KA$^Z-::+*"GB7G)4K#E02-Z[EW$4TO!P[? 'YRW)J]-;A,5DH]
M.>,VGWNA$X0",^L8&'U>\ J%<$0DX[GC]/J0SG%_O6._:7*G7%;,X)42OWAN
MB[DW]B#'-:N%?5#;;]CE,W1\F1*F^85MBTU&'F2UL:KLG$E!R67[9:_=/>PY
MC,,C#G'G$#>ZVT"-RJ_,LG2FU1:T0Q.;6S2I-MXDCDOW*$NKZ923GTVO5%G2
MY2RMRI[@TR-;"32?9X$E:@<(LH[FLJ6)C] D<*>D+0Q<RQSS]_X!2>IUQ3M=
ME_%)PCNFSR")?(C#.#G!E_1Y)@U?<H3O^KGF]@U^7ZR,U50*?P[EV%(,#E.X
M]IB:BF4X]ZC^#>H7]-*/'Z)1^.6$P$$O<'"*/5T6C$CAH27.@?H-;FI;:X1;
M8VHF,SPD^23I8<E=)+T?:=U&XETD8!;H!;*B?P(@'V"&P(+ZV$SA>UVN4(-:
M0U="IBFA=ZP]'1E31Q/!=5D)]8;8P:N:@E!30268A"@:^>-)!/>U-9;)G,M-
MAU.5ZV$#0W\X&?KC0?0^ZNZ8O3 N7 WO)[713%H7/AI 5P:W)$JZ<0 +%W>0
M^$D4.<0Y'>5UAC1V[#'PR(^'H0-/X+Z4?%6;(\@D2OS)> R/RC(!62?X/VY_
MY+N;B,<1'"JL8*_;2]2;9J89XJ^E;1N_W^W'YD4[+?[!VYE+;[SA=&\"U^0:
MGIT//=#M'&L-JZIF=JR4I4G4+ L:_:@=@,[72MF=X0+T?R;I7U!+ P04
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MYZ(H9S#_7^2Y?GM3%M@\F73Z+U!+ P04    " "5-JM6U*^/$H "  "X!P
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M1YW3T7\ZC*-#EN! 9#LEB+L2Q(<XC/%;#N/+I)[#Z&_U57NGF?ZTHEP!P]S
M@K./IAJRN2>:0(O*M=I[H4WC=L/"7*TH;8)9SX70SX'MWMUEG?X%4$L#!!0
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M3/%2!FD"\/E*"+V?F+[?7//17U!+ P04    " "5-JM66RP3@;,"   +!P
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MH&P KB^D--N!/=3;.SSY!U!+ P04    " "5-JM6R'42G] "  ""!P  &0
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M+AT='0APW;WK)F2;V.M+2WQSXG##3Q6Z$,#[*VOI:1*NS_#X%7\ 4$L#!!0
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M ,$:\EM4\EMHY6>S%8L?&"]6(][]]KY+:5I$W_$0";.1, <)<Y$P#PGSD;
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MC"L"&Q ADX6SD"+$<\1KMHVBU.?O>\/W_7:.8<TQ[.28"CBY6F81QM0]%1A
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M1X0I _E^0:G8WZ@!JK/YZ;]02P,$%     @ E3:K5H:/\B)[ P  ? L  !D
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M"!V U]><JX>)OD'=]H8_ 5!+ P04    " "5-JM62Y#=6H8"  #$!0  &0
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M@Z25K=(51PIU[IM: \^<J"K], C._8H+Z26QF[O32:P:+(6$.\U,4U5<OUQ
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M&/NFOQC>G-Z.G][LO_T'4$L#!!0    ( )4VJU:2+*"6N $  .<<   :
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MO?ZRO&ZBA,,+S@'^:[[_ E!+ P04    " "5-JM6C$_JC[H!  #N'   $P
M %M#;VYT96YT7U1Y<&5S72YX;6S-V<ENPC 4!=!?0=DB8CR4#@(V;;<MB_Z
MFSQ(1!);MJ'P]W7"(+6BJ(A*O9M$B>UW7VSI;#)^VUKRO4U=-7Z2%"'8!\9\
M5E"M?6HL-7%D;ERM0WQT"V9UMM0+8F(X'+',-(&:, AMC60Z?J*Y7E6A][R)
MKWUIFDGBJ/))[W$WL<V:)-K:JLQTB.-LW>3?4@;[A#2N[.;XHK2^'R<D[&1"
M._)SP'[=ZYJ<*W/JS;0++[J.L]BF8CYL*_+I^1(G>C3S>9E1;K)5'9>DWCK2
MN2^(0EVENZ+]\\DA[C#MKOSJ_*[,N< X<^:,]?'$'%T>=SB2=O7 QD+D0GG^
M$X^)L?35WT?M:>>4_S([;N^'<<ON/#SK;M?O\=<S/M:_L \!TH<$Z4.!]'$#
MTL<(I(];D#[N0/JX!^F##U$:01&5HY#*44SE**AR%%4Y"JL<Q56. BM'D56@
MR"I09!4HL@H4606*K )%5H$BJT"15:#(*E!DE2BR2A19)8JL$D56B2*K1)%5
MHL@J4625*+)*%%D5BJP*15:%(JM"D56AR*I09%4HLBH46=5_ROINS/*O_\"U
M][3697/(9]UOSNDG4$L! A0#%     @ E3:K5@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "5-JM6
MJSN0\.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "5-JM6F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )4VJU;["<\!X04
M +$?   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " "5-JM6B"OP%;0%  #;%P  &               @($D
M#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ E3:K5L*/
M7^3] @  70H  !@              ("!#A0  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( )4VJU;RR^6K\0,  #0.   8
M  " @4$7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "5
M-JM6P\&";<\"   2"   &               @(%H&P  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ E3:K5@0:7.<M!@  7"@  !@
M         ("!;1X  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( )4VJU9ML"%[10(  -$$   8              " @= D  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "5-JM6+T64&QL&  !J&0
M&               @(%+)P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ E3:K5J0Y^%OB"   B!4  !@              ("!G"T  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( )4VJU8VZ 8(?!T
M $E8   9              " @;0V  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ E3:K5M"&^?-_ P  G0@  !D              ("!
M9U0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "5-JM6
M(,+2G3X)  "+%@  &0              @($=6   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( )4VJU;+7HXF'@0  . )   9
M      " @9)A  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ E3:K5AJR*5GG"@  9R$  !D              ("!YV4  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "5-JM6]?2B$D$-  "W(P
M&0              @($%<0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( )4VJU;K&:_?AP,  &D(   9              " @7U^  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ E3:K5F-YAU-7
M!   PPD  !D              ("!.X(  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " "5-JM6 RLP;L <  "<7   &0
M@(')A@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )4V
MJU8? +PS(@,  #T'   9              " @<"C  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ E3:K5K$; )>J P  M D  !D
M         ("!&:<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " "5-JM6'RTV5YL"  #"!0  &0              @('ZJ@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( )4VJU;O?2>Q\P(  %@'
M   9              " @<RM  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ E3:K5O?G&&++ @  6 8  !D              ("!]K
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "5-JM6;:K$
MFQT%  "V#   &0              @('XLP  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( )4VJU:[@GLBP@,  (D.   9
M  " @4RY  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
ME3:K5F!!57JR"   I50  !D              ("!1;T  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " "5-JM6U*^/$H "  "X!P  &0
M            @($NQ@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( )4VJU9>PA"6UP(  &,'   9              " @>7(  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ E3:K5@L/88'[ @
M\@<  !D              ("!\\L  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " "5-JM66RP3@;,"   +!P  &0              @($E
MSP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( )4VJU8.
M;7JQU@(  ,\'   9              " @0_2  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ E3:K5LAU$I_0 @  @@<  !D
M     ("!'-4  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M" "5-JM6.*W(?K@$  "@'0  &0              @($CV   >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( )4VJU8DGH:*NP(  -@'   9
M              " @1+=  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!
M A0#%     @ E3:K5F4^Q@'> P  \!8  !D              ("!!.   'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "5-JM6HM610TH"
M   (!0  &0              @($9Y   >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;%!+ 0(4 Q0    ( )4VJU8UQOUDJ0<  %M+   9              "
M@9KF  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ E3:K
M5EL\#Z,X P  #PL  !D              ("!>NX  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " "5-JM6<K@=:.<"   R"0  &0
M        @('I\0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( )4VJU:$.?.'&@(  ,8$   9              " @0?U  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ E3:K5MBG>PAI @  AP8
M !D              ("!6/<  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " "5-JM6=LEGEU0#   B#P  &0              @('X^0
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( )4VJU98LV1L
MH0D  -IJ   9              " @8/]  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ E3:K5@V..6%$!0  IQ<  !D
M ("!6P<! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "5
M-JM6AH_R(GL#  !\"P  &0              @('6# $ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( )4VJU:Z*V^F> ,   (/   9
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M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ E3:K5I>*NQS     $P(   L
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64$L%!@     X #@ /P\  ,<E 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>121</ContextCount>
  <ElementCount>239</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Description of Business and Basis of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</Role>
      <ShortName>Description of Business and Basis of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/BalanceSheetDetails</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/FairValue</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommonStock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Description of Business and Basis of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Basis of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accounts Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Fair Value - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueAdditionalInformationDetail</Role>
      <ShortName>Fair Value - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Common Stock - Shelf Registration Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails</Role>
      <ShortName>Common Stock - Shelf Registration Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Common Stock - Equity Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockEquityOfferingDetails</Role>
      <ShortName>Common Stock - Equity Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Common Stock - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockCommonStockDetails</Role>
      <ShortName>Common Stock - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Common Stock - Pre-funded Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails</Role>
      <ShortName>Common Stock - Pre-funded Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Common Stock - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockPreferredStockDetails</Role>
      <ShortName>Common Stock - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail</Role>
      <ShortName>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vtl-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  vtl-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="vtl-20230331.htm">vtl-20230331.htm</File>
    <File>exhibit2312023.htm</File>
    <File>imux-33123xexhibit311.htm</File>
    <File>imux-33123xexhibit312.htm</File>
    <File>imux-33123xexhibit322.htm</File>
    <File>imux-3x31x23xexhibit321.htm</File>
    <File>vtl-20230331.xsd</File>
    <File>vtl-20230331_cal.xml</File>
    <File>vtl-20230331_def.xml</File>
    <File>vtl-20230331_lab.xml</File>
    <File>vtl-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtl-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="406">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vtl-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 406,
    "http://xbrl.sec.gov/dei/2022": 31
   },
   "contextCount": 121,
   "dts": {
    "calculationLink": {
     "local": [
      "vtl-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtl-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vtl-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vtl-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtl-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vtl-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 375,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 11
   },
   "keyCustom": 31,
   "keyStandard": 208,
   "memberCustom": 21,
   "memberStandard": 23,
   "nsprefix": "vtl",
   "nsuri": "http://vitaltherapies.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://vitaltherapies.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Balance Sheet Details",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://vitaltherapies.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://vitaltherapies.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stock-Based Compensation Plans",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlans",
     "shortName": "Stock-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://vitaltherapies.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Balance Sheet Details (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Fair Value (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://vitaltherapies.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://vitaltherapies.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansTables",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Description of Business and Basis of Financial Statements (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
     "shortName": "Description of Business and Basis of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "vtl:NumberOfFinancialInstitutionsUsedForCashDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "financialinstitution",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i68a332d0cac3410a9bf57d9923328244_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ibbacc1604fd34d488c15218cae45490d_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ibbacc1604fd34d488c15218cae45490d_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
     "shortName": "Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
     "shortName": "Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails",
     "shortName": "Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i6756bb299bd64a4c8756ee0392611ce8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i6756bb299bd64a4c8756ee0392611ce8_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i00dbb5ea0444479bb49ade8df06bec2a_I20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Fair Value - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
     "shortName": "Fair Value - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i3a93cf1f6efd47c68682b156780ea43f_I20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Common Stock - Shelf Registration Statement (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
     "shortName": "Common Stock - Shelf Registration Statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i3a93cf1f6efd47c68682b156780ea43f_I20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i7adc4e97d78648e5a2e35c0c4f324c4f_D20221010-20221010",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Common Stock - Equity Offering (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
     "shortName": "Common Stock - Equity Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i7adc4e97d78648e5a2e35c0c4f324c4f_D20221010-20221010",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Common Stock - Common Stock (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
     "shortName": "Common Stock - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "vtl:NumberOfVotesPerEachShareOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i1b55fff4633243a0adf3497ef994823d_I20230131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Common Stock - Pre-funded Warrants (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
     "shortName": "Common Stock - Pre-funded Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Common Stock - Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
     "shortName": "Common Stock - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
     "shortName": "Common Stock - Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie2ca6e9222044db0b2b0c86717d4704f_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i01801c5e4d9a456585f4460c4186beac_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i01801c5e4d9a456585f4460c4186beac_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
     "shortName": "Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "ie77c7569e81e41379e5f5c057ddcd669_D20230101-20230331",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails",
     "shortName": "Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i781801a508af47b1a07f6605aa4e43d7_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i0c71bdc1a2f64a69a40ac91eb07d2ad7_D20221228-20231231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "vtl:SalaryCostsMonthlyBaseSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i0c71bdc1a2f64a69a40ac91eb07d2ad7_D20221228-20231231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "vtl:SalaryCostsMonthlyBaseSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://vitaltherapies.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i84a305ee03d94715b753a2c6643dd24a_D20230426-20230426",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i4656bcc3b5664116bbc2110cb69413a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i4656bcc3b5664116bbc2110cb69413a6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i8b791530e898489c8c22614be6c3f978_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i8b791530e898489c8c22614be6c3f978_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statement of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
     "shortName": "Condensed Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Description of Business and Basis of Financial Statements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements",
     "shortName": "Description of Business and Basis of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230331.htm",
      "contextRef": "i09350f81250c464d865db34f18f61a93_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r395",
      "r460",
      "r493",
      "r494",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r206",
      "r211",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r235",
      "r338",
      "r360",
      "r396",
      "r397",
      "r408",
      "r413",
      "r418",
      "r457",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r235",
      "r338",
      "r360",
      "r396",
      "r397",
      "r408",
      "r413",
      "r418",
      "r457",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r227",
      "r235",
      "r266",
      "r267",
      "r268",
      "r337",
      "r338",
      "r360",
      "r396",
      "r397",
      "r408",
      "r413",
      "r418",
      "r451",
      "r457",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r196",
      "r227",
      "r235",
      "r266",
      "r267",
      "r268",
      "r337",
      "r338",
      "r360",
      "r396",
      "r397",
      "r408",
      "r413",
      "r418",
      "r451",
      "r457",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r206",
      "r211",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r236",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r156",
      "r236",
      "r426",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r409",
      "r417",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r382",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r409",
      "r417",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r156",
      "r236",
      "r426",
      "r427",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r443",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r416"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r122",
      "r356",
      "r365",
      "r366"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r22",
      "r25",
      "r90",
      "r324",
      "r361",
      "r362",
      "r432",
      "r433",
      "r434",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r416"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r439",
      "r440",
      "r441",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r83",
      "r84",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r65",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Options to purchase common stock (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r103",
      "r118",
      "r140",
      "r174",
      "r176",
      "r178",
      "r182",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r289",
      "r291",
      "r304",
      "r416",
      "r455",
      "r456",
      "r497"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r114",
      "r124",
      "r140",
      "r182",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r289",
      "r291",
      "r304",
      "r416",
      "r455",
      "r456",
      "r497"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time Deposits",
        "verboseLabel": "Time Deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r44",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r116",
      "r398"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r36",
      "r42",
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r94"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrant exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r99",
      "r107"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r190",
      "r191",
      "r383",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total common shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, cash dividends paid (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, cash dividends declared (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r439",
      "r440",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r416"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,403,838 and 39,307,286 shares issued and outstanding as of March 31, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r26",
      "r127",
      "r129",
      "r135",
      "r353",
      "r358"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r40",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r40",
      "r173"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r240",
      "r271",
      "r272",
      "r274",
      "r279",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r136",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r157",
      "r159",
      "r161",
      "r162",
      "r163",
      "r165",
      "r295",
      "r296",
      "r354",
      "r359",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r136",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r159",
      "r161",
      "r162",
      "r163",
      "r165",
      "r295",
      "r296",
      "r354",
      "r359",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which compensation cost will be recognized, in years"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r65",
      "r112",
      "r131",
      "r132",
      "r133",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r166",
      "r183",
      "r226",
      "r275",
      "r276",
      "r277",
      "r286",
      "r287",
      "r294",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r324",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r297",
      "r298",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r207",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r298",
      "r334",
      "r335",
      "r336",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r207",
      "r228",
      "r233",
      "r298",
      "r334",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r207",
      "r228",
      "r233",
      "r298",
      "r335",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r207",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r298",
      "r336",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r207",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r334",
      "r335",
      "r336",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r301",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r41",
      "r489",
      "r490"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Unrealized foreign currency loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Presentation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r186",
      "r187",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r40",
      "r184",
      "r185",
      "r186",
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government assistance recognized.",
        "label": "Government Assistance, Amount",
        "terseLabel": "Government assistance, amount"
       }
      }
     },
     "localname": "GovernmentAssistanceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "auth_ref": [
      "r315",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government assistance.",
        "label": "Government Assistance [Policy Text Block]",
        "terseLabel": "Government assistance"
       }
      }
     },
     "localname": "GovernmentAssistancePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes government assistance.",
        "label": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r31",
      "r172"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Investment Interest Rate",
        "terseLabel": "Investment interest rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r446",
      "r447",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "Investment [Table Text Block]",
        "terseLabel": "Schedule of Investment"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal option period (in months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in years)",
        "verboseLabel": "Lease term (in months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r140",
      "r182",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r290",
      "r291",
      "r292",
      "r304",
      "r403",
      "r455",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r98",
      "r105",
      "r416",
      "r438",
      "r448",
      "r488"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r115",
      "r140",
      "r182",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r290",
      "r291",
      "r292",
      "r304",
      "r416",
      "r455",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r140",
      "r182",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r290",
      "r291",
      "r292",
      "r304",
      "r455",
      "r497",
      "r498"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r58",
      "r59",
      "r192",
      "r193",
      "r194",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r28",
      "r41",
      "r101",
      "r109",
      "r113",
      "r125",
      "r128",
      "r133",
      "r140",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r160",
      "r174",
      "r175",
      "r177",
      "r179",
      "r182",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r296",
      "r304",
      "r404",
      "r455"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued and/or Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r174",
      "r175",
      "r177",
      "r179",
      "r404"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r123",
      "r416"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r65",
      "r126",
      "r129",
      "r134",
      "r306",
      "r311",
      "r312",
      "r352",
      "r357",
      "r432",
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Foreign exchange translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r416"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r100",
      "r108",
      "r429"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-Term Investments",
        "terseLabel": "Investments - other"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r60"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Underwriter commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r416"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of March 31, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Other current assets and prepaid expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock through At The Market Sales Agreement, net",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of investments classified as other.",
        "label": "Proceeds from Sale of Other Investments",
        "terseLabel": "Sale of investments - other"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r81"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r54",
      "r106",
      "r355",
      "r416"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r234",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r111",
      "r327",
      "r328",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r234",
      "r327",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r325",
      "r326",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r86",
      "r110",
      "r505"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r72",
      "r104",
      "r364",
      "r366",
      "r416"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r112",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r183",
      "r275",
      "r276",
      "r277",
      "r286",
      "r287",
      "r294",
      "r361",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r322",
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of use asset obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares issued in private placement transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r79",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense for Stock Awards Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets and Prepaid Expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r237",
      "r239",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r61",
      "r62",
      "r64",
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r72",
      "r119",
      "r120",
      "r121",
      "r167",
      "r209",
      "r210",
      "r211",
      "r213",
      "r217",
      "r222",
      "r224",
      "r408",
      "r425",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Purchase price of the stock, at discount from market price at purchase date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares issued under the ESPP (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Other Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, Ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Stock option granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted in period, weighted-average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "periodStartLabel": "Outstanding, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest, Ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r244",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted-Average Remaining Contractual Term, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Stock option vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r44",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r65",
      "r112",
      "r131",
      "r132",
      "r133",
      "r143",
      "r144",
      "r145",
      "r147",
      "r153",
      "r155",
      "r166",
      "r183",
      "r226",
      "r275",
      "r276",
      "r277",
      "r286",
      "r287",
      "r294",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r324",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r166",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r20",
      "r65",
      "r66",
      "r72",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Shares issued from exercise of pre-funded warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r65",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r65",
      "r72",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r21",
      "r65",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Shares issued from exercise of pre-funded warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r65",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r51",
      "r416",
      "r438",
      "r448",
      "r488"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r139",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r226",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r313",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r313",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r313",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r313",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r331",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r0",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r168",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r428"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r158",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r157",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtl_A2017InducementEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Inducement Equity Incentive Plan [Member]",
        "label": "2017 Inducement Equity Incentive Plan [Member]",
        "terseLabel": "2017 Inducement Equity Incentive Plan"
       }
      }
     },
     "localname": "A2017InducementEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A2019OmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Omnibus Equity Incentive Plan [Member]",
        "label": "2019 Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "A2019OmnibusEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A2021EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee stock purchase plan"
       }
      }
     },
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_AccruedClinicalCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Costs, Current",
        "label": "Accrued Clinical Costs, Current",
        "terseLabel": "Accrued clinical and related costs"
       }
      }
     },
     "localname": "AccruedClinicalCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AccruedCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Compensation, Current",
        "label": "Accrued Compensation, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensationCurrent",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AccruedLegalAndAuditCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal And Audit Costs, Current",
        "label": "Accrued Legal And Audit Costs, Current",
        "terseLabel": "Accrued legal and audit costs"
       }
      }
     },
     "localname": "AccruedLegalAndAuditCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Sales Agreement",
        "label": "At The Market Sales Agreement [Member]",
        "terseLabel": "At The Market Sales Agreement"
       }
      }
     },
     "localname": "AtTheMarketSalesAgreementMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_AustraliaAndGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Australia and Germany",
        "label": "Australia and Germany [Member]",
        "terseLabel": "Australia and Germany"
       }
      }
     },
     "localname": "AustraliaAndGermanyMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents And Other Investments",
        "label": "Cash And Cash Equivalents And Other Investments [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Investments- other"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtl_ClinicalCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Costs Payable, Current",
        "label": "Clinical Costs Payable, Current",
        "terseLabel": "Clinical costs"
       }
      }
     },
     "localname": "ClinicalCostsPayableCurrent",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_December2020ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2020 ATM",
        "label": "December 2020 ATM [Member]",
        "terseLabel": "December 2020 ATM"
       }
      }
     },
     "localname": "December2020ATMMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_DuaneNashMDJDMBAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duane Nash, MD, JD, MBA",
        "label": "Duane Nash, MD, JD, MBA [Member]",
        "terseLabel": "Duane Nash, MD, JD, MBA"
       }
      }
     },
     "localname": "DuaneNashMDJDMBAMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EmployeeStockOptionsforFutureGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options for Future Grant [Member]",
        "label": "Employee Stock Options for Future Grant [Member]",
        "terseLabel": "Common stock options available for future grant:"
       }
      }
     },
     "localname": "EmployeeStockOptionsforFutureGrantMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent",
        "label": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Maximum Increase (Decrease), Percent",
        "terseLabel": "Increase or decrease not in excess of percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentWarrantsExercisableOwnershipLimitationMaximumIncreaseDecreasePercent",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage",
        "label": "Equity Method Investment, Warrants, Exercisable Ownership Limitation, Percentage",
        "terseLabel": "May not exercise of percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentWarrantsExercisableOwnershipLimitationPercentage",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period",
        "label": "Equity Method Investment, Warrants, Exercisable Shares Change Limitation, Notice Period",
        "terseLabel": "Increase or decrease not In excess of prior notice period"
       }
      }
     },
     "localname": "EquityMethodInvestmentWarrantsExercisableSharesChangeLimitationNoticePeriod",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vtl_ExecutiveChairmanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Chairman Agreement",
        "label": "Executive Chairman Agreement [Member]",
        "terseLabel": "Executive Chairman Agreement"
       }
      }
     },
     "localname": "ExecutiveChairmanAgreementMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_GovernmentAssistanceRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Assistance Rate",
        "label": "Government Assistance Rate",
        "terseLabel": "Government assistance rate"
       }
      }
     },
     "localname": "GovernmentAssistanceRate",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_GrafelfingGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grafelfing, Germany",
        "label": "Grafelfing, Germany [Member]",
        "terseLabel": "Grafelfing, Germany"
       }
      }
     },
     "localname": "GrafelfingGermanyMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_IncentiveEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Employee Stock Option [Member]",
        "label": "Incentive Employee Stock Option [Member]",
        "terseLabel": "Incentive stock options"
       }
      }
     },
     "localname": "IncentiveEmployeeStockOptionMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Increase in operating lease, right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_LegalAndAuditCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal And Audit Costs Payable, Current",
        "label": "Legal And Audit Costs Payable, Current",
        "terseLabel": "Legal and audit costs"
       }
      }
     },
     "localname": "LegalAndAuditCostsPayableCurrent",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period",
        "label": "Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period",
        "terseLabel": "Rent holiday period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Extension of Lease, Rent Holiday Period",
        "label": "Lessee, Operating Lease, Extension of Lease, Rent Holiday Period",
        "terseLabel": "Lessee, operating lease, extended rent holiday period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vtl_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_LesseeOperatingLeasesNumberOfExistingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Leases, Number Of Existing Leases",
        "label": "Lessee, Operating Leases, Number Of Existing Leases",
        "terseLabel": "Number of existing operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesNumberOfExistingLeases",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_LongTermEquityIncentiveAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Equity Incentive Award",
        "label": "Long-Term Equity Incentive Award [Member]",
        "terseLabel": "Long-term Equity Incentive Award"
       }
      }
     },
     "localname": "LongTermEquityIncentiveAwardMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "label": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "terseLabel": "Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_May2022ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2022 ATM",
        "label": "May 2022 ATM [Member]",
        "terseLabel": "May 2022 ATM"
       }
      }
     },
     "localname": "May2022ATMMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NewYorkCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York City",
        "label": "New York City [Member]",
        "terseLabel": "New York City"
       }
      }
     },
     "localname": "NewYorkCityMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NonStatutoryEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Statutory Employee Stock Option [Member]",
        "label": "Non-Statutory Employee Stock Option [Member]",
        "terseLabel": "Non-statutory options"
       }
      }
     },
     "localname": "NonStatutoryEmployeeStockOptionMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NumberOfDevelopmentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Development Programs",
        "label": "Number Of Development Programs",
        "terseLabel": "Number Of Development Programs"
       }
      }
     },
     "localname": "NumberOfDevelopmentPrograms",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_NumberOfFinancialInstitutionsUsedForCashDeposits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Financial Institutions Used For Cash Deposits",
        "label": "Number of Financial Institutions Used For Cash Deposits",
        "terseLabel": "Number of financial institutions used for cash deposits"
       }
      }
     },
     "localname": "NumberOfFinancialInstitutionsUsedForCashDeposits",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_NumberOfVotesPerEachShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Votes Per Each Share of Common Stock",
        "label": "Number of Votes Per Each Share of Common Stock",
        "terseLabel": "Number of votes per each share of common stock"
       }
      }
     },
     "localname": "NumberOfVotesPerEachShareOfCommonStock",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_OperatingAndVariableLeasesCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Variable Leases, Cost",
        "label": "Operating And Variable Leases, Cost",
        "terseLabel": "Operating and variable lease cost"
       }
      }
     },
     "localname": "OperatingAndVariableLeasesCost",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_OperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Incremental Borrowing Rate",
        "label": "Operating Lease, Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate on operating leases"
       }
      }
     },
     "localname": "OperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_PlaneggGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planegg, Germany",
        "label": "Planegg, Germany [Member]",
        "terseLabel": "Planegg, Germany"
       }
      }
     },
     "localname": "PlaneggGermanyMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_PrepaidClinicalAndRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical And Related Costs, Current",
        "label": "Prepaid Clinical And Related Costs, Current",
        "terseLabel": "Prepaid clinical and related costs"
       }
      }
     },
     "localname": "PrepaidClinicalAndRelatedCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ResearchAndDevelopmentTaxIncentiveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Incentive, Current",
        "label": "Research And Development Tax Incentive, Current",
        "terseLabel": "Australian research and development tax incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveCurrent",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_SalaryCostsMonthlyBaseSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salary Costs, Monthly Base Salary",
        "label": "Salary Costs, Monthly Base Salary",
        "terseLabel": "Monthly base salary"
       }
      }
     },
     "localname": "SalaryCostsMonthlyBaseSalary",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_SaleOfStockRemainingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Capacity",
        "label": "Sale Of Stock, Remaining Capacity",
        "terseLabel": "Sale of stock, remaining capacity"
       }
      }
     },
     "localname": "SaleOfStockRemainingCapacity",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "terseLabel": "Additional shares authorized, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_SharesIssuedWeightedAverageSharePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Weighted Average Share Price Per Share",
        "label": "Shares Issued, Weighted Average Share Price Per Share",
        "terseLabel": "common stock at a weighted average price (in dollar per share)"
       }
      }
     },
     "localname": "SharesIssuedWeightedAverageSharePricePerShare",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "label": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "terseLabel": "Commission, percent of gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_ShelfRegistrationStatementAmountRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, Amount Remaining",
        "label": "Shelf Registration Statement, Amount Remaining",
        "terseLabel": "Shelf registration statement, amount remaining"
       }
      }
     },
     "localname": "ShelfRegistrationStatementAmountRemaining",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ShelfRegistrationTerminationPriorWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration, Termination, Prior Written Notice",
        "label": "Shelf Registration, Termination, Prior Written Notice",
        "terseLabel": "Shelf registration, termination, prior written notice"
       }
      }
     },
     "localname": "ShelfRegistrationTerminationPriorWrittenNotice",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan, Evergreen Provision"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20230331",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342957-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r422": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r423": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r424": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001280776-23-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001280776-23-000010-xbrl.zip
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M,V.IM2SZSLT4&F,^KO7#4[Z[FB:8H$RU'MS76]_F"EU?YH=? 5!+ P04
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M^LO#_[2_#,=HL<!@<Y5CE/+K.%BE&T7R!65IHWU8FL;10GACW;(2A!M0F>,
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M^29 )1^E<(M_X%'[KQG2HRAF2L[(Y<B"3^OG-KH.;,I+J1:$T7FF0C3S>^R
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M]>KZR5?V]6?X 8'_*</Y;U!+ P04    " "5-JM6 B6?X:4$  ">$@  &0
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MBQPX,3['1^=!X/5',LU)MK%O?O\48JELR!P!2@H,65-X1U240-.OV_VN#J2
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M+LO;G)YB ON?.[9WO?&YMFW#X'UV(0LL\)4^['+HI^K!NY+J6=[<V#NDBS\
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M$\3$V[GS^-KH=GCPOIJ0&7;[4N\WV??[=>\%2OE97.?8BZ7S/P!02P,$%
M  @ E3:K5E-& \\6; $ ETX- !    !V=&PM,C R,S S,S$N:'1M[+UI5UO)
MDB[\_?X*O73?OE5KD3CG@:K#793!'.I:HHS!;O'%*T<0:* E,?[Z-W)+PB#
M!B.0!+OZ-):TI]P9$4\^$1D9^>?_/6\U*Z>QVVMTVO]:($MXH?)_5_[\_Q#Z
M[[^V/U;6.OZD%=O]ROMNM/T8*F>-_D'E:XB]HTKJ=EJ5KYWN4>/4(E1<\[YS
M?-%M[!_T*Q13-G:PN\QQXD1RA0()%'','=*6$:29UU)Q;B6/B_O+2:ADI3!(
MD<@1IRHBQQ-!-&%L3/1&6;\8EC'!,D3,(V$23B*:"FT2CR[XD(@F^;$'?7@[
M>,-V[U\+!_W^\?*[=V=G9TMG;*G3W7]'C#'OSO,Y"X.3EAN]#J=$W3CYW'6;
MQ>D48_9N>,;H@GRP\:/3V[V^;?LX.K_9:!_]X/1\V-G>U>GGO<9=#8=SR;O_
MKG[\[ ]BRZ+QAX3X_:KB_KWHE_8[I^_@ %Q+Z>C$TW[SZL331M\V^P>Q:X\;
ML;?D.ZU\*L.,D='IO6[_ZO1D>ZYH"_QXXYZ-\SZ"Y]UH]NCYC3:\8,R:]:[?
MM>U>ZG1;M@^:!W<@ F&-OC_L_%97W9!:/CHZ]:2']JT]OMVVX8&Q]MW7_X1=
M:^#H=-\Y:?>[%W?WY_#@^/O?_8 ?O3S%"%-$Z'6U"F-"' I>OAL<O'KY?O=>
MA3+OX&AQXG+3MO?_M1#;:/?S MA%M&'ESU;LVTJ^%,7_.6F<_FOA?:?=!VM'
M.Q?'H$Q^\.U?"_UXWG]7F,F[E?_UO_[7G_U&OQE70'G02$/^?#?X[<]W@SN[
M3KA8^3,T3BN]_D4S_FLA-'K'37NQW.ZT(SR_<;Z<3XS=P<=&"+%=?(3C-4"<
M;L,/'G_>WX[I7PL-;)C 21,JL.>2!RU%< Q002=)K&'?UHJF$$S0=ZUMVU9^
M=&PLCW#L0Z/G;;,>;?<#_-);J#0"W#RP+Q=NK7/ZD6Z?UEGU)!RNG^YMF,.M
MP]7SZMK>T=[.*M[;6;^L'7ZZJ%VN\^KA+M_Z6L=[7_\^JM/M5G5G__PCJS7K
MEYVSZLXJW=O8/:MM[)Y7+^NX>NC/M]8VR=9:LU7;^-+8VZ@=[1W"/;YH_)'N
M7=2_>KFW$PYK&W\?UEK;S>KEW\W:VB>X]@ ^[[7J7[\TZSOUB]KAZF7]:_TT
M;'QHN(U=65L[.*Q_W>35G3JOM6J-V@8\GVZ2ZLZGRZVU55%M_=VH7U;/ZY?[
MPVN^P+-$>V^G@[<V:@?UP_WSVN$^A6MPG7XYK!_NGM?6JKRZ=G11;_U]6+W\
M<+CU05]\W%GO5S_C\X\[G\ZVUCS^9ERB1 :-C%<&<>\DTIYAY G5R7&O,)4+
M*UD(?[Z[(="7D^\_</].*"7\( E?WI(PML928PF,OR&!A*E'UNF G)12B,@8
MUFEAY1-Y0?FN@G!#(>"FW5^H#* 3;GO>7TZ-\QA0LLT\:I;"_K&P\2UA"Y $
MP0(C*TT 87.*K \8!<UL$#8%*_W"RH?5CY_77U#>[T^ZW1MPO=X.:T! YU+"
M7WCX]]_-/=H\=8?'S1JMXGJKFI]Y66WMXMK:^N46?*ZU]@[VOGXYJ!UNTNI:
M[6"OJ2^W5K])'3GQBJ,HC$?<*H!;YS5*V@9I&4[,D845!-P!L9>TR/4VC/@7
M[T%(7=O<;(=X_O_BQ=L2#ZV=?;,1;(1RBP J+>*$&62Y](AZ(C P'.J-6%C!
MP->IQDK)QT@H>DR5X(*Z0+@&8_3$>A:8=89P*_ /)#0DOLO_=#O'L=N_^ ?H
M7W^U'=:!YQUG'-WMQ732_-A(4S:IR]J%:?G6A_;6X69^SD$5Y%:EZW1KYQ/?
M.SSB\%P!YV*0%:_O- _JEY_81[;=C/_>OMC[&HX=Y;)ZN'Y6:ZV?@=PN0;8"
MP+2UM0/RAN=5=[8/]@X/#K:^?CBLK8546]NEU?UOS#@AA93("\; QXP.Y 8
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M*>R=\U1X;P.X/(N2FADRXK<37AID]OD;8</!Y&HW'MM&J,3SXSRS?'\T^4<
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MI* 4C]6I9QWV2HB::75R7$MP*9$W#)@]IQ)9KC@*Q ?MJ2 XUP=K=W[.O![
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MNMD^!<W)J5:#L7ZD2^60_H@A?>OS[;"J2EKP&)&)7"/..45&JX0<I=0XJE7
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M%QW]S%S2MRLKY0-3"FM"L,9,8FH\\=QF@3+N";;?BG-;45\J!08<I+UZ/1[
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M<DLU1)]W.S_B.5$,0 U;RYQ02EIG14:DU=9*[%,9WIO8<9IV?@]NI:F[*@#
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MW Y@K4MXGET(4)5!/4M+5B[%])3L3=X&>Z5C7YT%6([6XVAI/@7DAO4$/IM
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MWR^<@_ )A-%[E?+V[-7QC,5SO^?2GZ519;AEKI4?@/R'7]LG@G OO2$H  -
M3$F!%+$9\MYYKG(1..9/UU=2G996?5Q:,P<D'>M9'\J3X12+>%8B=7*?U.L
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MB%%;E1&S,@#VFP&M"S9T;GC0V"I#;<XHTXHXGX'6S$!7PIFDZY)3OFU[7^Q
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M>O-%Q_;6]0D_FWW\PC-33,AN:NA:1V&DPHT)FR(9P.R"_MP?)#Q:Z.)5=DV
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MU$!?M+.G7+"]P,MV'N;EW% 737%0M$P1$T%ST?,1&6&G;=O W*(-"0QVN^'
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M_KC;/M/,WD^Z[CCN?DE'NJO/H:;GNN0^;U6X!)[IO9;X;7JO*1%JE.H_'4<
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M+)\P1+]+(2.%OV6UJVW%B7N,Y7Q6[521Z7<PR/W2Z[5 J6O-M$IFWI*(*QG
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MD?)93#?,#5(N]EZR+G,4>VMS%JGQK37^)@E@ZR6J]%Y$M5'\MQ:2_8+Y>L2
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M)]9QL$^D1T'E*1 .V*R/45M&.:]SXO)HIJ6#A-),C"%NMRJ-G"M))1& 0=S
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MMC.9H?_)]R++S?W<=-(D,;W42<S$B1TS86X0I)F59G'TY$?']D>!O4UM-%9
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M%.NLFR6PT[U7\E>F*]Q)&#]0.>MU;&./J^2_$N]81D_+4XM[D96;F1U1J__
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MQ-I@5.WA_APE0JJXQ<F5#NTT-H[@X&79V!)$2J/N-V',\ (55CA=/D72R+D
MH*I1V2AJ1&/:&\2?6B'JK =V%!=CH)LGB9TFN>7F2>*!,A[$G$<9"]*<^R%W
M0[Y:-W_(EF2GU*-%@C8T1Q>L*-&> N6'P#CVVFZ_AP[TSCN]_#N(0C>C[# K
M#$#S\7TSBD$1"N+(MS,G<5(/[&[/';FVO:R=2T[)U)83^Q3@1#W,(7'SL8YR
MR21\.)0FCS .'^D"@4AZPV=SCI1(?&S()I,**!67GP'?2.<5B"HVF]5@@0@M
M8\#)@(.=%[!-:"G#+:%:+628V/"6ZE7AGI["C]OWC8UW[8X/QKKEA8ZRR'?2
M&.QKU_5LH([48ZZ;Q@'SHA"N.%YH.P3CQSI<Z*VZT&>?3H[^MJDCAA.:/ "[
MTW,XF#(1 XL[3P.>NID3<Q<N=# "JW7MA5:Z;4N]NA(D9"L\!C8K5V# A+("
MJE6Y: BKAS@!0J#\LX KFR/<HL1N0YSB*?7.A6\:U)7$@ AE/*OY15$M&OA]
M!YT" VEW!O%5< !%X(A#5Q>,@%N8%.?\?Q#';$X VBTT"SV-RI$L#Y]P-B6%
M+3=>+X!U^8'K/TV?/?6>*:WJE#49^\?XM1"8=OA4,WXX>?^H_.HV[O4@S5S7
MS8*8)1X&+N/428,L#5)NN5Z4W[[YJ.SYP+/5'$(VK3C +R]UA#CR7_W^MV-'
M >,\-), 6_HQVS9CQTG,.$H"V\O!1,JRVV5RVK$7<2L$II][L9>PP$]XZ/M^
MGJ6A'46W;]%\..#['+!O^[YG^:$9AVED>GD*?SE18OJ@4 =9E-E)E#_Y\709
M77N9GRN?**H1Z/>L48]0J*_"SF'+3IT[84..!ISQ@.T]8+F.M578WK>27(\H
MI9:!T&X&%.^A!JYJ_[2!" _'P09"/&PE^*J=QJ%IRL \@XQ;'K?=P'. J3I^
M!,R6)UF:Y79D_^W[3WI-9:X9\4L?Q6KO</3%T1=?<P*/_HW5\RO-H=6\*!J$
MK5[46P.M>/I&RH4/.'YV?OKAY.HO;'OV]C7P]O/SDU]>ER>??__TZL_7)<@-
M>.?)U5 NG+R [YR7SLGG_Y:G;T_LTU^.G5>_O+R$.7P^??'2A_\%N7'FO__\
MW_SD[7OKU=MCY_3S[];IBZ//8+=;@1U9F>>;+$Q\TTLLRV0IJ/E^:K$P\&W0
MUY(AS&+$L8=:XF5VZGN,6Z N  UZ>9+&F,V4#=M(R0,QZ$1T'V.SMO7:S02\
M\D;?.+-EAKZ=,927GWBZ(%?E\W-6@'(S-8[.0(*VQH?Q8L&F9%J<K^5":]>W
MCL4\PKY<R[:[F(I/2H(E8+][T5JT*(LYV&K*VOI).4A>M,:>_$;Z;='JXS-.
MZP,#$4U%?BG=(JTKA02\<,^C03C5C3_6/PD<>L5YZ=,9:<<U,DY>C(S_PG].
M?CKJ.:&O._2>MWNVJ)L%.L=@:LT"FUC0M%DYTESUH;YE:NGXZQ?UF"8BUD@N
M(!GAOFX"8XQ/7?L$PKFSI"R:<P(O5:MBN$VE"F#I^RB4-& #Y\5L;,!AO^"I
M=$1%(ZD+;C;YHPSA(A83X[3"X,BB5FXOH&2A;)(.*OL(:U,@9;5]K=1%'=S7
MX8>N.&QF8$,YHV&E#''>)OW$ C,()+7-G#SP&-C!GL72V.:)%68.DXF[CNTX
M$0DWV^D;2):2=!?S\OLW- /J;$@MF<HK-(_$I[OAV/K:TJ^+UL/S+]YY?ULQ
M!VW*BDT[B;GIQ0XSF9,&IFMG"??M. 'U\,F/KK7:Q34#VB![QG@J:*V8IN4B
M ]HG'H4T6O,Y Z96&S-VU;JUT=U%_J*I3MRMATRRKUIT)TSG H98/+J*M3P3
M8:B*XDM(X2V[N_:NRA -/M< 38TWL+DVEQT;!J?NJ>E&3VXV0;ZXX%HMON,O
M#S&^2!K^SP+V].4%-IO<%I7VU?/6U?$)+MMGN)@?W[\]]M^__=TZ^7Q:_#4Y
M@0O]SGWO'%^=.L>7K_Y\N72I85XN7.;/)Y/7YR<?RO/3%[]_/G'^.WG_&2[T
MV^S#^P_'[OL/1S FJ;3VR>7?=N#&S'>P5T'BP%5.'3.*W,Q,G-0.+"=,F.,/
MU=@X]2TG L,OM!R/>U%L16%H^2'C <L";@_5V&[+#;'GQHWJZT/=BI7*[HWS
MO_,4'E__/9K-*I#LQ*K0L0[\%=GBZT568/;$R?C%&(7TLJYW"PMB>S9G,R78
M";7D5TTIFE:+:2I5'-;?-]26^GM'@0]C(E2;337FD<'S7/A!9.Q5SBB0L5?C
M"$=]7K*F,8Z/C]LXRTC,@-[<2CA2P^#1.:+9SV&856*0-*ZC*1!\:9QP/I<1
M%LHQ42DZ8VUT;*^+D1\&LA:MS'DU$JW=*BZ^H#0,W# Q-Y2P&#ZBO]O83PNJ
M7$Q']+">5U5C A?9!%GK29#AZ>,YGQB>Y3UE%/1YS<\60K4UWIC_1YHS9I%0
M< K^IXU;4DR*1@#->8HYX(V1\/DE9HEH2R/#!"8C9#SH'0WV$]:- *& G O_
M;,-+@9M!1ZV.8GU\?*V7;H<OS3$:AM,IUU*9SHNF=SU@=U:1*6VARN9A1EE-
MSTRBV*7T/9&?()4H5+CQZ%$[FRVEX8FDJ-:&@Q.#TX-K"98$D_G(78[PIN%U
MC[F6S[GE9K$7VGX2^BZJKX'G9IGC,:E$>$Y@JC^^5)Q=+*^AH'IS/!4YP[_4
M5=/LAB7R"$J+\L.!)9+ZIV=_QY&5IPD/33L$W<7S$LN,/6RC$<=)YG,66+D#
MMHBSLFA%"[>OXJ6]H'OK(.B8-QKVDFAURMP*<KP+U(8DQS\HU[V? W*@QYOI
M\>P2X3-8Q),X2^&P+(2:"5,SMN+$3#,_<'B:,]L-;Z1'K#9HD$-.A(<"F6>M
M))\HF=BL0N).Q/5 S(W^"VD)Q+/@;*OK'RZK.FOX]-LFG4\GO__-PL#E21*;
MMN4DP,J"V(QSRS59BGXNW\]X[#_Y402$J>IAJ1:"O'+(R82(16 %P:5D<O&Y
MR-[AGWB=%IAH"[^B8AM!>"BJ12(/>6) 4T.E33RT(8M\VZ7MB+3F$U9_Y'/E
MM,$9X5 TOV]+LT)?*P7,65E>C89JJFZ9++F7AYM.2B^:'DIYPO5-ID5>"" 7
MS=&>]Y.WII@CIKQ;50X_X$O%,]?F#3S<R3S\B=[/+1;8RP'@K^W^0G-(%-(Z
M8[@Y4W;6QC#HX#$2NV@:.F(XRB.@I:NF(/WEYV+*IBG:8L^KJ2 T>N8UU4O0
M(Z]:3)6=2:%;Z_U8FT6OU?ED_=UBVF[E[6ZEO=VJN]W2$&B:\VI19J)TD5'F
M+_SJPV*J&4E8,M)!W) Y7$S60=UT;]= ;_#U8&\+-WC-*4N3_.+TPHXR;&4;
M=2?^IAU%!8O(N(*E_KX HY[7H$&\YK.JGHN-D+-\KL]IU6AMHA))&YE]M!ST
MD0E(ME;G(\ME\J*$7[3!OC? >6K8;"Y6^U(583W'4*0XJ*=/WKQ\_N09Q>-P
M3Z4G0\X>/OP969YMF?]'_^!)O<!X$CIW6H<*I<*J':CIER,XG)(W,L0@-"2C
M69R=D:)%_H%+$(@CM;>7?*2V4GZR:(:?8+1L\-& 6>,WL(.J5$9LC?JBYCD&
M'H851K@Q!<RIK5J"W5H6E%N8GP('@PJ?^6M5?<3;UY'17A3H' .#D (<#PU(
M"R0J=A4 2A-*+561K;YU;80KEYM4RDW2[O_JS.B<9]2IMNFN3LDN&PS6KAT)
M-3D@GP_HH8.I@HC':)I1%\U'<?'0[4F?S:EH<D(^LEPZP_#7";\"SB6K[Z;S
MNBK'QAN,EVMOD6L:&<EB+EUT<Z,L)L1:T(NH/3L#!81G5 @VD@Q:5(41?V'S
M[@:J86D?R#)H[V3"RX)?+%W,";M:^@C/;?AARJ9+'R%;'WZ(,?>ESU8]**3"
M\%.T=] MNOPN$4(9?@YZ<)$6LQ6_0"$R77XKYQ^'GV$>Z=)G=84$L#0]0LY<
M>ACD#LR#+2T<#@Y4U'G'^S ."V=<,JK  W'9D(14*NR4GU'ZJ'2I5(U('KAM
M??:6\H!K[IS4-= C/D<7.U&UNA4:L\C!TH?;^VI17\<+BNE%55[(^DD)WHPC
MCHR"S#"P$= +H-SOL 0\&,K @0M;H[H_,HBZC92!.*2;K'0;8 E9D>?:[[%:
M1%B.>&#R7$69Y=IS^R83B.U# O$MMZR8S,I"\'I*N%I/]&/C>(W2.B(]E']B
M6'5-A=H3]I%?,]3(8),*Y2=*E09KQL\8EJ2?&2VC,ZCA.S\K4H6._H.FEBLF
M+AB;9*7B(<7IF@5:SP6?IE=MH3J;4?8^W![X9\KIJN4+*4@[>V+GF2'U $!;
MBX1U(^O@48NXEJ>M48ZD=86,DBPL/"L5A /M'>O<IG/AUQ!<==KNN"B@0(F-
M/V7I.2H(F6"OP&@7XC"(ZX&:H-B>QNLZZ4L60W4]6Y93P@%Q!A>@G%>+AGAZ
MA70F=!=1N8&CHSF'9B.H.UHY+I )+4:*6$SN-8Z/1R(6:A^9KT%/,WZ68RJY
MJ\A.+ &HCHLE);SEXN3IP_8[^'LYIYNT-'UU>ML>W(CY9:4#?.$U.*O9I!/V
M<Z!6CN. \..LX7 [J*JEO6-X;2^*K,IQ5R:P4R !TV(QH1&.3]YAYT::!,NQ
M8I&\4RI>#O\6XP]&G[+YHN8C=7_%K_(*A._ 1?F#(70=:<-W/$"[JL5GUIK^
MW>UO[Z]XH[X'^""Z/-%_"D]V2Y7T#WN4+4#M3C$JG1$'&<Z*27[ DJ(L*. N
MT]U:15T$JJ<<3(L)WA 9JR8F,CVK: V=<X).HS(P*XU^W64<D!=B*GP<J,.+
MT(&^3AP=AMMYAB127TJX=8NS\YMN,1C>)9E&Z">O*CAYA@Z*#XOL3*5_X B3
MUOTVDFTI!B:6 $BNIMAH9"H4.T%(\NJ!P5:+3.F/T^IRBB)PT<B,#\%$D&-@
MJ(=<LS5RA@6>*1?,$$.*)4LI56)!7;4*.#@N7>G-]0)0V'+-#+00,4764B+Y
MX-'%5.4B!?(ZC@>SZ@J(A7E:U.BA+H!HKT1CCZ)1,Z>>+^K7(H_D4J9ZS%%D
M3X&*$Z >ILQHS"%O2'E=S&A>S<#*I&?$>?$+E?F1%G6ZF* 7'-D@*5G#E8VP
M%IK/*%M!Y)\()02,YQ74OJ&'V-O>Q,E7%Y@=RR]WK_]3W_WU](GZ]Y-;^N(T
M"Q5IX8EDN$^>$8"XD13 J]/S*:P*A(8$)E>\G7*%C10F1T;:K)AQG"C>&)$4
M1.$2],,4.#LQQERUG1+BAWB!,0>]GX1H>EY7V)JHF.8EFX",KNHKZ7V=5S0*
M;R7;V/A39#F=<Y;](_0CV6$"]OA]57\TGJ.H:#W-E(*L0Z1/C5]@ QPG^@$D
M:8[OGW(PT4]P)\]'QB\<LYBOZ#T=6Q*975@!\8FT7?@H=+NZ_UMZ';>I"(8(
M2^XII7O1B:CCU04Z=:LB"UCA0.'6@WHQP>94DPH.'WL3*-T'V IHF9VS# .J
ML,?_ '_..6DFC2'\-D*]$J$W&CVKE?]Y,9V 6C/E/".>#-IGT7H ,<N=E,K;
MT8_0_'3?V4J]ZRDI76[T3"U("8J":.@W2E]Q5^\4*G/]J4ZP$1>89$:3EKRN
M,+2B6J^=O.G5W72;!<K^Y51>'0XR(Z54_0N1("8GX'03F*-B2W-K7XV&EZ@P
M(CT>M=89QJG-FF,]$WZQ8F(XBTF%OM0Y!R8(-'6!J86+,N4"^ N[:Q=S;0GO
MGJLE=-JWTEF7=Z_5A4E@G1&^& BCI+H$-8[/L(M5J33?FD2^T,\P.P+6F;"Z
M+E YDT$E-;+PX;1J9DD*/US9$G8'ZR)@8Z88_$>*.6.@$U?:H(H\1K+6">@
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M3.H+AZ1NJ9HH:0E4.4>H35'-AG?F-3=?EE(WECVW5HB[?3O-ZY%A>GWDJNE
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MM*55Z";N;D';=4IYPL>4V5=R$DI=+YVT^U!HDXBQ?H$G/FCYLKZ[&V6FU-?
ML@^A7I2C>H+=]3...:/%M.NG36[M0KQ*]FZ&\19ULY"MK:I+8X+N% 5Q@;V^
M!;0QMEYCW2]%JF/+3!,*8 KC@2I]%1L:8EYHY*C<SFL[MDG?B^IAV@+,JZ6L
M_E6;7JEYN-MP\0YZJW_1FF@=]9MH[96_^I?US<*6/-:=78:7><G.&E'+-H'D
MB>R.2].KY&<8-4)E"U.,,8EXSCY)N2T0;I3O3P" "6<'J@'-HA9^$4RJ6\@F
M9]3_QTS:_ 1XN4PKNC^9W> 2W+9QOLE =K"[@>Q'8F8]V^>IY%_/1C#\?%>8
MV"WSTHZ10#GP++'H75GE#5X0N29I5DNVW*AZ>OH.S)JIR+%"'7-23?F5"D4+
M=P*Q73;]J/AQ(W435'C8,)%J?1NUA!&XLH@>%H.9M4YBK;.B](A4BSE9[<I\
M=U&K."NKA"I,Y3!UA\DR&&9G5.1;TNL>W-#K:R,D H)8G]08GG4DW%,MV'K[
M'!4'4?4E$B-$[U:]8X4T +OP1#'MT*@P.5[Z_40)E/+(KGZ;<,/)XB58SE3:
M]^F5#OYIG('5(BY6V^.UG5<)BK1)161$W:HDN*RH'@V-!T)E9E?D4+@FN8?\
M@DMCP/V87^(542Y1K$06KNK.1WI)N,'S>2D8@U8&+,JXG ZC<4J7G+*[\T73
M]FGLC0ZKZ@:_A8OY\?).EI,:;W>IMI-G4&%;732=3_8M^7%/*FHF^7**SM1^
ML*AUFMYX:%)!Q*CW8V[)M4SE;0_Y2/1+:1839"2?>3-H [LF&B0[;_+K-JN%
M3Y*O4"HT9GJ;E-,P:_CWZH\?LJ*9E>SJ^V)*4Z8?_=#?5E0T+Q >&SB69-FT
MJ^)KJ8/&\3BT0E1#YS7\)U,OEAKJF#34?\^SY>\\=QPX]MJOK?'Z[ZX;UK;'
ML1??:=CKOXN<X##9G9JL[VTT[+^)<@7UPOW 6_2_3]PG@PR;[YW9)\/N:S"8
M13*\(N)V/#2SB6[B-9;(K[$#JTVO40MOUQ1OLB9A-C_.JI9$B"4XZ'J!L7:M
MR^=GX4J?[,^V/*<RF=X&?#.4W*U)"CB2^[.Y0<%10TUOI\X3I?E#+7@MK2^-
M(V7]\E![M;'.0_");W'OOCM0Y!?8U7_M/-=>O:ZG&9H7M:S_J18P5-8\6TM"
MCKV';/SI8LH663'GV;/;G'+"TH]G-79<,.5$,6"?Y]<M?M7QPPY^?4.7%OYJ
MR8K]?@--],9U;\(X[CS&7>=QZ\/,Z?\-#].@_XVW^537E0H-C_8V*[>,1^5E
M&ZY\2?3=:HGZTFH<=:O6YCBC.'!7*]EWH>%;+/=6]WCPRN$]/A#=+A&='8X\
MSS\0W8'HON+:_)%O1SM/<YW*?#L=8R7];=\AN<ZCG-!C+/56IM^F1L$.Z)'K
M4_C6FX>WVX<=H75OY$2W94C7G/J78DB;6E#[>4CN*(ZMPR%M]R$Y\>$>;?D1
MA8]R0%LOUU7RQ;2:\NL)ZO!D_\F'=+RYX38K3&]%,>J24_5.ZI+<A;5>]EWD
M+4XX<GS[;H;#9ANQ0T;??IVL/?+<.SJ*#B>[S2?KCR([.!SLKOIIG-OJ<P<_
MS1;$[C=<\:]5(P&,J^4,]#N8*WO%N)X*;6,IE^%A-F&'C- ].U72- ZGNE^G
M2EK&X5!W\.ANK6!\(PZC336KK58PI$=#*[+\(KZ,'>5:]B@.XP<VC7;8.MJW
MXPWN:CL=#G?[#]<>N?X=4QCV\7AW\ 2=N[JEOCW-8P==&Z=\3ET/[F@2R(H4
M=X:0%PNLKKZQ)&6OLP ?>'>V^[8\=?R1$SIW-2?ONSN/;&\>;LCAAMQ\0ZQ1
M9$6'&W*X(8<;LOJ&>",O\+[1"[+O+LO;IJ#LE<ORW]0XZ,<U.%N[ARQ\;6?O
MFV'3NB[HR97QG3_V6_ 4#13]QIY.HR&"_2:_<L:R^9KL!%_SO.2(Q?BT>&8P
MXSMO;&E(+AK<^BK4$M&46NL0AS/XC7"IW:[-\WI(:_SEC#HJ3K!A[@P;4J4E
MKZNF:$8P(S$E:QP_R)0<"9)]S81HSMCU]X*OF]+#SLD>-/LCS&D!S()ONY O
M\U:^;*EM\;78.]K[67^<<\XRZI\YPG?9[;M:B MLNB>! :;5U*0&FM2YV%CN
M7$SO?:HF[BQ/7&]T*,"DTAIS"J8$3T/G,>=G55T@Q(%.JXV PB#4-E92>\6\
M 9,=[A 2+[PPX_(=,'-X>:!C$MV>6I9/9AW9+,J4RT;3P&2*N41BE@0\F)5+
MLZ)I#5XL\<75S;D!HGW/N.8FS;O[?%-MY:/PS4NF-_J4E^-IL9[LL==%S2ZT
MRZJ12&\M[4\>X&(L49\^LPTNLYSK->W(;T-3.TR>O::O?3JT-?;\R'3(YL"K
MDH7H[=@1I*TQ]4X^8+-) >8[^!4VIB4H)GB?O1'(U,_%M(4%[D@Z6GD+A@V6
M80%,86/ 4 BAP;4VS+7 NEE>]!HQ,+A,+?DCN*!L?,L_I=0436MVVTW:6?G3
MS9KX-NOPS-JFO</5JG=DA+XF\'"GUXZP)9 Y#X:8^TVV_0_7M_W'Z1;9_SXI
M+-L*,FYYW'8#SPGMR/&C./=XDJ59;D?VWZ'UY,=MQ KXXINZNH7PK\4_BR+#
M?L\$&RB001'P3B 4[DKK<1IQ\\;)@O.B?OJ\ OZ!]V!75GH3%BWUS)]6+4A2
M!YM$7%9#GV>E!!\2OY@;9Z1,HFJ-S<5KX-<(X4:23*']X(^:#OQ2X%\)--BZ
MR@LA#-M!6T3IKM)*]D='TP)1A$A@-JM!51%.=6RT[V*(KI4N)@NA_6<\+])B
MO@)8U87+V1DQ;+ZJJ?-WKAUJ\HY1<_ 7/!5=T3NMP7BS2!H$I!9"$_Y+ 2,L
M+4F()]QGW#!=^Q9[4" <%=B=HF/\"ISWZ4JT3R%I:<RS]<K^>AQY#;IPUTF<
M9.F?"I)0 A(B0GC1PGH-(6%;\(FEXU)-P-=B&+80A )33 $:#K"UUD*YR5/*
M-']#'WJ.)B05.=70GTX-"5V@06<W@AF^%?HOFNF(4Y )7H;82P+JH^;]MTXX
M1>L5(D'9<O\IYUFS KV1?^(I* >TR!:KB<B.GUT1^.<0"@WF<]4B5 N /534
M);Z 1!(5( I< )=D/ &2Q9%'^A(D#D$N>/7TK$&<:=JK1&*KR:[WH&RV0&-&
M"ZV;BSV (4MLEPCOQJ4QXE07149,$BZ,Q)=24X>Q!B,@S:CEL M6E$0J9!,P
M.%BA_L-F[O[]$J(1.4W'AU=#3FNHKZQ /7S*YP(A9@4[]GV-'4MI4ERHFS5;
M)""ST1SAM3ADI'0._ZI)$)%I#9:=L+;'QA$]L7(ZV35H-<OSBAW-U!+< FR1
MN0"Z,V4J+9K_7F>I@N3#&RKH1)+7I<Z0D$:D/4@8O7T.#%]?58@F><G+B]9>
M;4U%@AZ40 X%4":3-V054&TFT-E[D+5YJ]6TX+5[0I3'4^,4=!@!66(Y%NUZ
M7I2$^MR<\S)'@$,I#HE66O!>,+TKX'1O3-=XBAOY!']OO*'?O-9_\T;]YLDS
M!(E%T_G&1Y&Y3XIY0T>D2'C4'1Z!U:&>U6)2?^?XUEAV/]$\QCJ-CS3ZEQ]<
MLAJ!:(#:D%<:#?#D6B+EPBO^#7QQ,<5I%(@,R9%/3D"L:9=*T#?I=<O\DV0@
M@3UVU^O*<-3=PHN !&E\%_K#J==\ OQ=&N#S<WCHNM/8??!D18VMJKA$C;_5
M%6%1+QK0'6>S4M")TC8VHA%F3!CPJ<7$8&=GL)."+8@?(N\47.$[)"1C#0T)
M>888JHG@)9*7 K/(@%8R7I.:,3=A4J9$!R/='EY9<S%G4D;>_/&3\2O'5W\D
M5>4,OWGZI+=^X^CM"5X:I:D32KF@.)#*,F;1J12+1JA1*#,(RQ<UCY8)+HT\
M_#GQ5=I+"5#:^GTVU\OP. 2#5SIU6M6SBA2RV0+^:@3Z9(IA"WB%T@/X)Z!J
M D5%R=7J' A2W<ZBI[>OU-E6KI)4#(4;"WLXJP02%!@'92$D$3KJ>K)!)QUI
MFN#WS3GH?1T"O7Z$<E#25\3/%\D'*;L(O5J9PX07A?L$-" QJ9;G#+M(+D -
M[E;-8?EAM+%PRR\+U->(;U(4![E+<K5N6R0)MQN3H4&';(P0F9,K@Q=TCNC8
MO)*[QA$-^*J1@+1X8V"B8.#"Q1GAG.%7/;+6!D0C38(0IT4-UB8:?VF?&(CV
M4EV%Q0L+,T12 ,T=]'TX-KBO!'H.Y#Y^)-\C,2OCL?"ZZ>TKQ,EW42\P"U=C
MQE)4](4L:21[6DE$C[R3>R.^Z$ LQWDDR17=5W()WGV]^'KZ1*U2R*=.GKUI
MU2?CUU^?MV*-!%@GLJX74^VJ]E$ZZ1OWA073X"SN(Y]ZL[Y&-/6>VT0J]7[P
M!072D"Z_K%S"QY\+F_(@H/H"RNJE<UTGH732V ]3&W@@\ **!TBW^Y6X*.F\
MN,!-N$VP_A;8H%N]*<?3S=(,2)Y*E]@9I:&TD@/EGJMG5P$G1V[9LK85AH_F
M,U7<U!G%EC>R;5<QTZ'X1*YAB,4@;X);#\)-D[VV-?8]Y'1B ,'A-C7%*&/F
M.R<>AYWG#..E(-Q0D"!=T-VX!#;&1;0)9 *Q:Y%($W>>M!TCC#6!1!$QZ.*F
M_RR*6GC>=FQ]:]DC< (DI*2ZX)W;]S;A0I+C\,.LHI]]G%:7QN4YGY+H*W(:
ME)0,->!ZTO@FTQZB]6D/6Y7!L(*0'VG+-@A?2V+L//<M\=U S(MIB2$PI.D%
MZ-<E4J^(<J'3$X/357TE@^X8A\.8E0QBB, [K(/>L=8&&!M'<\GS0?-#]4\/
M,N!OVB"G"('*O,=![$ZS052,>:0;(2-0#J>+'.0ZQ3QQCH,$JBH?"1V<\X_K
M%C=:NPC89!A$Q6BUN-Z:6'4;H*6(J P+R:#'V#B>MD.,=*- ;+U8Y/($40>^
M;JM7!C 5.\*0*+Y*Q?^'X55\Z9J@OCP%+?"\#_%WNENO8'DR3MZ+M:=2!-::
M"*3X<U;D>9%BYAZ:QU7-4];,A4S 7<XXIO"A03+!HT)ZK&K=KAD9R6).E[4L
M)H5(_/[^IJV\!KQ<U@:96-_W?;C!=IMV]&B[C2:C$_SP>!92?[ML3U >*<-P
M&M+7T,SKA6 C\L+)! &,Z\Z$M8Z/P8?3AM%5P0.F1W^XQ4D>3NYA3@X9\$@_
MOVHQIZ1B>7KR>F-)QAFQKL,A?=U#:E.&3%7KHEBM[N\!?835% -.0'?)"PP/
MDPUHKB])$,=-#JI57_>J>FI.'D29'3%PI+53/-#&U[_ 30I:Q:BMNQNA3X8)
MU4AD(4J13(I6E:_/,21J&#JJA?9W.-?'8<SBL@G>3!EHQ(LUY18T4N54.9S1
M5IR1O%%*FH+A@=:%<I)V5I8(@E68CBD34%':=H&:9?OD<,!;<< R;:HUX&7)
MKO"(%WVI7/-BDBSJABL;&X.39,9TSK ,<Z.P=@R'(2Y]..BO>]!HI+.D*#&@
M@5G.#58N%,VY")8BT'I22;-]!(IP"LH1T8(*S%(^WIFR<F7(M\N_%/%+H)QF
M@5)7Q:0/Q_P(]WFZH!@&*43GK(9;"^/#[J7-P-Y9$8V_Y"),PP\']SB,&%-:
M+ZKR0GD)$TY2=N >/)S.HY\.M0'A,R92A'+@K/B_<*4P5UG(/XR=2V<M.J)S
M6;F+%Y-/01M*23]BJ WU)&KGAU"N8Y5BT[DMB,]J#@M\9BU1'$C@(3V :'.F
MO)@)I8E-L"5*%T,62@]&$D!VUM45*RF_!4W59=:[^RYR*E%[1W$A(DD1O2ER
M PLE1RI& U-JPTUZ@$%)(!E^&A:7Y+)? $48&"DK&*]7:0)+I5$B(: M I#%
M UT]U4CST[*R+&1&45_]H5/M-"!=\1D;KSF&1G67 OS^O+H4JR7__H1]Y$8Q
M%P4)72Q ^2?**S*$%DT7S&F#*Y0'UUOKZM =2\\+CK5(ZZ-V(N5*9EHLFC8Q
M;76"'P6+A(01:7*B7*DKIX"!4$'0I],FRU#2PUPX[63S'%%1UI:DC8VC8:$>
M9I7A*,,:,Y9B(5978R;<YG.<^[#X3\6N*/VD%V^3D9E5Z22RQDXO*"'.>@G4
MV9P7LZZCA(RA$4V=5V4&W[=E<5F!D729\]\F;U+F&^K!-#,J1805YNP"2$O6
M2"VHIF\X[F.EHXE>#8^5CD9O?R/9Y?+!B,VFB&K"A[>)? ESH^086EM3U9KP
ME$G*5VFE(+OADI,1)',HY6N%U=JHDG'8")Q!67S$RR/9&,Y&%#[I];<93ZE>
M58X'_"7KY?ZV9PUC8RL5LJK0&)M.07"D;='6JW1>4>J1S*Q2R9NR 5@B"+.8
MP ]9>=44M&G%9VKZ<X83@0E,JHQX+$@-.(\+ZO;35'7!X/&Q8;SH<4-QL]3=
M&Q$12^T&M@ 8"]9?H2<5+'>1Z32H[9.$K%F52Y%OXK^M#7G'RV$< 0V,C-95
M00XH?27 BO2F3[++$CY?%X-F,M0F!B@#1.M4AK-%0INL?C_.5W(4P;,4/]E8
M7@@5?GY>U)EH1",EW&6U*#.-G]=8\@R$B"V6-.E(/1N%G%C@[J7G4[B59Z1.
MB'T::!.D<YQAX9R<$"D>^KYK;'>P]6.Y=LIXHQSOR:SDF!YB (F=D7CC]'MM
MMBA1,/1?5Z517<@4T:H&>FQ]1B3VU'+K@C)U,PXTA3N$3)I]DCFZWS(;%'N/
MMV(Q56>BJ!!8% KCKOH6#X&D+]R2!>9(E[ULC[4]%43Q.^E@9$74>GL'UC0<
M-9PCD3XB*WY%<H(\P7-63P:M(/K1%WQ(-BV"BZ63LN22S;5LLE?W?#O%>!L2
M1:XMU%Y1B]TO+*6TZW7%W-3!0RO+%FT$EJJWK\DQ_283">.=2B14-.S1\%O3
M.N@Y$N//H+DTM\Q@WH8[^9940Z5W";NB.<>U,.!/DPFKVV0YNG0YK5.5@-V8
M[D\7$U6'-C]+OD+='>JH3?K"K.'?JS]^4&#TQ92F3#_ZH>^Z0PH;PL?CKHJO
M.^(;6X( )>B*?+/\>DQ?#9I(B^]"9^RYT=JOK;&]]KOKAK7M<6#'=QKV^N\B
MQ_TBDW76?ZT/>P.PS5;@UT0;]=U>W6"\75.\R9H$6W^<52UQ*0$'2%?U1%S5
ME_VK>AN$HOTY2*W)_BU0P;;[E)'G/M2"UR(++(TC.?+R4'NUL<[.7Y/52WM*
M)D>U@"&R9@DU8P7?VY]3?0K&Y"+#%/)GMSG<AT)I@QU\)&P)TEF?4EN68OI,
M-4##/LS?;\(^[@Q*\IAC/!#HK\!)B;?Y=%]UE3-M1M)]D!;W#0UIU1*W&POF
MJ1V/?-O='-/H8? R'Q+2]$!P.T5PCC4*(OM1".Z!I.\.,.IC<E%>SZCW'-#+
M'[FN_RB87@?4M5N(G]LCLCX*)]A9E>WG-E9[3TZPNZ#@_FVA_;9/Q]GS$W+B
M4>"YCW=*UV,@/F:,Y98AHVL-M%U.='QQ*]RF:L4VB%ZQW]FQAN:('8U8<RXZ
M$\F,)8I&=8A-?:P%;#^'(:NI1**G7D..K^,[9+AW$@.CQ>_"<H S+A_76GYI
M-;#KZFD)\\]?]8O%M.;4Y"-KD9-D2[8K,3E1@SFK.7:_4#DA;%+!3="21!2T
MDJNM M>GPROU<P]$QH+,;!!92(1Y]IQ0FYI-?W"K_E[4?[R@G>T.![9SB*#F
M]A'4L)GY @/U,W;5(H;(PIHTK1=:P;.>:\;Z0(M+6R'*FFFSY_KJ*#&]Z,;<
MN=Y3][Y]SK6WS[&T?EX/=/MT'+--;I]SN]OWP+?,T<@*UZ$CKSWZ+7/6WS(-
M(TYLXPH\Q-O>CB'8FFR[25V%4/"S>KZ8J2P!!5O;0:Y=ATXK#F$ ++L!@.Q*
MC,;!VJT[LYA;-RG<3BWC6N_"CO(Y6MCMM QQ?9>WHHMZ?*=K!I*[C99A2?4T
M>?A)+]F,>K(">\$<L-6@BOCKV0*FINC3MKP1[),$\@'V("'7,*]M)L 1=EXL
MT7&=*B@8&6]:?1H(1@F;XM">W(89CC1TY0$2L+[?:_9X'RYZYSPXVJ^+WE*.
M%J#4TMH'U/.=;]^6>%I]5=;U3[47#GJ?ZO@[O?ZJ YKCG[ I@*(Y;F):,A:K
M2L"6G2]HN\O!.+'6YO8NBL[-QZ,8<^]HNK;,V(UYU[CI&M]!GIL_L9)(\<TY
MHK<=:145.[;$=4FIUT.,4;$?5:P0HDPE6V@,>E2+S&V@G_-B)BM-%M,>/!9V
M69G+:I&N5<.PV8/HV-!H3^?8O[U%9,+W$P*>Z'B7=569-:(1TYBR27\[QJAK
M,"&M("FNZ"DL"V0I&@9,4GX.-H\X\H:.O%=$T]8/4:4)-I8AU6,*#U67^*UJ
MDRC'OP\+>BRBI_4]IT+*KL7&*]A 4=Z]'W3_!ICA:35'2\B$Q6IDV+OCR@;#
M1QLE=CH VQ:+#-6A,U:W4 "RM[\$'8!ANNW3.*7HSSA$?7K!"M"Q"N,-FWZ\
MJI3*)4KRN2CZT]H6L2L%:B$+L'I=9O6^K!(6HD'I %<"L<KDK_M5A5VAN"9N
MCT_>F9$?7%N7%,'_?9FJ*#JR+R/.#UC?2QOM6CM5J[*E'.:$S57UL&0B&@RN
M\)RT3(&J[5@CRT,:"8G<E\DWMMU=M2LR#W3EIGS=\I X&EMQ?)?JD,@;.['W
MX&4<]MAS[U8<<D,91Q2$#U'&\5"9KX\;QMPP27X?UKJ4H[;GF2J^%: /X/$2
MBAXH966KB0HND'>G"_1MIT]$CG4'VMR^Q,IMITW_BY8P["??]&+_P#>_ FT&
M![YYZVVSO0/?_!JT&1[XYAUHTSOPS2^]R6^K.2L?FW&NK7K=1;)U1HYGWYVI
M;K87!W9[7>6/:+AV8+EW*$T3^L N5Z1L-6W^AITBIW.$K5B(WF.M3_@AF/ N
M;,'=W&9][B@=T2Y06E8MT*U-''+/Y(AEW5^.W&NGOF(QR98&=:[IJT?)$IA>
M/4VY:"&LY0BL"  K2/D.H$*/MV)^[\KFB1=%5N78G'VR: S8\+183$84GHU=
MGX*\,E0+HV!2&Z8(]?O]>6.OU^YOI%HORD!S([N!BHDD&"4N*)>00,5W+Z'A
M.4;A$%OK2*0EXY;\!@2>%A(1YB7,#C=G/S(;$".T[;6"-)AAHC7]U:7C="DX
M39?"P*A]*^((B-Q1^$5>U1-LJ$N)">_&;\;&+T='OXGZ!/%HV_"\NOM[IUE+
M^EG1I&75+&I*/R TTT8V**=FYER=%?WJPR([$V.(3K[4NU5TV^6SJJ:VV!.1
MBHX]QRGO?J27 HPT5(,.YD]A''23$>EN1#N##'Z]KD!F^Z]:)'4K3RCJBQC"
M[2I@[\Z+9E[51*%=7]H1075/C7G-L=TOS>^BW:T+5A<5MBBF7!W5&54U(4]X
M22W9&6&7L:82;5R[O).TJ-/%!!NBIJKIN&J>VK(!/'GZ)L&.S90W!0> =Z?;
M=)94"['=*:OK*_R2%!EMMY?VJ-=R&6:78=8W<"A&I1&B SRM2O1M%QO'<5CJ
M M_;/*IH:)K%1.*<4F%)BZF7B%;3>!\D$U:+Q*:UV+\;]TXF-38Z:8F=$D_(
MX^[>0;E?HANSF!RQ_II?%/R29W*L5/$<UO&<F<YS5M&[[-#,C2.\1#(%:\[;
MGK0_5:S.]B.I52LKR(N:^J9KZ:FP7B%8D1!D&^AIU6MUGO9+?J[=;T2Z%ZU^
M)WQ^7F78N/I*9,@C6;?G+FA%?\O*TZ,<JP;>F @V*=K!<^I]#/_$DBR962;E
M^-VXHDSX@GM?-OR2-H)6 9?Q]P4#WE;#Q7E-;*XKI^J_6'OM#2]3:9%7G-4J
M/?@%3SFA-[49PK+#J(T0,V+M^):CZ10OEYP*W,&?D778EOE_] ^>U ML;8KG
MN9$&H5K<(0UOK5(AP#?@!(Z!-\!>:+K%&^"K&=S4_5 GWA+E"89-8#.TZD*L
M6KL?C5JU%$.R2S>*H=Z5*B8SX,;4"IYJVRA/\G^:FVGT7CGE-R3[%=G_/BDL
MVPHR;GG<=@//">W(\:,X]WB2I5EN1_;?H?ODYI=OEE:X^D=?FXB/86N%*>".
MD:E@QC1E-=)-AP]*]>\7FI@24O^$4"J,UT7S<1_J>I23T'B-:L8;!%"@NHJK
MO;C$?XK&[]<W==>;N&/17!QJA;FK,A+;:C#D$.>\%.+TLJI)353(-S(3O@\?
MA+LMZ@GTMY(4DMWX94;_0J39KAQ%Z;E*[VW+$5":4WDKZ--"?4<0B4YC(+6#
M%77G=A-:FSZ702&N]NL!@$=7L0@#-N<@ TT$N3"FF/_)Q\9_%"+3=XY>B=_A
M&A">!U-;""_X!7X.-)*PZ<>NE%8N$AX#$4UX(0F?7W(^->RQ_R\3<VO_U4UM
MU7$1ZHHHVI4ZD?K'TJ*&.%)@$"Y$E45;]BNSS;LMPZ\J!-R"8=!] *=67HVZ
M4BW"25*G)!?=HBWE-+0:Z@$J!6_'?P_IX;=)#[=W*CU\.^7-S[)QPG/5..'E
M)\%B[B!1MU3HO"(<F()P#3#,0<Q(M(;H_)H:AA.R0#20%N1Z5+X449PEO2N"
M,UYU9O=2:1J:]JIA H$+ZY*&$.$DC%+G=AWUNFOT/+ (%$-F93,'4PJE#^KY
M5.:#O$UQ,UW,+'7$X.I@Z]9GD9=8OR:7K=@X<DGRL&68>B\P<P>#D<.JFRSQ
MU45=M?ZJHP5B"B*6H!Q$26@!A\,RX.@-^H"EHZSOK)+>$1W]4[!TX<.IFF%'
MF#7=.-X*?+[U-83"P;8$W2>[8\Q*H+G^T4FXRN'.GO/LC+P(-?P"ZV"E?R;C
MA!F(:H.&"JT]) S]:T^MAELH9)\Z+#*_%<@5O*'*1)T&C-2C[I9F=#+7JG1A
ME)<++)"GI]LCDQH&D;;<BO*JA6T=&%$2Z+,'EX2(K$V1*76&:&DO^ CAIBRF
MJ4)4;.^"6K\Z/ 1Y*K("+H=TT^ VL-D,.#(I&665]GX_N,UTG03Z%X$ ZO>V
M?V6E\8HETFKOE38WX&=2?9.>)H3L0S(4Q;+&&1PL$:R\6Z)SRF*R$#Q(%9I.
M9C4_1X/D@JL+^11_\8P<AH4LP)8(=;+B4&()@LKW\Y"RM8L@9Z!=;XW_E=7T
M3&BRQ#BEI0X?T_547ES5X45IU<O0A\(+C?LLN+JH+SV6"WDIG.[/Q)64FF][
MD.AHT&Y#_Q*@NTF+/22+!E&]:#DCVOCV9-7EPD=MZU]JLFM8]"H6.VIAQ\BA
MT1H8/6]&H7-3I=<1]&[G7._H8S\NYU&)> 9GYUIQ&^SN\*:16*;2:-'?0>Y:
MKO';=9=LY=ZI,Y?TTF.D?3XP6C$RH4N**<C^2JL\3^T!2J#--?&, 0\:W']U
MW96*H@GXI@?;+4'GM)GTJM"15ZVTP#?;!;+^J:-#OP75TXS#@M&1UPR_*O$J
MJ<^T!3_#*OWD@T)%7LE=)']#&3H2O;'LKBD%K*37GVX0G7;ZK:163/I2Q_;K
M&[IR4RBHPXSSJQGR4!$8P'LO%2#%#6#X?Q;5?%4;L_4<06M0A(P!<3JG+3PG
MLAI\4?<"Q12O4PDWAO@:Z6Y50<$H)_3^;\G5-1MZW3KVP8GWLI/>Q].\[*=1
M[3*7_;,S-&1\&%NY*21AO=N<#&?WG5=G9970<W)/=/?.:F]:^ZA0:9%:6XA,
MP4U6"D&I#*]@V*3^@/J@-.>92'R#=6!\H9BNH+\-G?+!YD[YQ_.O>V/C>478
MM$*"_(9-=3)TIV\8#8O&D;\<#WND=;T4X7BI?'6Q@;NN<2?NX-%4I2'@NK'7
M$B8]%,2 YR,MNZ)9 )%?%(W<'MR*-K)/W>K28M;+FH&I,=%O1+>]\9OGYP7/
MC9>?>+H@<_858HYSX1N@#I"@.N!HI=:31#XS4G:@,&G@UZ0<RU=JF2VI?F:S
M]LR,I[!"I1X 8WF]P-8AMLM,VW_*G]'3MI_!OPSXYS-M_6\ZV/36J74DU#T[
M=CWJ-<(F0KX]?8*_T!][\FPDA3I-'A<J_A2<@^# :]$$BV+A(M%G;/Q$C4JQ
M'17V$.I.:G3?C12<%W9)AN.)/VZXAZ@"MOLO?!K"XX!CD"9,&59271+I3BKK
M3@XOEKIHXQ9BO>B%H2@\Q4D6"6K6W0GTMEWTZA/VUTA,#O2H;"0Q1ZF-J\A(
MD1E3TJHDC01;+2J630V6\D*0 QWTR^=M@YN:R$/ZK":;&S>/E1/8A7..A5NP
M5,Q+@(=W9"#R&N!&;LBIK?%FB0O;P]E$B!_I9%IIJBO2>*$VIX>LKOL,Y>;(
M:Y&2CIOIC>?^$<DJJUL"TJ_.6=,J$ZUS$BD4@T)-E\*&)N1'U&DI&7#P_.AV
M\[V[OA'K^L9#I!5$SO*(7_L^_ 9G9!P?&Z;QZNU_7KXVCD]_?O7ZY.CM\:O3
M+;_)G8YECXU?^1D<\F^B8R&<\GYH'G_R-F%2]X6A+D%W@=QR('#/I,";HJY-
M>7,&NV0B>57HWE,56D=3$VX0RO;NEP8C?R!($DH*[2>3"LMSZ=KU7&]ZH_,V
MFJ!W^Y-YDY1$V4)<"]<?;#3Z+H3'[YQAWCP7P@G;7:)L1!= 6K)BHIPP[;P[
MI:GI= ]]1^3/NAYM,T;AZ*XO-3*.LN0B3[3M7TNU#8UTZ],0:,? UQBD:KTB
M5^2<40;7J#7[R?]))A9ZG!(*EE?EA1"@*H6W))*==20K4U)1\J)]_O^W=ZW-
M:2M)]*],9:NVDET02.*9[*8*8^>&&\?Q&N?N_;8EQ&"T$1*KAVW^_7;WC!Z\
M;+#!$J#[X<9QA)CIF3[=,WVZ&_Y<;TQ/,ORLK0\_;P&Z]7>YC%EGCZ(=1?R
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MHJUN'(?(;EV9KK!S>>YF/Z>@$WWN6*!0J:4\Q'4+4K3BEZ]@[1!6L*:P[VB
M^\:(@PZF$T%/=^6:AP"G=27F6L<D@U><L?.Q?J] 3+5:7;5L,!:S#!-$!^NC
MX$3,<L*S2M:RH;"+Q[$U0,_KY7U LJ*+_?FU=]:[[>\=UC;K(S1?/^UMNZ#
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MX7[YQR/V%I!OT:I5K3#=;P-%&2;6J(I6X- 1XI#V+ XM-^<L<.C@'CT:'-+
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M7C!UO<!']CUY)OAP%U'!M=D/=%J2T+%X%+-9\!N6HLU)$V]F.?,<N&N0C@L
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M*9%O'3[9T_IV]O>[<7/-C):PITPJS)P%>U>)MII/B2RF@=M[^K:6TVEW8"A
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ME3MM;F>!T#NV^E(2DRT/!)EBZEX\Z\B11#[I1:61M01:+2Y7]2HNI&2-RW0
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MH\.C<(M].LFUF64924/C@X$@EYDUU7)[7-F\ 69I;"A76^GK?HY,R]-YTF2
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M/Q;L2]P5B)N@IGH<DQLLOA.E4WQ9T9U:R1J@6CSOZSP72VD:^DC4%D5&U1:
MBMLV *RPOF0J2XMEFC,\Q8[Y/O?JY*6$J*%PU8H^-QC(-@AL<(^];J8B.PB$
M,];EDRJNM0)M$Y2,-EBD/4K531F%- VUYZ)$^I2,*-.S<2,+%16X_?"%BOC<
M2:9&'I\.OEP^AFP^_6 /WU_&M!DA?%Q22>U]@TQZ)/#$OCV]D.8'UV*6"[Y7
M+&NL]WK+ZIWW11+SWJF5.M;FT]!:7,'"FEP<NS?'_*IE,';Z/]6GFQ,9$N;?
M!']Z\S]02P,$%     @ E3:K5B-_Z107%   BKH  !0   !V=&PM,C R,S S
M,S%?8V%L+GAM;-U=6W,;QXY^SZ_0>E\7<=\OJ22G'#L^Y2HG=OFR.?O$Z@O:
MXH8BM20E6^?7+YJ4%$JB)(KLH49YL"Q1HQDT\#7P =V#_O$?WXY&!Z<XG0TG
MXY^>\>_9LP,<ITD>CK_\].SSI]?@GOWCY^^^^_$_ /[URX>W!Z\FZ>0(Q_.#
MEU,,<\P'7X?SPX,_,L[^/"C3R='!'Y/IG\/3 /#SXH]>3H[/IL,OA_,#P82\
M_MOI#XH5Q8VRD'D6H)B*X(+DX&1RQBH5C,+_^O)#T;8$HSU8C@J4L A1%0ZB
M,.8])F]#6MQT-!S_^4/]$L,,#VAPX]GBQY^>'<[GQS\\?_[UZ]?OO\7IZ/O)
M],MSP9A\?G'UL_/+O]VX_JM<7,V]]\\7O[V\=#9<=R'=EC__UV]O/Z9#/ HP
M',_F89SJ V;#'V:+#]].4I@O='ZO7 >W7E%_@HO+H'X$7(#DWW^;Y6<_?W=P
ML%3'=#+"#U@.ZO^?/[RY?.3I<!Y&\T.<AN,ASKY/DZ/G]9+G+R?CC.,99OIF
M-AD-<S7T+V%4Q_#Q$'$^HY$L[CP_.\:?GLV&1\<CO/CL<(KEIV>G\Q%4BS.Y
M%.<_-[CI\[]$3F&43D8+#;VEG\]O7:5K+CU^FR/]Q5)A%\\?3=*5BT;57)/I
MQ5^.0L31XM/!R0R^A' \>#L,<3@:SDF6 ;<F,E$(K5HS4)DAA"P(V9QED85*
M,EY35QW3C :UL&\)L[@P\OF]R=A"/,?1?';Q256M6*AUS>.7>FPRDI<GTRE-
M]H%$'Y3+&DKB'I13!0)W%FP0/(>LDT'5W8#.I;@ZKA6$O)BF@\DTXY0<V+.#
MKUC=S;DO6XH4IND*=&[.I/,KGL].CHX6]X3A'(\N_KXZMC;6GD^:ZGII4A*^
MH<U_GXS3N2@^J<!$YH!.6U H+ 2)!3Q3):!@/N?8G=G_$F03RXNG:_DM-=Z%
M\5^,\\?Y)/UY.!F15F>__M_)<'XV\%9($S,%Z4@A6$G%P+'@068GHLG(K>AP
M^J^5:=<QKQEETHD;61R$) /IGI'NA2M@I<H:2?7,B\:CO&]<O7%RN^/B.OYW
M-$ 7X!_D)&5A-!0CZWPV.H#+5@$O//J0@O8N["MN]\;+M3?]MBIO9O.7DZ.C
MX;RF,75TQ!/GE.Y0VE,%BIRKH(.&Z!2!,&D',1D!R2I,D8#(A6Z,@3O$V003
M\N^ B58FZ9@1*19"L%9 Q%#S4![)624#(CLB ]9@QK1_1O3PT;T[IKRIJO@M
M4NIX\8BS52:"Z#EW"C )4KIA#KR0#G+"0@[9.HFF\4CO%:JGP7%+?%R? FUM
MTFPBK)GH#(M2)I._UHR^*$'C-3R#0YEX<92]L-;8:,\ WY-@2'I=>K+_#J,3
M''#-*/I(\EN9_)9*E(6Y:CY?7$*K1?#%-A[8&C'Z!/,=K7\=X[LJO2D%F(Q7
MI!"(1$.D!H$F$OET 7Q$#MYS$DD:Q5-K[G==ACX1P,9VWTG=S8S^(N=A'7L8
MO0_#_&;\,AS7(N* +*-EL!H,]X*&IR1XYS3HC,(8XC!:M*[7W2)*G_A>8PBT
M4'X[)*1T<E15B_E=K2$3/H^G>(CCV? 4WXS3Y C?3F:SWW'^KGP*WP8^&,6*
M9Y 23Q37%8<8<P1OM8]2AX*I->][H(B;($<]4>1T:*QFB/J \S <8_XU3,?$
MX68K0K_",DS#^0!C-*PH 5E[7=>Z/-%$3_1-R>B"8MIPV1A$]TNU"6[TT\1-
M8Y.T<SZS&<XOZ_W.*VTI/0:K#1):BZ=(&!)(J05G0:&QK8NK5P38.96L4_+C
MX60Z_X33HS?C4YPM\_@!X]IX9S/Y<S*;RH&2(1X9:*=X5L8&9UWK%/(V8?K$
MJ;>W_XV4L8GNVY'J,#NLU1OZKT[?TS!:U'/F+\-T>D8S<$G]/!.>>6[!(K%\
M)9R%ZI7!6"9RH8GM4^LD:R/!^D2_VT&DO4V:P862P6.B@K]^.Z[K]23D LY7
MAXZ9&TH1'"1;';3@GG!L(W K FD610BM?<@&8O6)IK>#2FM[=%&+O9"C<*=9
ML$3ON%&4/WH# ;6 )'-R612=L.QY1\*6H7/-X%2,7$NOP'I%I$<( SXI!X5+
MH4/*BB9K%X'SR>RYV 8%:V/GCLIOF8].3S"O$<=[Y5$P77<$T(0.I=:6303-
MBK-6%XNR>6WB-F'Z%"$;HZ&- 5KB87)"<?I]. MQA!>R)!ZC8)39>E93(G*W
MX*0O( 5Z'Q-:WCY76"M)GP)@>R3LJOK&F>* V4QQMY /,L(3!!T].Y, 7%IF
M0\[9B-;K+<LGMUUF_%#!\*Y\)FY1[SZ0ACLT# &YYZ"\KCL_6((<<W R!BER
M\_SP+H'Z%.RVL/S=ZXF[*+\AXY^04/.S]Z,PGA/!K!G)<4U8?R>)M(R<"R7!
MH*09%C1-6HJVX+DN3B>;<VR-\KODZ5.P:X"&9JIO!H:5[&)EC=OFF'PR";Q&
MRD155.!E,4!Y:<I,(A>R]3K<6D'Z%.%:.(.=E=U1^3/J[+Q%&I0U 91V#KP[
M#]4A:Q.S;KWK\L&I_+[631K8>7OE7K/OC\^O*^0M_=SXI9*/<_JZ*%A.RGFX
MHM]>E6C[MTMNN7N'KYEL,IY&[YN0V_YKZ6N@M$2L.R>"<D1X;=TW;K,'E-IZ
MJ:,LH77%X(H S8CBRIBX\C';2MV-TZ (]Q!=#,!R8%PJEHKQ7='#VT;VN*1P
M>YO?R@VWU'>S8$#!:')5EO/RXZ 4#(&B$=A85W$CL50?E(9(_A U1ZM=Z\+'
MK<+TB0NV T$;W;?C@Q>RG$M!@9!R=DYH!)82Y2@B>@J$!$N!.09O+-?-5XIN
M"+'[OH 9DG+J&LPK/,719$&Z+Q2=A5.D60O9:9IS49(AM9 @C?7.N1(U:UW&
MOE.@/GF[W?!P<S- *SLT _P_<4PC')%$+_+1<#R<S>MX3R]G(0913%(T 8NN
M.Z/J=M\L&-#,YEHHK8UJ_2K"/2+UR0^VA4=+6^PA..92& TJ R^4)ZB<#$3O
M'>CHDC1<Z(RMW\S<,#@^?)1_;5M8WO;->(Y3^F1 @^$^Q01":,I>6$)PT2,H
M8B*&T23EI?6FN]MDZ9-?;(.*ZQ.@B17:UH;N&"A3E!O; -$J4]\T2N!<\$!D
M* ?T,3ELS0WOEJA/CK$;?#2T2'O&N$*(ZP*M348!*TB1O(9SE^I;A42%A;!.
M=E _O"]K;,&%>1:98V801<P4W+R'F$O=IA.+\V15EO?,A>_U@K"?^+^E\6]-
MB;=2^6-7SZ[LB5X@L(,BVLV'[*F6=L_H&I74UNPKO]Q3SC5QOH@)N"5&J9AC
MX)&P4++!X+!(W[P#RAWB[$PLK]00C.**O#?%@4"T5H7@(!8>0)1LI=8Z&MLZ
MS[BC>/BXY*H5!F[46K;6>%M.M69\KR=3TNQXN6:0SCY-PW@6TD+_X[SXZ=P:
M^7]/E@SQ0B/O)]/%+^;SZ3">S.MVB4^3]V&Q]&"XT])( <0W8DV8$"+6]0?)
M*)<2);#8>L+L=8!]8GQ=@;:_B'G4<$OQ*,P.7X\F7]M'V=5[[R.XWCJ65C&5
M[GYM[_D'RBJGPT12G.]-O_K!RI7O<3J<9,+<M.Y@>87+_^GGT4E>$+5T&,9?
M\ .-Y==2,,T'/AOGK3%0M&&@;'+@,#LH,1O+$664S;MW['6$#2)_%>']='(Z
M).O^<O:9D/%F?$E^7] T/EVV9K'9).ZY BN9 .55!.^9!DN)G?(T)5/B[6G!
MAM+UBC/T%^-K:$@7YF]7\5POW[(X=54^Z1-'[S5P5M\,3$6!RXJ!--&ES+CB
MLG5U<'/I>L4.GCP\=S5_U_!\/1R'<;HJ'_-"L<(]&!(3E$P,G'4)DO"1=,*M
MP0Z2J@VEZ]/FMJ</SUW-WPR>RR&^*ZO#?C?>2<$#%WR,"1UPER30K$((&"5D
MGVMI5R7C6M<=.QA&GW;Y/2' /S:@'L-Q%Q,4]RF#XX&#*K&^06DX"*NS,<;S
M(G-/'/=6&_ 38IZ])E2^F<U.:E/L=V6E.\_ <IF%=Y2%>V5!N>(@.EN *^^+
M]IDIW\$N_+N%ZA/9[PA):[;K-S14RQ<X+L5:B/'N>+'%]==O.$U#TL0@2\L6
M&P@Q1ZP+@8&FMW,0G,HD(\LRM%Z:O5>H/K'Q1\#/[H;J!#]_A.DTU"U82XEF
M@X!),&D$B%P"99Q>@1=83X40A;D@3&C^3O==\O2))#\":G8RSV,4!(I'E9$5
MD+JV/!&2Y.-!@ G1Y\2"X,V9ZK8%@2TF3CA;K(5^FKQ(1*:F>.O[7 .3A4B1
M1J]"*J",31!98&!L2$P6RI)3\Y89&TO7JRT$'8'KQJSJQG;=!'5BZ>_*8N%G
MM9U08D7P1'+Q5).(0%]\T@F,R*RDDAV3K=_2NE^J)Q#6FT.IK:FZ=M-KZ\HJ
M">&+ LH#30TC%)]<B1"*YE$[9W/:4WYU[[+"P_5P^\KH/\-P7-?^/X\I8Q\-
M_TT,3,>0G; >'-.1)KNB3#A19FY(/;S8%,@;--;$0^1["JYZ5X!=GU^=V:_E
M3%O92.*5L]HI!C9Q39-=!'"!1T@4*C!YDY5OO@_\H5MW'MD%MX;(]@9HAH&;
MY;^;[6L&BKLL+&&2LQCJ[L4(,1!=ST(I@=IYX5H7<C:1ZPED5:T1T]Q<S8#T
M"H^GF(8+7='W(SS?P_/BJ.[3^??B\X$U@0NVV-HM9'W%D#@I9@F6:6]XT5XV
MYWZ;R-6GDOZ>@-3<7!UZI 4O_:L%S0K2-7G,6H4 F6P]Q<)X""%JL#HGC#XR
M;%Y@?X!X?>J'_&C^J8WQNHUWJTVZ!MPR[Y6P()*HNP%R;4L9/7"M@PO*:>9;
MEP[O%6H3))F_.Y)V,52'^#EO=?KJ_#22M2U/!\%B5B8XDI7\I\+:(BLBD7S#
MB?8Q-+JT#GS;2;H)TNS?+%/;@TW;':%T&*;X2UCLP3VJ4BTC-1:)OKZJK+,C
M7^KJ.\5%Z'H:BO<Q:,UL:Z>U7I)-\./^7IZJ@4DZWH.^>F3UJWJ2P6A6SQ//
M)R.<+*M^YUV>EL@.XWRU?_-L^4=;[%!O]>0V^]<[T4.CW>V;=,RNO%MPCI"0
M>5#1*()4BH!9,Z=,R<RW/O7CP1W,-Q\Y@>7B]B_I=\.TZ)GP 1>G:KR<S%9Z
MC^6HK2@&=/&%9B>WX"--46%-Q)"YC;'< \2-']:G#2*M,7'AN;K1_,XQKHJU
MOK?*I_"-@C1],SR][*++<W:4/W@HR9'++MQ!9#Z#3LDP)UEQUS=MKP7%Q@_L
M4WVR2V!T8X$N6GU>R,$\RL((FL+86$^<D.!3KEW7O=&JR.!R)SWN>WN.0U?P
M:&2#9EA8'#CR(E/P)7A^P(3#T]4^V]9&A872PL)R A60G!=B G2.I+122-ZZ
M.G2W1'VJ,W:-D8:V>4QV?*WHT T17O^0/7#>#4;7B-[>T@K?&!:"S08LEPX4
MDPB>:08\,J>%*-Z+UBU6-CF%X&&<Y8)#+9C3M0&6G+/WZ"&Z>BB]"PC1&II1
MH92@:N4@Y@U8RAV/Z!-A;6#E52K22K%-F.E;_+)LZG:2A_-U$GE!0TDN0O""
M7)HW$IS3$K)!%NA?*E9L8.K[GM,G'MK8WDU5W-4!*JMU@H$KF(LU%+P$6W0]
M%_2=670,=$E(&WEI33'N$*=/'+0A-%H;XI'Y1%VN[[:PMOXA^^$3]XVN'9^X
MY9 E(WU0+#%(QMM:LJ@'5^;: ,1J"@VLJ-1Z'].&IUQMF^S>.E3+N6/.*Q Z
MULE4%"7@BW:BV2HO?<G-]^7<+5'/N$@#A*Q/?9M8I DK.1?E"E.Z%$8R\GW+
M5CV\KCMH\)'B9@C%6>.B<-IO0$CN>$3/N$A#>[?4;5-#KRPQ78[/6VZ3IHA7
M^ZRK1(.,EA)J)UT./#J!0CW SC>?T#->T9&9=]1L2RO?),*7:4_,6ADF@/XM
MNHL3X]&VEMVDSZH>+!G"YK:^]3E]JE1U9O$V6N[+VNV*?KI?KKWYL#VOT-XS
MVD8L\[:#7;E4(BN"FPJUVEU2 %_??[4.M?1)NL);][/:Z%3=+49XY62_B_N?
M79[1++P.&0,(A>0 =<+Z!J@#9V2PBC'%FI?0[Y:H3PRS!3KN/FEQ)WNT77+[
M>#+.T[,UHY7$>[*I3=TCJ\?&, VURSL890N/*M7W?+N8"[<)U"=.V@E"FEFC
M\\Z71T?#Y9N$85Q;1E98XSC11;^%^<ET(??EX6;GB'\71\,OY[O2%^Y_BRC6
MZ,&M>F:VUT*CZ/869S/$6SS.Q9O&KTYP8-%QR5B Q$P]PTDS@BOQ+"62H-NZ
MB,V/4]U4MEU]VYW/^3S.P]FBYEAK6HDN?7%4?QH4XZ1!%<!@;7@1N *'C(.0
MF>>BK2_[5<AM@O8I6G:"MNO.L7MSMC]QXJJ0 WI\P)ID2EW?VZ\[2%WMO$&I
M9K19&RVO9WA=4:X^1=*]H*>%29Y$4!WP1PNK].@^!=;KFMAW:-6:E2CK$J:M
M!X-HF\$I+P&=45Y'I6QHW6&E%Z%UY3G_@V'ZB<:&@[J%K&CROEZA ^4,@U#+
MJ](&C88'56+K1J</%O))AM2'H.Q!(75G,S8+IP\2\^MD4)Q3/!0#7-9SZBT/
M$+G'VEJUYM)>I>9GPCY0Q"<9?O>&M >:<.\X^YTBR:>O.#K%WR@T'<X&"E/.
M'!D4H3TH%0RXNC28E8F8/)<%6]=)MI6U3^L]O4+>3D9]%%?W>G(R'7 GK6,N
M0I:)I*S-HWVL;:0=,5>NK#2N]?'G#Y6Q3PM.O8+<5D9LM.'Q#@D_37[!]V&8
M7Y0Y3B]EM#E$J=" R;5A&!H),2M)<R(&9Y(+.FVR.OGP)_>IU4*G\-F#8?;K
MIS[@41A2QC5]5UX/9V2Y*O. ;F:%TA$XKYU'@C+@*Z/4/#O+O8Q1/$JP7"MM
MG[HS],=W[6[8#4LIYY_7+Y$$^?F[_P=02P,$%     @ E3:K5B)JH)ZG00
M<MH" !0   !V=&PM,C R,S S,S%?9&5F+GAM;.V]67-;1[(N^KY_A:_/Z\UV
MS4/'[GU"UN"C$[+ED.7N<YX0-611N"8!-0#*YO[U-PL )Y @%X!: $AI[V@:
MDU;E\%559E96YG_^S[_.3K_[@I/I<#SZQ_?\;^S[[W"4QGDX.OG'][]_? /N
M^__Y7__Q'__Y_P#\GQ\_O/ONU3B=G^%H]MW+"889YN_^',X^??>OC-,_OBN3
M\=EW_QI/_AA^"0#_-?]'+\>?+R;#DT^S[P03<O7;R=\5*XH;92'S+$ Q%<$%
MR<')Y(Q5*AB%_^_)WXNV)1CMP7)4H(1%B*IP$(4Q[S%Y&]+\H:?#T1]_KW]B
MF.)WQ-QH.G_[C^\_S6:?__[##W_^^>??_HJ3T[^-)R<_",;D#Y>__G[Y\[_N
M_/Y/.?\U]][_,/_VZJ?3X7T_I,?R'_[/S^]^2Y_P+,!P-)V%4;H>@(;/LZM_
M>),:_</B2_KI=/CWZ?S?OQNG,)NKYU$6OEO[B_H.+G\&]2/@ B3_VU_3_/U_
M_<=WWRTD%R9I,C[%#UB^6[[\_</;NY0.1[,?\O#LA^5O?@BGIT3Q_ FSB\_X
MC^^GP[//IWCYV:<)EK747[)<B=*5G/]1G_;#SC1](D(FZ3PBT*<XJ@!O2.-]
M3]^=YJMG0<82SD]G#2F^^^RF]([/PK"E@.\\N@&U\P?!&9Y%G+0D]=9S;]!Y
M2>0JA5^&LW Z^X23\'F(T[^E\=D/<P)?CD>9F,9,+Z;CTV&N*^QO,_I;E]SI
MN/PV&Z<_/HU/,RW8K_]]/IQ=/,[&E]DIU+67R<5L_Q_;C'*#*4+/<#2L"]([
M>KL<JI+?/WOXUPSI$?G[[X;Y']\/4_*IA( BH55!NF!\#$HD[T*6PNG!-@-6
M1B]9/1VG6^.?UI5X? 6=TQ#Q=/[IX'P*)R%\'EP]G&2#;^GE=,"9R#H:#EHF
M#RKH""'9##QF[55(F'*^"[SI)9!+F,8Y])9#$ 2%^ %/9]/+3ZIVQ5RSZZE8
M*'![OMZ.$NWW4WR%B_^^'=T5W8?QZ>F;\>3/,,D#RXH@O43@Q3C:KQF"]P$A
M^&@3AH+6Q,9,;TCB;8E<@_K%Y%(VRV5CRW6E&D--L3$;[T\E"U@0?]]_-Y[0
MX_[Q/=L502_'9V?C!8F_?0H3G+X_GU6SJ%J: RL368$B$6V80>G$P"=;@%FG
M8@Y2%J<:P^4A>O:/C5Z5.>Y)$W=1PG=%R5VN!^ATT84)8%Q+4)9F2S3. 6UG
MUB>//AC9?/V\?P-\KHC84>IW<2!VQ<$O.",!C,_PW7@Z'>@H,HNT+AI:$RLQ
M&6+!!-DF9KS%Z(QK#(%;!#QO[6\OZ[N*E[LJ_D7^_\ZGL[EY]G'\(N>YG,/I
MKV&8WXY>DD%)IN5\U:I^+-EU9Y_)P)N[QQ^0I#(=SO WG'P9)OP5)\-Q_H!I
M?++0UC_#Z3D.<F2*D,P@A4+ =MF2I!*2S-#9%*UFJ!MCJ6^>GC<\CPH1=Q&O
M=D7\^^HI5;(G^*EZO%_P>C;2U'Q?/H:_!DX&9P6+@,X09=)K\#E[B$$H8U*2
MC-G&J.U"U_-&7G/-W$6/;F(PO9U.SS&_.I^0!;< ^<*P([=W&=I]7Q:O9\-X
M2M,AT4]GY)L/;,E:9"- ,V-(/)J#MUR #899I5 5W7HUW(WBYXVX/6KS+A9-
M3UB<K[*/$^\1E2PA@A11D"]L-02#%L@?UDGY2.2S_4"Q&\%?)1)[T.5=(-I>
M%\5?\,_Y5].!8EDH(1-X[0N9NJ* PR(@6N6X9B5RQO>Y^%U1]E5":Q?MW,60
MZW,QNR;2>9516 G1D:^LI+40"=O@1-0<518LM+;+.A'V52)H!]W<!9#O->"I
M<RC<V ",):(M!0&>*]JN.8]*2MK#I3]8P+-)V,XDG:3Q$H+E9!=;,HF=C?65
M="Y&E5F^Y[RMU[#=#L<Y'P-M< /MC$,I2%?!<$*4K-S5&!E3@0M>K-*FKZ.<
M.04-I_6-(_O>CRIV$.-],>;O%@>P?T^G8_+X__'];'*.UQ^.1S/\:_;Z=#[@
M/[Z?XDE]T0P)"V!5KW \JC&)%W\-IX,H@M3!!7+]&'&47 ;G:&+GZ@+21%=1
MMK=='R"H(4X>2*-X #=;*'H=9G86> _'%"LTO9IOD9V(&JPD=C1"P[T$M30"
MUB6F/("!W14W[DOJ>X.$1T:;H"[@4V%$'#E"]6 %."V8(;BD X:G"X5;.3^'
M1\(FPNX! 3<,K)_GQC*Y,()GSSQHZXC%'!0$9Q78K(0/)6F96T?7[A"Q?T^@
M@7+6GUAO(=D>DAG6'$,LB4,4&)E1D'0A4XG9 B%S2YZ.R%XZ<F=]:^/^08*>
M P3:2;R'F?\BI?.S\].:7;;NS. 2MSE*;P0#JV0A*]J3PRM)!!Y=3$R$2%YI
M:VAT)>Y9P*073?20X/ !9\0KYM=A,B('?+JD2N?J3XGY+DB\UPB!LZB <\PQ
M,(%.M\;'_90\!S TD/':#(?__&%%,.0I_['7S-]?PX2^^H2S80H=LN];I '?
M'O)0.<$/,+Z2(&R9XL5IC24S)0@K4<EHA76L,">UWR9!^/;HS;.%'0L\%4=X
M%[$>X=6K,-QRVLY*C%(%:VWK5*?VV<*=4C:N8[CU;[T?\W(\G4T'5O'$/$U/
M(1-)("0&02L!K&3#C<TDDG2(!)TU]!Y%'O$FJ-DJOZ:%LGJPPU?B363\.V)9
M@ O:@M*L4F,X"-HJ4C+<V=(^F^%(XK.[0& ',1Y-?/8\3H=Y&"87OX53?+]8
MN.=QAE0/("1YB5SB/)/5D*MH I!5H6R)G/M26H-B'3%'$I?=2,&K6&DBZ#Y2
MQZ_)^26<T<N/DS":AE3ENS0FNU#84X#V<>H.%*UMH\Y5D/2CB\.@1CN>A15$
M9$X*5 P18@D!O)2&1>M5<<U/,@^$EL<"NH<"RR8J: @2\ID&+V8?/^'/8?('
MSBJATQ<G$YPOI4MODCDK,?-ZJ(6TEF:N(40O@5L3I)3*\Z0>\<0Z#', *[.Q
M5L;]B'2M4=G807^%TS09?JX/&I<?SZ=D=TVG891_#-,A^8EOAB,RBH?54KYT
M'E_5Z,/I= O/?/NQFKCDC5A=\<6EP!1=\8YYKS+]M=Q:E66*FISTY ?;#[N[
MY8C_/J_'5%]N6=0B%Z6T%Z"33Z!<,>!31N#%!AT*.J&;K_MK:-EV <LX'+P>
MS8:SBU_.Z]1Z7UX3_L87B/.$#HU9D_VH5'7== "R_JK_X#0MVE+D!U/7IIC^
M=C+^\@,-L>",7EPS],# !UC*6FCX<@%K)=*&WG!=4R^)>85?\'3\N<Z/7R?C
MDTD@-M&P)'60X*R/H*03$)%9"%:DJ*Q/W/$.6]0#0SQQG;848 \VZFH<^\8A
MQRL2=1K.!K0GEI)XA*R%J_F$OMY"(2-,)*]LM-)%T?.YP5VJGC@J>A)_#X=)
M!-2$F*=O2""7\;GWY=?)\ L1^>MI2//]<F!<4H3C!&Q^O2T&!=[K#+EHIHOB
M(>K6L>5NE#T3H/2@AAYNV+X,TT_U?_4XXPN9WV1(?<#I;#),!.CZQ8M1OOW!
MC5\.5&0YZ!+)&">2R9"SX%7-ZPLY\F28%+QYXO(N!#\3:.U/:7W=</WMTW@R
M^XB3L[>C+[@\;QA8[@,&1)!6:R+,(#A$!0F+3R$(6CY;QV;7$O-,D-)&V'W<
M5+W-[2(235A421D/L98<4*5>%&.805CK:.<4*<OFQYWWT+&W<YL^-+ZS8 ]]
MAC.=S*Y/*'Y+. J3X7@>5E1,D^E=&(AY=4B# 6*( 90WV7@OA-"==AL:X08T
MZ-TU+-8.?K"SFIW5.6XIUH;^S)R@)1V_CZ:?,0W+D(SH132Q"U&;',X\IO-U
MA.SW'*:1DL9]27AOZF<IH?.$\%0<6<7($S@3#>1H><K!\Y0ZI7T<E]K7'*CL
M4^N;"+8G;;\93S"%Z65\/POKN?,2,!A)%%D)OD0))0<GA$\QBT[5WCJJ^O;H
M^S/S&JKE'D7O(--]G9G\=GYV%B87X_+;\&1$O*<PFKU(:7P^FM4[N^/38:+?
M7Z<<O1V5\>1L7KIG^\.3!H,V.45IS?S*<0HJYLA,9*$(64,(,3*=I'7"1T,V
M 0X:C+]S4(JLGMG%KZ=UY%&N#NGGE3NE0?$@8H1$-BXHD0TX%A@441-RM:"I
MT;HTZN-4[5XJ]=+E>DM6\H1>?Z"%?N SB\AJ\?)2:#G7@BQ\R1(8(8T+I7"M
M6O-Z/R7[]W,;(^%N(=2=!=Y'O=-%4&8E%/-B]C),)A<T Q>UQUB2M';E#-;0
M'Z480LR*@=4^D/]'CM]J]D"3<-JCA#T[D+171^,\D\OSIZMS[K>CZ6PX.Z]2
MG_Y./CAM^)7Z5_AY/!W.I@/AT0A&6[R7V1'(#4((4D&0"4D:4?K59-<'3_6Z
MCOMLD-&[T/LYZ+E?%$1K.3]]-RPX<#Z(4DJ$X#.OJ5B1#$M%KXS43J/*,;>^
M0M2!K&<#F[Y4T<-)#Z&6?(3AW*8;D(.18@T92:R.96$,HA0*B@G.)N>U=*TC
MK3?'?W;ZWUJX/1RP? RCDUJ![<5TBK.W9Y_#<%(9??DI3$YP.M#"!T9 !%JX
MR!PR28!'VM_H0U%\\C&(UA6T'Z;HV8&AH0)Z.'GY:3S.?PY/3Z\)FU=Z%L7(
M8C@#YDTMTI<5.!4"[65"1!^TBK[U;9G[*7EV<&@@\(;E.:NA\]/X"TY&E1*"
MZ'#1CFKN);&4E',H +F31)/S-1F!WBI6:S?&['*7W+!USW\VJFTFQ![*7=Y'
MUXNS&ND9<.&9+)X!^34U<\TX\-D8T"FQC,IIRUL?L*^GYMF H;'@>ZA>>1]E
M5P<.[\NB$L+[^\HCO*YQQFG=S%Z/SL]PLC!P7+8REI@@S._,UVY[07!R?@HR
M$S2AG;>N?->8A:\"?/M2<0_E,M\AV4[X_O.<G-')NUI#M&:PS$L,SR8AS0;D
M-1GMB@5AO*H4.G"!D57EA:PY=1R;%RM_G*IGAZO&BK@G3+93HOM]Y$VO4O'_
MHHEP]>F ,Y-#CAJDB;;6YL_@=:T21+Y9+JZ@6TU6O->XV6#(9X.&/D5]#R2:
MWN-<4KBH<KNL6C"Z<7UM(+P)"ID#I6N3*T%(CCG+FE*CE!*>S+@^;W0^1M^S
M 5'ORKD'23O'6%^>ANGT??E7F!!1L_>3#[5[\1795S7N7X;34\P_7BQ_-UW^
M<#K(A/M:;09R2F3Y<6MI"RWD\=/FFFDKI=6R>8;T;B0_.[SM4X7W0'#GP&WM
M&YW/3^>7!]8(:I$66#"@Y#E U#R!RI)#W8+!<B84+]&QTKRW:$?:]I52V_?2
MU8<JCB'A]D,8G> \Y8S@G1(GHE&:VO(Q.S+\8]VZYUDE1LINQ:L?2<>Z&O!@
MB;6]J'*\JT@;Y]S-B5@FA74AHV%*[8VA]Y]$NZ7P5]6W@^1Z5*1-4LN(%K1C
MY' IS2 6I< FZWQDW%G;J<W(H17X0#IL6_UM(K#&>OLY_#4\.S];$N*M1IU]
M#??7HY^L$()+%J0PY#$5:XMOD>MZ:]#]IKAN+?9Q"YDUS-R:$T*BNB9$&%[K
MUQ -9"F0'4@V@PNEEIJ.RDNGE..=#DX?4][-09^@\K:66>MT\\OHYT]8+^Y_
M_E1+=,Z7%.L$SS0R.*MK+J!)X I7]-:6:+QFM,FWO$>T2L"S-7G:B+QAIM2<
MJ(5U?).D9=)]%Z):WC%:1\@![QCMIJAQ7U)NO12L)Z[,NP\*B QKWS%9:'U2
MC'Q#)8(2U@35Z43TN%3?Y9[1/C2_@7!;UVD[G\XFX708:''["2=G872QW)&,
M+-+7ZBW!90G*E "A5A27F8M@8M$^K"S^]U=H6S? GF\4M1'^N+7D&AIB\TLJ
MDXO![[\-:-NI86 R'VK1=\4(K-X@\21#L-9+;1ZL:W-9I&KYQ,6$7;ZYGJ_7
MXSUE56XIM8;3\)*"5Z\'.0C4C@R(D&M_0R%JJI/4X)+BJ)ET1CQTFW,SO;UZ
M_1STMJ'4&MI,EQ2\^'W 1;*&+'3P1"E1X&M3)A<A2)\]R\E%?.B(?3.]O?C]
M.>AM0ZGUD.=]?0'J(_V+^=9N4'";'8'(UHPT*P0X@;5\@->:9U8<:UT/["X5
MS]+K:23TWF'PDJR^D_%D^-_S[)[+#;T#A3T5P'Z<NL,4P-Y5CP_"HID2>J@J
MV(%2G:5%5138NAC2_(C@O.? F*;U4@I;?.L&Z8>"R2.5K_>/DDUDWP,Z?AZ/
M\&)1H_G-^2A?]DZR+G.9@X40 [F,H63P];:+%R*6(,DQ,*WWE?LI.42#\[8Z
M&S<7> ^WF'\,HS\^TBRYO !YV3S-F-IO1-2<YIJH$SG$>JS.7&9<VL)+:;TP
MW$_)LX-! X'WT25A;>%_J;E*15J@Q= 384[5O+\,)3,TEJF@3>L&M\?7764?
M]F8;%?1P^;!#HX N%'[KN[*-.C=OI;&-+@[3=T6(Y#"1/ZX7RZA1$)WFP+4U
M3%HM1;>C\R> EJW[KO0,EDU4T#B>_^L$JQV$^3([\[+05="!:TRT_S$$I3*M
MH9'3GF@\MS*BEJ9+V8LUCS_*/BL;:6'<5H3'52OL1CG;OBN$W3/4'NN"/<;H
M2C6PE%&C]MXIEU5F*@I2;[:!U4ZW+*>.U<#N&;6/(DCOKC)S$9G)2/9QX&3;
M*I\M^*0T9&(#60C%^];7"A\AJ;]:UZ0,:U$4T":F>J^A+M5*@$26M6=!&-^Z
M+LL1U;INB83N):\WD7D?[4FO'(/[V5]X!=QK%#%:X+EZ!8B&G/VL0+*H"F?(
M0_O;2%T(VU<&?Y_0:*^!0^?N/RRU1612,^_J83UCJ$%963O5) _.Q\!]8J5@
MZP[*ZZDYO%/>3//=2LIMJH%>&@:MM(98H?'^3R^/)SK0WI.SO@O=AW'C6V'@
M3LNA/2OPV$#HK>:>" :;./$@L8 3'FE><EN$ESEU*Q']I,'W2%3@&+&WB=YZ
MP-R:Z'D.R<@2!41C:CW8+,%;E4!X[;(T1:KFE:Z.Y;AB?]KL=I"QB2J.*_9P
M:5",RZ]C<KYG0S)J+UX-3\]GPR]X?:GXE_'L[2B=GI-S/AR]#*>I=HJ;]S2=
M_Q;S+SBO!O:YNBQA@GW',7HF>X\QD7TJ8+7:NI<AL(0FZZRTEDX9RT(*49?D
MA>I:;;UG#G9;.U\0/?D.+:__6A!2>]K54D+GLSDI[\ME-\1?ET1<^VN)N\2E
M\&13B[PH<Q>T$.2#"U9T\4JKV'BU;47[KOO/CG0L:X>98JU+S$ )G(%R@H'/
M,D,(4>K"M7#-*_@V(7S_N]M!,+NZT^U?Z;V&JG9D9^%79Q6DMI(8$8'7_O U
M>D.6@P@N&H>.&].Z[F!;#O85_#H*!!]0^<<23MN1\1\O[G_ W!MC,09FO 0R
MH V9T;61M/<6DN08HC,BY-:G'#VR<_B WOY!VG;%;P:6'CSH^RFK)].7?:LZ
MT-=3>/ QV@X3 CP:,'0"Z8Z:/ 3B>$%M62(ZE:CI#Z% 5%F#34'2_SG+XW[,
MX;Z1]DB\[\D";1,%]I%J5G-KWG^^D:!KF;"HF ?ZKP?%4("+G-Z:8+BRFDG9
MO&S:*A''XBQMJZ=5$W(G(>\KTD<3Y&RXR T(HUSKV=(,P5$/;0BW':E)/*T)
MFRLA,&Y4M%8(X911Z$U G5 XEE%RJ9$/MAUTQ[+1X^GTUEC7'I&0FAG'-43#
M(ZBH$SA1&& *1J?L@F.M+RFLIV8/Y;%SYMP(S<"E>GNX3N2HK*NU#G4T,@?-
M6L?=CK$\=B-$;%$6>Q,%- SAK"O5_".>#$?5!'A?YN\_T-3\7^/380X79!,,
MQWD0+7<AYPR9N]J?BE;]H+,!43!IRZ6343VRSFT]^),'QG[$WCBK^CZ"E^T
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MG&R=&]:,^'U%=X]GG3J,W@\=0[[#_8\72U[K4]],\-_G.$H7\VA*B30%+3?
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M>6E9)' A(P1AI HTX=6W]H&'CDX?1-G'TC[P=JE#(VJ>B(W /2,YQE3 ^V#
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M:B<8'T39QY)M=2LV'5*N9]WUO+#VE568(49MR!V)EM-TY-&T[OWPO,[H-D+
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MAAN%^P2W 0>!!^#1X0GA*>%9X._ B\$KP>O"/X1WA/>!#X*/A<^ +X%O@.^
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M+^\QVF.KQ[U/;C^)?++_5.MI@S^IOY__PC.I9X7/L9X[/A]_<?=%6@!"@$5
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M<ZK.S2LHL2<7Z]5)?.TA6_)12$=]#FJ$H;VT1DYF%P*%/O/*HG7V!S/. C>
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M0OUT=-HW>>/AU*D09YT9H1MT:]O8HKE1Z561SU-8,#NUWN%:AVDF-:C@<K!
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MN3$41X&9YF<E K16G$6[!/AHR3L-7[(_4S@)3'BG'%@><49082(Q%LYRO[8
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MZS;KE%*-1RXX&N$1G!MC@@M?YX-+?78$WP  VXDK'$RKUP(5/L$8@% M#Z8
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M-+:49&6DAJP]0W-8EEQ,ME!E!7?$45JB?LCNU;;(>ZD:EJ&JPQ8I,3(,YA+
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M-](.(LW!EZ%-#G,DVL^35=5097G4#M:23]4V*T5YR,!IZ[-!ER2$GM8P:I+
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M?L+4=<L>*JV:N?'!WK4OA\I_FV>?-^5Z Z%$Z[,*LB:$,UC!T(6(J=?;FU=
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M!SEW:CF7)(WPN_*H-CLO0E$AG[THX6KO=92T*-'M86[GX87O9I+*K?>\V?=
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M,L6/)F+0\3$P1N)UIZWNRHSX2=VZ"@M?E_TP*&%]46$O+(^1=@J"!6(H0VP
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M//W&H;-:J=_">=GD]61%(8V=!RLAA>W.*E?JXS+@=&J.B04\4TJI@*&)SB^
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M:L2$S^1Y7[N.ZM57@=6PVHJ< ZN<WI*M8NF*HU=IX\?K1&M9QNR_AHNEF 9
M:QC_<IY3!D,?_H-R^HQ+35$K7: ]_=*/\\2M1&18<F_VU=D-QA!B>P1K8/7S
MXARX[$&@%8D*1PR>F8NSA=F28%_K_-$+LH=3R9"9KBV)VL/\A.B[9#0YDX5X
M\S*_F@.<H1XZE.[;G8V00KVI/76W S=&.29W-,T,*U)/!^V&IKX<+A];7?]^
MF:PE>:#Q1E_WZ?,:Q[ZBIJ$EL@J(CU6SU1K1,WZS:9V;H_@UE[;U.RP1.^5K
M34K33D%N?YQIJ1B(!]-EV&#4;9H.^8,YWS'.W=ON^-5^+;QRD:6JY9T!PY28
MH1>P_4WP BI;<QU783@ IPM99-V5F8[1=D]2T\I!ZZNU:5C;&F393E)GED\I
M453%>1:NARVM'1=:-:_!0<S(-6&E$_CF,@-]XKJOE#H"N"51V@WT(#<YK6>R
M]8)P7]Y9<WL#(.QW^=<_&7NY+6O]ZDU3?W;!F^CA0,6ZZ3SA@?)Z+H1*&?%^
M_<GFB!<BA4RN>I&P.7X9=.ORMB^([:]UZ+'TJC<JA:P,88D@""Y8>665<1I5
M!2U?N3^' 7P-+WCY1C3S^1A2Q5>M*R8AG8R]3 )OIZXMHTIR[%TR[,K>\I(,
M6K2<"K--!CWZ-O_?-TY([R='C)T.UI^BW:*K<] CP-TC5'I+8O5[AIJ.S >?
M(&@K'*%>9?2C4*,_=S<BO.O1ED2E&_\[RV(ZYE[,YO-PC-V;/G2&K?5%S<*(
M!KH9YR.^'M;9Q9];?;D6UM9BK$B?W59S3_)I(D(L'U<U5F&G ><#\P7PC3?5
M*N0="O=N>Z>B$/@^9F_:4"C$DM</0W(T($[5,,AL'"DRO]A@EL__ 3W2-] M
M?."0ME#D3 5]U94>Q>&NI!:N8]VPG@LA@R$%%"Q! ,^+@W;F9VUZX=15F^9;
MA5++* HO\=$F1#!WG]$"11!3A+63<2!(&4+5S_(XO=CNRW72>*A0H9Y-$8UQ
MX" APAW]=J:^?'I')=W9#&EU0$<1GW>6DHZ&SM0>$E79KRP3\W6^OX>FO<I(
MR$;4R4D/9IYTCA%9N]8J MB5-D*'F%^&B$%XXQ>S%_N!GZBRP@?N/$6W)+/4
M8(=0FR/"CU?$2KZA ATINVDP/2*68$"T5Z?]A7\-E%=H6GB1PT2PX2Q(+WJU
MTOYM0J#A5_3X5!;6-+7+N%<#G%)\AP4'1R#& 1-0$>U#'33#&J_[M HLU:DI
MN^-#,&4>CO&O]4-LEM'6T128I"N4#\3R;V"^&U9<G','JDE&>*RJQ=-X9+54
MJR%BBD$KK/6.FK8\8% C6A.C1MV2Z,#5??.G?#,9.G(>6Z%T/<.F3J47O>"/
M]$^(<D">F]J2"%@/PJGU8R;ZKB">[#:)&,_G]5ZI+?LQ.@*:%VQXMZ9*-'&@
MG^&P%^*7#5:V(L3&9@;[&-383;? 'K=-NA;;[W[=_7)V8,JO6ZP'[,I>-^P4
M*6OMDTYG1J0A$_/*1_E+:AD]69<>M]XHRZG=OY:N_P3I7.[A''6)O>YMO9R2
MCT<.LO:9>6U*,E[J2LW H:_F7L9OB--15T(ZJO-M0)L\\>;'0\@I(D,0G3',
M7^[_J *#K&ZTT'[:626F4/>A71#L0?<9SY)P&+)J9_E<,D/J/3D5U?L-]S:=
M3^XJ+CCIV[(<%?:DXJTENS[FH4HJ*3+.+%'/*SQ6YZ:86"2272$'F1W]A<6!
M$]8'O[[\A$DF9M;C?OY:*Q64,=;%R.1.84S%)XI<N[1[AQS<Y-*_HG+MF+#E
M=(.4<2'I]<;Y^#/Z.6AX.NI-,*N\:<F"MX[(!9'Z-?2BQR+=$"=8'')D\?57
M1]>7RZP=0C5X8P:^,QXE-F(%]C!-11^/G4Y)YW-?T]QBH[U6*@1:[3N6;X/Z
M5QO3T#2H<L?EQ$*A93U^&QFJ>G!,',Y+MB@8TI':F^T_)'?P;OV2P/+%R FS
M",[4TL7TDQ=^G4U[42]"GK2S$"-6[VP(_.4<=$,US@<AU0KO=G-6!LV5V*M"
M2^(PH2%@*X-.M#MK?<%Y7$.2W8 J,O@:W$$EM0\.5W\:T%B>93=OH)$ZIK[2
MR[G4'X[E(@1D[#5<.VV7Q;Q1WM=:1_#"0ZF]#RK#6:FA-^?CPF<:1,H8M<TQ
M=P<>><:CO)= )4<RS&4'AX\P]#(B+G-&XQ.*(S@S#G%^&[2S[^8?2DJ:?JYP
MT5;15@YD0^0<O59*2YBPZ4D 8C@S92WUM@=5?2!FE"F6?&M=@Z,8)O_-^%$2
M(S^^YKN=AYKP+<8+QV@4KQZ.G?A:>V8WA0&I+!:YMJW_\G:GUZ>[Y!V/+GF+
MFEUDXKD[!:!5E1SN!V@-D7^4W^CS41NM%@JC:&TDB7HJ0](WGOW4G^^A<S%.
M[U$UOME=;IO:9XQ3YQ-4+4>4?0=DQ7B-)Z1Z(7 &;U#ZQZ;^\A'AN8,8HCG7
M=)R?%2R.KR(R!@3*D2D=+*J!BS,0>@1\@.UMR21 _)**,4OR7\$Z>7P4? >_
MT29+^=MB:Y)@]MX:_1Q,XZN !Y)I[JI/,GN:O,%3'M4'WRXISQ"%L$_QE[*8
MXI#/KB'Z3S9D2L!>8KQ4Q(3<IE@][L!,W*I%KLN1D;9<1=:='\F/9W'=-TC"
M<P='K_D=%!??KCJ'17'0(HK[(YT[O:*T!&*U16  1S3\K)Y"Q=1.TUPHP3SB
MI9$+#_^2C^DEJJI/L#F,LN\5^JYA>ODZJC^+P9JK3V,*]7U6X2<V_FM!QL8E
MBY-*L]%G):>/_V3&_CA]?GDA_GA_ _R74>C?'-G]M>/?G1J!;TFH$7Y$S'Z%
M+[_Z269'3?9'AD(>,Y2VGA@,47XX)+151R(7#=VV)%9^7 _YHE!]"O>F7K[Y
MWDOJ8?F=[2LU0CUX<J*?74;;40XE+;!>ZE2'N-$A*/?5&5-93;#Y]?P01L^F
M]B16-06(:G\^$Q7XZP<Y3@G<M^,:-K*3=AZ5"K#RW@$2-A(ML>AL5*.D9Z66
M9>4&S?ZY4F"D\$:BTJV5T7#[C"_V<YP% 1E];W?(FU=/)"B9:>.0:Z\.OS\1
M/X*KNY&Q)I/Z-,MPS+3W^$\0_%E?HJ!H?2S1(F;P:;35.*9B[TC&LY8@ZO=3
MH%58&LCWJ?Y%R)-9T!+6:9;Z)>MRN\Q*FV.M06M+46G@W!1QE&+0*;\C(*O%
M[!G][/EBL8KCM8/.U+W>4^IEA35RFG9<D?F!L!\:Y0Q\+R1RUWQ47 T*BZU2
MOOV>TW]:-P=5"#>GB"W@0Y;+!T\=L(TZ'QZ=VG/14UGNLZP2.4"W&F=<"NTI
M%[W;DKA*>;"VH^98MWK.YCWXKB7)@"LYX&L;VWC[)F6[H_[EX(-MO*NN9>#;
MI"O_;LK_%91<CD?8]'B]ICS[LU;B=U ]SB[.3X#[>V@Z8F7.[([#>^@J<]AI
M(0GH-8@QH,?,Y?>O%._E'U>/B6CSMX:C9MJV)&#@7?)=1)$HU>JUJS[.[^ K
M)Y>JE5]& %KL\EYZ$,]>HN.T)UP-E_(L2#>/Q?=].PA!5UN>&KA]]%2"95W6
M[*WX2=9^N%V% UU<%&'2/2+)@2<;"_&6WACN#$<DZGYF8,J=_8K71_0/KHP9
M"OD$2U3J*W4C%S1C6_<-SS)+,T02#*=^+)#S7%[_5-]IOS)9;X2.TBGZ&-\@
M<$=_'P#CF&BH#Z:1]B8JD=<TY4+WOA1H6,#'Q:)QG;'(3KZOD\XE2KHK8/3^
M0HV6#IVO)#%_-FE1M+I^P2VKA$U,U6>_:T6?ABAH$V@?IWTF/\"53=E(_=GR
M#.MKF*"U\5[Q>]DX[>C\?IX?O*8>_*4K4?TZ'<$Y9SJM1;F?J_H&?I8&9^9U
M5@>"5'TUH3J^B2H/^<D'D:$&OYU5GPQ'./+$^X7U/LK5 _Q!JBVPFI0YB%K!
MMP[EOR+1D6@3(,GU7&S;\ZXP3$ >U.F!:*4\@OUS3_Q?ND 'J$]P0194<"[-
M.:9)UGTQDH=9[G13LH4>O-,%>$]8)@:R*/W)2<*&DKJ&7IRY%R8R/^3*O6FC
M#8^_64PX/59$&KS0B*8-O#+\.T,ZVC]EA W=_K#KW-Q"_I ?X7J;_=P>_>8H
MRMQF>3DQU7RP:)YE?J-35#3<( (R+I9G<.T)?!)(M.3.5ZJ;!@+%:T%M!#$;
M+;M80B8L.;'\UL\)DR$L 'I+0E#G+=6W%O</DR$A[I+JV:8#]:+UMJ/^I)2&
M(2=>,JQ'E&J>1:(GQZ&!6.0^[\]H-RI^\_- <F=AKZ*LF")Z/I'+II0/.ZL%
MJ!-"?88]4C-$'/W_*#QIP361QM#"P WX/IH3[Q.OTZZF^=K/JN/>@0J.:505
M>,+ =(I2$TV8<R+2J9QK21^-.]!:0#VTH^13OWTN%YS>RT*OUIB3HL--^[+!
M(59<"O:&9V$A%_R\CPU8J(E6QW6:/MO@,"ILPZ,*UIZ_$V^8?HK:WA^]UO W
M3V;M+%Y;\Y<OB+<)SYN9TRV)"F%-9_=(QGPLXH4U U+ML17O3&<9]*%#7U4&
MXDYO28SP #?]Q<\ZA/GD ,Z<Y&HPR:AX,<W>'&3&^:V2IL4#+;6C(Q]$80+:
M"B+&%]*KTTL'_T_1P?'DUP@W54VG$7V=JO'FJMQYA2RHT,QBAJ(A)_:U7?/7
MB(OY2.-C8,$$3 "?UI5)4/:X'58*$]%-G."?WARMF;-(,O]^!O_KQA!M9L_M
M@]8U6%\T^-\W4D/?ALD7-6^/_+7_<]SX#?CW@J#__T_LKSV]F$I-ETL3)9U5
M8.K?@S\4;Z@;)W9C>0\MXXJ6:$K^-F<M<SADQK1'JF_HC=3"-PR@)Q^-O\MQ
MW-<=ZJZV#%P/LB:J%C"E-_A&=#NZLS:]H0A_UP8A7WM'YW(RD9&1U<A&\M:)
M]!GMS ;'4E5=*=@84@_(PTTL:&FH"8T1_(<6L60]#/1%87/=*NJ4D,D5-?'/
MJ;[/#RF5EXQ]*\!!ERH>ZI#W%D+DF!VPBT-5&@&#*?,"^RIF&CG:MM7@XMKR
MWR;Y4E\\A*3NZ8R[JEL9L N@+C'>E'-DH&9[ANS/H5[=TD&@[_Z5T)N<7VHP
MIKTYS_X<^O68ZWT.)=\&M'[\]TWYCY#DT4VJ6\26Q-^DY5AHE/1.WC>50Q^6
MJW8=G@S-7*E:;S@[ 1BM5/0%OT0)^&\J"VL=G8GP)%([$[.,1Q&L9K34E[\L
M" \IUCB-BX_F![JF;F?1]*."NCI-QE[-#0B^?=>O.=_(5R#=F2$EFF/R!7
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M\CV0#,GZ/5#X$-?Y[9)"T'R!4_DZM%/HFSGLZEPSH5Q3.HA\0)^T>XFKO S
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MY7=CC3Y>GM."MB:#6(JYK;D]E;U9+<\Q/OYNC1J"N9)2=OY&[>HQ4QUU39;
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MM51J!WW=;C1\.,SJ 3YL;58+AAT>#/#3S:,1A<O.E8^4+V8]'R(&WUWZ]-\
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MDU?O+^4JLW+5@T85]6&@TS/FG"\<Y:UOIL8C+2?S6##\SA%,<^6DB%08YPW
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M)21T)J(=-;,8>C$[8T?6J>ZP?X?)+]THA'V,8G]NI$1\>CM,8B7(I9Q:VZ@
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MGOA%;#8>1[ 0[K7Y8*^_3(^7:E%J8ERZ5,HLD&+^DCSZV2.@!HPGW]3C2SZ
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M1M1L3L=D;;#.U,OVF/*0$\C+SE,;+7;=#<5D6[Q)TQUX!#!7UL0_J.N[(FS
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MY)#MT%1&/<](U,<G$8%$S_E\;>3(FYF_;2<P47G0SR6.53+BQ7C+-]S&J^O
M Q ]1$3TI7@'1;\S+SP"YN+G 538=Y\V/\]?)TQ0<A.??Z<.1M?^V%K6/P?
MY=+/V*>W'GL-3T6/[$]'66Y>X=C7F)B@W7I.?K\*S8BR)9^VC0ROG0YG+\HK
M4>6!UJD4J%<=^AF5#3%C]*0C'%/1YQ6<,DT@<ML_Z_Q6DSW%%6#**X#CT0G_
MI:G@R$7B?R7UW& !OG\GZO>IGWN\G+-&G#J^:KUW';O)-/0E=2-D0(J_%"'3
MEYYT<!"R:*&'P'=A%01FQ.!OT,U?U+B!(=(F[!RL5(G(9F*E;R)A["!\4 LI
M ,EDY'C<?KPAN9^(3@K$)^@/&E*?TB%$'WX$:.>*GOL$I?FY>H_IQ!NX.?S)
MCQ59^VYMG77Z.D8I1G&LOCZEEGF076W(9B LG0]+M/5 1>]=E>>T82BMR%5
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M]#J\,/X'^C@B>^T*LSJ-%,>GR\(XNCCZT,I"WFWUVYB J;S ]82RBWGV9X0
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M5-)1@HC&?OFXTE?&YG#*I<WH5MM-W->L>+'R />E@!!+AF'<4^<XJS3+I=I
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M%(2AX61.G4W[)AJ@8-V96A7+6..F;QYN'P6480/!');8)I_J+)[D9,!X%G0
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M.W@1!PJN9+'>'8[H%X[+MD5CF8H1_4QDC>"H-.-$K';NI-^W^;!5DK/3'^!
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M>_F[VX'&9(Y\2*,0OBFN#;/&(X <,D K-5*)6A7>I$@O"AJ4)?DPB2N21=1
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M7<+FVC<B!Z(**HW98CSFV\UMMV.[[[,$K24ES8[R%4GV*#\KE\XB2G5S,+"
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M)R)%<4Y?H7S%P8$648'SXY&(2RP*"J_?(QX8%<F?_.JS'-R^SVL3CY,F"3)
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M=)\ -2-07+H%O;288]*S)6?K*F5"35-9POL69!7A>A"R_>GB)>QD&Q!*&AQ
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M'5L[A#<,P@SE7A$F!!URNCD;%8D9U]@^WI/,LGYS(\^[/^-KUITJTV-!1%&
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MR=M!;X1TQ*3 U5UO*M3"?DUN^W+/GPA?VV_QGKW-3O ]K2D2JW+REWD#-J<
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MY-NZ5:&)Y>X(9Q6A[4MO7<4AMKF"(I;QZKM+5C1O.&EU8"H\@Z>JMSY^NW!
MRE^\T(M:SF\X<TG_F?MXL')FJD5X?4[DU4P6<>U"60/(*K<)+$O/O@:5@! M
MPC&]Y]9_ >"IJ9,-CTYQ7^D [Z@M=VE+CTQ\-9F[=BK.UY/JB;!U-JM>V86V
MW]QYV$68^'VL[T]LXBE;Y/-[.0@+4>PU/DM9+1=X8;9GMN,0QIO_>A;79TN^
M:';KJ[=O@*@F-VW,D*IE-L+W/=\RG_:M<X7?^I>&S(GNT,-7LIODX#KK/$Z)
ME[P .P-5I4YR#'HCKD&[=J9U;F-W0'.T(YR02@QQ;=TC/>6U9-$HW:2EG4*^
MH2NZ[O[8:/#:5:=O]'L/Q@IG?KJ3_<G_5.K</!A),&P^[YZ$X-BB?V.>^*I[
M@$7=)R%XD/D/K6V3)$7N1C@*)_;@%C./H&_\7X!\2[3%.98DV '9%'%ZXA@7
MN'-?(+H',X;%<Y</Z_+_J#392=\="'9SS+FP7>""(%DMI&Q";QT?ROCH(*HM
M=<#_O-<3]"TGY.?,@,NM1PK!JWWC$9R3Y.0,4F[^=K?M<W$FH ,&YH!%U 6H
M>2FKEG7J*LZW&HX?UW',Z")P,E2@#[LJ<03 U<=P_2_ ^N E=[IT[Y@V9O%/
MIIZ[04R?2T&2H P#2%0.Z$=(O5KE*B609XE$0K >P:AX-9941P\0F U<VS/*
M$B@'HW,E&[,I_P7T+-Q$;:E5_FJ!5APV> ]-M$=+'NS,1>OV_2.,.)\8WOI6
MH][NRT#[@;#DD8-*<,Y0\_TOW+QG5!-,U"X:$*0)8FC2E!8@@:#T9H'0DM!#
MZ$5%0!((O0B^*"(=@0 )':6%!!!$" G50J]*+PF]*55%%!7+?;_[W>_^.-^Z
M:]U?YYQU?N]9>\W,VL\S>_;,?C)M?B:=Y]DDW?A,3Q_Y=U1S_X.)/FWU7U>.
MOZDF/<C@^"F0SH"RD1"="W"IL3C!WYQ7%P+ZMGJ'L/*O0IY(QJBY\SWC\+8!
MWW(FL+-#@E^"/'P&\UVQ#'ZO#GK(]#U,<:%C1G[[CJ2HW)NVUEJ)Q!1?0-O0
M11RAI8H0E0:N@?5-Q6&,C-+OM%V]I6;2;^5^M-=Z5EMU^EKN$V3V?)@(=RJ"
M3RRKJ_11%S[XY<7O=0]VK*!#*;6W?,G-WCNP>D<P[TO2 "ZAC2&3H#K,FIX0
M-*ERZ[M/V_N(G[51$8NVK/N!VSBM;TZY#CW?8(0$S4E6H$/I,HL@>.3N)_6@
MR8 +B[G4II[I>Z^RFZ'#;J^+]XB%SQJ:V>70AXT4&R4"42H[./"/)QVPE_S3
M)6P\\"DF%Q$BF)"M&%=>SFHM5UGMM@'F!FN(W0OYB;0H\LEM<"JKN>);#R;H
M[0P]C'+F'#&  YZPW[D"41"#^-!:7H7F!*9#V"(K\60!R7/++C:D+WDF4#.U
M%(=%LOC;F>P23XW?5X4_RIQI5531%)JM;,N11HC#<6#-JH4:&PF=AYWZN2=U
MD>P0>,1.W/3K&C^5^[;<[]!3,]5R(7 V5/Z4@(8H;E]M5YM\<P-ACO7&PB@$
M"EJF,I9SZ_,MV^:2)5?\QSRG\>5$YH&\$JZ A2I-\\.?GH@25_*PU4W1L=IY
M!JQT#:LOI!MX+K/*IGI7OO=2?A9_+G\L/NXN:X0=SO]GOTM':_0CZQU-QIHU
M'ODD1)^(0.9B'4((<=9GC;D8JJ0#U](9WKFOQ-2IGE.D>J (?]@S@![<SQ!
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MPJ9H.5DJKY!:>:B(N(H&T%NB4#DLJS%M++38_)A'<TT=$=5@$)%1AE/F.U<
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M-K2JATZC!Y5&>.ICX?#-9Q/-$/M_\9=U9U'ABS3P_06'8@3V'04JK7(ED1>
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MTV&TA?9ZT368,>%W9PC7)3,TISP 6JF:0K9RORO0T"B;-TQ7:/OR3Z/V[>R
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M>U6X'CT"U$QFDI9:O08+-\U91NM[E-C_E"CZ1_%;BLIPA#KPO!W2[B-4$;;
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MNU?*,G&YJ5F:_C:KI3R1/<'1AF#C5]=:.@<,6CR(;;JC[1]O^G7X58W*:TJ
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M_B[9UH"89I=KQ0I)T_D7][)T*RNJ]6/#KQ4)P&RR-Z9%D20C1]LQ,W1:XT0
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MGCO.%WQ%T.3W+ACHOS!?G$..0X4-"RNGF+U#KQ)ER5U\I6$65<9S)@%_M?!
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M'5KJ>D*5$TX7>YG/O9,F27[E?\<4P;-LDYF<S#$SC_ ("SCESTU+I/"0J5F
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M:(SZ-$[<(MT(!M7-M-<%:Y 74[6X;8EML:MVF@XCN7=BE77%3BG= XR-N;U
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M;6P>BRRF]GGQWW ULG_GRR1C*EMQSNJL]STQGH_&X1]X7".YGUUARN%M=L5
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MR!%'CISRA-B"S#^F @]T9GA,?&D%,F.Y36 .#E7=S=<*ZBFKCO9$S6OQ6!W
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MB?B:L[1P7/L?L]S9,X.5EI:!5-<>#9O3A<=Z394:Z\8CA1-[2DIG;T3R4;_
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M:6&VS",=4>\Q^BC.$*_FND4-&W'5I156*832"1I:+*KR:<"6@SS03$)2\'2
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M!5DKCN0P$SN[N_EG$-;3OZP7GK.[+\S]J'_OE.&B3F=6.3SSFM_4M<9UV+S
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MK[#9:</(NWFT[8K9D+W[=7D8<A5ZKLM=Q9;5$WVU\K--5[?W$GU[\-;G[N5
MG+341%0Y$INCW\RE]G6N.7R%U_987$H0,3/"&F>,>DXF=)B]9K"'><'V^N9&
MBR##B6(M2H=RHI VP3LC!(@4_3\5:1RGWHWEC"9[Y_Z&YDG7=M8&JCBH!8EC
MC&(:@2KST! .X@B4DGF,]GC+$>7%4D^4Y<LO0->*VWY13,>7R2V/,YL<?.H+
MNR0,^'!KB9TMKC7O?EGWJ7@)N3F_2HNBR:^UYA:BQ:,E]71@QNV,L@(U"[ZI
M(H=!K,R' J[,CTTRBM,#:\\KG"H=(/*+*^_U,Y_&K/!Y%SEDRUY\UHROU_S
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M1A1&@1+_Y\O&UR1;OS];4O">YK'SAE-O,V3EXH<FRY#O#-A=*KQ)6@>^BN>
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MJ2> M"1Z<K@L*J'2*V5R>6TS#.N>[2^=!Q1F!4)$18Z1NA'*0CU)IE$_R1/
M>9ZEIB12&[S47E1CD98NN2O-W8A.60<FPH]D05&;RMH]M70J9>;4LM1"T)T3
M"*!('[!$PP#9E/W!8N1?EU/2;DB-.YM\9#QR82W+"/::_305*<MMZEP40C)E
M]S%4B3$_?:A0%O1U>8!72^KD[>%Z.2T:DOW&<8R@I!ZG-UC,I;5ZR9'?ZZX!
M.N5M..?Z8.J'; *GKOISPU!Z,*O0Q,M/4I>?\3]'?V"SHMA3;X'0FYZ/VLJA
MR6>AM:"TN/'R*[VD6,LX F"C-T@][7:(KQ^5_K9D0&EU"Q1:M-.3PVTQ4D X
M>EY?]_MIQ6V,2?_N+6GKGWW/VTZL<7,F;;]:47>__;8NL(2/33_[8>9RN)"#
MUIS_):19V_GN[>[>2OC1[]N&9OL?0SZ?:83<>_3J^<14V_G*SR>I!7.K'S=/
M H^Z3I]>*RT/.FW__C\M4X*94?,8**?^ZIV?YQVS,SIO3/ZC:OK_-5/P.N<[
M-0U"8]KCSI6<9;A74P=WS7\\+?][,JT?BA8M!.4%I'60C4)G-,*@G;JZA.8(
MML+_ZL)6?U) 9N^#LO9Q [TQ$DOH(K>+MU04U?P*05F)_E<>XITKM>N-A6N?
M"+<*4JJ:>&AJT&-V^50SV-#U>E[2*'EGDY=3&.TN O: !G 1TYAI(]+MY;C?
ME+U+71MJ*C!"<6G&2A0]?Q6!3Z1Y21-KF!;3,CF):)2B)0 3.73F=:[JVU88
M>S>EQ8@"0/_9Y_ &L -NK4B\8[2\!(\CEAC+MA!D";+J.$$C8%$%AD8;B1'N
MT9 +/Y[O+TZC<5L\Z+>0?1V<G,Q]@?L7[&W&T@(F+A%?'Y?&D3^D;%$$0&8@
M'OXSK^KH;\G<VC;YP@<<)+JM%,5)(K7M@.DCD PT(N%-;W_\+OI%O2%0])V"
M_L)S:W_B6K?-'T#^_UDFP'][L!2A%#2%Z/,*J9-A3V#_05^R(8\QW9V>O;]@
M1Y/V\ JN--],5902^!-O5&\Z,S+R7"I6A7"]XHZ,3#PM'*IR'%$N+.Z>QUB>
M^G4HH-*)3_;6<JA9T;:4$WS)6*ZR': [YJR=.\<IG[4@T].L[W''*%W4 U.6
MIUV)IU9$I#%.PGHQ\@]F+H:ZO UC2DH7-@F^YM_(['&:JP<''ABQ;@LE4 Q?
M_GZYRC"F538J'#FH:$-0)XS"#29)TI\0:<B'D6^/RN)?-?W:;;KK(Y@)U ^=
M[9\LRP U#4>P9&0H #B#63:>'-[_!Q.6N\"7@UO;ML5>U!KQ)]*3):/($O%.
M%5BO!S9W?*YD527Q5(59$\AWAI]T"L"86)25-$TYU09ZK4,RPMSH6V<4G$C-
M+K! MEB88PRE.[V_NC5\<7U_]N#HP.%J\GL]$!,K9D?P]WYU&UYM04EI)!W%
M;YU=(/8'4.'<6!4T&OQ@WMA7[0\@2Y09:Z(RQ%$N: ['P3 0HYJIA-Q7.G?Y
M6M"8/H]<1#S'09 *C@2:M8<[Z  X:0P6!:G]S<U>6A:7*9>O+CX-%H9VV:);
MYRWRLDDDF>T0*;[)@OS%9(7*YNA@MQ7?S$95+HHTNE[0MM)\6 J>C]7'E"",
MUI5Z-]NK*A]H>:,NJV@LA-U\MCVTM<<7SH05M3-#6.KIZ;T\O[0G:U.Q:+HJ
M66"0(&S29W@J?.RVS/;B4W7LHVQG6W<!_"-*KJF>O[.\(@Q6@GLX22ST1]+&
M7^U-$:W\*BV[(IJ6D_+62;^8JU!RML='M'2%U5P\^:(JY9!7"J=T7C?2:"\0
MRJCN0FM< /*/(=)E9PP64Z3\QK*;/ ?ZD>4=A9HU#:+9M9KVK0*X30]7_8*H
MI,6_$S=5Y-.0Y_8'\%B_7':"BPMYYB0BNX&C,1K ,8] 'U;%R?,O!@1_]R?5
MT60)PJ>YQ73K&^<'N#Q+^X/9%1E%;;]25I7K7;MO+F S@'B2B;8O";?NH B2
M%=FQ0,2-L6R<4Y0(/SB]%SUJ"O=%+;:4KKH7FUU@L<= $,@8, S,4B&@X+4R
M'0X3VO^UKL#-KFEZ:TW"DRY]LIES0<\KB(4%+HBPTF6F+;TL^E'X9)IO*A+I
M_@RSP.E@I 0QEA%]JYC249+?SD0Q$'KE,WG4-RD3HL%'\Y*HT?-B.:B<UM[[
M0(G5J)8;R_^N SUE7CX"LW^(:3S)D=96DK[X,EZ0:3X4*JKYEUM)HF'E<$AK
M=OQW:B>(4[RR$>$BKLB#HQTO=B"C$,7+WU!3BV=GTU[MH_&6#'%W"4"5ASQE
MI<5]Q9()<( P9%VC-H37]M0+E8FV3.;DBK_2'<]1Q+/XEMV*!"EFQ(MS!O;M
M6]8GF+^X[-JV'"H/3?VLM+N"6_)T9;G@R&([% SYVWPOK\/VK"W@$_#E<%U^
M6KSLF-' >1$)U.8*)P^-_IIH%+0/[$@)K$BQ=[I]V=\)VJ+T!1;*P(!1$S^V
M3O,D8/D%45\U0T[+=]M=263FSG]0JT'S"SJ7U'1U!Y77!BU&RT;8U"N4;[J1
M4N/+4/SAL^)9KRUU3I<PIHI()A&UQO3NRHO*#V;/(C,E-05-9 P]]KQ\%$C7
M @WT8IM2H#P=19]MV+R\M+J5DN@^=U!:=X.T:)SEG-[#[(M%:&&2&7HH\W65
MNBIG/'G\+>'9<;+,UF3</>@XXE7LI.LI5O$'RVZOJ87?L[/&,WM'?X&T<SOF
M,B3>''3_>!J?^WE#N12VNMCJ:?MMX/C(6YE?3Y1*EC*.X16 2PE:21&D5Y?B
M3^(HTQC5D&<TF;VVQZ[9,TO?OP@UT[GEN==S,2XZR55-3)4N5W\Q%WP.4>Q>
M0CU4N=S/WLT^G:8#B+K^+64FC!#G4P>WE&VR2P<IP%, :9ML%#;A713.\.K5
M=YB=8=$</U?[P"\C1JD;]AZS<[X('%&6GJ0=;:[3F^);^UYBQ26Q;/*$H+(9
M"9J)&U=L)%3,P.F<GOR^S&L9SA>\NKUOX5 K)-,>D#HL[6E9\Q;;RNH>UWU5
M%QD3?R7+'0 I9?<P=:Q 0;=CWC\!&@!-@M*@3P6S1ULG#HI+CG,Y/$QN5*N&
M!CP/;NA"XHV2*R.(7]**W(E26)*VE'?%4D+ 5SE2ZD!L8+IK*%'IO):YSIS0
M->[1".X+A*'@L_C,J6S:REPG'O(4[@ID!ILZW?*\B".++TC4W98%$('06:0Y
MVC06OKW\Z-4_MCW6LFOWYA."0VFFM5V;7>%2-UEE#/5201)QB0AM)25-A1LH
M=^,I7E:K1O7M2EU[O;HD#VGS( ))KB@F2EMJVS+#WBLIN'GF,FIBHI!:;MR6
M]+CCHZBWU#!$RL-8W6&(,;#\I[(@G:TORZ'PC <"%[?R.+>%FDAB:TJSIJ8W
M0SBMM$U5!+7*&QD^MZH&"^QE,7R[EP1L_G5"%66C> AZ&HEX4R"W)OY]%.[Y
MNO0?P)CX(^/;^^HOP(?B?P "U[;3#R&_*PV'J_[+"!SPTN]O<D_F#%1-B51C
M6JN2)XT>9(M!4;GFK1I<+"(>0H:R*UBD&(CV>:J.6ZP/4S,Y,G^F[$[R[^+[
MS35NEN(4IW#PA^RJ#TKMFB%?KR ^>/FU+*:=8S.P>K*\O58M[T5E6W80U4OJ
MXKPI,Z/+/=5UMU@V>U"UWW#/:DG7CC^*BJ(UN&,J7(N+BOH+FS_2Z(05))E(
MU"2RLH[*7@3)"W876]EJ&O1T*Y0H'3:;R-O6N4Y]^?@9(VPG+'X75=Y#"Q]Y
MT4<Q 3Z1"<!1WT.EL$YNC/L.=?<.0H;#9]^%!I]C OMV[\(>6E ?( 1]%9$1
M[C4PD6TZ@<[?CME\LL=$:8-[LQ?^ '*7K0K%DVX:N1E5)OS^=#7)5T33<<7U
MQ=#*HO^O&Z%\*'C&ZS ULC1L'4[H2_G@2V?F\^/7O2!?A*8C='C/UN*BD1]*
M%YTX"4QK),X1_4J>8>$P9026]7&(PT6*@&=P#V3N$3;$"-'1JN/A+X9_-D1&
MNW"]-Y<$73%/-_$-";W4C1DUFJW-\/%TCE9<3!577-<+VGF &///Y8Y(HR1<
M[=1O%%68[_0YD^T/$^#3.\YNY1$(NN]7K3Q 7C+Q'7_49OQ[@'W3R/=C<.;
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M31[483<,G/(5G2Y&JQST[@F,Y F_KZ$R#)Y3CKR]^TAM19FY>JXPW?J_7B4
MS&7MZ3>]VES^LZ/S018KDAQ?&\RZL>I8"L8'.B%M%N!#/(U31-UT@CXW,K]8
M?J7YM=)*TX!XYB9:IM^$S+!!3-NO+V0C M**)XI+4;'<B>;[2YV?Y\=ND+]J
MGF;KQ(+A>JRI4_<U<\ T03KS++'@9G;?WD[>70;WZ;U/8ZX_[N"3XO$[PUGR
MAAFN 6ZCWY664@P["_JHY4<*ROF: 392S<U;!@HD]'A9;BCU^E*!N*=N:N"Q
M55[$9'9TV(IBX^'0PI:'6WC9X52?S=_YNN=D"?,;C[HR0>$"N+$ #SI\3Q]_
M1%^N] GNEZF3G77ZL-$3-4S:X/I2# F=$Q2%6^O'3$$\F4J_M2=YA $S,X='
MJR(Q%! $=LH$=/Z=ZT-&>5GN9B<%[(;XXOXZF6P$BO'%FW:8WIMQ7RQ8^) &
M0T!7H^G<]K O\Z_V,>[$<*5S-G++L]0IUS+'?MT$<]=&L&ZE>A:J"G,]Q*YM
M3JFK>.(SUX9WAN_SX>>*5]C!<&/YXLS9+-R$%2>1#()Q;272IRQ^%$#P:?3)
MEVV-GBFYU(O;\Z>Y7"^SNW#L/:U$HSX]3S:WJ_ R6I5P/V>U,O;_RMTR2)#%
ME#ME"0N,DH@:=;^^<HG,1D?EHL,T*W/8)5HG<,1.!EZ.5\ L86<=LD*AY7T*
MC0<=Y+6UI4->@,3,C;OV,IE,W[Q&FQY[L=6=OG/\'7E"F2,-88ED8SAM],6F
M18OL'=0^W.<T[-M[IY)_2.+O<O.7DFS#W=;YV)0G@$#B! QDA\]E9]E$NK-R
M+OILAC6,10KY5I"(+><07?B0[C-3LTD:I8W^PHE3*Y76IBI]IDMDG+&G_\U
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M5@CVKD:6>J.M\G>P%^%EYC $LESUA(?N)7I#N6/*'')@7[YA88\SK06U<$/
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M&X_/JG*VQO$1<Y=QE&J\I0 "7X:*-%P3Q/CXMQB\IK7QSN&V$\+1MOI$60*
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M[F(6LYLM8)0G:'6W["NO,D?E"HO9)%BFVE*/]2V%PP^=!,SZ<\JU9)P&G)G
MZV:4M"#57@D%1\H\N'&_=Y!JU#O6KH?=FQ\<";*5U((Q?)&#WH$MDX);#*#P
MQ=QB]2JSP:"SQ2?N\3SLHT%F/13*3QD6OT$<>H0'F38KF)W\>"?E8?[@Y%_
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MQRH?993WYM3Y'Z[_J?V7T?"_".:\&4+=XY\P3F;7.VR30@#EE)?P.0 '22?
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MT,+[6^O?^NT:CR#P.65S$U",MQB^3HD>)1+O5#9T?"NJ]"_ &U+;E4&=5U=
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M6(+>,0XZWN;ZPQT')I^$,(>7%B\^;#8UVV))D+$1<(21;0B>JOH$X*!\L_T
M K(.&/!(X-%ME+:5\F2^R.0SX1;E3Z^61L6<B1' 5IF6LQV3J<\=F@)8G6%D
M_;)V?=+3]U@ (+_E3],&S4;[F=V6P8\ZTXFXVRU&[X?ZJ472CLB!J%8&O8/C
MHY,HX$R.'NBJ6_\-C8UJ\_? =U?2&V!!]5.(=')0#I#W])[%!5-SM>A=A0[O
M8M8WS3\C&_IQE]S*@5B,YY;?J^V30NQ7O[L!P7<)RR;])@C %Q791/'Y.71
M3F_E&1_/&XCNW;%GXU-);!>_G#@%NB_\+H%4W$FSTY_M_-FR>7EG@_@:.XZ4
MKV=GC%H'I@W1X24QO!RF%Z72KV9DDYK+[<ZBKZ&MS-[,[>Y5#14;LDX]5"00
M8@?)3!!/87%R$ETAM]I)+7IM_S[GDR- _\'/ />2M!VW(:SN$>#-N]C^E9PM
MOS/6)GEEW@[6O@188(FS[*PH02R'8H!EY 6TKD:$(H'O&]A*E#T8LDUM!9GN
M96#%9V(Y#8_,JO417KQP@TD[),1.5(Z\STX+R6#K/!KX5"*M%<-;*'/\0AZ_
MQ5=YYI1$U"UH^%-=7#"5\<H6&F\B7G*67+JI-MJ4PHX^]O:0C3X"7$G>ZNQ8
MW;8.["6F_+&:6X3U@II-DIC;UQ1M+VNE*EG"QS8^F9[<*?BM4EEX_]2[3'9!
MR^^OBK]?SCC'"LA4E /6.8=C]-$B(K]S9)M?M'+@1STHMEV6^^J1,V]QO:&5
MD."X*BKC;I#T= Y^G4U'XU12X6EVX#F$S^1P)^<?4R/._M-DX^ V89 @I4Y8
M 2K*:8)]F]+MVU3'&2HX.^[O]M8,P.(_G<J .(XS&AJC?@2[!V01+\ZCUXBS
MJ@*X#-K@.*'5+?0>3 (]7"XA]\K('O!N;6?W>;"-T; HS;;QGEEI:3@0SA>4
M*L(W8R!D=@2X=SLR KVDNR+9Y'BJ"]]6WG-J93N3DV]"M"@F9"1F. 8<_!SY
M54H:K5HXG*H;_%Q(E*9_!#"C4ANZX>)QQT"0.!3CB_A"GJ_M&3$,6U= SOH.
M3AW7,2[W=-#S6$51N$H5EI_.R; 'Z(YIOC8XS""YNUW.3);2^JW/7TNDS4Y<
M'NCIP'>-'U8VP:,AO#K?FU:ZF9$M&6YO$0Q/DQ N4VO\9!MFJ0[J99VGVPKT
MKFQ@'#7+]QXFY)H=)FAK%8M2!OZZ*LO?Y<CC+DIQ'0?HGL:MM'SL^R'QSU+I
M#^/&_DL6?RWM^U3J$K^LM;9?_392]$NPFVSLBEH7KRY/.M @[!N-3*L^/Q/%
MNU,JO\5HN)OP0]KS@]#PCE?A(%/&0GFEPB-><?JFM5D6R8/;@PMD^@2%<.0D
M^;Z01UY]W+0B*I462IK/%@-JD7E&5MO V)RD(@Q<C(6/]59/_E2#9"O9ARP!
M$W(UN=)-T":DNQ+X==W9TZ.)D3V'F% MOW.]F-2+ORWHC?DU5G:;2.(K(455
ME!/F8D9@;Y!PV!&@I[[4KA#'F8M!9*L'JT,JM!#,*C6X#/\$ A]2/YS";,]7
MI]6<&POH&%'I>"Y;"6(Y.Z.-/Y14@*B"0A^EI1&E%IMB-UK3:*V#U*<?RRH5
M8DD,8$8W/BAF=L4!/1IPLN%4R'5_JK[J@0J"M)+'>TF?B. M["2UI,TO]G:W
M[EWS',4M[CS"?NBTG^,<;"/WX MB&@@^%HZOC-%<-FX7H@L#.IJ=[F*7KH5A
M[O%ET+:@)<5D<OVRVD7+.%?5K$>5NJA&ENWK2?TKRNDSD0:7Q/*5M 8*H>?(
MC*!9IZ8'Z+AFRU"<>X&[J3=(L YC)#A,/;85^XRGZX^#&HL#ZRL+ VNN9^L4
M-*,&]DKF&UVH.=!E&I*A%G>LLI3DP^\(RG)4B6<Z7CI);W]WW7I]TF8^7!H5
M*TZ\GE6AIAQ;>D=2Z=^_,JGL('/_V>W.$50%I(F@U3#IQ^C>8&YC)?R:S/GF
M[94#Q0?DRA*;'\:H53PMS<?'Q1E9\--%X^QB^6"!UT,1XMO0:5K-4%TU&K[6
M[]E]]UF\)_1!ON!Q D-=+9C?SN/I,*W5EW6R/?K<".;'=U5*??786O?^6D:1
MULI"?/_ Q4]OS"UY;9V,D($&29^!M+G@P3U0%=OYX<C7WQ03^G]S2P;)6&,5
M'A_,((W+FE8K!(OF]BO G\''>,T7V>EC81?,]9AY-"I8%3]TGDOW?+;F"":<
MF2#"R!&GJ]*5IXX'*-RXDN5O$'''Q3@IJX]];[M748ST^0+5%.]I:&@)L8)O
M]9^XO,&0*\&N<Y4B:@-8F?J6KJ'N25'?!>.\:+'E%&0G,JFVJ'(D#.E^D;KF
MS;1RC(W-=(5CN/WG51;FY4.%!EYZ028*VOAM)!5=9B=1[*)8IEZG"UB*3\KN
M)C=N;>94_WYQHI"U]DX=#6R3R:]_\O%7!SDY/E37>L_Q[W-VV/P=[&1/LS45
MLLIZ2_1+C\\B3",R?B"IW"H"3\JZRD6L5&0;4+-[FYYID8.V<&W_0?]-'MJ;
M<#/RO? G\#0GM4<.'Q&*1C' <1;L9DMS. $CZ!98-REOEUX)BI(1R"L' TK3
MH5SHV<]<$=+W$>TM;U-=B. .4'5\1&PBG&W:52YIS&&N$!3T[81YMQWF,*$6
M6^:PONN=? ,^*YU:6$+_]*V, .4R(G##RI^F! <-96;E]A YGN0K 967YQL^
M'8<;H4(==/FDS,TY)*1J"_="_1)5#:> 0AY8>T,$.MQ^)]S:!>;$8^KZ)N@I
MMCN%))YE5>=\>T+.AA2+FH,CDP8(!7939,J>)O6^6CL(PO83HW8103Z61E]O
M:/0K<.44ZJDC](0%@SV>MUAS'P'V&ML" Z8&QU6TXL_HC.KHN2I:T>DZ$C!D
M75D21PGC8TZMW.5\:,_8M$T"%Y$T1.7SA(!??2+S2@V_X'/0.378YW*K,_ZL
M).]N I[T>%!O@([6$NO<0"6PVZU)@ZBL0:D')=(2/"/B1OL[[2FSOI=DZ/-3
M\XKI>GBVM&<<#T(D!IF X^= 1_VTF++;K"0R"C8IC:?-Z[2Z4R\OZYX@K #*
M$\AVN@@Z'&2K$9D4(IL6FA\5\#4Q46WK7GW,9X78NXOS\ARVQ0$]F(EI:,XP
M8K/?'=I.'0=";[O*!MX*?;/U$EIZ15C#@:WW<O.^99LYM4JG)PP79NT0I*HN
M]<BT2[QWD!ND7LII!2!IG[R?77D/1_%%PD*UO":^P+TQU"NM3) Y# 'OTW\D
M50Z#J8Q\?NT[[VC&0N?'/Y'\T%6NW)ZT'*03:\0-IP =.4MO\@%.T+;\B#<2
M^".4* (P-8W2PEL04B6^%&MKSC?^J"%ZD;-/?XGVI5L;HET5 -16A)B;PS@\
M%6CE#C)V'>)T%4]EIPW[^_I(I[KW8?'2"9I+B+7W\V6'FBO=X!F "C1^VU.J
M 0QHW/"-1-T)_,&_MN497ZPO31:R*IUS=E#P[Q+45L6C2D PQS\-&$,3I- -
MUY!A%U:GOV)9 /CY4VN_ G1:1Q9B+YB^IZXDFZEQ?S+=I;++V-)H0@HB2HZ]
M^X]S*%U\0@^4C(=\<Z9.0ZYF^0NT!$93LOF&SUVP&G$7J6PC%=;LAVE&L(\
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ME570^TQKBN7V>M<O/&.]<7WIY>T>EO]HX*5<><^F@*;PM;%MR&3H9)_7^^R
MR>KI2*AA-VX*MSU>^\O :%:S8M5GVN8=E@WSI9RVQA3G1!8#XNNB^9);I9Y
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MSHL5FPLKH)C^I2A_^&$AV*K$_*Q>X.03]E]P\QBT/X(HA@GZ\_="_ND__@F
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M&..(0RQ(!*G."22$<JI8A&7J=7^[/U7'1F\;Y8 1]F#7$-797P%^>%9LV>G
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MX,.<TRB$/+\Y(F7X(YO3IAX]I6EY_ (NK0ZB/QJUZR\61Q%C*"%08H(@5EI
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MMG;TS?Q)U?$(DU3IB.(X@5S:>HX\$I#CA,)$4LJ2+$)4>%4/.2EI;#S;4 U
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M%.Y];Z1K,\"M?E'Z=M<)[P\[ 7PK[>EVR^&B?G$_KQJJ?P8ZQNJ]G[S.N$*
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M"($(BJ#Y4T%,\Q@RG2M(-<-4(\W2S/GVO9?DL4T2HE&5 [ 58.#WV@3 *AO
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M$%!;<J[\;J ><-] ]MX3 VTD>^L1KSWE16BV["V[M3O8'O,BLYM[S<L:ZEQ
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MOH=BH[=9XC_KW@$O!%["-_%C85,@WZOZOS>K:U$E0):&5&SLN*"*2,2M6(U
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M7I7-NF%U#,+Z=06N'ZH@<\SB#*/W0/"S?:'M?*/#@"/!??KTX%@-3KP>\OK
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MU:D+!V;=F&?*Y?V3K1O^58FGHMI=_FQZMRZWLD@U1E&4<!AE20(122)H*V-
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MWWY"KG.:SU-\M];*3N96G"W1LJ;5;];0^/]SZ>;XB9.K3^G;;+X<>9N%292
M\T*!R$:@'(P'19DDS%GALJRB_ <+=\(!:Q\'Q\BS$4A\3//Q++Z9QM=X&H\B
M\DUM84#+#$(9 L:&#%DAG+5@EK Z@+BW;"<X\/;A<+@L&P'#E[F;+L9%\!M
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MP!C=SXA>LW9U)]-%94)'SB@(B5) IRZ"ISE!C$)G%CG+KO;%U[-$->-?'PN
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MQB2O7.T:BV>)&M;R] &ENGIHX,BZ[5J_9F<UQQY_,J+<<R=,F0<F& @E*9A
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M#+P6ADJ2??W)X-TH&_R)X]"P/$9338P6?VJ[W;)EK(B):0[>$-Q67&OPN)/
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M^3_3LC"V.#N?I]7NVU2H$J-YBK24+R;<?I%*<![=2*J5XYP+2X-XQGOJL,S
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MKF4 $[@"(EQ)+J@8=.TBT.[4-7D]?U)H]J/()E)!W<4[LH%Y*[('H7( P7S
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M9+:R[INYFAN6@M34:J8@K2JWB<M@LM- ,S?1FNSK3\/H0%8GG-D7AK/:ZF@
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M&44[B1FX/O,4?E(=1;2 J%ORW[L+_/++W$T7+JRJ;];!!V/!I(!QAUQO.R7
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MU%#''>% 1*D\<BR#%:M7)8X9;XR@KO9(HT'#T1LB[G7WO=;8U4W*FUCGO"5
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M$WC,"P%//9&_R)*>W]URT^5[EN^;VELI]%+AL\_"_1?\'"R&0>I_E$$@.FN
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M_GHYC8L-%T)*3LO#WA2H ^&Y INX@90SI<2YE$CM<;O;*6D)/L?K>U9=^ U
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M<S4*8+$HJ$_S@#_XD'^;SQ:+C_-92"DN/DS7,KAS_3S22GH:!48/Q&L,:DD
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M=5^.I#HZI9X@0+O54G2*Y$<66621'0#GMFI=5N33BUO'GN_FMU2-N!4#>L:
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MQ'^KA[U;FHHU,K!L0!=R5%0H#F*2&EQ"G8L(.J%]QO??Y7D39WUZP=IH(NK
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MI0:U@THO>A.?9T;<V8?^@/5.-?U]/3*76',9SNOT!7$6H_'<U?8<NM3)5BF
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M2P$"% ,4    " "5-JM6-G4ZRZ\'   P(0  &0              @ %\ P
M:6UU>"TS,S$R,WAE>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( )4VJU:\K%O"
MH <  "4A   9              "  6(+  !I;75X+3,S,3(S>&5X:&EB:70S
M,3(N:'1M4$L! A0#%     @ E3:K5@(EG^&E!   GA(  !D
M ( !.1,  &EM=7@M,S,Q,C-X97AH:6)I=#,R,BYH=&U02P$"% ,4    " "5
M-JM66X>V@:P$  "S$@  &P              @ $5&   :6UU>"TS>#,Q>#(S
M>&5X:&EB:70S,C$N:'1M4$L! A0#%     @ E3:K5E-& \\6; $ ETX- !
M             ( !^AP  '9T;"TR,#(S,#,S,2YH=&U02P$"% ,4    " "5
M-JM6=;G+U/ .  !5EP  $               @ $^B0$ =G1L+3(P,C,P,S,Q
M+GAS9%!+ 0(4 Q0    ( )4VJU8C?^D4%Q0  (JZ   4              "
M 5R8 0!V=&PM,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( )4VJU8B:J">
MIT$  '+: @ 4              "  :6L 0!V=&PM,C R,S S,S%?9&5F+GAM
M;%!+ 0(4 Q0    ( )4VJU:Z<\N--M\" .NI P 3              "  7[N
M 0!V=&PM,C R,S S,S%?9S$N:G!G4$L! A0#%     @ E3:K5D'.X+2PK
M,TH' !0              ( !Y<T$ '9T;"TR,#(S,#,S,5]L86(N>&UL4$L!
M A0#%     @ E3:K5KZ\P5Y ;@  OO $ !0              ( !QWH% '9T
H;"TR,#(S,#,S,5]P<F4N>&UL4$L%!@     ,  P (P,  #GI!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
